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Abstract 
Clostridium perfringens, a spore-forming bacterium that produces >20 toxins, is 
known to cause both human and animal intestinal diseases including; foodborne 
diarrhoea, preterm necrotising enterocolitis (NEC) and necrotic enteritis (NE) in 
chickens. Currently, there is very limited information on genomic virulence 
determinants, and the phylogenic and epidemiology landscape of this enteric 
pathogen, thus in this thesis I sought to comprehensively explore intestinal-associated 
C. perfringens strains using both genomic and phenotypic methodologies.   
Whole Genome Sequencing (WGS) and bioinformatic approaches was used to 
examine a novel collection of C. perfringens isolates and publically available genomes 
(n=552, including 109 public genomes) from a diverse range of hosts and disease 
states including; NEC-associated preterm infants, foodborne diarrhoea patients, NE-
associated broilers, and healthy humans and animals. These genomes were analysed 
in combination or as discreet disease subsets to determine infection-linked virulence 
features, genomic epidemiology and hyper-virulent genotypes, and indicated a highly 
diverse pangenome (7.4% core genome), toxin-specific and novel virulence factors, 
widespread distribution of conjugative plasmids, long-term persistence, and inter-
regional transmission events during disease outbreaks. This work represents the 
largest WGS-based phylogenetic and comparative genomics on C. perfringens to date. 
Furthermore, a sub-set of C. perfringens isolates were characterised phenotypically 
using microbiological assays to determine hyper-virulent phenotypes, which linked to 
genomic analysis. These hyper-virulent strains were then used to establish a novel C. 
perfringens oral-challenge mouse model. This enteric infection model will allow 
further mechanistic work in understanding the role of C. perfringens in relevant 
intestinal diseases and may be used to facilitate therapy or vaccine development. 
Overall, this multidisciplinary work provides important novel insights into the 
intestinal pathogen C. perfringens at both a genomic and phenotypic level and 
provides a platform for subsequent translational studies into efforts to reduce C. 
perfringens-associated disease burden in both humans and animals.  
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Chapter 1 General introduction 
 
This chapter is a general introduction that forms the background of this thesis. The 
contents of this chapter are primarily based on (verbatim) the peer-reviewed review 
article published in Emerging Microbes & Infections that I am first author 1. The 
published review article is reproduced in Appendix 7. 
 
1.1 Introduction 
Clostridium perfringens (formerly known as Bacillus aerogenes capsulatus, Bacillus 
perfringens, Bacillus welchii or Clostridium welchii) is a Gram positive, spore-
forming, anaerobic, rod-shaped bacterium (Figure 1.1) 2. It was first isolated and 
identified as a novel bacterium in 1891 by William H. Welch from the autopsy of a 
38-year-old man, where gas bubbles were observed within infected blood vessels. This 
gas-forming trait (the original name Bacillus aerogenes capsulatus, ‘aerogenes’ 
literally means ‘air-producing’ in Latin) was later linked to gas gangrene symptoms 
seen in British and French soldiers during World War I 3. This organism was later 
named as Bacillus perfringens (in Latin perfringens means ‘breaking through’ which 
mirrors its tissue-invading nature) by Veillon and Zuber 4, and designated as Bacillus 
welchii in 1900 by Walter Migula in Germany 5. In the 1940s it was given its current 
name Clostridium perfringens, in the Bergey’s Manual of Determinative Bacteriology 
6.  
C. perfringens is associated with diverse environments including soils, food, sewage, 
and as a member of the gastrointestinal (GI) tract microbial community (i.e. 
microbiota) of both diseased, and non-diseased humans and animals. Notably it has 
been associated with humans for thousands of years as evidenced by the recent 
identification of C. perfringens using Next Generation Sequencing (NGS) technology 
in the mummified GI tract of a >5000-year-old Neolithic ‘Tyrolean Iceman’ (also 
known as Ötzi), found in an Alpine glacier in 1991 7. 
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Figure 1.1: Electron microscopy images of C. perfringens vegetative cells and spores 
(A) Scanning electron microscopy images of C. perfringens LH019. (B) Transmission electron 
microscopy of C. perfringens Q143 in spore forms. (C) Scanning electron microscopy image of the 
germination of C. perfringens Q143. (D) Binary fission of C. perfringens Q143 under scanning electron 
microscope. Images processed by Mrs Kathryn Cross. 
 
Clinically, C. perfringens has been constantly associated with various significant 
systemic and enteric diseases, in both humans and animals, including gas gangrene 
(Clostridial myonecrosis), food poisoning (FP) and non-foodborne diarrhoea, and 
enterocolitis 8,9. Importantly, C. perfringens strains are known to secrete >20 identified 
toxins or hydrolytic enzymes that could potentially be the principal virulence factors 
involved in pathophysiology 10.  
This introductory chapter will explore phenotypic and genomic features of this 
important and re-emerging pathogen, including virulence factors, and antimicrobial 
resistance (AMR) profiles, and the clinical impact of this bacterium in relation to 
several medically important intestinal diseases, across several host species. Finally, 
some of the important unresolved questions in relation to C. perfringens-associated 
infections, and implications for future research directions are highlighted towards the 
end of this chapter. 
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1.2 Isolation, identification and typing methods 
There are numerous methods for isolation of C. perfringens, and biochemical and 
molecular methods for identification as detailed in Table 1.1. 








Direct plating Direct plating on TSC-EYA + 18-24 h anaerobic incubation at 
37ºC. Pitch black colonies with opaque halos are presumptively 
C. perfringens. 
11 
Ethanol pre-treatment Ethanol pre-treatment (50% ethanol) for 30 mins + plating on 
Fastidious Anaerobe Agar (sometimes supplemented with 0.1% 
taurocholate). Colonies that exhibit beta-haemolysis are 






















Nagler’s reaction Known as lecithinase (alpha-toxin) test. Egg-yolk agar plates are 
split into two halves, where one half contains anti-alpha-toxin, 
and following anaerobic incubation, positivity is defined as 
turbidity around colonies on the anti-alpha-toxin-free side which 
confirms C. perfringens. 
13 
Reverse CAMP test Streptococcus agalactiae is streaked on blood agar, and C. 
perfringens streaked perpendicular to S. agalactiae. After 24-48 
h of anaerobic incubation, a ‘bow-tie’ zone will form due to the 




















16S ribosomal RNA PCR Appropriating full-length 16S rRNA universal primers/smaller 
region of 16S rRNA gene in PCR to amplify 16S rRNA gene + 
sequencing and identify using informatics approach (based on 




Rapid and inexpensive identification method based upon the 
mass spectrum analysis of highly-conserved ribosomal proteins 
from whole bacterial cells – apply bacterial colonies straight onto 
the MALDI-TOF metal target and followed by appropriate 








Multiplex PCR Multiplex PCR approach is commonly used to amplify key toxins 
genes to classify C. perfringens into 7 (A to G) different 




Genome-wide search on relevant toxin genes using sequence 






This technique is based on selective PCR amplification of 
restriction fragments from genomic DNA digestion. It is a rapid 
and highly reproducible PCR method to discriminate sub-types 
in epidemiological study. 
18 
Table 1.1: Common isolation, identification and typing methods in C. perfringens research 
Table adapted from Kiu and Hall (2018) under the Creative Commons BY licence 1. PCR: Polymerase 
Chain Reaction. 
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Historically, bacterial typing systems were developed to distinguish distinct bacterial 
strains from a single species, and more importantly, to recognise epidemic clones with 
specific pathogenicity. C. perfringens strains, clinically well-known for toxin 
production, are typed (recently updated for 7 toxinotypes: A-G; previously only types 
A-E 19) according to the combination of typing toxins (Figure 1.2) they produce, i.e. 
α-toxin (PLC), β-toxin (CPB), ε-toxin (ETX) and ι-toxin (ITX), enterotoxin (CPE) and 
NetB 20.  
This toxinotyping method indicated that certain toxins were associated with certain 
hosts and diseases e.g. type B (particularly CPB it harbours), is exclusively linked to 
dysentery in sheep, and rarely seen in other hosts 21. FP associated CPE was genotyped 
in type F strains (previously named as CPE-positive type A; not to be confused with 
heat-resistant type C strains) although CPE can also be produced by certain type C, D 
and E strains, whereas β2-toxin (CPB2) and θ-toxin (perfringolysin O; PFO) could be 
found in any toxinotypes 2,17,22. However, it is important to note that no single strain 
is known to produce the entire panoply of toxins 17.  
Since the advent of the Polymerase Chain Reaction (PCR) technique, multiplex PCR 
toxinotyping has now replaced the classical antisera methodology and is the routine 
rapid typing technique in clinical laboratories 16,20,23,24. However, this recently-updated 
typing system is still largely limited to the identification of the 6 ‘typing’ toxins (or 
previously 4; although some do pick up accessory toxins) 22,25. Moreover, linking 
toxinotype to disease phenotype is also highly debated as detection of typing PLC has 
little diagnostic value, as it can also be detected in healthy individuals 26. Importantly, 
type A strains (most strains are type A, as this toxinotype is universal in the 
environment) were also associated with enteric diseases, these strains were detected 
to harbour other additional ‘minor’ toxins (linkage with diseases were suggested) that 
are not addressed in this current toxinotyping method 17,27.  
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Figure 1.2: Current toxinotyping scheme of C. perfringens  
Figure reproduced from Kiu and Hall (2018) under the Creative Commons BY licence 1. 
 
Most recently, Whole Genome Sequencing (WGS) data of C. perfringens has revealed 
substantial genetic divergence in the sequenced genomes, when comparing similar 
toxinotypes 2,17,28. Potentially, with the aid of bioinformatics tools, more novel toxins 
or virulence genes will be discovered and identified for investigation of C. perfringens 
pathogenicity, and disease transmission tracking in hospital and environmental 
settings. Genome-based research in a related Clostridium gut pathogen, Clostridium 
difficile (it has since been suggested to be taxonomically moved to Clostridioides), has 
highlighted the utility of WGS as an appropriate tool to understand bacterial 
pathogenicity, including identifying AMR genes, and monitoring C. difficile spread 29-
32. Importantly, WGS has also identified ‘hypervirulent’ clades of C. difficile that 
appear to be linked with more severe disease outcomes, which includes at least two 
different ribotypes 33,34, and was used in monitoring bacterial spread, and tracking 
sources of infection, at an international level 35,36. These studies indicate that WGS 
will be key to understand, classify and characterise pathogens, including C. 
perfringens, in this genomic era.  
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1.3 Genomic characteristics 
C. perfringens has a relatively low GC content, between 27-28%, and genome sizes 
range from 3.0-4.1 Mb, with 2,500 to 3,600 predicted genes present in each individual 
genome 17. The first ever complete genome sequence of C. perfringens (strain 13) was 
published in early 2002; a historical gas gangrene-associated strain from 1939 (this 
also represents the first Gram-positive anaerobic pathogen to be sequenced) 37. 
Virulence-linked genes within the sequence data include phospholipase C (PLC; α-
toxin), hyaluronidase (µ-toxin), collagenase (κ-toxin), PFO (θ-toxin), and CPB2. 
Moreover, 61 sporulation- and germination-related genes were encoded, which 
supports the fact that C. perfringens is a spore-former. Notably, most virulence genes 
in this type A strain were not found on genomic islands, or near insertion/transposase 
sequences, and GC content of those genes were similar to the average GC percentage, 
implying that horizontal gene transfer (HGT) of these toxin genes was an ancient 
evolutionary event. This study also highlighted differences in environmental adaption 
genes, including glycolytic enzymes, and sporulation-linked genes, whereas recent 
studies indicated that phylogenetic relationships between C. perfringens (based on 
core genome analysis) does not relate to clone origin or toxinotypes 2,17.   
Two more C. perfringens genomes were sequenced and published in 2006 28; strain 
ATCC13124 (a gas gangrene strain isolated 1941 by Mollby, et al. 38), and strain 
SM101 (a FP strain isolated in 1953 39). Key findings indicated that ATCC13124 
contains a putative restriction-modification system that is obstinate to genetic 
transformation, a range of glycolytic-related genes that are strain-specific 
(highlighting differences in environmental adaptation capabilities), and additionally 
that sporulation capacity is strain-specific, based on the comparative studies of 
sporulation-linked genes. Importantly, this study revealed an unexpectedly high 
degree of genomic diversity, with no two strains identical with respect to genomic 
islands. 
Following the reduced cost of WGS, another 9 C. perfringens isolates were sequenced, 
and analysed alongside the pre-existing 3 strains in 2015 2. Core-genome regions were 
first reported to be highly syntenous (similar in nucleotide sequence arrangement), GC 
content (approximately 28.3%, similar to what was previously described), and 
importantly the core-genome phylogeny constructed did not show any potential 
relatedness/ clonal origins amongst different toxinotypes. 
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A recent large-scale genomic study (that I co-first authored) that investigated 56 C. 
perfringens strains, representing the largest C. perfringens genomic study to date, 
revealed a diverse pangenome (a repertoire of genes in a defined number of genomes), 
with only 12.6% core genes (common genes that are present in each genome; Figure 
1.3) 17. A wide array of toxin genes was profiled in this study: plc, α-clostripain (ccp) 
and microbial collagenase (colA) were conserved in all examined genomes, the pore-
forming toxin PFO gene pfo was found to be encoded in most genomes (>90%), 
whereas the FP causative toxin CPE gene cpe was consistently detected in historical 
FP isolates (isolated before 1950s), and was also linked with enteritis in dogs and foals 
40. Importantly, prevalence of aminoglycoside-resistant/anti-defensin gene mprF 
(100% detection), and tetracycline-resistant efflux protein genes tetA(P) (>75% 
detection) encoded within the genomes underlined the potential antimicrobial resistant 
threat of C. perfringens-associated infection. This study also suggested that these 
diverse genetic variations may have been driven by HGT, especially prophage 
insertion, within the ‘CRISPR-free’ genomes (Clustered Regularly Interspaced Short 
Palindromic Repeats [CRISPR]; no single CRISPR prophage defence system detected 
in >70% of the genomes). 
The substantial genetic divergence in the C. perfringens pangenome suggests there 
may be additional novel virulence-related genes encoded within the ‘accessory 
genome’, in addition to the plasmid-borne toxins, known to be primarily responsible 
for specific disease pathologies. Thus, it is important to analyse plasmid-encoded 
genes/toxins, in tandem to chromosomally-encoded genes in the accessory genome, to 
provide a more complete genomic picture of C. perfringens. Potentially, with the aid 
of bioinformatics tools, more novel toxins or virulence genes will be discovered and 
identified for investigation in relation to C. perfringens pathogenicity, and disease 
transmission tracking in hospital and environmental settings, as has been performed 
for the related gut pathogen C. difficile 30. To fully determine and research the 
pangenome, and discover potentially novel virulence genes, more isolate sequencing 
will be required, including addition of isolates from a range of hosts and environmental 
conditions, which may pave the way for translational research into new treatment 
strategies against C. perfringens infections.  
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Figure 1.3: Linearised pangenome of 56 C. perfringens strains 
Each coloured block represents synteny (or, homolog: identical gene) in the pangenome. Figure 
reproduced from Kiu et al. under the Creative Commons BY licence 17. 
 
1.4 Plasmids 
Importantly, C. perfringens strains are known to carry plasmids, which often encode 
virulence-associated proteins including toxins and antimicrobials 41. Disease-
associated toxins including; CPE, ETX, ITX, NetB, CPB2 and Binary Enterotoxin 
(BEC) have all been detected on C. perfringens plasmids 17,42. HGT of plasmids 
between strains is reported to be via the tcp conjugation locus that exists in most 
known C. perfringens plasmids 43. Important toxin-carrying plasmids will be briefly 
reviewed in order of toxinotypes. For comprehensive reviews on C. perfringens 
plasmids, and other related insertion sequences see Freedman et al. (2015) and Li et 
al. (2013) 41,42. 
CPE is known to be involved in FP and non-foodborne gastroenteritis. It was reported 
that up to 70% of FP cases, causative C. perfringens strains (mainly type F, previously 
known as CPE-positive type A) were shown to encode chromosomal-cpe, rather than 
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plasmid-cpe, while the latter was associated with non-foodborne gastroenteritis 
(responsible for 5-15% of all cases) 44. Some cpe-associated plasmids have also been 
shown to encode cpb2 genes or iab/ibp (ITX) genes (e.g. pCPF5603) 41. Type B strains 
carry plasmids which encode one of the deadliest toxins on earth, ETX, and CPB. 
Plasmid pCP8533etx encodes etx and cpb2 genes, but not cpb 45. Most plasmids in 
type B strains also possess other virulence genes encoding λ-toxin and urease 46. 
Similarly, plasmids in type D strains also carry cpe and/or cpb2 genes, and plasmids 
range in size from 45 kb to 110 kb 47.  
C. perfringens type C strains possess plasmid-borne CPB gene cpb, and other plasmids 
reported to carry other toxin genes including cpb2, tpeL, or cpe 48. In type E strains, 
two major families of plasmids have been identified: (1) plasmids carry iap/ibp (ITX) 
genes, λ-toxin gene and cpe gene, however, cpe contains nonsense and missense 
mutations and is thus non-functional 49; (2) These plasmids, including pCPPB-1, 
encode both iap/ibp (ITX) genes and cpe gene but not the λ-toxin gene 50. NetB is a 
chicken NE-associated toxin, which is plasmid encoded. These netB-encoded 
plasmids can potentially carry other virulence genes including tetracycline resistance 
genes (e.g. pJIR3537 and pCW3) and cpb2 gene (e.g. pJIR3844) 51.  
Notably, many toxin plasmids of C. perfringens are highly similar, sharing up to 35-
40 kb of identical sequences 42. In addition, some C. perfringens isolates can carry 
multiple near-identical plasmids that encode different toxin and AMR genes 51. 
However, no one isolate has ever been found to possess plasmids that encode all key 
toxins; only certain plasmid combinations could can be maintained within single 
strain, which suggests plasmid incompatibilities due to presence of distinct plasmid 
segregation systems, and warrants further research 41,52,53. Furthermore, the universal 
existence of tcp locus indicates that conjugative plasmid transfer could be a key HGT 
event for increasing virulence of C. perfringens strains. 
 
1.5 Virulence-related factors 
C. perfringens can generate a complement of extracellular toxins and hydrolytic 
enzymes (>20), survive in aerobic environments (i.e. oxygen tolerance), produce toxic 
gases, and rapidly grow. Therefore, it possesses the capacity to effect various 
histotoxic (i.e. toxigenic to tissues) infections in humans, including gas gangrene in 
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contaminated wounds, gastroenteritis (including foodborne and non-foodborne 
diarrhoea) in human adults, necrotic enteritis (NE) in animals, and recent links to 
necrotising enterocolitis (NEC) in preterm infants 54. Relevant virulence factors of C. 
perfringens are represented and summarised in Figure 1.4. 
 
1.5.1 Transmission and colonisation 
1.5.1.1 Oxygen sensitivity 
C. perfringens is commonly known as a strict anaerobe; however, this bacterium can 
also survive in the presence of oxygen, and/or low concentrations of superoxide or 
hydroxyl-radical-generating compounds 55. It was shown to survive in aerobic 
conditions for >72h, which was attributed to its generating capacity of Superoxide 
Dismutase (SOD) 56. Genomic analysis indicates there are putative NADPH 
dehydrogenase genes (yadD and ycdF), which generate enzymes that help maintain 
intercellular redox balance 55. Notably, as an aero-tolerant anaerobe, C. perfringens 
could potentially survive through aerobic environments (such as on surfaces in 
hospital wards 57) and trigger disease development in aerophillic environments (i.e. 
adult/preterm infant gut), and additionally oxygen-exposed tissues (such as gas 
gangrene), which may facilitate bacterial host-to-host transmission 15. 
1.5.1.2 Sporulation 
C. perfringens is a spore-former, which enables this bacterium to survive in extreme 
or nutrient-depleted conditions. This spore-forming characteristic plays a vital role in 
the transmission of this Gram-positive bacterium from diverse environments to hosts, 
leading to infection, including FP in human adults 58. Some spores of C. perfringens 
(especially FP associated strains) had been demonstrated to resist extreme temperature 
conditions, which may contribute to C. perfringens survival and subsequent disease 
pathology 59,60. Although, capable of sporulation, C. perfringens appears to be a less-
prolific (in vitro) spore-former than its Clostridium relatives such as C. difficile 15,61. 
For lab based assays, sporulation can be achieved using the well-experimented 
raffinose-supplemented Duncan-Strong sporulation medium 61. 
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Figure 1.4: Disease-linked virulence factors of C. perfringens in intestinal infections  
Figure reproduced from Kiu and Hall (2018) under the Creative Commons BY licence 1. 
 
Molecular regulation of sporulation in C. perfringens is less well studied compared to 
the model bacterium Bacillus subtilis. Previous studies have indicated that the 
transcriptional regulator CcpA (encoded by ccpA) is required for effectual sporulation 
62 and Spo0A (spo0A), a transcriptional factor known to be present in Clostridium 
species including C. perfringens, is associated with sporulation initiation 28. Sigma 
factors, including SigF, SigE, SigG and SigK (genes sigF, sigE, sigG and sigK 
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respectively) are known to regulate the sporulation process of C. perfringens 63,64. In 
addition to this, it was also reported that C. perfringens sporulation processes could be 
regulated by an Agr-like quorum-sensing system, potentially promoted by the codY 
gene in type A FP strains 65,66. Importantly, CPE is known to be produced by C. 
perfringens during sporulation, which correlates with the pathogenesis of FP-
associated diarrhoea 58. 
1.5.1.3 Germination 
Germination of C. perfringens can be triggered by small molecules termed germinants 
– commonly known as sugars, nucleosides, amino acids, salts and purines 67. 
Importantly, primary bile acids (including glycocholate, cholate and taurocholate) in 
the human GI tract are also known to act as potent germinants in Clostridium species, 
whereas secondary bile acids, such as deoxycholate (derivatives generated by certain 
gut microbes), can inhibit the in vitro proliferation of C. perfringens 68. This proposed 
‘colonising germination’ survival modus operandi of spore-formers, including C. 
perfringens, potentially acts as a signal to initiate growth, and to persist in the intestinal 
environment 15. This persistence, and long-term gut colonisation may correlate with 
the ongoing symptoms (up to several weeks) of nonfoodborne diarrhoea in patients 69. 
From a colonisation resistance perspective, inhibition of germination, by secondary 
bile products produced by resident commensal bacteria, implies a long-standing 
competition for limited nutrients and niches within the gut.  
1.5.1.4 Rapid proliferation 
Notably, C. perfringens represents one of the fastest-growing organisms currently 
known and is reported to have a very short 8-12 min generation time when cultured at 
43°C in optimal media, and 12-17 min at 37°C 70. Rapid growth of this bacterium 
potentially predisposes the host to tissue infection, as in the cases of avian NE, bovine 
necro-haemorrhagic enteritis (could be <5h), and gas gangrene. Also, as C. 
perfringens has a two-fold quicker generation time, when compared to intestinal 
commensals like wild-type Escherichia coli (typically 20-30 min in Luria-Bertani 
broth), this could represent a potent mechanism for outgrowing other resident bacteria, 
leading to efficient gut colonisation. 
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1.5.2 Disease initiations 
1.5.2.1 Histotoxic gas production 
Clostridial myonecrosis (better known as gas gangrene), is accompanied by profuse 
gas production, which could in theory be the mechanical determinant of tissue injury, 
alongside rapid cell proliferation of C. perfringens. Importantly, C. perfringens is 
known to generate hydrogen sulphide 71 (using ubiquitous sulfuric sources from the 
environment), a readily-permeable toxic substance to human cells, which when 
produced in excess is associated with other intestinal inflammatory diseases (e.g. 
Ulcerative Colitis) 72. Thus, C. perfringens-associated gas production represents an 
understudied virulence trait in the pathogenesis of gut infection, such as preterm-infant 
NEC (discussed in more detail below), which symptoms significantly mimic those of 
gas gangrene; necrosis of tissue accompanied by abundant gas production 73,74.  
 
1.5.2.2 Toxins and virulent enzymes 
Presently, 23 virulence genes that encode toxins and virulent enzymes have been 
identified in C. perfringens (summarised in Table 1.2) as the most prolific toxin-
producing pathogen currently known. Some key toxins will be briefly discussed and 
summarised in this sub-section. 
1.5.2.2.1 Alpha-toxin 
PLC (encoded by gene plc or cpa) was identified in 1941 as enzyme phospholipase 
(i.e. phospholipase C), which was the first bacterial toxin shown to possess enzymatic 
activity 75. This toxin is present chromosomally in all strains of C. perfringens and acts 
on egg-yolk lipoprotein (lecithin), which results in increased turbidity- basis of a 
medical diagnostic test for C. perfringens, such as Nagler reaction or egg-yolk agar 11. 
Biochemically, PLC has been shown to hydrolyse cell membrane phospholipids, 
which eventually leads to cell necrosis; a key characteristic in gas gangrene 38,76. 
Indeed, this toxin is essential for gas gangrene pathology, as shown in an in vivo 
myonecrosis model 77. Mechanistically, PLC may play three major roles in gas 
gangrene pathology; firstly, it is able to impact on the movement of immune cells such 
as neutrophils to infected tissues (mechanism currently unknown), hence potentially 
reducing pathogen clearance at infected sites. Secondly, it can cause constriction of 
blood vessels, which may reduce the blood supply to tissues, thus creating a micro-
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aerophillic environment conducive to C. perfringens overgrowth. Thirdly, this toxin 
can activate inflammation cascades in host cell metabolism (arachidonic acid and 
protein kinase C), which may lead to direct immune-mediated pathology of tissues 78. 
1.5.2.2.2 Beta-toxin 
CPB, encoded by gene cpb, is a plasmid-encoded pore-forming toxin that is thought 
to be intestinal-necrotic, and also important for systemic enterotoxaemia, in humans 
and neonatal animals, as shown in in vivo studies 79,80. C. perfringens type C strains 
that possess the cpb gene were associated with historical Clostridial gut infections;  
Darmbrand (post-world war II in Germany), and Pig Bel (Papua New Guinea) 81. 
Previous intestinal loop studies have indicated a synergistic effect with CPE (encoded 
by cpe) 82. Furthermore, this toxin shares sequence similarity with several pore-
forming toxins produced by Staphylococcus aureus – ɣ toxin (A: 22% and B:28%), α-
toxin (28%) and leucocidin (S:17% and F:28%) 83.  
1.5.2.2.3 Perfringolysin O 
PFO (also θ-toxin, encoded by gene pfoA or pfo), is also a pore-forming toxin that acts 
on cholesterol-comprising cell membranes. This toxin has been shown to be involved 
in the pathogenesis of gas gangrene, and haemorrhagic enteritis in calves 84,85. Notably, 
PFO shares structural homology with similar pore-forming toxins identified in 
Streptococcus, Bacillus, Listeria and many other genera 25. PFO is also known for its 
capacity to induce tumour necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) 
expression in the host, and it could activate apoptosis through p38 MAPK (mitogen-
activated protein kinase) pathway as demonstrated in in vitro models 86. Interestingly, 
it has synergistic cytotoxic effects with PLC on bovine epithelial cells, highlighting 
the significant role of this toxin in disease development 85,87. Please refer to the work 
by Verherstraeten et al. (2015) for a comprehensive review of PFO 25. 
1.5.2.2.4 Beta2-toxin 
CPB2 (encoded by cpb2 plasmid gene), a pore-forming cytolytic toxin shares <15% 
sequence homology with CPB, distinguished itself as a novel toxin produced by C. 
perfringens 83. CPB2-producing C. perfringens strains have been associated with gut 
diseases such as necrotising enteritis in piglets, and enterocolitis in foals 88. 
Importantly, this pore-forming toxin has been suggested as an accessory toxin in C. 
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perfringens-associated non-foodborne diarrhoea 89, and proposed to play an important 
role in preterm-NEC in potential synergistic effects with antibiotic gentamicin 90.  
 
  Gene Toxin name Abbreviation 
in this thesis 
Alternative 
name 















plc/cpa Phospholipase PLC α-toxin Disruption of cell membrane 76 
2 cpb β-toxin CPB - Pore-formation 91 
3 etx ε-toxin ETX - Pore-formation 92 
4 iap ι-toxin component Ia IAP (ITX) - Cytoskeleton disruption 50 
5 ibp ι-toxin component Ib IBP (ITX) - Cytoskeleton disruption 50 
6 cpe Enterotoxin (CPE) CPE - Pore-formation and tight-
junction disintegration 
50 
















cpb2 β2 toxin CPB2 - Pore-formation 88 
9 lam λ-toxin LAM - Potent protease 94 
10 pfo/pfo
A 
Perfringolysin O PFO θ-toxin Pore-formation 95 
11 cpd δ-toxin CPD - Pore-formation 96 
12 ccp Clostripain CCP - Digestion of collagen 37 
13 colA Microbial 
collagenase 
ColA κ-toxin Digestion of collagen 97 
14 nanI Sialidase NanI - Mucolysis 37 
15 nanJ Exo-α-sialidase NanJ - Mucolysis 37 
16 nanH Neuraminidase NanH - Mucolysis 98 
17 nagH Hyaluronidase NagH μ-toxin Digestion of connective tissue 37 
18 tpeL Glucosylating toxin TpeL - Induction of apoptosis 99 
19 becA Binary Enterotoxin 
Component A 
BECA - Pore-formation 100 
20 becB Binary Enterotoxin 
Component B 
BECB - Pore-formation 100 
21 netE NetE NetE - Pore-formation 101 
22 netF NetF NetF - Pore-formation 102 
23 netG NetG NetG - Pore-formation 101 
Table 1.2: Pathogenicity of the currently identified C. perfringens toxins 
Table adapted from Kiu and Hall (2018) under the Creative Commons BY licence 1. 
 
1.5.2.2.5 Epsilon-toxin 
This deadly toxin ETX, is plasmid-encoded by etx gene C. perfringens type B and D 
strains and is essential for pathogenesis. Epsilon toxin is involved in animal (goat and 
sheep) enterotoxaemia 103. ETX is currently thought to be the most potent of all toxins 
produced by C. perfringens, evidenced by the LD50 of 70ng/kg body weight, ranked 
only behind C. botulinum and C. tetani neurotoxins. It has been demonstrated to affect 
various organs, such as kidneys and liver, through unknown mechanisms, that allow 
this toxin to enter systemic circulation 104. Due to its potential use as a biological 
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weapon, ETX-producing C. perfringens strains are on the export control list in a 
number of countries including USA and the UK 105,106. 
1.5.2.2.6 Iota-toxin 
This cytoskeleton-damaging toxin ITX (also considered as a typing toxin produced by 
C. perfringens), consists of two cell-binding monomers Ia (enzymatic component) and 
Ib (binding component; encoded on plasmids by iap and ibp gene respectively), which 
act synergistically to first translocate the toxin into host cells, then exert enzymatic 
activity on ADP-ribosylating actin to disassemble the cytoskeleton, which eventually 
leads to apoptosis and cell death 107. Furthermore, ITX shares a certain degree of 
virulence similarity with oedema and lethal binary toxins from Bacillus anthracis 
108,109. 
1.5.2.2.7 Microbial collagenase 
Microbial collagenase (also known as κ-toxin), encoded by chromosomal gene colA, 
is a key toxin produced by C. perfringens that degrades collagen. This enzyme might 
contribute to intestinal infection, as collagen, the substrate for collagenase, is a primary 
component of intestinal connective tissues/basal membrane of human and animal hosts, 
thus disruption may damage basal integrity, which may lead to eventual tissue necrosis 
85,110. However, Awad et al. indicated that κ-toxin is not a major determinant in a 
Clostridial myonecrosis mouse model (gas gangrene), despite its capacity to hydrolyse 
collagen 111. 
1.5.2.2.8 Enterotoxin (CPE) 
CPE (encoding gene cpe) is recognised as the key toxin to cause FP and non-foodborne 
diarrhoea, it has also been demonstrated to disrupt the intercellular claudin tight 
junctions in gut epithelial cells 112,113. Importantly, this pore-forming toxin was 
demonstrated to bind and necrotise human ileal and colonic epithelium in vitro, and 
can induce cell death i.e. apoptosis, via the caspase-3 pathway 114. Hence, the potential 
pathogenesis mechanisms underlying FP could result from CPE-induced tight junction 
rearrangements or pore-formation.  
1.5.2.2.9 Sialidase 
Three sialidases, encoded by genes nanH, nanI and nanJ in C. perfringens, are also 
named as neuraminidases or exo-sialidases (NanI and NanJ). This group of enzymes 
represent important virulence factors during C. perfringens-mediated tissue infection; 
Chapter 1    General introduction    38 
 
they catalyse hydrolysis of terminal sialic acids from glycoprotein, glycolipids and 
polysaccharides of cell membranes that aids in bacterial attachment to host cells 115. 
This mucolytic potential suggests that C. perfringens may utilise intestinal mucus as 
a nutrient source, and thereby potentiates intestinal colonisation, which has been 
modelled using the in vitro Caco-2 cell line 116. Importantly, in vitro studies have also 
demonstrated that α-toxin associated with NanI (exo-alpha-sialidase) increased the 
virulence of C. perfringens 117. Furthermore, NanI was shown to potentiate the 
virulence of ETX, CPB and CPE, via binding-enhancing (ETX) and proteolytic 
activation (CPB and CPE) mechanisms, potentially enhancing C. perfringens 
pathogenesis 118. Notably, in a gas gangrene mouse model, NanI and NanJ are not 
essential for virulence 119. For a comprehensive review of this toxin, please refer to 
work by Li et al. (2016) 120. 
1.5.2.2.10 NetB 
NetB, a pore-forming toxin (encoded by netB), shares limited amino acid sequence 
similarity with CPB (38% sequence identity), PLC from S. aureus (31% sequence 
identity) and δ-toxin (40% sequence identity) from C. perfringens 121. Less than a 
decade ago, this chicken-NE associated toxin (plasmid-borne), was discovered and 
shown to be essential (instead of α-toxin) for lesion formation both in cell line models, 
and avian in vivo models via genetic mutant strains, and thus fulfilled molecular 
Koch’s postulates as a disease determinant 122. This toxin is important in avian 
agriculture as netB-positive C. perfringens strains recovered from broiler chickens 
(healthy birds) can be as high as 61%, however expression of NetB was shown to be 
lower in healthy birds, when compared with NE-associated chickens (92% vs 29%) 
123. In addition, netB was later identified as part of a plasmid-encoded pathogenicity 
locus named NELoc-1 capable of being transferred via conjugation, indicating the 
potential spread in relation to chicken NE epidemiology 51,124. Please refer to Review 
by Rood et al. for a comprehensive description on NetB and poultry NE 125. 
These extracellular toxins represent potent virulence factors central to intestinal 
disease development. However, not all toxins are secreted by all strains of C. 
perfringens (excluding PLC), hence, in silico identification of virulence genes using 
NGS techniques and bioinformatics tools are essential for rapid and comprehensive 
geno-toxinotyping of C. perfringens, compared with conventional molecular tools. 
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1.5.3 Antimicrobial resistance (AMR) 
AMR traits in C. perfringens pose a serious clinical treatment concern, due to its 
capacity to generate an array of lethal toxins. Presently there are several phenotyping 
studies published (based on in vitro susceptibility testing of Minimal Inhibitory 
Concentration; MIC) on the AMR profile of C. perfringens, however, there is 
currently limited genetic/WGS-based AMR genotyping studies (Table 1.3). 
Tetracycline resistance in C. perfringens was first described in 1968, when 11 strains 
of C. perfringens were tested, and found to possess ‘some degree’ of resistance to 
tetracycline, thus penicillin G (or, benzylpenicillin) was recommended as the drug of 
choice for treating Clostridial infection 126. Plasmid-carrying tetracycline resistance 
(tet components) in C. perfringens was genetically shown for the first time in porcine 
samples (3 strains) 127. Tetracycline resistance elements tetA(P), was then detected in 
81 tetracycline-resistance C. perfringens strains (100%), with 93% of these strains 
carrying a secondary resistance gene, either tetB(P) or tet(M), notably, no single strain 
possesses all tet genes 128. Multidrug-resistant C. perfringens strains were first 
reported back in 1977, multiple strains (n=7) isolated from porcine faeces were 
demonstrated to be resistant against tetracycline (MIC > 32μg/ml), erythromycin 
(MIC > 128μg/ml), clindamycin (MIC > 64μg/ml), and lincomycin (MIC > 128μg/ml) 
129. A PCR-based AMR study on 160 environmental strains (water, soil and sewage) 
revealed encoded macrolide resistance genes erm(B)(26%), erm(Q)(1%), and 
mef(A)(18%), in addition to the commonly found tetA(P)(53%), tetB(P)(22%), and 
tet(M)(8%) 130. 
Macrolide and lincosamide resistance (mainly erythromycin and lincomycin) appears 
widespread 131, and therefore is considered ineffective in treating C. perfringens 
infections. This is supported by a recent multidrug resistance study of 260 strains of 
C. perfringens isolated from diarrheal neonatal piglets in Thailand, where higher 
resistance was observed for erythromycin, lincomycin and tylosin 132.   
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Ampicillin   129,133-137 




  134,138 
Imidazoles Nucleic acid 
synthesis 
Metronidazole   134,135 










Chloramphenicol   129,134,135 
Carbapenems Cell wall 
synthesis 

















  Erythromycin* 
Tylosin 
129-133 
Quinolones Nucleic acid 
synthesis 






  Gentamicin 
Streptomycin 
133,137 
Polypeptides Cell wall 
synthesis 
  Bacitracin 
Colistin 
133,137 
Table 1.3: A summary of C. perfringens antimicrobial resistance 
*High-prevalence (both pheno- and genotypic) antibiotic resistance reported. Table reproduced from Kiu 
and Hall (2018) under the Creative Commons BY licence 1. 
 
Recent WGS studies on AMR genes have detected mepA (multidrug-resistance gene), 
using various public AMR databases on C. perfringens strains 139, and also tetracycline 
resistant genes tetA(P), tetB(P) and tet38. The genes, mprF and rpoB (rifampin-
resistant) have also been reported to be encoded 139. Anti-defensin gene mprF 
(possibly involved in multidrug-resistant, including resistance against gentamicin) 
was recently reported in a large-scale genomic study of C. perfringens (n=56 strains) 
to be present in 100% of the genomes 17. In this latest genomic study, tetA(P) was 
detected in 75% of the 56 strains, which is more prevalent than tetB(P)(42%). 
Interestingly, ANT(6)-Ib, an aminoglycoside resistance gene, was also reported to be 
encoded in a C. perfringens toxinotype C strain. Although mainly anaerobic bacteria 
like C. perfringens may have reduced transport of aminoglycosides intracellularly, 
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there are also findings that C. perfringens are sensitive to aminoglycosides like 
gentamicin at higher concentration, which indicates that C. perfringens might also 
have acquired additional resistance to aminoglycosides 140,141.  
WGS will be a key tool to tackle C. perfringens AMR, particularly in rapid 
diagnostics, however gold-standard phenotypic MIC tests will also be required to 
clinically determine the antimicrobial susceptibilities and facilitate antibiotic 
management. 
 
1.6 Clinical associations in humans and animals 
C. perfringens has been constantly associated with gut diseases across both animal and 
human hosts (summarised in Table 1.4) as described in this section. 
1.6.1 Animal hosts 
1.6.1.1 Poultry NE 
Poultry NE was first documented in England in 1961 142. Since then, NE has been 
consistently reported in every continent around the globe. Importantly, C. perfringens 
is unequivocally identified as the key aetiological organism of NE in broiler chickens 
143. Global financial impact of NE is significant, with an estimated economic loss of 6 
billion US$ in 2015, projecting profit loss per bird at > US$0.062 144. 
Classic NE pathologies are characterised by gaseous lesions and mucosa necrosis in 
gas-filled distended small intestine, however, these can also involve kidney and liver 
as secondary infection sites 145. Proposed key biological factors that contribute to NE 
are hydrolytic enzymes (e.g. collagenase) and toxin production (traditionally 
understood as PLC, and more recently NetB and TpeL, both are pore-forming toxins, 
were linked to the onset of NE) 146,147. Other NE-predisposing factors include: a high-
protein diet that favours the growth of C. perfringens, and environmental stress (e.g. 
high stocking density), which alters gut microbiota/host immunity that eventually 
increases risk of infection 148. For a more detailed introduction to poultry NE see 
section 5.2. 
 














Distended colon; mucosal 
necrosis 
 
Type A/ CPB2, 
PFO 
87,149 










Type A, C, G/ 
CPB, NetB, TpeL 
150 
Pig Swine enterocolitis 1-7 days old 
neonatal 
piglets 
Severe diarrhoea, necrotic 
mucosa, villus atrophy 
 
Type A, C/CPB2 151 
Dog Canine 
gastroenteritis 













haemorrhagic and necrotic 
intestines 
 
Type A, F/ CPE, 
CPB2, NetE, NetF 
& NetG 
102 





8-14h after food ingestion: 
intestinal cramp, watery 
diarrhoea without vomiting 
(self-limiting: 12-24h) 
 










Abdominal pain and 
diarrhoea (prolonged 
duration >3 days to several 
weeks), often accompanied 
by blood in the faeces. 







Intestinal gangrene (small 
intestine as key infection 
site) 
 










(gas cysts formation); 
intestinal necrosis 
Type A/ CPB2 8,9 
Table 1.4: C. perfringens-associated intestinal diseases in both animals and humans 
Table reproduced from Kiu and Hall (2018) under the Creative Commons BY licence 1. 
 
1.6.1.2  Equine Acute Necrotising Enterocolitis  
Acute necrotising enterocolitis (ANEC) in foals/horses (caused by C. perfringens) is 
a severe intestinal disease that resembles the classic clinical signs of C. perfringens-
infections; rapid disease development and necrotic intestines (mainly the colon) 154. 
ANEC symptoms are characterised by bloody diarrhoea, followed by a haemorrhagic 
and necrotic gut 155. Type F C. perfringens strains (previously type A) harbouring both 
CPE and CPB2 are often associated with this deadly condition 154. More recently, 
NetE, NetF and NetG toxins (pore-forming toxins) were proposed to underlie the 
pathogenesis of foal NEC 40.  
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1.6.1.3 Swine enterocolitis  
C. perfringens type A strains (also less frequently, CPE-harbouring type F strains) are 
widely considered as the invasive agent of non-haemorrhagic enterocolitis in piglets, 
although the actual pathogenesis remains undefined. Similar to other C. perfringens-
intestinal infection, this disease commonly affects one-week-old piglets, suspected to 
inherit (i.e. via vertical transmission during birth) the bacterium from the microbiota 
of mother sows 156. Symptoms involve severe diarrhoea (non-haemorrhagic), 
accompanied by necrotic mucosa and atrophy of intestinal villi. CPB2 was initially 
believed to drive the development of this disease (backed by epidemiological studies 
in 1990s), and as such was used as a diagnostic biomarker, although this has become 
controversial in recent years 88. Type C strains that carry CPB are associated with 
haemorrhagic enterocolitis in piglets and largely affect 1 to 4 days old neonates 156. In 
contrast to type A-infection (to a lesser degree, type F-infection), type C-infection is 
characterised by haemorrhagic enterocolitis, which is proposed to be driven by the 
presence of type C strains and low trypsin secretion (trypsin can inactivate CPB) in 
the immature host gut 157. 
 
1.6.2 Human hosts 
1.6.2.1 Darmbrand 
Darmbrand, which literally means ‘burning (fire) bowels’ in German, was used to 
describe a particular type of necrotic inflammatory gut disease (also known as enteritis 
necroticans, EN) associated with C. perfringens, that occurred epidemically post-
second World War (1944-1949) in north-west Germany 158.  Darmbrand causative 
strains were later classified as type C strains that carry CPB, and these strains are 
highly resistant to heat 159. Many of these type C strains also harbour CPE, which has 
been shown to act synergistically with CPB in an intestinal loop model and therefore 
CPE was suggested to play a role in some cases of EN 82. Notably, the heat-resistance 
of this strain might be attributed to the production of a small acid-soluble protein 
(Ssp4) that could potentially play a central role in dissemination of C. perfringens 
strains 60. Darmbrand was believed to be facilitated by poor post-war sanitary 
(bacterial contamination), and malnutrition (protein-malnourished) conditions, as this 
disease disappeared within a few years after its first recognition 160. 
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1.6.2.2 Pigbel 
Enteritis necroticans (EN), or commonly known as pig-bel in the highlands of Papua 
New Guinea (PNG), is a form of inflammatory gut disease that was associated with 
pork-feasting activities that took place among PNG Highlanders in outbreaks first 
documented back in 1966 161. The classical description of the symptoms is 
‘spontaneous gangrene of small intestine, without obvious vascular or mechanical 
cause’ which resembles Darmbrand, and occurred particularly in children 162. The 
aetiology of this fatal infection was thought to be large co-consumption of C. 
perfringens type C-contaminated pork (due to poor hygiene), and large amount of 
sweet potatoes which contain trypsin inhibitor (trypsin secreted in the gut could break 
down CPB secreted by C. perfringens) 163. Similar cases of EN were also reported in 
Uganda 164, Indonesia 165, Thailand 166, and Nepal 167. Notably, EN-like cases were 
also reported (rare cases) in developed countries, including USA, in exclusively 
diabetic subjects, who also have attenuated trypsin production 168.  
1.6.2.3 Acute Watery Diarrhoea (FP) 
C. perfringens has been associated with FP since it was first documented in both the 
UK and the USA in the 1940s 169. C. perfringens-type A FP, is ranked the second most 
prevalent bacterial FP in the US, estimated at 1 million cases per annum, after 
Salmonella 170. In the European Union (EU) member countries, C. perfringens-linked 
FP outbreaks were projected at approximately 5 million cases per year (2011) 171. C. 
perfringens-linked foodborne cases are suggested to be under-reported due to its self-
limiting symptoms, thus the statistics published based on laboratory-confirmed cases 
may be lower than the actual numbers, suggesting a higher actual epidemiological 
impact. 
Hallmark symptoms include, rapid appearance within 8-14 hrs after food ingestion, 
intestinal cramp, watery diarrhoea without fever or vomiting 172. Currently, FP C. 
perfringens cases are thought to be caused by CPE (encoded by cpe gene). This 
secreted pore-forming toxin is also demonstrated to disrupt intestinal tight junction 
barriers and initiate disease development 112. For a more detailed description on C. 
perfringens-associated acute watery diarrhoea (or, foodborne diarrhoea), see section 
4.2. 
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1.6.2.4 Non-foodborne diarrhoea  
C. perfringens has also been associated with non-foodborne diarrhoea (a distinct 
disease entity from FP, characterised primarily by more severe symptoms and longer 
duration), which includes antibiotic-associated diarrhoea (AAD), and sporadic 
diarrhoea 173,174. AAD typically occurs in 5–25% of patients after administration of 
broad-spectrum antibiotics 175. Non-foodborne diarrhoea typically affects older adults 
that are >60 years of age (although sporadic diarrhoea is also associated with younger 
age groups) 176. Clinical symptoms are abdominal pain, prolonged diarrhoea (>3 days 
to several weeks), and bloody stools 153,177. Patients suffering from non-foodborne 
diarrhoea, particularly AAD, can become seriously ill due to diarrhoea-induced 
dehydration, and may progress to develop colitis, although full recovery is common 
178. 
Although other pathogenic bacteria including C. difficile (most common AAD 
pathogen; ~25% of cases 179) and S. aureus have also been implicated in AAD, 
enterotoxigenic C. perfringens type F strains (producing CPE) are estimated to be 
responsible for up to 15% of all AAD cases 173,180,181. CPE, produced by C. perfringens 
type F strains (encoded by plasmid-borne cpe gene), has been reported to be the 
aetiological agent for C. perfringens-associated non-foodborne diarrhoea, as 
evidenced by the high prevalence in diarrhoea patients, but not healthy individuals. 
Importantly, type F strains have also been linked to sporadic diarrhoea, although to a 
lesser extent 173. AAD-associated C. perfringens strains are also described to be more 
adherent to Caco-2 intestinal cells, when compared to other FP strains, which is 
attributed to the production of sialidase NanI 182. The spore-forming nature of C. 
perfringens could also potentially contribute to the commonly observed disease 
persistence and relapse 183. Molecular detection of faecal CPE or PCR confirmation of 
cpe gene represents the current clinical diagnostic method for C. perfringens-AAD 
24,184. 
1.6.2.5 Preterm infant NEC 
Preterm-NEC has been clinically linked with C. perfringens since the 1970s, as type 
A C. perfringens were isolated from necrotic tissues in many NEC cases. Notably, it 
was even called ‘gas gangrene of the bowel’ owing to its reflection of the highly 
similar diseased histology with the infamous tissue myonecrosis 74.  
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NEC has ~14% prevalence in preterm infants less than 1000 g birth weight (i.e. 
extremely low birth weight, ELBW), a high mortality of 30% with surgical NEC, and 
overall mortality up to 50%. NEC-related deaths account for 10% of all mortality 
causes in neonatal intensive care unit (NICU) according to a UK-nationwide study 185 , 
and is the most severe and lethal neonatal GI emergency worldwide 186. The additional 
annual cost for treating NEC in preterm infants is conservatively estimated at £13.5 
million in the UK (excluding long-term post-surgical treatment), whilst in the US $1 
billion is estimated to be spent annually by neonatal departments on NEC 187. 
The involvement of bacteria in the pathogenesis of NEC has been strongly implicated 
since the disease was first described 188. Both Klebsiella and C. perfringens have been 
linked to clinical NEC in recent years 8. Most recently, the emergence of two extensive 
preterm infant NEC cohort studies that profiled metagenomic faecal samples, have 
both indicated that C. perfringens is significantly abundant in the infant gut microbiota 
prior to NEC development 8,9. These studies are supported by the substantial number 
of NEC studies (14 studies to date since 1970s, more than any individual bacterial 
agents, as summarised in Table 1.5) that have reported C. perfringens as a potential 
pathogenic agent 189. Thus, C. perfringens appears to be a pathogenic agent of 
microbial-NEC, i.e. C. perfringens-associated NEC, and may link to specific disease 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 1.5: Studies reporting clinical cases of C. perfringens-associated NEC 
Table reproduced from Kiu and Hall (2018) under the Creative Commons BY licence 1. 
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Table 1.5: Studies reporting clinical cases of C. perfringens-associated NEC 
Table reproduced from Kiu and Hall (2018) under the Creative Commons BY licence 1. 
 
 
Continued from previous page 
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Recent advancement of WGS and genomic analyses, particularly those focussing on 
other gut pathogens including C. difficile, Klebsiella pneumoniae and Salmonella 
enterica has proved successful in understanding the pathogenic role of these bacteria 
in disease development and tracking bacterial transmission 200,201. These enteric 
pathogens have all been sequenced extensively with genomic information made public 
on NCBI (National Center for Biotechnology Information) genome database (as of 
November 2018; bracketed digits indicate number of genomes): C. difficile (1404), E. 
coli (13475), K. pneumoniae (6503) and S. enterica (9798). Yet, including two batch-
additions of 30 genomes towards the end of 2016 and >55 genomes in mid-2018, there 
are only 112 publicly available genomes of C. perfringens, highlighting the lack of in-
depth understanding of this pathogen with respect to its genomic information. WGS-
based investigation may allow identification of putative/novel disease-associated 
genotypes and virulence factors, that may facilitate intervention strategies and/or 
therapy development. 
 
1.7 Unanswered questions 
The clinical link between intestinal diseases and C. perfringens is clear and defined, 
however the underlying factors responsible for specific aspects of pathology remains 
uncertain (Table 1.6).  
Deciphering the genes that are involved in the sporulation, germination, enzyme/toxin 
production, oxygen tolerance, AMR and other novel virulence factors could lead to 
more targeted clinical preventions in C. perfringens-associated adult and neonatal 
intestinal diseases, whether it be humans or animals. Important questions may be 
answered utilising WGS and in silico tools, to delve into the genetic makeup of this 
notorious, yet under-studied pathogen. In tandem further in vitro and in vivo studies 
should be carried out to confirm the importance of suspected novel virulence traits, 
i.e. to fulfil Molecular Koch's postulates. 
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What are the key knowledge gaps in understanding C. perfringens as a pathogen, and what are the 
potential approaches to investigate/mitigate the virulence of C. perfringens in clinical diseases? 
Questions Approaches 
• Compared to other pathogens (e.g. C. difficile), 
there is limited WGS data for C. perfringens, 
what is the genomic diversity of this important 
pathogen?  
• Can we use WGS to ‘type’ C. perfringens 
isolates, and can WGS be used in diagnostics 
(including AMR profiling), and to track spread in 
outbreaks settings? 
• C. perfringens causes diverse diseases in a wide 
host range, but what are the microbial virulence 
factors responsible for pathology, and is this 
host/strain specific? 
• What are the host immune cells/ signalling 
cascades involved in C. perfringens-associated 
clearance and/or pathology?  
• C. perfringens can reside as a ‘normal’ member 
of the gut microbiota, what are the external 
factors that may lead to overgrowth and disease? 
• Can C. perfringens be directly linked to NEC 
pathogenesis?  
• What are the therapeutic approaches that could 
be used to prevent C. perfringens infection in 
multi-host species? 
 
• Isolate diverse strains from various 
environments, i.e. from both case and control 
samples 
• Perform comprehensive bioinformatics analyses 
to understand evolution e.g. SNP based 
phylogeny, and investigate variants and spread in 
clinical settings 
• Carry out pan-GWAS/comparative genomics to 
identify/predict specific virulence genes related to 
disease development. 
• Develop/optimise clinical diagnostics from faecal 
samples via e.g. ultra-long read real-time 
sequencing method such as Oxford Nanopore 
• Develop and characterise in vivo infection models 
for different disease types (e.g. NEC and 
gastroenteritis)  
• Pinpoint specific virulence genes involved in 
infection via bacterial transcriptomics (RNAseq) 
and knock-out bacterial strains, to fulfil molecular 
Koch’s postulates. 
• Perform microbiota profiling (e.g. 16S rRNA 
metagenomics or shotgun metagenomics) to 
investigate the impact of C. perfringens to 
microbiota members, and the role of microbiome 
in C. perfringens infections 
• Understand host defence mechanisms using 
immunological approaches, and knock out in vivo 
models  
• Develop therapeutics for C. perfringens infections 
including phage therapy, vaccines, microbiota 
treatment i.e. probiotics  
Table 1.6: Knowledge gaps in understanding C. perfringens and proposed research approaches 
Table reproduced from Kiu and Hall (2018) under the Creative Commons BY licence 1. 
 
These approaches may help establish future platforms for disease prevention strategies 
such as vaccines, phage therapy, microbiota-based therapeutics, or implementation of 
specific antibiotic administration policies. Furthermore, understanding the genomes 
will potentially enable epidemiological tracking (as is taking place for other 
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pathogenic bacteria), allowing us to pinpoint the origin and route of spread of isolates 
in the hospital settings, which is vital within clinical contexts.  
 
1.8 Hypotheses 
1.8.1 Overarching hypothesis 
C. perfringens plays a causative role in intestinal diseases, including preterm-NEC, 
foodborne diarrhoea and poultry-NE, via an array of toxin and accessory virulence 
genes, which are widely disseminated via clonal expansion. 
1.8.2 Study-specific hypotheses 
Chapter 3 - Specific nosocomial virulent genotypes of C. perfringens are linked to 
preterm-NEC disease progression 
Chapter 4 - Specific epidemic strains of C. perfringens are responsible for 
gastrointestinal-associated outbreaks 
Chapter 5 - Broiler caecal contents exhibit microbiome signatures for poultry NE, 
and specific genotypes of chicken-associated C. perfringens are linked with poultry 
NE 
Chapter 6 - C. perfringens is a genetically diverse, zoonotic and widely-disseminated 
pathogen 
Chapter 7 - C. perfringens isolates exhibit strain-specific virulence properties, and 
certain disease-linked strains are ‘fitter’ than other non-pathogenic strains 
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1.9 Primary research aims 
This research had 5 primary research aims: 
1. To isolate and sequence (WGS) gut-associated C. perfringens from clinical 
samples, cohorts including preterm infants, FP patients, care-home non-
foodborne diarrhoea patients and broiler chickens. 
2. To genotype C. perfringens: using bioinformatics to determine full virulence 
profiles and genetic variations of C. perfringens isolates, and link disease 
outcomes with pathogenic genotypes 
3. To determine genomic epidemiological spread of disease-associated C. 
perfringens genotypes and understand global phylogenetics of C. perfringens. 
4. To phenotype C. perfringens virulence traits and characterise C. perfringens 
pathogenesis using in vitro models for the selection of phenotypically ‘hyper-
virulent’ strains to be employed in animal models. 
5. To set up and characterise a novel oral-challenged mouse model of C. 
perfringens intestinal infections. 
 
1.10 Structure of the thesis 
The thesis is organised into 9 chapters. 
Chapter 1 is an introductory chapter that presents a comprehensive literature review 
on the research background and summarises the hypotheses and aims of the thesis. 
Chapter 2 comprises the details of materials and research methods, including various 
bioinformatics approaches used in the studies. 
Chapter 3 presents a study on the genomic virulence and epidemiology of preterm-
associated C. perfringens. This chapter provides insights into the full virulence 
profiles and pangenome of hospital-linked C. perfringens, and a novel understanding 
of the nosocomial spread and persistence of C. perfringens in a multicentre neonatal 
study. 
Chapter 4 describes phylogenomic investigation on food-poisoning and care home-
associated C. perfringens isolates across England and Wales. This study determines 
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specific virulence plasmid disseminations and identified potential clonal expansion of 
enterotoxigenic C. perfringens strains. 
Chapter 5 contains a microbiome study on chicken-associated caecum contents and a 
genomic investigation on NE-related isolates. The findings identify specific NE-
diagnostic microbiome marker and combinatory role of NE-linked virulence genes. 
Chapter 6 is a population genomic study on the complete set of isolates available to 
date including public genomes and newly sequenced genomes. This study presents the 
pangenome of C. perfringens, and identifies potential zoonotic relationship, 
genetically distinct lineages and intercontinental disseminations. 
Chapter 7 describes the phenotypical characterisation of a sub-set of preterm-
associated C. perfringens isolates. This chapter identifies hyper-virulent C. 
perfringens strains that were selected for use in a novel mouse infection model study 
described in Chapter 8. 
Chapter 8 presents a novel oral-challenge C. perfringens infection model that reveals 
unexpected immune-mediated microscopic pathologies. This reproducible infection 
model has the potential for use in future therapy development against C. perfringens 
intestinal infections. 
Chapter 9 is the final discussion chapter, summarises the impact of the new findings, 
future perspectives and conclusions of the thesis. 
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Chapter 2 Materials and methods 
 
2.1 Materials 
2.1.1 Reagents, kits and equipment 
Primary reagents, kits, equipment and tools used/mentioned in this chapter are listed 
in Table 2.1 to Table 2.3. 
 
Materials Components and conditions Supplier 
Phosphate Buffer Saline (PBS) PBS, pH7.2 Sigma-Aldrich, Dorset, UK 
25% sucrose in TE buffer TE buffer: 10mM Tris and 1mM 
EDTA pH8.0 
Sigma-Aldrich, Dorset, UK 
Lysozyme Lysozyme re-suspended in 
0.25M Tris pH8.0 
Roche, West Sussex, UK 
Proteinase K ~15-20mg/ml proteinase K Roche, West Sussex, UK 
RNase A 10mg/ml RNase A (boiled before 
use) 
Roche, West Sussex, UK 
EDTA 0.5M EDTA, pH8.0 (pH 
adjusted) 
Sigma-Aldrich, Dorset, UK 
Sarkosyl NL30 30% Sarkosyl Sigma-Aldrich, Dorset, UK 
Phenol-Chloroform-Isoamyl 
alcohol (IAA) solution 
25:24:1 (Phenol-Chloroform-
Isoamyl Alcohol) 
Sigma-Aldrich, Dorset, UK 
E buffer 10mM Tris pH8.0 Sigma-Aldrich, Dorset, UK 
Chloroform:IAA  24:1 Chloroform:IAA Sigma-Aldrich, Dorset, UK 
Ethanol Absolute ethanol (>99.5%) Sigma-Aldrich, Dorset, UK 
Phase-lock gel tubes for DNA 
extraction using Phenol-
Chloroform 
MaXtract High Density tubes Qiagen, Manchester, UK 
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Equipment Model Supplier 
Anaerobic chamber Ruskinn Concept Plus Baker Ruskinn, Bridgend, UK 
Autoclave (portable) Classic 2100 Standard (9-litre) Prestige Medical, Blackburn, 
UK 
Centrifuge Eppendorf 5810R Eppendorf, Stevenage, UK 
Microscope (fluorescence and 
brightfield) 
Carl Zeiss Axio Imager 2 Carl Zeiss, Cambridge, UK 
Gel electrophoresis unit ENDURO Gel XL Labnet, New Jersey, USA 
Homogeniser for DNA 
extraction samples 
FastPrep-24 MP Biomedicals, Santa Ana, 
USA 
Incubator Cooling incubator Binder, Tuttlingen, Germnay 
Micro-centrifuge Prism Labnet, New Jersey, USA 
Micro-centrifuge (refrigerated) Prism R Labnet, New Jersey, USA 
Microplate reader FLUOstar Omega BMG Labtech, Ortenberg, 
Germany 
Microplate reader (anaerobic 
condition) 
Tecan infinite F50 Tecan, Männedorf, Switzerland 
Nanodrop spectrophotometer Nanodrop 2000 Thermo Fisher Scientific, 
Loughborough, UK 
PCR station UV HEPA PCR Systems UVP, Upland, USA 
PCR thermal cycler Applied Biosystems Veriti 96-
well thermal cycler 
Thermo Fisher Scientific, 
Loughborough, UK 
pH meter Martini MI 151 Rocky Mount, USA 
Pressure transducer (USB 
connection) 
PX409-015GUSBH Omega Engineering Limited, 
Manchester, UK 
Qubit meter Qubit 2.0 Thermo Fisher Scientific, 
Loughborough, UK 
Safety cabinet Walker Class II MSC Walker Safety Cabinets, 
Glossop, UK 
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Item Supplier 
Agar  Oxoid (Thermo Fisher Scientific), 
Loughborough, UK 
Agarose for Gel Electrophoresis Sigma-Aldrich, Dorset, UK 
Brain Heart Infusion (BHI) Oxoid (Thermo Fisher Scientific), 
Loughborough, UK 
Caspase-Glo 3/7 Assay Promega, Southampton, UK 
CytoTox-One Homogeneous Membrane Integrity Assay Promega, Southampton, UK 
D-cycloserine Oxoid (Thermo Fisher Scientific), 
Loughborough, UK 
DNA ladder (1kb and 100bp) Promega, Southampton, UK 
DNA lo-bind tubes (1.5 and 2.0ml) Eppendorf, Stevenage, UK 
DPX mountant for histology Sigma-Aldrich, Dorset, UK 
Egg yolk emulsion Oxoid (Thermo Fisher Scientific), 
Loughborough, UK 
FastDNA SPIN kit for Soil MP Biomedicals, Santa Ana, USA 
Feeding tube 20G Instech, Plymouth, USA 
Inoculation sterile loops (disposable) Microspec, Wirral, UK 
KAPA 2G Robust PCR kit KAPA Biosystems, Wilmington, USA 
Lead acetate test strips (detection of H2S) Sigma-Aldrich, Dorset, UK 
Molecular water (water for molecular biology) Merck Millipore, Billerica, USA 
Perfringens Agar Base Oxoid (Thermo Fisher Scientific), 
Loughborough, UK 
QIAGEN Plasmid Midi Kit Qiagen, Manchester, UK 
QIAquick PCR Purification Kit Qiagen, Manchester, UK 
Qubit dsDNA BR assay Invitrogen (Thermo Fisher Scientific), 
Loughborough, UK 
Reinforced Clostridial Medium (RCM) Oxoid (Thermo Fisher Scientific), 
Loughborough, UK 
Spreader Microspec, Wirral, UK 
Staurosporine Abcam, Cambridge, UK 
Table 2.3: Materials and kits 
 
2.1.2 Ethics approval and consent for participation in human studies 
2.1.2.1 BAMBI study 
BAMBI study (Baby Associated MicroBiota of the Intestine study) carried out at 
Norfolk and Norwich University Hospital (NNUH) was approved by the University 
of East Anglia (UEA) Faculty of Medical and Health Sciences (FMH) Ethics 
Committee. Sample collection followed the protocols outlined by NRES approved 
UEA Biorepository (Licence no.: 11208). Written consent was given by the parents 
for their infants for participation in this study 202. 
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2.1.2.2 NEOM study 
NEOM study (The Neonatal Microbiota Study) was approved by West London 
Research Ethics Committee Two (ClinicalTrials.gov identifier NCT01102738; 
Licence no.: 10/H0711/39). Parents gave written informed consent for their infant to 
participate in the study 8. 
 
2.1.3 Faecal samples, bacterial isolates and isolate DNA extracts 
Samples (faecal samples/isolate/isolate DNA) were obtained through collaborations 
with various organisations as described (Table 2.4).  
 
Collaborators Organisations Sample cohort/sample 
type 
Location 
Dr Paul Clarke NNUH Preterm infants (BAMBI)/ 
faecal samples 
Norwich, UK 
Dr Gusztav Belteki Rosie Hospital Preterm infants (BAMBI)/ 
faecal samples 
Cambridge, UK 
Prof J Simon Kroll 
Dr Alex Shaw       
Dr Kathleen Sim 
Imperial College 
London 
Preterm infants in SMH and 
QCCH (NEOM and two-year 
NEOM)/bacterial isolates 
London, UK 
Dr Corinne Amar Public Health 
England (PHE) 
Outbreak patients in 
England and Wales/isolate 
DNA 
Colindale, UK 





Dr Ron Dixon     
Dr Joseph Brown 
Lincoln University Poultry and farm/bacterial 
isolates 
Lincoln, UK 
Prof Paul O’Toole University College 
Cork 




Dr Alan Walker University of 
Aberdeen 
Healthy adults/isolate DNA Aberdeen, UK 
Table 2.4: Brief description of sample sources and relevant collaborators 
NNUH: Norfolk and Norwich University Hospital; QCCH: Queen Charlotte’s and Chelsea Hospital; SMH: 
St Mary’s Hospital. 
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2.1.3.1 Faecal sample collection in BAMBI study 
Faecal samples were routinely collected from infant nappies in the NICUs into sterile 
stool containers and stored at 4 °C and stored at -80 °C within 5 days. 
2.1.3.2 Faecal sample collection in NEOM study 
Samples were collected by nursing staff from nappies into sterile Eppendorf tubes and 
stored in a -20 °C freezer on the NICU within 2h of collection and stored at -80 °C 
within 5 days. 
 
2.2 DNA extraction 
2.2.1 Using FastDNA SPIN kit 
This method was used on bacterial/faecal samples for 16S rRNA metataxonomics, 16S 
preliminary identification and qPCR bacterial load estimation.  
Briefly, DNA extraction (~100mg for faecal sample or ~100μl for bacterial sample) 
was performed using FastDNA SPIN kit for Soil, according to the protocol described 
by the manufacturers, with a modification to the homogenisation of samples - 3 min 
at speed setting of 6.0, using FastPrep-24 instrument. Samples were suspended in 1ml 
of Sodium Phosphate Buffer. DNA extraction protocol was then performed 
accordingly, with a final elution volume of 65µl. Extracted DNA was stored in sterile 
DNase-free and RNase-free DNA lo-bind tubes at -20°C after quantification until 
further analysis. 
 
2.2.2 Phenol-Chloroform extraction 
This optimised 2-day protocol was used to generate ultra-high quality pure bacterial 
genomic DNA for WGS, originally obtained from Dr Derek Pickard (Wellcome Trust 
Sanger Institute; WTSI) 202. 
2.2.2.1 First-day protocol 
10ml pure cultures in Brain Heart Infusion (BHI) were harvested (5-7h) for phenol-
chloroform DNA extraction (washed with PBS). Briefly, bacterial pellets were re-
suspended in 2ml 25% sucrose in 10mM Tris and 1mM EDTA at pH 8.0. Cells were 
lysed using 50μl 100mg/ml lysozyme. 100μl 20mg/ml Proteinase K, 30μl 10mg/ml 
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RNase A, 400μl 0.5M EDTA and 250μl 10% Sarkosyl NL30 were added into the lysed 
bacterial suspension after 1h-incubation at 37°C. This is followed by 60-120 mins 
incubation on ice (until complete lysis is observed) and 50°C overnight water bath.  
2.2.2.2 Second-day protocol 
Two to three rounds of equal volume (5ml each) phenol-chloroform-isoamyl alcohol 
extraction using 15ml gel-lock tubes to separate DNA from bacterial waste after 
reconstituting the overnight samples in E buffer to 5ml. Chloroform-isoamyl alcohol 
extraction was then performed to remove residual phenol, followed by ethanol 
precipitation and 10ml 70% ethanol wash by centrifugation (at least twice). Air-dried 
DNA pellets were finally re-suspended in 200-300μl of E buffer and stored in -20°C 
after quantitation until further analysis. Refer to Table 2.1 for details of materials and 
conditions. This adapted and optimised extraction protocol was originally provided by 
Dr Derek Pickard (WTSI). 
 
2.2.3 Pre-sequencing analysis of genomic DNA quality and quantity 
DNA quality was assessed by Nanodrop spectrophotometer (acceptable thresholds: 
260/280 ratio ~1.8-2.0, 260/230 ratio > 1.8) and DNA concentration was quantified 
using Qubit 2.0 dsDNA BR assay kit. 
 
2.2.4 Plasmid DNA extraction 
Plasmid DNA was extracted using QIAGEN Plasmid Mini/Midi kit and performed 
according to manufacturer’s instructions. 
 
2.3 DNA Sequencing 
2.3.1 Sanger Sequencing on full-length 16S rRNA amplicons (bacteria)  
2.3.1.1 PCR primers, conditions, product confirmation and purification 
Full-length 16S PCR was performed as a culture-independent method to identify 
bacterial genera. Briefly, KAPA2G Robust PCR reagents were used in preparing the 
PCR master mix. DNase- and RNase-free sterile water was used in preparing dilution 
and master mix for PCR. 5μl of each diluted bacterial DNA extract (optimal DNA 
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concentration for PCR: 10-30 ng/µl) was amplified with PCR master mix comprising: 
10 µM primers (1µl/sample)203, 10mM of each dNTP mix (1 µl/sample), GC buffer 
with MgCl2 (10µl/sample), Millipore H2O (31.6 µl/sample) and Kapa2G Robust DNA 
polymerase (0.4µl/sample), master mix was prepared according to careful calculation. 
Table 2.5: Sequences of universal primers used for full-length 16S rRNA PCR 
Primer abbreviations: f, forward; r, reverse; D, distal; P, proximal 203.  
 
PCR Step Temperature Duration Cycles 
Initial denaturation 94 5 min 1 
Denaturation 94 1 min 35 
Annealing 43 1 
Extension 72 2 min 
Final extension 72 2 min 1 
Table 2.6: PCR amplification conditions for full-length 16S rRNA PCR 
 
PCR was performed in thermal cycler according to the conditions detailed in Table 
2.6. PCR products (~1,500bp) were separated on 1% agarose gel and DNA bands were 
stained with ethidium bromide for x-ray visualisation, negative control (molecular 
water) was included to detect any possible contamination of DNA. 1kb ladder was 
used to estimate the size of the PCR amplicon bands. Primers and reagents were 
removed from the PCR products using a QIAquick PCR purification kit according to 
manufacturers’ protocol before performing Sanger Sequencing. 
2.3.1.2 Sequencing  
PCR amplicons were then prepared according to sample submission guide (Eurofins, 
Luxembourg) for nucleotide reading service at Eurofins (Sanger sequencing method). 
Most final PCR products ranged between 900-1000bp (after quality trimming). 
Illumina short-read sequencing 
2.3.1.3 WGS 
This work was performed at the WTSI (Hinxton, UK) facilitated by Dr Derek Pickard 
and in collaboration with Prof Gordon Dougan. DNA libraries were subjected to WGS 
Primers Sequences: 5’ -3’ 
fD1 AGA GTT TGA TCC TGG CTC AG 
fD2 AGA GTT TGA TCA TGG CTC AG 
rP1 ACG GTT ACC TTG TTA CGA CTT 
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pipeline on Illumina HiSeq 2500 platform to generate 101bp/125bp paired-end reads 
as described previously 34. The sequencing library preparation process was detailed in 
Table 2.7 and Table 2.8. 
Step Step description Instruments/ details 
1 Quantitation of DNA Using Biotium Accuclear Ultra high sensitivity 
dsDNA Quantitative kit 
2 DNA shearing mechanical shearing using Covaris LE220 
instrument 
3 Purification of sheared samples Agencourt AMPure XP SPRI beads on Agilent 
Bravo WS 
4 Library construction (end-repair, 
A-tailing and ligation) 
using ‘NEB Ultra II custom kit’ on an Agilent Bravo 
WS automation system 
5 PCR using KapaHiFi Hot start mix and IDT 96 iPCR tag 
barcodes on Agilent Bravo WS automation system 
6 Post-PCR purification Agencourt AMPure XP SPRI beads on Beckman 
BioMek NX96 liquid handling platform 
7 Quantitation of libraries Biotium Accuclear Ultra high sensitivity dsDNA 
Quantitative kit 
8 Pooling libraries Pool in equimolar amounts on a Beckman BioMek 
NX-8 liquid handling platform 
9 Normalisation libraries normalised to 2.8nM 
10 Loading to sequencer loading on requested Illumina sequencing platform 
Table 2.7: WGS library process with details 
 
PCR Step Temperature Duration Cycles 
Initial denaturation 95 5 min 1 
Denaturation 98 30 s 5 
Annealing 65 30 s 
Extension 72 1 min 
Final extension 72 10 min 1 
Table 2.8: PCR conditions for WGS libraries 
 
2.3.1.4 Metataxonomics using 16S rRNA 
This work was performed at the WTSI (Hinxton, UK). Library preparation was carried 
out by Charlotte Leclaire. Bacterial DNA concentration was quantified using Qubit 
and normalised to 5 ng/μl for all samples. Extracted DNA was used as a template for 
PCR amplification (Table 2.9) of the V1+V2 regions of the 16S rRNA gene as detailed 
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in Table 2.10 for the primer sequences. 16S rRNA gene libraries were sequenced on 
the Illumina MiSeq platform with 250bp paired-end reads.  
 
PCR Step Temperature Duration Cycles 
Initial denaturation 94 3 min 1 
Denaturation 94 45 s 25 
Annealing 55 15 s 
Extension 72 30 s 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2.10: Primer sequences for amplifying V1+V2 regions of 16S rRNA gene 
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2.3.2 454 pyrosequencing 
This work was performed by Dr Kathleen Sim and Dr Alex Shaw at Imperial College 
London. The V3-V5 regions of the 16S rRNA gene were amplified using forward 
primer 357F and reverse primer 926Rb (Table 2.11) as detailed in section 2.7 in Sim 
(2015) 12. Briefly, 16S rRNA amplicons were sequenced by Imperial College London 
in-house 454 Life Sciences GS Junior Titanium machine, or the Department of 
Biochemistry of University of Cambridge, using 454 Life Sciences GS FLX Titanium 
machine following the Roche Amplicon Lib-L protocol. The workflow and protocols 
of the 454 sequencing are detailed on p.64 in Sim (2015) 12. 
 
 Primers Sequences: 5’ – 3’ 
357F CTATCCCCTGTGTGCCTTGGCAGTCTCAGCCTACGGGAGGC AGCAG 
926Rb CCATCTCATCCCTGCGTGTCTCCGACTCAGNNNNNNNNNNNN CCGTCAATTY 
MTTTRAGT 
Table 2.11: Sequences of primers used in 454 pyrosequencing 
This information is taken from Sim (2015) 204. 
 
2.4 Bioinformatics 
Bioinformatic tools/pipelines applied in this thesis are described in this section. Most 
of the written scripts developed for use during my PhD can be found in my GitHub 
repositories1. 
2.4.1 Computing environment and resources 
All bioinformatics command-line computing tools were run on Norwich Bioscience 
Institute (NBI) High-Performing Computing Cluster (HPC) on CentOS Linux 
operating system. Relevant tool and dependencies (modules required by another tool) 
are loaded (using command source) on to the shell environment before usage of a 
software/tool. SLURM workload manager2 (v16.05.8) was routinely used to submit 
computational jobs to HPC. 
 
                                                 
1 https://github.com/raymondkiu/informatics-tools 
2 https://slurm.schedmd.com/ 
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2.4.2 16S rRNA full-length amplicon sequence analysis 
Primarily for bacterial species identification, 16S rRNA nucleotide sequences for 
bacterial isolates were mapped with NCBI nucleotide database (16S ribosomal RNA 
sequences: Archaea and Bacteria) using NCBI BLASTN, reference bacterial species 
with highest identity hits/similarity scores (sequence identity must be ≥97% for 
species level threshold) were assigned for preliminary identification3. 
 
2.4.3 16S rRNA microbiome analysis via OTU (Operational Taxonomic 
Unit) assignment 
Software ‘Quantitative Insights Into Microbial Ecology’ (QIIME) v1.9.1 was used for 
analysing the 16S amplicon data (454 pyrosequencing and Illumina paired-end 
sequencing data) 205.  
2.4.3.1 454 long-read data 
454 pyrosequencing Standard Flowgram Format (SFF) files were converted to FASTA 
files (process_sff.py) followed by demultiplexing and quality-filtering step at quality 
score 50 (split_libraries.py).  
2.4.3.2 Illumina paired-end data 
FASTQ paired-end reads were assembled/merged using PEAR 206, at Phred quality 
score 33 and followed by quality filtering: --phred_quality_threshold 19 and --
phred_offset 33 (split_libraries_fastq.py).  
2.4.3.3 OTU assignment and clustering 
Chimeras were removed (identify_chimeric_seqs.py) using USEARCH v6.1 207 prior 
to open-reference OTU assignment (pick_open_reference_otus.py) to representative 
clustered sequences based on SILVA rRNA database (SSU_Ref_128; released in 
September 2016) 208 using UCLUST clustering algorithm at 97% sequence identity 207. 
Taxa read counts <5 and samples with <100 total reads were omitted for clarity of data 
representation. BIOM files were subsequently generated for data visualisation in 
software MEGAN v6.10.4 209. Reads were normalised as Relative Abundance (%) 
before visualising using R programming environment 210. 
                                                 
3 http://blast.ncbi.nlm.nih.gov/ 
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2.4.4 Bacterial whole genome de novo assembly 
2.4.4.1 Short-read genome assembly 
An optimised and standardised approach was employed to generate de novo assembly 
for data consistency. Bacterial genomes sequenced at WTSI were assembled using the 
presented pipeline (Figure 2.1) 211. Briefly, de novo assemblers Velvet v1.2.10 or 
SPAdes v3.8.1 are used to assemble short-read sequencing data, initial assembly was 
further improved by Sanger assembly improvement pipeline v1.7.0 which comprises 
SSPACE as scaffolder to scaffold contigs and GapFiller to fill up gaps in between 
contigs by picking up unmapped reads from FASTQ reads (Figure 2.1) 211-214.  
 
Figure 2.1: De novo genome assembly workflow used for short-read sequencing data 
 
2.4.4.2 Long-read genome assembly 
Canu v1.5, successor of long-read sequence-assembler Celera Assembler, was used to 
assemble long-read sequencing data in this study 215. Canu assembly mainly carries 
out 4 major tasks: noise detection, sequence correction, sequence trimming and 
sequence assembly. Workflow was demonstrated in Figure 2.2. Standard workflow 
was carried out to obtain long-read assembly for analysis. 
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Figure 2.2: De novo genome assembly workflow used for long-read sequencing 
 
2.4.4.3 Genome contamination checks 
Genome assemblies were checked for potential sequence contamination prior to 
downstream analysis. Genome contamination checks (based on assemblies) were 
firstly performed using Kraken (based on MiniKraken database 216) to detect 
sequences of other bacterial species. Any genome assemblies found to be 
contaminated with >5% of other bacterial species were excluded from analyses. 
Genomes were subjected to Average Nucleotide Identity (ANI) method (using 
mummer-based pyani 4 ) to ensure genome quality. ANI >95% (mapped against 
reference genome or pair-wise comparison) confirms species assignment 217. 
Sequences with <95% ANI were excluded from analysis. Assemblies >500 contigs 
(considered as highly fragmented assemblies) were also excluded from studies. 
 
2.4.5 Genome annotation 
Prokka v1.13 was used for genome annotation 218. Specifically, an in-house genus-
specific database (genus Clostridium) was generated (Table 2.12) and compiled using 
CD-HIT v4.6.6 as BLAST database based on NCBI Reference Sequence Database 
(RefSeq) high quality genome annotations including 35 Clostridium species. This 
                                                 
4 https://github.com/widdowquinn/pyani 
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genus-specific database was used by --usegenus command with priority over default 
protein databases. 
No RefSeq Genome Strain NCBI Accession 
1 C. perfringens 1207_CPER SAMN03197169 
2 C. perfringens ATCC13124 SAMN02604008 
3 C. perfringens B_ATCC3626 SAMN02436295 
4 C. perfringens CBA7123 SAMD00057672 
5 C. perfringens C_JGS1495 SAMN02436294 
6 C. perfringens CP15 SAMN06252080 
7 C. perfringens CPE_F4969 SAMN02436168 
8 C. perfringens D_JGS1721 SAMN02436277 
9 C. perfringens E_JGS1987 SAMN02436167 
10 C. perfringens FORC003 SAMN03140316 
11 C. perfringens FORC025 SAMN04209542 
12 C. perfringens JFP718 SAMN05323879 
13 C. perfringens JFP836 SAMN05323894 
14 C. perfringens JJC SAMN02317206 
15 C. perfringens JP55 SAMN03372134 
16 C. perfringens JP838 SAMN03377063 
17 C. perfringens LLY_N11 SAMN07624709 
18 C. perfringens NCTC8239 SAMN02436239 
19 C. perfringens 13 SAMD00061119 
20 C. perfringens 2789STDY5608889 SAMEA3545297 
21 C. acetobutylicum ATCC824 SAMN02603243 
22 C. baratii  Sullivan SAMN03222823 
23 C. botulinum ATCC3502 SAMEA1705919 
24 C. butyricum KNU-L09 SAMN04293668 
25 C. chauvoei JF4335 SAMEA102059668 
26 C. difficile* 630 SAMEA1705932  
27 C. difficile* BR81 SAMN06286529 
28 C. difficile* E15 SAMEA3138880 
29 C. difficile* M120 SAMEA3138368 
30 C. novyi NT SAMN02603464 
31 C. paraputrificum LH025 SAMEA104287982 
32 C. pasteurianum DSM525 SAMN02990135 
33 C. sordellii# AM370 SAMN04263499 
34 C. tertium LH009 SAMEA104287969 
35 C. tetani E88 SAMN02603289 
Table 2.12: Genomes used to generate Clostridium genus-specific annotation database  
*Recently suggested to be moved to genus Clostridioides 219. #Recently suggested to be classified as 
genus Paeniclostridium 220. 
 
Chapter 2    Materials and methods    68 
 
2.4.6 Pangenome analysis 
Pangenome analysis software Roary v3.12 was run with annotated GFF files (from 
Prokka annotation) as the inputs at BLASTP identity 90% (-i 90) to obtain the 
pangenome statistics (also with -s option, thus paralogs were not split in the gene 
clustering) and core gene alignments (-e -n; via MAFFT v7.305) 221. Core genes were 
defined as genes present in 99% of the genomes (-cd 99; or default setting). Similarly, 
accessory genes were defined as genes not present in 99% of the computed genomes. 
Pangenome statistical plots were generated using R scripts from Roary package and 
visualised in Phandango 222. 
2.4.7 Phylogenetic and SNP analysis 
Core genome trees were constructed based on core gene (genes present in 100% of the 
computed genomes) alignments generated from Roary pipeline by concatenating all 
single-copy core-gene sequences and aligned via MAFFT v7.305 221,223. SNPs within 
core-genome (multi-FASTA alignment format) were extracted using SNP-sites v2.3.3 
224. SNP distances were computed using snp-dists v0.2 based on multi-FASTA 
alignment files 5 . Snippy v4.0 was used for reference-based (read-mapping) SNP 
analysis. FastTree v2.1.9 was used to construct Maximum-likelihood tree using 
generalised time-reversible (GTR) model on 1000 bootstrap replicates 225. Trees were 
visualised, rooted and manually annotated using iTOL v3 226. Phylogenetic clustering 
was assigned via hierBAPS analysis (as described in section 2.10) 227. Binary trees 
were generated based on gene-presence-absence matrix outputs from Roary and 
parsed with in-house Python scripts to construct binary nucleotide alignments. 
Phylogenies were constructed as described.  
2.4.8 Genome-wide sequence search 
Genome-wide screening of genes was performed using BLASTN-based command-
line tool ABRicate v0.56, with 90% identity and 80% coverage minimum cutoffs to 
infer identical genes (best-match approach). Gene sequences of interest were retrieved 
from public databases, primarily NCBI Nucleotide database and UniProt database, to 
build the screening BLASTN database using makeblastdb command. ARIBA v2.8.1 
                                                 
5 https://github.com/tseemann/snp-dists 
6 https://github.com/tseemann/abricate 
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(assembly-based) was also used as a secondary approach to confirm detections of 
genes in raw sequencing FASTQ files 228. 
Databases used for gene screening include: toxin genes (custom, n=22; Table 2.13), 
AMR genes (CARD database v2.0.0, n=2239 229), putative virulence genes including 
collagen binding protein and enterotoxin genes (custom, n=8; Table 2.14), Tcp 
conjugative loci and insertion sequence (IS) elements (custom, n=14; Table 2.15). 
Gene cnaD was recently associated with chicken NE and putatively identified to 
encode collagen binding protein 230. 
 
 Gene name Product Alternative name NCBI Accession 
1 plc/cpa Phospholipase Alpha-toxin D63911.1 
2 cpe Enterotoxin CPE - M98037.1 
3 ccp Clostripain - NC_003366.1 
4 colA Microbial collagenase Kappa-toxin D13791.1 
5 nanI Sialidase NanI - NC_003366.1 
6 nanJ Exo-alpha-sialidase NanJ - NC_003366.1 
7 nanH Neuraminidase nanH - Y00963.1 
8 cpb Beta-toxin - KP064410.1 
9 cpb2 variant 1 Beta-2 toxin variant 1 - AP003515.1 
10 cpb2 variant 2 Beta-2 toxin variant 2 - CP009558.1 
11 pfo Perfringolysin O Theta-toxin BA000016.3 
12 nagH Hyaluronidase NagH Mu-toxin NC_003366.1 
13 etx Epsilon-toxin - M95206.1 
14 iap Iota-toxin component Ia - NC_015712.1 
15 ibp Iota-toxin component Ib - NC_015712.1 
16 netB Pore-forming toxin NetB - FJ189503.1 
17 becA Binary enterotoxin component a - NC_023918.1 
18 becB Binary enterotoxin component b - NC_023918.1 
19 tpeL Peptidase - EU848493.1 
20 cpd Delta-toxin - EU652406.1 
21 netF NE Toxin NetF - KJ606986 
22 lam Lambda toxin - AJ439340 
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 Gene name Product NCBI Accession 
1 cna  Collagen adhesion protein BAB62495.1 
2 cnaA Collagen adhesion protein A ALJ54440.1 
3 cnaC Collagen adhesion protein C DQ366035.1 
4 cnaD Collagen adhesion protein D CP000246.1 
5 entA Putative enterotoxin A ABG85708.1 
6 entB Putative enterotoxin B ABG85644.1 
7 entC Putative enterotoxin C BAB80858.1 
8 entD Putative enterotoxin D ABG83751.1 
Table 2.14: Accessions of additional virulence-associated genes 
 
 Gene name Product Protein function NCBI Accession 
1 tcpA TcpA Conjugative locus ABF47308.1 
2 tcpB TcpB Conjugative locus ABF47311.1 
3 tcpC TcpC Conjugative locus ABF47313.1 
4 tcpD TcpD Conjugative locus ABF47314.1 
5 tcpE TcpE Conjugative locus ABF47315.1 
6 tcpF TcpF Conjugative locus ABF47316.1 
7 tcpG TcpG Conjugative locus ABF47318.1 
8 tcpH TcpH Conjugative locus ABF47319.1 
9 tcpI TcpI Conjugative locus ABF47320.1 
10 tcpJ TcpJ Conjugative locus ABF47321.1 
11 IS1470 IS1470 transposase Insertion sequence element ABG85734.1 
12 IS1470-like IS1470-like transposase Insertion sequence element BAE79022.1 
13 IS1469 IS1469 transposase Insertion sequence element YP_473486.1 
14 IS1151 IS1151 transposase Insertion sequence element YP_473484.1 
Table 2.15: Accessions of conjugative loci and insertion sequence elements 
 
2.4.9 Bacterial pan-GWAS: gene-trait association analysis 
Scoary v1.6 was used to infer specific gene-trait statistical association based on the 
Roary output gene-presence-absence matrix 231. Script scoary.py was run with default 
parameters with an additional 10 permutations. 
2.4.10 Plasmid in silico analysis 
Sequencing reads were utilised for computational plasmid prediction via software 
PlasmidSeeker v1.0 232. Plasmid prediction was based on 8,514 plasmid sequences 
available on NCBI RefSeq databases (including 35 C. perfringens plasmids, 
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downloaded in April 2017; Table 2.16) 7. All sequencing reads (single FASTQ) were 
searched for matching k-mers at k-mer length of 20 and screening cutoff at P-value 
0.05 based on FASTQ reads. Top predicted plasmids appeared in each ‘cluster’ (with 
highest k-mer identity; k-mer percentage 80% is the minimum cutoff) was extracted 
as predicted plasmids.  
Potential plasmid sequences from high-sequencing-coverage assemblies 
(unassembled single contig) were extracted using in-house Perl scripts. Plasmid 
annotation (GenBank format) was generated via Prokka v1.13 and Artemis v17 233. 
Plasmid comparison and visualisation were performed using Python tool Easyfig 
v2.2.2 234. 
 
No Plasmid  No Plasmid 
1 pCP-TS1 19 pJFP838C 
2 pCP8533etx 20 pJFP838A 
3 pCP-OS1 21 pCP13 DNA 
4 pCPPB-1 22 pCPF4969 
5 pCW3 23 pJIR3844 
6 pIP404 24 pJIR3843 
7 pJIR3536 25 pJIR3537 
8 pCPF5603 26 pCpb2-CP1 
9 pBCNF5603 27 pNetB-NE10 
10 pCP8533S12 28 pDel1_1 
11 pFORC3 29 pDel1_2 
12 pJFP55F 30 pDle1_3 
13 pJFP55G 31 pDel1_4 
14 pJFP55H 32 pCP15_1 
15 pJFP55J 33 pCP15_2 
16 pJFP55K 34 pCP15_3 
17 pJFP838E 35 pCP15_4 
18 pJFP838D   
Table 2.16: Plasmid sequences of C. perfringens included in the PlasmidSeeker database 
 
                                                 
7 http://bioinfo.ut.ee/plasmidseeker/ 
Chapter 2    Materials and methods    72 
 
2.4.11 Bacteriophage in silico detection 
Web tool PHASTER is utilised for detection of bacteriophage species existing in 
bacterial genomes. Annotated GenBank files were submitted to the PHASTER web 
server (either manual submission or via API server)8 and annotated data were parsed 
with in-house scripts, visualised with heatmaps generated within R programming 
environment. The detection of phage species is based on the PHASTER scoring 
method and classification as follows: (1) intact: >90; (2) questionable: 70-90; (3) 
incomplete: <70 235. Prophage with scores >70 will be considered as complete 
prophage, whereas ‘incomplete’ prophage will be specified wherever mentioned. 
Sequences of prophages were extracted by default using PHASTER, manually 
annotated and colour-coded using Prokka v1.13 and Artemis v17 for visualisation in 
EasyFig v2.2.2. Phage-related genes in the pangenome were obtained using string-
search based on ‘phage’, ‘head’, ‘tail’, ‘integrase’, ‘recombinase’, ‘terminase’ and 
‘capsid’. 
2.4.12 CRISPR array mining 
MinCED9 (v0.2.0), a command-line software derived from CRISPR Recognition Tool 
(CRT) 236, was used to perform rapid CRISPR-search in genome assemblies at default 
parameters. Outputs were parsed using BASH text-processing commands to generate 
CRISPR counts for each genome. CRISPR counts were visualized in bar charts 
generated using R package ggplot2 and function geom_bar. 
2.4.13 Pangenome-wide functional annotation 
Functional categories (Clusters of Orthologous Groups [COG] categories) were 
assigned to genes for biological interpretation via eggNOG-mapper v0.99.3 based on 
EggNog database (bacteria) on default parameters 237,238. 
2.4.14 Linear discriminant analysis (LDA) 
LDA was performed using LEfSe (Linear discriminant analysis Effect Size) via 
Galaxy server10. Alpha value for non-parametric Kruskal-Wallis test was set at 0.05 
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and threshold on LDA score at 2.5 for statistical significance. Graph was illustrated 
using the LEfSe plotting module 239. 
2.4.15 Nucleotide sequence accessions 
All genome assemblies were submitted to ENA (European Nucleotide Archive) as in 








NEOM isolate assemblies (Chapter 3) PRJEB25762 ERP107717 185 
PHE isolate assemblies (Chapter 4) PRJEB25764 ERP107719 109 
BAMBI (Chapter 6) and Lincoln (Chapter 5) PRJEB25766 ERP107721 83 
NCTC long-read assemblies (Chapter 6) PRJEB28310 ERP110497 25 
Zoo microbiome study (Chapter 6) PRJEB28310 
 
ERP110496 17 
ELDERMET study (Chapter 6) PRJEB28308 
 
ERP110495 17 
2-year NEOM study (Chapter 6) PRJEB28307 ERP110494 25 
  Total 461 
Table 2.17: Accessions (ENA) for all newly-sequenced genomes described in this thesis 
NCTC (PacBio-sequenced; NCTC3000 project) genomes were newly assembled in my work. 
 
2.5 In vitro methods 
2.5.1 Bacterial isolation 
2.5.1.1 Direct plating 
Direct plating method for isolating C. perfringens is an effective yet reliable approach 
11. Firstly, faecal samples were weighed in sterile Eppendorf tubes (approx. 
100mg/sample) and then serially diluted in sterile Phosphate Buffer Saline (PBS) - 
neat, 10-fold, 100-fold, 1000-fold and 10000-fold. The mixture contents were 
homogenised using a horizontal mixer and vortexed, and plated (100µl/ sample/ plate) 
on selective media Tryptose-Sulfite-Cycloserine Egg Yolk Agar (TSC-EYA; Table 
2.18) 11,240. 
Chapter 2    Materials and methods    74 
 
Composition Concentration 
Perfringens Agar Base 46g/L 
D-cycloserine 400mg/L 
Egg yolk emulsion 100ml/L 
Table 2.18: Composition of TSC-EYA agar used for primary isolation of C. perfringens 
 
After 18-24h anaerobic incubation at 37°C, pitch-black colonies with opaque halos 
(halos represent lecithinase activity of C. perfringens, which morphology was 
presumptively identified as C. perfringens) were re-streaked with sterile culture loops 
on fresh TSC-EYA agar plates to obtain pure colonies and stocks (see Figure 2.3). 
After 2-3 rounds of re-streaking of isolates, pure colonies were obtained. 
 
 
Figure 2.3: Distinctive C. perfringens colonies with opaque halos on TSC-EYA. 
 
2.5.1.2 Ethanol-shock method 
30 min-ethanol treatment (50% ethanol in Robertson’s Cooked Meat Media broth) to 
the collected faecal samples at room temperature, aimed to eliminate non-spore 
formers, followed by plating on autoclaved Fastidious Anaerobic Agar (FAA) 
supplemented with defibrinated sheep blood and 0.1% sodium taurocholate. After 48h 
anaerobic incubation (in anaerobic jar), colonies with haemolytic characteristic growth 
on agar were presumptively identified as C. perfringens, which were subjected to 
further identification.  
 
Chapter 2    Materials and methods    75 
 
Composition Concentration 
Fastidious Anaerobic Agar 46g/500ml 
Defibrinated sheep blood (0.5%) 25ml/500ml 
Sodium taurocholate (0.1%) 0.5g/500ml 
Table 2.19: Composition of FAA for isolation of C. perfringens. 
 
2.5.2 Molecular identification of C. perfringens 
2.5.2.1 16S rRNA PCR and sequencing 
Genomic DNA of isolates were extracted (section 2.2.1) and 16S rRNA PCR (full 16S 
gene) was performed. This method is described in section 2.3.1. 
 
Figure 2.4: Agarose gel showing full-length 16S rRNA gene amplicons 
16S rRNA full-length amplicons were approximately 1,500 bp as shown. 
 
2.5.2.2 Matrix-Assisted Laser Desorption Ionisation Time-of-Flight (MALDI-
TOF) 
All samples provided by Prof J S Kroll were identified by MALDI-TOF, performed 
according to manufacturer’s instructions using Bruker Microflex LT by the 
Microbiology Department at Imperial College Healthcare NHS Trust. For details 
please refer to p.66 Sim (2015) 12. Isolates used for phenotyping studies were re-
identified (for reaffirmation) using Bruker Microflex at UEA Norwich Medical School 
with the assistance of Dr Emma Manners. 
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2.5.2.3 Multiplex-PCR toxinotyping 
A sub-set of C. perfringens isolates were toxinotyped by Dr Joseph Brown at Lincoln 
University using multiplex-PCR technique to screen for toxin genes including plc, cpb, 
cpb2, etx, iap/ibp and pfo 241. 
 
2.5.3 Culturing 
2.5.3.1 Pure cultures 
All isolates were cultured in sterile BHI for further analysis unless otherwise indicated, 
including genomic DNA extraction for WGS and phenotyping. Briefly, stocks are 
streaked on BHI agar and incubated in anaerobic cabinet at 37°C overnight 
(approximately 15-18h). Single colonies were then picked for further culturing 
according to specific experimental protocols. 
2.5.3.2 BHI Agar 
BHI agar was made using BHI supplemented with 1.5% pure agar. BHI agar was the 
primary agar used in phenotyping studies. 
2.5.3.3 TSC-EYA Agar 
Isolates were streaked on TSC-EYA for brief identification (<18h overnight 
incubation, Figure 2.3). 
2.5.3.4 Bacterial culture stocks 
All bacterial culture stocks were preserved using autoclaved RCM with glycerol (30%, 
V/V) in sterile cryogenic storage vials and stored long-term at -80°C until further 
analysis. 
 
2.5.4 Colony Forming Unit (CFU) enumeration 
Calculation of CFU is performed according to the formula below: 
CFU/ml = number of colonies (CFU) x dilution factor x 50 (ml-1) 
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For faecal sample, 
CFU/g = number of colonies (CFU) x dilution factor x 50 (g-1) 
For calculation of Limit of Detection (LOD), 
CFU/ml = 1 (CFU) x lowest dilution factor x 50 (ml-1) 
 
2.5.5 Cell lines and maintenance 
Rat (Rattus norvegicus) small intestinal cell line IEC-6 (ATCC CRL-1592™) and 
human colonic cell line Caco-2 (ATCC HTB-37™) were employed for cell culture 
experiments.  
2.5.5.1 IEC-6 
Frozen stocks were resuscitated/resuspended in pre-warmed (37°C) media Dulbecco’s 
Modified Eagle Medium (DMEM, Thermo Fisher Scientific), supplemented with 10% 
Foetal Bovine Serum (FBS; Thermo Fisher Scientific), 4mM L-glutamine (Thermo 
Fisher Scientific) and 0.1 U/ml bovine insulin (Sigma-Aldrich). Cells were 
immediately transferred to T25 sterile culture flasks (25cm2; Corning) and incubated 
at 37°C in 5% CO2 incubator for 24h. Spent media was removed after 24-48h, replaced 
with fresh warm media as described and incubated until confluency was reached. For 
making cell line stocks, cells were grown to confluency (70-80%) before trypsinisation 
(1% trypsin for 10 min at 37°C) and cell density adjusted to approximately 1x106 
cells/ml. 5% of DMSO (cryoprotectant) was added to 1ml aliquots before transferring 
to -80°C freezer for 24h. After 24h, stocks were stored to -196°C liquid nitrogen for 
long-term storage (cell banking). Cell line passages 6 – 20 were used, cells were split 
at ratios 1:10-20 for each passage. Cells were counted on haemocytometer (Neubauer 
Chamber).  
2.5.5.2 Caco-2 
Cells were resuscitated and maintained as described above except the working 
medium – DMEM supplemented with 20% FBS. Cells were split at ratio 1:5-10. Cell 
line passages 30-45 were used in experiments. 
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2.5.6 Growth kinetics assay 
2.5.6.1 CFU kinetics: culture setup and drop-plating 
Bacterial stocks were checked for purity on BHI agar prior to experiments. Single 
colonies were picked and cultured in BHI broth anaerobically overnight 
(approximately 14-16h) to reach stationery phase (approximately 1 x 109 c.f.u). 
Confluent cultures were diluted 1-million-fold (106) at the start of the 24-h experiment, 
estimating 103 starting CFU/ml/ well. Growing cultures were homogenised by 
inverting 5 times before taking 100μl of total liquid for plating.  
Serial dilutions were performed with sterile PBS in sterile Eppendorfs before drop-
plating using Miles and Misra method on BHI agar 242. For each time point and sample, 
3 technical replicates were drop-plated for statistical accuracy. This experiment was 
performed in 3 independent cultures (n=3) for each isolate. Plates were incubated at 
37°C in anaerobic cabinet for 15-20h before CFU counting. Plates of highest dilutions 
with CFU were selected for maximum accuracy.   
2.5.6.2 Optical density kinetics measurement 
200μl of each sample (triplicates) was transferred into sterile 96-well plate 
anaerobically. Culture setup is described in section 2.5.6.1. Plate reader TECAN was 
used to monitor the growth kinetics for a continuous 24h. Plate reader was set to shake 
plates every 15mins for 1min to avoid cell clogging. 
 
2.5.7 Gas production assay 
Autoclaved gas vials filled with 30ml sterile BHI were pre-reduced overnight in 
anaerobic chamber prior to experiment. Overnight cultures were diluted to 
approximately 103 CFU/ml each vial and air-sealed with butyl septum and aluminium 
crimp, then moved to 37ºC incubator.  
Briefly, gas produced by each culture was measured by USB pressure transducer 
connected to a 3-way stopcock – inserting a 23G hypodermic syringe needle (attached 
to a 10-ml syringe) into the sealed vial headspace, the gas pressure readouts were 
indicated on the display (using the recommended OMEGA software on a laptop). By 
withdrawing the syringe plunger, the headspace pressure returned to ambient pressure 
as indicated by a zero reading. Gas volume was indicated on the syringe barrel after 
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the headspace pressure returns to zero 243. Each reading was then recorded every hour 
for an extended period of 10h. Measurements were carried out in a fume hood. This 
experiment was performed in 3 independent cultures (n=3) for each isolate. 
 
2.5.8 Hydrogen sulphide production assay 
Overnight pure cultures were inoculated in 20ml fresh sterile BHI in 50ml Falcon 
tubes at 1% inoculum and followed by 8h anaerobic incubation (negative control 
Bifidobacterium longum was inoculated at 5% and incubated for 20h). H2S test strips 
(also known as lead acetate test strips: H2S detection range 5-400ppm) were attached 
in each tube to visually determine the amount of H2S produced by each strain using 
blackening score (1-10). NaHS was added to BHI to serve as positive control as it 
produces H2S when dissolved in liquid (which gives a blackening score of 10). This 
experiment was performed in 3 independent cultures (n=3) for each isolate. 
 
2.5.9 Oxygen tolerance assay 
Pure cultures (12 strains) were grown anaerobically to confluency for 24h in BHI. 
Cultures were spotted in a dilution series onto BHI agar supplemented with 0.1% 
sodium taurocholate. Spotted plates were dried and incubated under ambient (aerobic) 
conditions at room temperature (21ºC) for specified time periods (24h-336h) before 
being returned to anaerobic chamber for determination of CFU count. All CFU were 
counted after 12-15h anaerobic incubation. Cultures (spotted plates) that were not 
exposed to oxygen acted as controls for each strain. Viable percentage was shown after 
comparing with control cultures. This experiment was performed in 3 independent 
cultures (n=3) for each isolate. 
 
2.5.10 Sporulation assay 
Pure cultures were induced to sporulate using the modified Duncan-Strong Medium 
(at pH 7.8) as detailed in Table 2.20 for 24h anaerobic incubation unless otherwise 
indicated 61.  
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Sporulated cultures were treated with sterile-filtered 70% ethanol for 4h to eliminate 
all remaining vegetative cells and spotted on BHI agar supplemented with 0.1% 
taurocholate (a potent germinant) for spores.  
Composition Weight/litre 
Yeast extract 4g 
Sodium thioglycolate 1g 
Disodium phosphate (Na2HPO4.7H2O) 10g 
Raffinose 4g 
Proteose peptone 15g 
Table 2.20: Composition of the modified Duncan-Strong Medium 61. 
 
2.5.11 Bile salt assays 
2.5.11.1 Germination response of spores 
Ethanol-treated sporulated pure cultures were serially diluted and plated on BHI agar 
and BHI agar supplemented with 0.1% bile salts (taurocholate, cholate, 
chenodeoxycholate and deoxycholate), followed by anaerobic incubation for >24h. 
CFU were counted and fold-change was calculated compared with CFU on BHI plates 
without bile salt supplementation. 
2.5.11.2 Responses of vegetative cells 
Pure cultures were incubated anaerobically overnight before serially diluted and plated 
on BHI agar (control), BHI agar supplemented with 0.1% bile salts (taurocholate, 
cholate and deoxycholate). 
2.5.11.3 Mixed-bile assay 
Pure cultures were incubated to confluency overnight before serially diluted and plated 
BHI agar supplemented with 0.1% taurocholate + 0.1% cholate + 0.1% deoxycholate. 
CFU were checked after >24 h incubation. 
2.5.11.4 Deoxycholate assay 
Pure cultures were incubated anaerobically overnight before being reinoculated into 
BHI broth containing different concentration of deoxycholate at 0.01%, 0.05% and 
0.1%. 
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2.5.12 Minimum Inhibitory Concentration (MIC) assay 
The MIC of each antibiotic against C. perfringens strains was determined based on the 
modified method of microdilution technique for antimicrobial susceptibility testing 
244. MIC is defined as the lowest antibiotic concentration that inhibits the visible 
growth of C. perfringens after 24h-incubation. 
Sterile-filtered antibiotics were pre-made in stocks at desirable concentration prior to 
storage at -20C. Bacterial culturing was described previously. 96-well plate was 
utilised for this assay – approximately 104 CFUs of each strain was added into each 
well (sterile BHI) containing a different antibiotic concentration (double dilution) 
accordingly. BHI without antibiotic served as a positive control for growth and 
supplemented with thiamphenicol at 15μg/ml served as negative control. FLUOstar 
Omega microplate reader was used to measure liquid turbidity at 595nm (absorbance) 
to determine whether there is microbial growth in each well after 24h anaerobic 
incubation. Absorbance >0.5 is considered as significant growth. 
 
2.5.13 Cell line toxicity assay 
2.5.13.1 Necrosis assay 
IEC-6 cells (passage 6-20) were seeded at 20,000 cells/well in 96-well plate (tissue-
treated). After 72h 5% CO2 incubation, approximately 56,000 cells per well (firm 
monolayer) were subjected to experiments. Briefly, phenol-red DMEM was removed, 
cells were washed twice gently and replaced with sterile phenol-red free DMEM 
supplemented with 1% FBS. Diluted sterile-filtered (0.22μm) bacterial supernatants 
(in ratio 1:2, 1:4 and 1:8 as necessary) were added into each well at 5% total volume 
followed by 2h 5% CO2 incubation. Necrosis measurement was performed using 
CytoTox-One Homogeneous Membrane Integrity Assay according to manufacturer’s 
instructions.  
For Caco-2 cells (passage 30-45), cells were seeded at 20,000 cells/well. After 72h 5% 
CO2 incubation, a confluent monolayer was formed. Protocol follows as described in 
previous paragraph, with an exception that supernatants were added in 25% of total 
volume. 
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2.5.13.2 Apoptosis assay  
Cell seeding follows the above description. After 3h 5% CO2 incubation, caspase 
activity was measured using Caspase-Glo 3/7 Assay according to manufacturer’s 
instructions. Staurosporine (1μM) was used as positive control. 
2.5.13.3 Hydrogen sulphide toxicity assay 
Sodium hydrosulfide (NaHS) was used as a sulfide donor as an equivalence of H2S in 
this study 245. Concentration of soluble NaHS was prepared ranged from 0.0001% to 
1% in PBS, sterile-filtered (0.22μm) and stored at 4ºC prior to experiment. Cell 
seeding was performed as described, with all NaHS solution being added to working 
volume (200μl) at 5% each well. Supernatants were harvest after 4h 5% CO2 
incubation. CytoTox-One Homogeneous Membrane Integrity Assay was used to 
measure potential cell toxicity according to manufacturer’s instructions. 
 
2.5.14 PFO expression assay 
BHI agar supplied with 5% sheep blood was used to identify PFO expression of C. 
perfringens isolates. Briefly, C. perfringens was streaked on the blood agar and 
incubated anaerobically for overnight (<20h). As PFO is known produce beta-
haemolysis in blood-supplemented media (complete lysis of blood cells), therefore 
isolates with clear transparent halos formed around the colonies (indicating lysis of 
blood cells) visualised were defined as PFO-positive isolates 246.  
 
2.5.15 Bacterial transformation 
Plasmid pMTL8315fdx-gfp+ was the target plasmid (see Figure 2.5 for plasmid map) 
to be inserted into C. perfringens isolates. This modified version of plasmid 
pMTL8135 with green fluorescent protein (GFP) gene was a gift from Dr Duncan 
Gaskin 247. This shuttle plasmid (stored in E. coli TOP10 strain as stocks at -80ºC) 
comprises catP gene for selection which confers chloramphenicol resistance in Gram-
negative bacteria and thiamphenicol resistance in Gram-positive bacteria. Optimised 
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transformation protocol 11  (electroporation) was obtained online from Clostridia 
Research Group at the University of Nottingham and performed accordingly 248.  
2.5.16 Plasmid stability test 
Plasmid stability test was performed to determine the stability of the specific plasmid 
in the transformants up to 60 generations. Briefly, transformed isolates were cultured 
in BHI without antibiotic supplementation (thiamphenicol) to reach confluency every 
12h (starting cultures at 1000-fold dilution, 1000-fold increase equates approximately 
10 generations). Sub-culturing was carried out every 12h (10 generations) for 6 cycles 
(60 generations). Cultures were serially diluted every cycle (12h) and plated on both 
selective (antibiotic-supplemented) and non-selective (without antibiotic) BHI plates. 
CFU were counted after 15-20h incubation to compare plasmid retention percentage. 
 
Figure 2.5: Plasmid map of pMTL8315fdx-gfp+ 
This annotated circular plasmid map was generated using Unipro UGENE v1.23. 
 
2.5.17 Real-time PCR (RT-PCR) 
RT-PCR was performed with help from Dr Lukas Harnisch to semi-quantify the 
relative total microbial load in mouse faecal samples as described previously 249. 
Briefly, DNA of faecal samples (similar weight) were extracted and amplified using 
Quantifast SYBR green mastermix (Qiagen) and full-length 16S rRNA universal 
primers (Table 2.5). Cycling was performed on a Roche LightCycler 480 using the 
PCR amplification conditions in Table 2.6. Cycle threshold (CT) value of each sample 
                                                 
11 http://www.clostron.com/CacElectroporationProtocol.pdf 
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was compared directly as a relative comparison of total microbial load in faecal 
samples. 
2.6 In vivo methods 
2.6.1 Ethics and licence 
All animal experiments and related protocols described were performed under the 
Animals (Scientific Procedures) Act 1986 (ASPA) under project licence (PPL: 
80/2545) and personal licence (PIL: I7382F677) and approved by Home Office and 
UEA FMH Research Ethics Committee. Animals are monitored and assessed 
frequently during studies for physical condition and behavior. Mice determined to 
have suffered from distress were euthanised via ASPA Schedule 1 protocol (CO2 and 
cervical dislocation). Trained and qualified animal technicians carried out animal 
husbandry at UEA Disease Modelling Unit (DMU). 
2.6.2 Experimental animals and housing conditions 
C57BL/6 wild-type female mice (juvenile mice: 3-5 weeks, adult mice: 7-9 weeks), 
obtained from UEA DMU were used in animal experiments. Animals were bred and 
housed in DMU barn under specific pathogen-free conditions and moved to DMU 
infection suite prior to the study. During infection study, mice were housed with 
autoclaved bedding (and cage), food (stock pellets) and water with 12h light cycle 
(12h of light and 12h of darkness). Cages were changed in laminar flow cabinet. 
2.6.3 Bacterial strains and growth 
Bacterial stocks were recovered on BHI agar for purity checks each time and 
subsequently cultured in BHI broth overnight to reach confluency (i.e. 109 CFU/ml, 
approximately 14-17h). Bacterial pellets were washed and re-suspended in sterile PBS 
before feeding the mice via oral gavaging using 20G plastic sterile feeding tube. 
2.6.4 Faecal sample collection and CFU enumeration 
Faecal samples were collected in sterilized tubes daily and stored at -80ºC until further 
analysis. Serially diluted faecal mixtures were plated on fresh TSC agar and CFU 
enumerated <24h anaerobic incubation. Pitch black colonies were counted as C. 
perfringens colonies. Black colonies were re-streaked on new BHI plates to confirm 
morphologies of experimental strains. 
Chapter 2    Materials and methods    85 
 
2.6.5 Tissue processing: fixation, embedding and sectioning 
Intestinal sections were fixed in 10% neutral buffered formalin for <24h and followed 
by 70% ethanol. Tissues were processed <5 days in 70% ethanol using an automated 
Leica Tissue Processor ASP-300-S (Quadram Institute Bioscience; QIB) and 
embedded in paraffin manually. Sectioning was performed using a microtome (5-μm-
thick sections; QIB) and left overnight for samples to air-dry prior to staining and 
further analysis. 
2.6.6 H&E staining 
H&E (haematoxylin and eosin) staining was performed for structural imaging of 
intestinal samples using the protocol provided by Dr Zoe Schofield (Table 2.21). 
Step no. Reagent Time 
1 Xylene 2mins 
2 Xylene 2mins 
3 Xylene 2mins 
4 100% ethanol 2mins 
5 100% ethanol 2mins 
6 90% ethanol 2mins 
7 70% ethanol 2mins 
8 Running water 2mins 
9 Distilled water 30s 
10 Haematoxylin 3mins 
11 Running water 2mins 
12 70% ethanol 2mins 
13 Eosin 6mins 
14 95% ethanol 2mins 
15 100% ethanol 2mins 
16 100% ethanol 2mins 
17 Xylene 2mins 
18 Xylene 2mins 
19 Mount slides with DPX  
Table 2.21: H&E staining procedures 
 
2.6.7 Mouse infection model 
In-house wild-type C57BL/6 3-4 weeks old female mice (after weaning) were treated 
with a five-antibiotic cocktail that comprises kanamycin (0.4mg ml-1), gentamicin 
(0.035mh ml-1), colistin (850U ml-1), metronidazole (0.215mg ml-1) and vancomycin 
(0.045mg ml-1) in autoclaved drinking water for 3-4 days administered ad libitum 34. 
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Drinking water was then switched to sterile water, and 48h later mice were orally 
gavaged with 150mg/kg of clindamycin. After 24h, mice were challenged with 109 
CFU of C. perfringens in 100μl and all mice were closely monitored for signs of 
disease symptoms including significant weight loss (>20%) that will require 
euthanisation. Tetracycline was supplemented (0.001mg/ml) in drinking water post 
oral-challenge in tetracycline model. 
2.6.8 Pathological scoring method 
All colonic section images were examined and graded single-blinded by Dr Lindsay J 
Hall. The histological severity of infectious colitis was graded using a pathological 
scoring system (0-14; denoting increasing severity) based on three general 
pathological features: (1) inflammatory infiltration (0-4), (2) epithelial hyperplasia and 
goblet cell loss (0-5), and (3) mucosal architecture (0-5) 250. The overall score was the 
sum of each component score. An overall pathological score of 1-4 indicates minimal 
colitis, 5-8 as mild colitis, 9-11 as moderate colitis, above 12 as marked/severe colitis. 
 
2.7 Bright-field and fluorescence microscopy 
Bright-field microscopy was performed at QIB Analytical Science Unit, using 
Olympus BX60 with a microscope camera Jenoptik C10 with ProgRes CapturePro 
software v2.10. Zeiss Axio Imager 2 (QIB) was used for fluorescence microscopy. 
 
2.8 Electron microscopy 
Scanning Electron Microscopy and Transmission Electron Microscopy images were 
produced by Mrs Kathryn Cross (QIB). Overnight bacterial cultures in BHI were 
provided and further processed for the EM. 
 
2.9 Graphing and illustrations 
Figures were generated using GraphPad Prism v6.0.4 for Windows, GraphPad 
Software, La Jolla California USA (www.graphpad.com) unless otherwise indicated. 
R packages (including key graphing packages gplots and ggplot2) were often used to 
generate various graphs and figures, and primary R-coding scripts used in this thesis 
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were made available on my GitHub repository (github.com/raymondkiu/Thesis). 
RStudio v1.1 for Windows and for Mac were utilised for R programming 210,251. 
Several plots created using Perl and Python were indicated in the legends. Microsoft 
PowerPoint 2016 was frequently used to edit figures and graphs. 
 
2.10 Statistical analyses 
All statistics were performed using GraphPad Prism version 6.04 for Windows, 
GraphPad Software, La Jolla California USA (www.graphpad.com) unless otherwise 
indicated in figure legends. P values <0.05 are considered as statistically significant. 
Data expression and statistical tests were indicated in figure legends where appropriate. 
Principal Component Analysis (PCA) was performed in R using package ggplot2 and 
function autoplot. Hierarchical population clustering of DNA sequencing data was 
assigned in R using packages rhierbaps, ggtree, and phytools, and function hierBAPS.  
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Chapter 3 Genomic virulence and phylogenetic 
analysis of preterm-associated C. 
perfringens identifies NEC-linked extra-




This chapter will focus on discussing genomic and phylogenetic analyses of C. 
perfringens isolated from preterm infants, including NEC infants and non-NEC 
control infants, delving into virulence genes to identify extra-virulent genotypes and 
tracing genomic epidemiology of C. perfringens within and across two hospitals 
(Figure 3.1). Initial faecal sample collection and C. perfringens isolation work were 
carried out by Dr A Shaw and Dr K Sim (Prof J S Kroll’s group at Imperial College 
London) under NEOM study. I obtained the isolates via collaboration, extracted the 
genomic DNA (with support from Mr H Bedwell), whole-genome sequenced at WTSI 
(handled by Dr D Pickard) and further analysed the genomes.  
 
 
Figure 3.1: Schematic representation of data source and analyses described in Chapter 3 
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3.2 Background 
3.2.1 Preterm NEC 
By definition, NEC is an acquired preterm inflammatory gut disease that manifests as 
tissue necrosis anywhere along the GI tract 73,252. NEC was first reported in premature 
infants in the 1820-50s (in Paris and Vienna). After World War II, the emergence of 
special-care baby units (SCBU) in developed countries facilitated the increasing 
survival of preterms, which also corresponded to increasing incidence of NEC-like 
cases and NEC symptoms (first clinically characterised in 1952) 252,253.  
Still, it was not until the arrival of modern NICU in the 1960s, that the rapid rise in 
NEC incidence began to be widely recognised. However, at this time each NEC 
symptom was categorised under different disease entities. NEC, was first coined in 
1964 to address similar disease symptoms under diverse designations including 
neonatal appendicitis, peritonitis, and pneumatosis intestinalis in infants 188. After half 
a century, NEC remains the most severe and lethal neonatal GI emergency worldwide 
186,254.  
 
3.2.2 NEC pathogenesis and risk factors 
Importantly, the treatment for NEC has been non-specific since the introduction of 
disease staging criteria i.e. Bell stage. This is perhaps due to our limited understanding 
of NEC pathogenesis and the view of NEC as a single disease. Gordon et al, recently 
proposed that NEC is as a disease spectrum – an outcome of several aetiological 
pathways, instead of a single disease. Preterm-NEC as a clinical endpoint of multiple-
pathway disease is represented with associated risk factors in Figure 3.2. Primary risk 
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Figure 3.2: Proposed aetiological pathways of both preterm and term NEC development 
NEC development was proposed as a disease spectrum. This figure was adapted from Gordon et al. 
(2012) 255. 
 
3.2.3 Clinical features 
NEC is commonly characterised by intestinal necrosis primarily affecting the ileum, 
though it can affect any part of the GI tract. There are several classic symptoms of 
NEC: feeding intolerance, abdominal distention, pneumatosis intestinalis (formation 
of gas cysts in the gut wall), portal venous gas and gas-filled bowel necrosis. Preterm 
infants with NEC often deteriorate rapidly, frequently within 24 h from initial signs to 
severe conditions that require surgical operation or cessation of vital signs 73. 
3.2.4 Staging criteria and treatment strategy 
Presentation of NEC typically occurs in the first 1-4 weeks after premature birth 192. 
A classification system, Bell’s staging criteria (or more recently, modified Bell’s 
staging criteria as in Table 3.1), has been developed to diagnose, stage and treat NEC 
in NICUs since the 1970s 73,256,257. These staging criteria encompass three major stages 
(stages I, II and III). Clinically, as Bell stage I covers general/non-specific signs, only 
Bell stage II and III are considered as definite NEC. 
3.2.5 The roles of gut microbiota 
The role of bacteria in the pathogenesis of NEC has been strongly implicated since the 
disease was first described 188. Notably, NEC does not occur in germ-free (i.e. 
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microbial-free ) environments including germ-free in vivo models 258, thus NEC has 
been postulated to be driven by a microbial infectious component. Ultra-rapid 
progression of NEC from non-specific signs to systemic shock also implies bacterial 
overgrowth especially quick-growing pathogens including Klebsiella spp. and C. 
perfringens, and both have been linked to clinical NEC in recent years 8,190,192,259. 
Importantly, opportunistic gut pathogens like C. perfringens have been isolated from 
neonates (70%) in the first few days of life, indicating that NEC may have a microbial 
infection component 260. Hallmark NEC symptoms, including pneumatosis 
intestinalis, also suggests gas-producing bacteria including Clostridium spp. as one of 
the key causative agents 261-264. Gram-negative bacteria (e.g. K. pneumoniae) have also 
been associated with NEC cases. This has been linked to the fact that Toll-like receptor 
4 (TLR4, sensor for the cell wall component lipopolysaccharide [LPS]) is elevated in 
preterm infants, which may account for the inflammatory cascade induced in the 
premature intestine prior to NEC onset 265. 
Other pathogens such as Cronobacter sakazakii have also been isolated from certain 
NEC ‘outbreaks’, which again emphasises the potential bacterial role in NEC onset 
266. Importantly, antibiotic-associated disruptions in the preterm gut microbiota may 
negatively impact on colonisation resistance mechanisms, potentially allowing 
pathogen invasion and favouring adherence and proliferation of resilient pathogens 
267,268. Preterm infants harbour more potentially pathogenic microbes, with 
significantly reduced levels of beneficial groups of microbes such as Bifidobacterium, 
which are present at very high levels in vaginally delivery full term breast-fed infants. 
Indeed, previous studies, and ongoing studies in the Hall lab, have indicated that 
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Stage Classification Systemic signs Intestinal signs Radiologic signs 











Normal or intestinal 
dilation, mild ileus 
IB Suspected NEC Same as above Bright red blood 
from rectum 
Same as above 
IIA Definite NEC – 
mildly ill 
Same as above Same as above, 
plus absent 








IIB Definite NEC – 
moderately ill 
Same as above, 
plus mild metabolic 
acidosis, mild 
thrombocytopenia 





tenderness, with or 
without abdominal 
cellulitis or right 
lower quadrant 
mass 
Same as IIA, plus 
portal venous gas, 
with or without ascites 















Same as above, 






Same as IIB, plus 
definite 
ascites 




Same as IIIA Same as IIIA Same as IIB, plus 
pneumoperitoneum 
Table 3.1: Modified Bell's staging criteria for preterm NEC  
This table was adapted from Lee and Polin 272. 
 
Despite the strong evidence linking bacterial infection in the pathogenesis of NEC, no 
single common pathogen has been consistently found/isolated in the past 50 years 273. 
Instead, more than 12 species of potentially NEC-linked pathogens were summarised 
in Coggins, et al. 270 (Table 3.2). This indicates that microbial-NEC should not be 
considered as a single-pathogen-cause disease, but as a disease with a multi-pathogen 
aetiology (which may also link to specific disease symptoms) 262.  
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Clostridium Clostridium butyricum 274 
 Clostridium difficile 275 
 Clostridium perfringens 8,9 
 Clostridium neonatale 276,277 
Enterococcus  278 
Staphylococcus  Staphylococcus aureus 279 












Cronobacter Cronobacter sakazakii 266,281 
Escherichia Escherichia coli 282 
Bacteroides Bacteroides dorei 9 
Klebsiella  8 
Pseudomonas Pseudomonas aeruginosa 283 
Salmonella Salmonella enteritidis 284 
Table 3.2: Pathogenic bacteria associated with preterm NEC 
This table was adapted from Coggins et al. 270 
 
3.2.6 C. perfringens-associated NEC 
Most recently, several extensive preterm infant NEC cohort studies have again 
implicated that pathogenic bacteria are involved in the onset of NEC based upon 
analysis of the faecal gut microbiota using NGS techniques 8,9. Importantly, C. 
perfringens, has been shown to significantly increase in the infant gut microbiota prior 
to NEC development in these metagenomics studies. These studies are supported by 
the substantial number of NEC studies 270 (>14 to date since 1970s, more than any 
individual bacterial agents; see Table 1.5) that have reported C. perfringens as a 
potential pathogenic agent, in addition to its established pathogenic biology in many 
other neonatal animal gut diseases, and further supported by in vivo studies 189,285. 
Thus, C. perfringens appears to be a strong candidate as a direct causative agent of 
microbial-NEC, which may be termed as C. perfringens-associated NEC 190.  
Being universal and resilient in habitable niches, spore former C. perfringens may 
readily pass on to in-hospital neonates through either environmental or oral 
transmission, and then initiate diseases in the intestine 260. Proposed underlying 
mechanisms for C. perfringens-associated NEC include reduced bowel peristalsis in 
preterm infants (increased pathogen retention time), universal administration of broad-
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spectrum antibiotics 286,287 (that leads to reduced microbiota diversity, and the potential 
rapid overgrowth of resistant spores), reduced gut barrier integrity (non-existent 
mucus layer), lack of protective bacteria 8,9,186  (including Bifidobacterium species, 
which may antagonise the growth of C. perfringens), and immature/underdeveloped 
immune system that is ineffective at fighting off pathogenic bacteria 73 (Figure 3.3). 
Bile salt factors may also be linked to disease onset. Reduced diversity of the 
microbiota in preterm infants, including bacteria that can de-conjugate bile salts to 
secondary bile acids, may allow germination of C. perfringens, which has also been 
directly indicated in the pathogenesis of the well-studied C. difficile colitis (both 
species form spores and secrete colitis-related toxins) 288. Finally, the presence of 
‘hyper-virulent’ strains of C. perfringens may be implicated. 
Presently no particular toxin(s) secreted by C. perfringens has been specifically linked 
with preterm-NEC, although CPB2 has been suggested 8. Notably, C. perfringens can 
also be part of the ‘healthy’ human microbiota, thus suggesting other factors play a 
role 194.  
Importantly, no NEC-associated preterm infant isolates are known to be sequenced at 
present, and genomic investigation may allow identification of NEC-associated 
virulence factors, that may facilitate intervention strategies and/or therapy 
development. 
Using various computational pipelines and approaches (see section 2.4), I assembled 
C. perfringens genomes and performed downstream analyses including constructing 
pangenome, annotating gene functions, screening genes of interest (e.g. toxin and 
AMR genes), analysing 16S rRNA metagenomic taxa abundance, phylogenetic 
analysis to track bacterial transmission and phage analysis. The work in this chapter 
will aim to fill up the knowledge gap in understanding the role of C. perfringens in 
preterm and NEC diseases via in-depth genomic analysis. 
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Figure 3.3: Proposed infection mechanisms underlie C. perfringens-associated NEC  
(A) In non-NEC ‘healthy’ term infant gut (B) In preterm infant gut that potentially leads to C. perfringens-
associated NEC. Figure reproduced from Kiu and Hall (2018) under the Creative Commons BY licence 
1. 
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3.3 Hypothesis and aims 
Specific nosocomial virulent genotypes of C. perfringens are linked to preterm-NEC 
disease progression, specifically to determine: 
(1)  Genomic virulence features in NEC and control C. perfringens isolates obtained 
from preterm population, including toxin genes, AMR genes, plasmids and phage 
contents using comparative genomics. 
(2) Genomic epidemiology of preterm-associated C. perfringens using phylogenetic 
approaches. 
 
3.4 Study population 
The work described in this chapter is based on the preterm gut microbiome data (16S 
rRNA metagenomics, sequenced by Prof J S Kroll’s group at Imperial College 
London) and C. perfringens isolates collected during a 2-year preterm cohort study 
NEOM 12, a large-scale multi-centre study which was carried out between 2011-2013 
in primarily Queen Charlotte’s and Chelsea Hospital (QCCH) and St Mary’s Hospital 
(SMH). These isolates were then obtained and prepared at QIB for sequencing at 
WTSI. Samples include 6 NEC Bell 2/3 infants, 3 NEC Bell 1 infants and 29 non-
NEC infants at longitudinal time points.  
These 88 newly-sequenced preterm-associated C. perfringens isolates were obtained 
from 38 individual preterm infants at multiple-time points (most individuals). Two 
public genome assemblies were used as reference genomes in the analysis 
(ATCC13124 and NCTC8239). 
Among these 88 isolates, 60 isolates were obtained from QCCH (24 in 2011 and 36 in 
2012), where important surgeries were carried out while 28 isolates were obtained 
from SMH (6 in 2011 and 22 in 2012) as shown in Figure 3.4A. All genome assemblies 
analysed were of high quality at <60 contigs (range: 11-59; mean contig number: 25), 
with 95.5% of the assemblies <40 contigs (Figure 3.4B). All isolates have a mean 
sequencing coverage (or, depth) of 142X (depth range: 82-206X), mean genome size 
of 3.2 Mb (range: 3.0-4.1 Mb), 3,009 genes per genome (range: 2,803-3,998 genes) 
and ANI> 96.0% (pair-wise comparison for all genomes; Appendix 1 Table S3.2). For 
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statistics on NEC and control individuals, 9 infants were diagnosed with NEC during 
their hospitalisation period (6 of Bell 2/3; 3 of Bell 1) and 29 were control infants, or 
non-NEC infants. In terms of isolate number, 24 isolates including multiple-time-point 
isolations, were obtained from NEC-infants whereas 64 isolates were isolated from 
control infants (Figure 3.4C-D). 
 
Figure 3.4: Statistics of preterm-study cohorts and isolates 
(A) Temporal distribution of isolates from two hospitals SMH and QCCH in 2011 and 2012. A total 
collection of 88 isolates (multiple time-points) from 38 individual C. perfringens-positive preterm infants. 
(B) Quality of genome assemblies based on contig number. (C) Distribution of NEC case and control 
individuals in this study. (D) Distribution of NEC case and control isolates. 
 
I also obtained C. perfringens isolates from 10 twin-pairs and 1 triplets (remainder 
singleton) for the analysis (Table 3.3). All relevant clinical metadata of preterm 
individuals where isolates were obtained from, including admission hospital and 
delivery mode, are shown in Table 3.3. Clinical metadata (Table S3.1) and genome 
assembly statistics (Table S3.2) of each isolate are detailed in Appendix 1. 










1 M009 Control CS SMH Singleton   
2 M010 NEC (Bell I) CS SMH Twin M011 
3 M011 NEC (Bell I) CS SMH Twin M010 
4 M030 NEC (Bell I) CS SMH Twin M029  
5 M087 Control CS SMH Twin M088 
6 M088 Control CS SMH Twin M087 
7 M089 Control CS SMH Twin M090 
8 M090 Control CS SMH Twin M089 
9 M091 Control NVD SMH Triplet   
10 M092 Control NVD SMH Singleton   
11 M094 Control NVD SMH Singleton   
12 M096 Control NVD SMH Singleton   
13 M111 Control CS SMH Twin M112 
14 M112 Control CS SMH Twin M111 
15 M124 Control CS SMH Twin M125 
16 M125 Control CS SMH Twin M124 
17 Q020 NEC (Bell II/III) NVD QCCH Singleton NA 
18 Q087 Control CS QCCH Twin Q088 
19 Q088 NEC (Bell II/III) CS QCCH Twin Q087 
20 Q090 Control NVD QCCH Singleton   
21 Q096 Control CS QCCH Twin Q097 
22 Q097 Control CS QCCH Twin Q096 
23 Q100 NEC (Bell II/III) NVD QCCH Singleton 
 
24 Q101 Control CS QCCH Singleton   
25 Q105 Control CS QCCH Triplet Q106, Q107 
26 Q106 Control CS QCCH Triplet Q105, Q107 
27 Q107 Control CS QCCH Triplet Q105, Q016 
28 Q118 Control CS QCCH Singleton   
29 Q126 Control CS QCCH Singleton   
30 Q135 NEC (Bell II/III) CS QCCH Singleton NA 
31 Q137 Control NVD QCCH Twin Q138 
32 Q138 Control NVD QCCH Twin Q137 
33 Q142 Control NVD QCCH Twin Q143 
34 Q143 NEC (Bell II/III) NVD QCCH Twin Q142 
35 Q164 Control NVD QCCH Singleton   
36 Q167 Control NVD QCCH Twin Q168 
37 Q168 Control NVD QCCH Twin Q167 
38 Q215 NEC (Bell II/III) CS QCCH Twin Q216 
Table 3.3: Clinical metadata of 38 individual preterm infants 
CS: Caesarean section; NVD: Normal vaginal delivery; SMH: St Mary’s Hospital; QCCH: Queen 
Charlotte’s and Chelsea Hospital. 
 
3.5 Results 
3.5.1 NEC microbiome signatures 
During the two-year NEOM study (2011-2013), 12/369 individuals were diagnosed 
with definite NEC. Further 16S rRNA sequencing analysis of the NEC-associated 
microbiomes revealed 2 distinct microbial signatures: Clostridium was statistically 
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overrepresented in 4 samples whereas Klebsiella genus was enriched in the remaining 
8 samples prior to definite-NEC onsets 8,12. Of note, clinical syndromes between these 
two NEC-signature groups were undistinguished.  
Importantly, C. perfringens isolation work had been routinely carried out in the 
NEOM study 12. With those Clostridium-NEC infants, C. perfringens was confirmed 
as the sole Clostridium species detected by 16S rRNA sequencing technique via 
Clostridial isolation method (culturing) in the laboratory 12. NEC-associated C. 
perfringens were then briefly characterised by toxinotyping schemes and all 
determined as distinctive-type A strains (only encode typing toxin gene plc; different 
patterns via fAFLP typing), three isolates were found to encode additional cpb2 gene. 
As C. perfringens was found to be the predominating species in these NEC cases prior 
to disease onset, it was proposed as the microbial causative agent of NEC 8,12.  
I obtained the previously generated raw 16S rRNA microbiome data from Dr A Shaw 
and re-analysed with the 16S rRNA SILVA database (Release 128; September 2016) 
using similar OTU taxa assignment approach as in Sim et al. to determine and visualise 
the longitudinal microbiome dynamics of these C. perfringens-positive NEC neonates 
(Figure 3.5) 8. The microbiome dynamics 4 C. perfringens-associated NEC infants 
(Q215, Q088, Q143 and Q020) indicate an evident and significant increase of 
Clostridium taxa prior to NEC onset (Figure 3.5A). Two other Klebsiella-NEC (with 
C. perfringens isolated during the NEOM study) showed a distinct microbiome profile 
characterised by increased abundance of Klebsiella/Citrobacter genus (they are 
indistinguishable at 97% nucleotide identity) rather than Clostridium (Figure 3.5B). 
Three suspected-NEC neonates (M010, M011 and M030, data not published 
previously; Bell I neonates) display diverse gut microbiome dynamics, although M010 
appears have increased abundance of Clostridium before suspected-NEC diagnosis 
(Figure 3.5C).  
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Figure 3.5: Faecal microbiome dynamics in infants with microbial associated NEC of different 
Bell stages 
(A) 4 infants with ‘C. perfringens-associated’ NEC Bell stages 2/3 as determined in Sim et al. (2015). 
Clostridium genus was detected in abundance prior to NEC onset. (B) 2 infants with ‘Klebsiella-
associated’ NEC Bell stages 2/3. (C) 3 infants with NEC Bell stage 1 (generic diagnosis, not clinically 
considered as medical NEC). The Day of Life (DOL) of each preterm infant when the samples were 
collected is shown on the x-axis and the day of NEC diagnosis is circled in red. Bar charts were produced 
in R using package ggplot2.  
 
Microbiome profiling also indicated that the beneficial Bifidobacterium genus (Figure 
3.6) was present at high levels in three control neonates (M087, Q087 and Q101), and 
potential pathogens including Staphylococcus, Clostridium and Citrobacter were 
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found at lower levels indicating a negative relationship between these microbes. This 
suggests enhanced colonisation resistance capacity of Bifidobacterium in the neonatal 
gut, which agrees with recent microbiome studies 289. 
 
Figure 3.6: Potential role of Bifidobacterium as shown in non-NEC preterm microbiomes  
Microbiome dynamics in three non-NEC neonates M087, Q087 and Q101 that harboured high 
abundance of C. perfringens (confirmed by culturing). These data suggest the potential colonisation 
resistance impact of Bifidobacterium genus against pathogenic bacteria in infant gut including C. 
perfringens as it appears the bloom of Bifidobacterium (yellow bar) directly antagonised the intestinal 
abundance of C. perfringens (red bar), potentially contributed to the prevention of C. perfringens-
associated NEC. Bar charts were produced in R using package ggplot2.  
 
In twin-paired gut microbiome analysis (one developed NEC in each pair), it was 
reported that NEC is an acquired microbial gut infection rather than genetic/hereditary 
in Sim et al. (Figure 3.7) 12. There is an obvious increase of Clostridium taxa in neonate 
Q088 prior to NEC onset, however, although the matching twin sibling (Q087) also 
appeared to be colonised with Clostridium (low levels) it also had a Bifidobacterium-
dominated gut microbiota in later time points (Figure 3.7A). Q143 infant was a C. 
perfringens-associated NEC case, whereas the twin sibling Q142 (control) did not 
acquire any Clostridium in this period and did not develop NEC (Figure 3.7B). This 
further suggests the impact of C. perfringens overgrowth in NEC development, with 
a strong influence in the wider microbiota in disease pathogenesis. 
 
3.5.2 Comparative genomics of preterm-associated C. perfringens  
In this section I will describe the results from comparative genomics of case and 
control C. perfringens isolates including linking pathogenicity associations with 
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‘extra-virulent’ genotypes, virulence plasmids, accessory virulence genes and 
bacteriophage contents in the C. perfringens genomes. 
 
Figure 3.7: Twin-paired microbiota profiles 
(A) Bifidobacterium-dominated microbiome in Q087 at later time points suggests protective effects of 
Bifidobacterium against NEC onset. (B) Infant Q142 did not acquire Clostridium throughout 
hospitalisation period. These data support the overgrowth of C. perfringens in the development of 
microbial NEC and the potential protective effects of genus Bifidobacterium. Bar charts were produced 
in R using package ggplot2. 
 
3.5.2.1 Pathogenicity associations 
Plasmid-carried toxin genes including cpe and netB have been associated with FP 
diarrhoea and chicken NE respectively, while key typing toxins ι-toxin, ε-toxin and β-
toxin are mainly associated with diseases in ruminant animals including calves and 
sheep 1,19,290. However, to date, there are no in-depth genomic studies describing C. 
perfringens isolates from preterm-NEC, and therefore the importance of toxins in 
disease pathology is unknown. In addition, accessory/secondary toxins (hydrolytic 
enzymes), AMR capacity, colonisation related binding proteins, enterotoxins and 
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virulence plasmids could be important in defining hyper-virulent C. perfringens 
strains that are distinct from ‘commensal’ C. perfringens 230,291. I therefore performed 
comparative genomics on 88 C. perfringens isolates to explore virulence potentials 
encoded within the genomes. 
Phylogenetics was performed to construct a SNP phylogeny (in core gene alignment) 
based on 90 isolates (including 2 reference genomes). Isolates from 4 neonates – Q215, 
Q088, Q143 and Q020 were defined as C. perfringens-associated NEC isolates (case 
isolates in this section) and the rest defined as control isolates. Genes encoding toxins 
(n=21), antimicrobials (based on CARD AMR database), collagen-binding proteins 
(n=4), enterotoxins (n=4) were individually profiled (virulence plasmids in the 
genomes were also determined) to compare between case and control isolates (Figure 
3.8).  
Via hierBAPS analysis, 90 genomes (as type A except reference genome type F 
NCTC8239) clustered into 6 distinct lineages (lineages II-IV; Figure 3.8), split into 
two major distinct clades (lineage I vs II-VI). Lineage I, a separate distant-away 
genetic cluster (>30,000 SNPs away from remaining clusters), comprises a number of 
the isolates from Q088 (other Q088 isolates clustered in lineage II), suggesting 
multiple strains can be present within one individual. NEC isolates are exclusively 
nested within lineages II and III (Figure 3.8), while lineages IV-VI encompass only 
control isolates, suggesting a potential genetic distinction between extra-virulent 
strains and commensal strains. Importantly, lineage IIIc appears to comprise isogenic 
strains (denoted by the apparent tight clustering), suggesting probable intra- and inter-
hospital transmission as highly-similar strains were isolated from infants are two 
hospitals (QCCH and SMH respectively; further analysed and discussed in section 
3.5.3). 
To further analyse the gene associations with disease representations (case vs control), 
single-timepoint isolates were selected according to the following three criteria: (1) 
isolates must be either case (C. perfringens associated-NEC) or control (non-NEC); 
(2) first-time point control isolates (one isolate for each individual); (3) last-time point 
(closest to NEC) case isolates. Isolates Q100, Q135, M010, M030 and M011 were 
excluded from gene-association analysis as they did not fit the above criteria, with 33 
isolates included for further analyses (Figure 3.9). 
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Figure 3.8: Phylogeny of preterm-associated isolates aligned with full virulence profiles 
A mid-point rooted maximum-likelihood tree constructed from 90 C. perfringens isolates aligned with 
clinical metadata of host neonates and full virulence profiles of each isolate. This phylogenetic tree 
(including reference genome ATCC13124 and NCTC8239) is constructed from 125,930 core SNPs (an 
alignment of 1,973 core genes). Genetic clustering assigned via hierBAPS analysis. Bootstrap values 
are shown on the tree. AMR: Antimicrobial Resistance; CBP: Collagen Binding Protein; ETX: Probable 
Enterotoxin; VP: Virulence Plasmids. 
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Statistical testing (Fisher’s exact test), indicates that overall toxin gene, cna-family 
gene and overall virulence elements (adding up all virulence-related genes and 
virulence plasmid count) were statistically more abundant in the C. perfringens-
associated NEC isolates, indicating these NEC isolates are ‘extra-virulent’ strains 
encoding significantly more virulence genes compared with ‘commensal’/control 
isolates (P<0.05; Figure 3.10). Individual virulence genes including pfo (encodes PFO) 
and cna (encodes collagen-binding proteins) were significantly enriched in NEC 
isolates (P<0.05). Genes cnaD, cpb2 (variant 1), entC (enterotoxin) and plasmid 
pCP13 were associated with NEC isolates (trending towards statistical significance). 
Only 4 AMR genes were detected including the intrinsic resistance gene mprF (100%), 
tetracycline resistance genes tetA(P)(~94%) and tetB(P)(~30%), and ermQ 
(macrolide-resistance, encoded in one isolate). 
 
Figure 3.9: Virulence profiles for selected C. perfringens isolates used in association study 
Isolates qualified for selection criteria for statistical analyses (n=33), aligned with full virulence profiles. 
C. perfringens-associated definite-NEC isolates were colour-coded in red (n=4). 
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Figure 3.10: Enrichment analysis of key virulence elements in representative strains 
(A) PFO gene pfo. (B) and (C): sialidase genes nanI and nanJ. (D) to (F): CPB2 toxin gene cpb2 in both 
variants and overall association. (G) Enrichment of plasmid pCP13 in the isolates. (H) Toxin gene count 
comparison. (I) Antimicrobial gene count comparison. (J) Comparison of all virulence element counts 
(toxin + AMR + virulence plasmid count). Data: (A) to (G) fraction percentage (Fisher’s exact test, two-
tailed, *P<0.05, NEC: n=4, control: n=29). (H) to (J): mean count ± SEM (non-parametric Mann Whitney 
U test, two-tailed, *P<0.05, NEC: n=4, control: n=29). All estimated P values are printed in the figure. 
P<0.10 indicates weak association, P<0.05 indicates statistically significant difference. 
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3.5.2.2 In silico virulence plasmid analysis 
Plasmids are known to be associated with intestinal diseases in both human and 
animals, carrying an array of virulence factors including toxin and AMR genes 
1,41,42,291. Importantly, suspected virulence plasmid pCP13 was identified in two NEC 
isolates Q215.CN1 and Q088.CN12, showing strong correlation with NEC disease 
representation (Figure 3.10). There are several known virulence factors encoded on 
this 54 kb-plasmid (first isolated from C. perfringens strain 13, a human gas gangrene 
isolate) 37. Collagen binding protein cna and β2-toxin gene cpb2 (variant 1) are 
encoded on this plasmid. Plasmid pFORC3 was detected in NEC isolate Q143.CN8, 
and all isolates in lineage IIIc (potentially isogenic strains). This 56 kb-plasmid 
encodes virulence genes including cpb2 (variant 2), collagen binding protein cnaC and 
AMR elements tetA(P) and tetB(P).  
To further confirm whether these detected ‘plasmids’ are ‘intact plasmids’, which is 
important in understanding its potential transfer and spread, the sequences of plasmids 
were individually extracted from these high-sequencing-coverage (depth range: 102 
X-206 X) genome assemblies using in silico-approaches and compared with reference 
plasmids. 
Isolates Q215.CN1, Q088.CN12, M010.1C and Q164.1C were computationally 
detected (raw read-based) to carry plasmid pCP13 and hence sequences were extracted 
(from assemblies) and compared in Figure 3.11A. Genomic mapping shows that these 
plasmids are near-identical in nucleotide identity (>97%), plasmid size (~54 kb), GC 
content (~25.4%) and gene content (62-65 CDS encoded), suggesting this plasmid has 
been circulating intact (Figure 3.11B; Table 3.4).  
A total of 9 plasmid pFORC3-carrying isolates were selected for comparative analysis 
due to different k-mer coverage (Table 3.4), which initially suggested these are not 
intact pFORC3-family plasmids (Figure 3.12A-B). Eight ‘in-silico plasmids’ (not 
experimentally extracted) including pQ143.CN8 were found to be 14 kb (~20%) larger 
than the expected reference plasmid pFORC3, while pM096.3C is more similar to 
reference plasmid pF262A (from bovine isolate F262) at 48 kb length.  
 










Similarity by BLASTN 
(Assembly-based) 







pCP13 54,310 25.50 63 n/a n/a n/a 
pQ215.CN1 54,407 25.47 62 99.52 99.98 100.00 
pQ164.1C 54,647 25.44 65 94.82 97.08 100.00 
pQ088.CN12 54,421 25.50 62 99.41 99.95 100.00 








pFORC3 56,577 27.28 79 n/a n/a n/a 
pM087.7C 70,121 26.05 80 91.13 99.56 71.05 
pM089.1C 70,119 26.06 80 91.12 99.56 71.04 
pM090.1C 70,120 26.06 80 91.08 99.64 71.24 
pQ137.1C 70,119 26.05 78 91.12 99.72 67.82 
pQ143.CN8 70,111 26.05 79 91.12 99.56 67.46 
pQ138.1C 70,119 26.04 79 91.12 99.55 76.91 
pQ106.10C 70,123 26.05 79 91.11 99.56 71.05 
pQ118.4C 70,126 26.04 78 90.00 99.56 71.05 
pM096.3C 48,245 27.27 57 98.64 83.85 99.97 
pF262A 
pF262A 48,604 27.15 55 n/a n/a n/a 
pM096.3C 48,245 27.27 57 as pFORC3 97.42 97.14 
Table 3.4: Similarity comparison of predicted plasmids with reference plasmids 
 
Importantly, pQ143.CN8 which is 14 kb larger than pFORC3, was found to encode a 
series of extra potential virulence factors including multiple ABC transporters that are 
linked to multidrug resistance (Figure 3.12C). In brief, no intact pFORC3 plasmid, a 
plasmid sourced from aquarium water in South Korea, was encoded within these 
preterm-associated C. perfringens isolates. In fact, these plasmids could potentially be 
unidentified novel plasmids (linked to additional virulence in drug resistance) derived 
from pFORC3 plasmid backbone that warrants further experimental validations. Of 
note, these pFORC3-derived plasmids encode conjugative systems (Tcp loci were 
identified via sequence search) and are expected to be capable to strain to strain 
transmission 51,292. 
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Figure 3.11: Comparisons of pCP13-family plasmids extracted from preterm isolates 
(A) Genomic mapping of pCP13 plasmids (shaded) from isolates Q215.CN1, Q088.CN12, M010.1C and 
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Figure 3.12: Comparisons of pFORC3-family plasmids extracted from preterm isolates 
(A) Genomic mapping of pFORC3 plasmids from 9 isolates where pFORC3 plasmid was computationally 
detected at different k-mer identity with reference plasmids pLLY_N11_3, pFORC3 and pF262A. (B) 
Colour-coded phylogenetic positions of the isolates compared in (A). (C) Potential additional genetic 
regions (light purple region) found on plasmid pQ143.CN8 that encoded extra virulence genes compared 
to reference plasmid pFORC3. Graphs generated via Easyfig and iTOL. 
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3.5.2.3 Lineage-specific virulence and evolution observed in accessory genomes 
The pangenome of the 90 isolates (including two reference genomes) comprises 1,973 
(25.8%) core genes and 5,674 (74.2%) accessory genes (Figure 3.13). As a C. 
perfringens genome is approximately 3.2 Mb in size and carries 3,009 genes 
(Appendix 1 Table S3.2), C. perfringens is predicted to harbour ~34.5% (~1,038) 
accessory genes, which is hypothesised to be important in virulence contribution.  
 
 
Figure 3.13: Pangenome of 90 preterm-associated isolates 
(A) Pangenome visualised in heatmap using Phandango. Blue cells indicate orthologous groups 
(syntenies). (B) Pangenome stats: core vs total genes. (C) new vs unique genes. Stats graphs generated 
using R scripts in Roary package. 
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By delving into accessory genome and trait-association analysis (Appendix 1 Table 
S3.3 and S3.4), I observed several NEC-isolate specific genes (n=56; sensitivity cut-
off=75%, specificity cut-off=60%) which might contribute additional 
fitness/virulence to the strains. These genes include thioester-forming surface-
anchored protein (cnaD), pilus biosynthesis protein HicB, cell-wall binding protein 
(cna; identified in 9/12 [75%] NEC-associated isolates, while not identified in 50/78 
[65%] in non-NEC isolates), and carbohydrate-related ABC transporters (n=3; 
identified in 9/12 [75%] NEC-associated isolates, while not identified in 49/78 [63%] 
in non-NEC isolates).  
Interestingly, lineages II and III (hypervirulent clusters) that comprise all the NEC 
isolates encode certain virulence-related specific genes (n=82; sensitivity cut-
off=80%, specificity cut-off=75%) including PFO (pfo; sensitivity: 35/38 [92.1%], 
specificity: 41/52 isolates in other lineages do not encode pfo [78.4%]), thioester-
forming surface-anchored protein (cnaD; sensitivity: 32/38 [84.2%], specificity: 44/52 
isolates in other lineages do not encode cnaD [90.3%]), pilus biosynthesis protein 
HicB (sensitivity: 32/38 [84.2%], specificity: 44/52 [90.3%]), cell-wall binding 
protein (cna; sensitivity: 32/38 [84.2%], specificity: 44/52 [90.3%]), S-layer 
homology domain-containing protein (sensitivity: 35/38 [92.1%], specificity: 45/52 
[86.5%]), germination-associated cotH protein (group_654; sensitivity: 37/38 
[97.3%], specificity: 42/52 [80.7%]) and carbohydrate-related ABC transporter (n=5; 
sensitivity: 92-97%, specificity: 86-94%), thus revealing new and important accessory 
virulence potentials. Specific orthologous groups of the pangenome (multi-FASTA 
format) can be obtained from my GitHub repository12.  
These data support findings via virulence association analysis discussed in previous 
section with regard to pfo and cna virulence genes. Gene enrichment analysis also 
showed that pfo is highly specific to lineage II and III isolates (92.1%; 35/38 isolates; 
P<0.0001) compared to lineage IV-VI isolates, collagen-binding protein encoding 
genes cna (78.9%; 30/38 isolates; P<0.0001) and cnaC (71.1%; 27/38 isolates; 
P<0.0001) are significantly enriched in lineages II and III. These three important 
virulence genes were rarely encoded in lineage IV-VI (n=44; pfo: 6.8%; 3/44 isolates; 
cna: 9%; 4/44 isolates; cnaC: 18.9%). Hence, it is proposed that lineage II-III 
                                                 
12 https://github.com/raymondkiu/Thesis/blob/master/Chapter3_pangenome 
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comprises extra-virulent strains that harbour significantly more virulence genes than 
isolates in lineage IV-VI, which may be regarded as commensal strains (phenotypes 
need to be experimentally addressed). 
 
Figure 3.14: Enrichment of virulence genes in lineages II-III and lineages IV-VI isolates 
(A) PFO gene pfo. (B) Collagen binding protein gene cna (C) cnaC (D) spore germination-related cotH 
(E) pilus-synthesis gene hicB (F) SHDP: S-layer homology domain-containing protein. Data: fraction 
percentage (Fisher’s exact test, two-tailed, ****P<0.0001, lineages II-III: n=38, lineages IV-VI: n=44). 
P<0.05 indicates statistically significant difference. 
 
3.5.2.4 Bacteriophage contents 
Bacteriophage, or simply phages, are viruses that infect bacteria. Temperate phages 
are known to reside within bacterial genomes and are known to contribute virulence 
factors to their hosts, including toxins 293. To date, prophage representation within C. 
perfringens is not well understood. Hence, here I determined the phage contents and 
virulence-related elements carried by prophages residing within these preterm-
associated C. perfringens strains to give exploratory insights and understanding 
towards this increasingly important aspect of microbiology research via 
bioinformatics approaches. 
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Using pangenome-based analysis, prophage-related genes were determined to 
contribute 4% to the C. perfringens pangenome (part of accessory genome) (Figure 
3.15A). No significant differences of prophage contents between NEC (n=0.5) and 
control (n= 0.72) were observed (Figure 3.15B-C; P=0.5663).  
 
Figure 3.15: Prophages detected in preterm-associated C. perfringens genomes 
(A) Contribution of prophage-related genes in C. perfringens pangenome (90 genomes). Core genome 
represents genes present in all (100%) computed genomes. Gene numbers are printed within the 
corresponding bars. (B) Statistics of integrated prophage in C. perfringens strains categorised by NEC 
and control groups. (C) Frequencies of integrated phage(s) in C. perfringens strains. (D) Heatmaps 
showing detected prophages (red-colour cells) corresponding to C. perfringens strains and CRISPR 
arrays present in each individual isolate. Heatmap and bar chart were generated in R. 
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A total of 7 prophage species were identified in 33 representative C. perfringens 
strains from different individual neonates including genera associated with 
Clostridium, Lactobacillus and Bacillus (Figure 3.15D). Phages identified in these C. 
perfringens strains including Clostridium phage ϕ63 has been reported to potentially 
influence sporulation of its host, which is critical for host persistence and fitness 294. 
Another key Clostridium phage ϕ3626 was suggested to affect sporulation-onset 
mechanisms 295. Clostridium phage vB_CpeS-CP51 detected in 5 C. perfringens 
genomes (15%; 5/33) has previously been reported to exist in a foal case isolate, JFP55 
(or, JP55) 102. Overall, prophages were not identified in 17/33 of the (51%) C. 
perfringens strains.  
Importantly, CRISPR-cas systems in bacteria are used to prevent invasion of lytic 
phages. Thus, CRISPRs were identified in these 33 C. perfringens strains, with the 
highest number of 6 CRISPRs present in one control strain (Figure 3.15D). No 
differences were found between NEC (n=0.5) and control isolates (n=0.93; P=0.7258) 
in terms of CRISPR arrays they encode, although it appears that control strains have 
more CRISPRs (Figure 3.16).  
 
Figure 3.16: CRISPR systems in C. perfringens strains 
(A) Number of CRISPRs present in C. perfringens strains categorised by NEC and control groups. (B) 
Frequency of CRISPR counts in C. perfringens strains. (C) An overview of CRISPR proportions in 
isolates. 
 
Prophage has been reported to have a role in carrying virulence-related genes, such as 
Siphoviridae bacteriophages which carry enterotoxin A that contributes to S. aureus 
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virulence 296. Subsequently I investigated the virulence elements potentially carried by 
the prophages of preterm-associated C. perfringens strains. Several virulence-related 
genes were detected via sequence search and/or annotation-based screening including 
genes that encode sialidase NanH, probable enterotoxin EntB and EntD, and ABC 
transporter (Figure 3.17A). Sporulation-linked genes were also encoded within  
prophages (Figure 3.17B), which may be associated with sporulation modulation in C. 
perfringens strains 297.  
 
Figure 3.17: Virulence- and sporulation-related genes encoded within prophage genomes 
(A) Annotated genetic maps showing putative virulence-associated genes within extracted prophages 
(from complete prophages). (B) Sporulation-related genes were enriched in these phage-encoded 
regions (from incompletely predicted prophage sequences). 
 
Importantly, enterotoxin gene entB has been consistently detected in 19 phage-
carrying isolates from 8 individuals (Table 3.5), suggesting this enterotoxin is 
prophage-specific which has previously not been described. This is evidenced by a 
dissimilarity in entB sequence identities between these prophage-carrying entB 
(~94.4%; Table 3.5) and entB in other isolates (<93%), indicating prophage-entB 
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differs in nucleotide sequence. This exploratory C. perfringens prophage investigation 
indicates an important virulence contribution which requires further research into this 
understudied area. 






M087.10C M087 Control entB 1-1650/1650 100 94.44 
M087.13C M087 Control entB 1-1650/1650 100 94.44 
M087.4C M087 Control entB 1-1650/1650 100 94.44 
M087.7C M087 Control entB 1-1650/1650 100 94.44 
M089.1C M089 Control entB 1-1650/1650 100 94.44 
M089.3C M089 Control entB 1-1650/1650 100 94.44 
M090.1C M090 Control entB 1-1650/1650 100 94.44 
M090.3C M090 Control entB 1-1650/1650 100 94.44 
Q096.4C Q096 Control entB 1-1650/1650 100 94.38 
Q107.12C Q107 Control entB 1-1650/1650 100 94.44 
Q107.7C Q107 Control entB 1-1650/1650 100 94.86 
Q107.9C Q107 Control entB 1-1650/1650 100 94.44 
Q137.1C Q137 Control entB 1-1650/1650 100 94.44 
Q137.4C Q137 Control entB 1-1650/1650 100 94.44 
Q138.1C Q138 Control entB 1-1650/1650 100 94.44 
Q138.4C Q138 Control entB 1-1650/1650 100 94.44 
Q143.1C Q143 NEC entB 1-1650/1650 100 94.44 
Q143.CN1 Q143 NEC entB 1-1650/1650 100 94.44 
Q143.CN4 Q143 NEC entB 1-1650/1650 100 94.44 
Q143.CN8 Q143 NEC entB 1-1650/1650 100 94.44 
Table 3.5: Enterotoxin sequences detected in predicted prophage genomes 
 
3.5.3 Genomic epidemiological analysis reveals inter- and intra-hospital 
transmission 
3.5.3.1 Frequent hospital transfer may facilitate bacterial transmission 
In this section, potential C. perfringens transmissibility inferred by phylogenomic data 
will be demonstrated. C. perfringens isolates (n=88) were obtained during the 2-year 
NEOM study at both QCCH and SMH (Figure 3.18). As inferred by phylogenetic 
analysis and clinical data, two clusters (Ic and IIIc; assigned via hierBAPS analysis; 
overlapping hospitalisation period) were identified to be associated with potential 
intra-hospital and inter-hospital transmission as highlighted in grey boxes in Figure 
3.18. 
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Figure 3.18: Isolation time-points for all 88 C. perfringens isolates in this study 
Mid-point rooted maximum likelihood tree for 90 C. perfringens genomes (including 2 reference genomes 
ATCC13124 and NCTC8239) from preterm babies isolated in two hospitals in between 2011-2013. 
Timepoints of isolation for each isolate were indicated in the figure. Two clusters of isolates associated 
with potential patient-to-patient transmission and inter-hospital transmission are highlighted by shaded 
boxes. Red-labelled isolates in the colour strip indicates NEC-associations. Isolates from C. perfringens-
associated definite-NEC (Bell stages 2/3) were printed in red.  
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Transmissibility of C. perfringens has never been studied using WGS techniques to 
date. Using the available clinical metadata (NEOM) and phylogenetic analysis, it is 
possible to observe and trace the potential transmission routes of certain strains in 
between the hospitals QCCH and SMH. Babies are transferred frequently between 
these two sister hospitals in central London as QCCH handles more surgery-related 
cases in neonates (Figure 3.19). It is therefore hypothesised that this will facilitate the 
transmission of bacteria, especially spore-formers like C. perfringens, which can 
survive for long period of time in hospital environments. 
 
Figure 3.19: Inter-hospital transfer map of 38 C. perfringens-positive preterm infants 
These include infants screened positive of C. perfringens (2011-2013) in between SMH, Chelsea and 
Westminster Hospital and QCCH NICUs. Colour-coded infant symbols indicate twins/triplets otherwise 
singleton. 
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3.5.3.2 Within-host SNP variations 
To define C. perfringens at a strain level, within-host SNP variation analysis was 
performed using two approaches: reference-based and assembly-based. A total of 16 
pairs of strains (two identical C. perfringens colonies isolated from same sample and 
time point were sequenced) from 13 infants were selected to pre-determine the SNP 
count range of an identical strain (normally assume 0 SNP). A narrow r ange of 1-12 
(reference-based, or, 0-6 via assembly-based method) SNPs were found to be the SNP 
variations at strain level (confirmed by core genome ANI>99.98%; Table 3.6).  





1 M010 M010.CN1 100.00 15 5 1 
  M010.CN2 99.99 
2 M030 M030.N1C 100.00 71 1 0 
  M030.N2C 99.99 
3 M087 M087.1C 100.00 31 3 1 
  M087.2C 99.99 
  M087.10C 100.00 62 2 0 
  M087.11C 100.00 
4 M088 M088.1C 
M088.2C 
100.00 17 4 2 
  M088.2C 99.98 
  M088.10C 100.00 45 5 2 
  M088.11C 99.99 
5 M089 M089.1C 100.00 22 5 1 
  M089.2C 99.99 
6 M090 M090.1C 100.00 15 10 1 
  M090.2C 99.99 
7 Q020 Q020.CN1 100.00 19.5 12 6 
  Q020.CN2 99.99 
  Q020.CN4 99.99 19 2 1 
  Q020.CN5 99.99 
8 Q087 Q087.1C 100.00 37 1 1 
  Q087.2C 99.99 
9 Q088 Q088.CN1 100.00 13 1 1 
  Q088.CN2 99.99 
10 Q090 Q090.5C 100.00 25 4 2 





Q100 Q100.CN1 100.00 29 5 1 
  Q100.CN2 99.99 
12 Q168 Q168.1C 100.00 30 5 1 
  Q168.2C 100.00 
13 Q215 Q215.1C 100.00 40 6 1 




Minimum 1 0 
  Median 4.5 1 
  Maximum 12 6 
Table 3.6: Within-host SNP variation analysis 
Two colonies were selected from the same sample (same time-point) and sequenced to analyse C. 
perfringens within-host SNP variations. Pair-wise ANI was performed via mummer alignment. 
Reference-based (read-mapping) SNP method was performed using raw-read FASTQ via direct 
reference-mapping. Assembly-based SNP approach was performed using genome assemblies FASTA 
via Roary pangenome pipeline, based on alignment of 117,731 core-SNPs (1,741 core genes). 
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3.5.3.3 Inter-hospital strain transmission indicated by sequencing data 
Although most twin-pairs harbour identical strains, indicating the role of 
maternal/vertical transmission (Figure 3.18), there are two important clusters 
suggestive of intra- and inter-hospital C. perfringens transmission events that took 
place during the 2-year clinical study. This section will discuss cluster IIIc that 
involved 6 neonates residing in both QCCH and SMH, carrying identical C. 
perfringens strains (0-6 SNPs) over an overlapping period of approximately 35 days 
(Figure 3.20A-B). 
 
Figure 3.20: Potential inter-hospital transmission of C. perfringens strain Q143 
(A) Epidemiological map of 6 preterm infants in both SMH and QCCH NICUs carrying NEC-associated 
C. perfringens strains. Same coloured infant symbols indicate twins. Black bars indicate period of 
hospitalisation. (B) Phylogenetic position of strains Q143. (C) Unrooted tree of 16 isolates from 6 infants 
constructed from 9 SNPs (strains Q143; lineage IIIc). Coloured symbols are indicative of the infants as 
in previous figures. 
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Lineage IIIc comprises 16 genetically identical isolates (longitudinal samples) from 6 
neonates, having only a range of 0-6 SNPs between them (Appendix 1 Table S4; 
Figure 3.20C), fulfilling the criterion of being isogenic or identical at strain level, 
confirmed by ANI>99.99% (Table 3.6). This strain was designated Q143 after the ID 
of the neonate who carried this strain and who developed NEC. Q143 was genotyped 
as an extra-virulent strain associated with NEC representations (section 3.5.2), 
possessing significantly more virulence genes (P<0.05) than the proposed commensal 
C. perfringens. 
With limited sampling of C. perfringens, potential transmission routes were likely to 
be sourced from SMH when SMH-residing neonates M089, M090 (twin pair) and 
M087 carried strain Q143 over time (Figure 3.20). M089 and M090 were transferred 
to QCCH after the first 10 days in SMH ward due to medical reasons while M087, 
having the same strain Q143, was never transferred to any other hospital, suggesting 
within-hospital transmission of strain Q143 from M087 to M089-M090 or vice-versa. 
Importantly, twin-pair Q137 and Q138 (within QCCH NICU) carried Q143 strain 3 
days after the arrival of M089 and M090. Neonate Q143, a baby residing with QCCH 
NICU, was colonised with strain Q143 at 3 different time-points prior to NEC 
development (with significant overgrowth of C. perfringens in the gut microbiome as 
indicated by the 16S rRNA gut microbiome analysis), eventually this neonate 
succumbed to NEC, diagnosed as Bell II/III, and ultimately died. 
This data demonstrates the transmissibility of C. perfringens extra-virulent-genotypes 
between neonates in two hospitals, highlighting the importance of high-resolution 
WGS techniques for tracking bacteria at the strain level within health care settings. 
3.5.3.4 Within-ward transmission of C. perfringens 
Based on phylogenetic analysis, within-ward transmission of multiple C. perfringens 
strains was also observed (Figure 3.21). Strain 1 first isolated from neonate Q088 (who 
eventually developed NEC), was detected in another neonate Q106 (control infant) 67 
days after its first detection and close to 30 days after neonate Q088 passed away due 
to NEC, suggesting strain 1 is a persistent strain within the hospital ward. Strain 2 
(extra-virulent genotype) was isolated both from Q088 (NEC) and the matching twin 
sibling Q087 (did not develop NEC), suggesting this strain could be due to maternal 
transmission as it was not detected in any other infants during the two-year period. 
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Neonate Q106 carried three different strains (from three different genetic clusters) 
during 100-day stay at QCCH NICU, demonstrating the underestimated diversity of 
C. perfringens strains present within an individual. 
 
Figure 3.21: Inference of intra-hospital transmission of multiple C. perfringens strains 
(A) Epidemiological map of 4 preterm infants in QCCH NICU showcasing the potential within-ward 
transmissions of NEC-associated C. perfringens strains based on WGS data. Strain identity is defined 
by SNP distance 0-6 SNPs. Black bars indicate hospitalisation periods of infants. Same-colour infant 




This WGS study represents the first of its kind to investigate preterm-associated C. 
perfringens isolates obtained from a preterm cohort of 369 infants collected over 2 
years. These analyses identified hypervirulent NEC-associated genotypes, putative 
avirulent genotypes, and inferred potential intra- and inter- hospital transmission of C. 
perfringens hypervirulent strains via in-depth phylogenomic analyses.  
Previous studies have indicated that a ‘typical’ preterm infant intestinal microbiota 
harbours a higher abundance of Enterococci, Enterobacteriaceae and Staphylococci, 
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and a lower abundance of beneficial bacterial genera Bifidobacterium and 
Lactobacillus 298,299. Importantly, healthy term-infant gut microbiota is dominated by 
the ‘probiotic’ genus Bifidobacterium (particularly in vaginal-delivered breast-fed 
infants), which is linked with improved infant wellbeing 300, and several clinical 
studies have used probiotic supplementation to reduce NEC incidence 268,286,301. From 
the metataxanomic profiling it appears that abundance of Clostridium species 
(including C. perfringens confirmed by culture) correlates negatively with 
Bifidobacterium levels, indicating an antagonistic relationship as shown in infant 
M087, who was also shown to harbour Q143 NEC-associated C. perfringens strains 
(Figure 3.6). Bifidobacterium has been demonstrated, both in vitro and in vivo, to 
antagonise specific pathogens including C. perfringens, although the mechanisms 
underpinning these findings is currently unclear and  further experimental validation 
is required to identify the most effective strains/species of Bifidobacterium that may 
inhibit C. perfringens-related infections 189,302.  
It is apparent that the resident microbiota plays a role in NEC, however WGS analaysis 
also indicated presence of ‘hyper-virulent’ C. perfringens strains in NEC infants. PFO 
gene pfo (or, pfoA) was shown to be more abundantly encoded in all 4 NEC isolates 
(100%) compared to control isolates (38%; P<0.05), indicating the potential virulence 
role of this accessory toxin, which is also known to act synergistically with α-toxin in 
the development of gas gangrene and necrohaemorrhagic enteritis in calves 84,87. This 
pore-forming toxin is known to potentiate the effect of ε-toxin in a mouse model of 
type D enterotoxaemia that primarily occurs in sheep and goats, which disease is 
mainly characterised by sudden death with macroscopic identification of necrotic and 
hemorrhagic lesions in the small intestine, which is similar to clinical findings in NEC  
303,304. Importantly, current dogma suggests that PFO is almost universally encoded by 
C. perfringens, however  in this study only 45% of the C. perfringens strains were 
identified to encode PFO. These data, which includes strains isolated from healthy 
infants, suggests a more ‘pathogenic’ nature for PFO-carrying strains, as most PFO-
carrying C. perfringens currently reported have been isolated from diseased 
patients/individuals/animals 17,25. Additionally, this underrated ‘accessory toxin’ could  
be included in the routine toxin typing scheme in reference laboratories, as this may 
indicate a  risk marker for pathogenic C. perfringens strains in relation to preterm 
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communities. To define what a ‘commensal’ C. perfringens is, with respect to toxins, 
will require a larger-scale genomic study including more healthy control samples. 
Alongside well studied virulence traits, it was notable that other less well studied 
factors were also identified to be enriched in the NEC isolates, including collagen 
adhesin gene cna. This collgen adhesin has been associated with C. perfringens-
porcine enteritis, and  chicken NE 230,305, which indicates that cna may facilitate 
adhesion of C. perfringens within the premature gut, potentially increasing risk of 
NEC-associated pathology.  
HGT plays a key role in emergence of hyper-virulent strains that are associated with 
severe infection. Importantly, analysis of strains indicated that plasmids detected in 
NEC isolate Q143.CN8 and several other strains encoded virulence elements cnaC, 
cpb2 (variant 2) and AMR elements tetA(P) and tetB(P). Comparisons with a similar 
known plasmid pFORC3, indicated that these plasmids are larger, and appear to 
encode additional virulence determinants such as ABC transporters. Notably, CPB2-
var2 encoded on the plasmid (linked to IS1151 in plasmid pCPF5603 previously) also 
known as CPB2h1 (detected in human isolates), was demonstrated experimentally to 
be >10 times more potent than CPB2h2 (CPB2-var1; linked to IS1470-like; more 
similar to veterinary CPB2) in Caco-2 cells, which was previously explained as 
possible host-adaptation 89, and may link to the enhanced pathogenesis of these NEC 
isolates. Importantly, gentamicin (an antibiotic frequently administered to preterms 
residing in NICU), and streptomycin were also reported to induce the expression of 
CPB2 in C. perfringens, which supports the accessory role of this toxin 90. 
As both NEC isolates Q215.CN1 and Q088.CN12 were predicted to encode intact 
plasmid pCP13, this suggests a role for factors encoded on this plasmid to be involved 
in NEC onset: CPB-var1 (more similar to veterinary CPB2, suggesting the veterinary 
source of these isolates), collagen adhesin and ABC transporter (important in AMR). 
Furthermore, the detection of plasmid pM096.3C as reference plasmid pF262A (from 
bovine case isolate F262) suggests another potential veterinary origin of this isolate, 
indicating a potential zoonotic reservoir of these C. perfringens strains 149. 
Interestingly, previously unreported factors, such as surface layer, or S-layer, were 
also detected within these C. perfringens genomes. Previous studies have shown that 
the S-layer plays an important role in both the pathogenesis and intestinal colonisation 
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in pathogenic C. difficile 307,308. However, there has been no S-layer reported in C. 
perfringens, although certain surface envelopes have been suggested 309. S-layer 
homology domain-containing protein was inferred to be encoded exclusively in 
lineages II and III isolates (extra-virulent clusters), which may indicate that S-layers 
in C. perfringens could be associated with the enhanced virulence capacity of these 
clinical strains, however further studies would be required to confirm these findings. 
Tracking of potentially hyper virulent strains is important, particularly within health-
care settings. Indeed, inter-hospital transmission, traced via WGS techniques, has been 
used previously 310,311. Spore-forming C. perfringens is expected to survive harsh 
environments, including on hospital surfaces, by forming endospores, as demonstrated 
in the related pathogen C. difficile. Indeed, this analysis indicates long-term 
persistence of C. perfringens strains in a sterilised hospital environment, as a particular 
strain re-appeared in the same ward, but in a different infant, after 67 days (Figure 
3.21). This could indicate the circulating strain is either present in the environment, or 
the reservoir could as well be healthcare staff 312. WGS surveillance could therefore 
be applied to track certain high-risk clones, as suggested by this work, i.e. extra-
virulent clusters of C. perfringens, to minimise the risk of C. perfringens-associated 
NEC as one of the major factors in preterm NEC 15,30. However, a larger-scale study 
is necessary to gain an in-depth understanding of C. perfringens transmission in 
different hospitals, tracing the routes of transmission, which is essential in infection 
control 312. 
Interestingly, lineages IV-VI consist primarily of strains isolated from healthy preterm 
infants, and which appear less virulent based on the range of virulence factors encoded. 
Circulation of these strains was also apparent, which also indicates hospital ward-
associated strains, or direct transfer from mothers (vertical transmission) to infants 
during birth, as exemplified by those strains existing in matching twin pairs. Further 
studies examining strains isolated from mothers pre- and post-birth would be required 
to confirm this hypothesis.  
A key limitation of this study is the number of NEC strains isolated from C. 
perfringens-associated NEC patients (n=4) compared to control patients (n=33). As 
the prevalence of NEC is low (however fatality is high) among premature babies (5-
15%), isolates from these case patients represent a realistic isolate number from a 
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relatively large longitudinal clinical study involving 369 individuals over a period of 
two years 8,12,73. To date, no specific study has ever described NEC-associated C. 
perfringens from a genomic perspective even though this pathogen has been strongly 
implied in many clinical cases 1. Although this remains an important caveat of this 
current investigation, these data provide novel insights into this unsolved question of 
C. perfringens’ involvement in NEC via genomic approaches. 
In conclusion, these data highlight that ‘hypervirulent’ genotypes of C. perfringens 
may be associated with preterm NEC, and that these strains may be transmitted within 
and between hospital wards. Identification of several important virulence genes 
including PFO may be vital for NEC pre-diagnostic purposes, which requires further 
laboratory validations. Notably, avirulent cluster of isolates were associated with 
‘healthy’ preterms indicating the potential binary nature of this species, a pathogen 
and a commensal. Nevertheless, experimental confirmation will be necessary to 
determine the differential phenotypes of isolates in both clusters. 
 
3.7 Future research directions 
This work represents the first reported large-scale screening of C. perfringens isolates 
from both NEC and healthy preterms (n=369), however, to more fully explore C. 
perfringens populations in preterm infants, a larger-scale multi-site study is required, 
including more frequent clinical samplings and isolation. Alternatively, in-depth 
shotgun metagenomics could be implemented as culture-independent computational 
approach to acquire individual C. perfringens genomes at strain level 313. This type of 
study would help define the potential role of e.g. PFO in preterm NEC, highlighting 
areas for experimental studies into underlying disease mechanisms.    
Tracking pathogens is vital to infection control within hospitals. Real-time 
surveillance of C. perfringens could be proposed in NICUs using new rapid WGS 
approaches e.g. Nanopore sequencing, which allows bacterial genome sequencing in 
under 2 hours 314. This real-time technique also allows rapid pathogen diagnosis via 
metagenomics in NICUs, which time-saving approach (compared to culturing-based 
method) may help identify presence of hypervirulent C. perfringens strains potentially 
<5 h (from clinical sampling to pathogen genotype identification) that could be critical 
in particularly NEC diagnosis 315. Hyper-virulent C. perfringens strains could be 
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predicted based on full toxin profiles and virulence genes including pfo and cna, could 
act as pre-diagnosis biomarkers for potential development of microbial-NEC. For 
routine C. perfringens typing, NEC-associated virulence genes including pfo and cna 
should be included in PCR screening, in addition to the conventional toxinotyping 
based on 6 typing toxins (α-toxin, β-toxin, ε-toxin, ι-toxin, CPE and NetB) for early 
prediction of microbial-NEC.  
To confirm the novel plasmid findings, long-read sequencing techniques e.g. PacBio 
and Nanopore should be implemented to validate the plasmid content. However, 
although there are several very good in silico tools currently used to explore plasmid 
content, this is not definitive and thus plasmid isolations should be performed.  
Crucially, to probe gene-specific disease determinants in C. perfringens-associated 
NEC a robust and clinically relevant animal model is required, as current in vivo 
models do not replicate the infectious component. Therefore, to advance these 
pathogenesis studies, and expedite development of preventative therapies 
development of a suitable in vivo model is required, ideally an economical model such 
as a mouse model. 
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Chapter 4 Phylogenomic analysis of diarrhoea-
associated C. perfringens identifies 
isogenic strains in multiple outbreaks, 
and novel virulence-related features 
 
4.1 Introduction 
This chapter described the phylogenetic and virulence analyses of 109 representative 
C. perfringens isolates recovered from non-foodborne diarrhoea (n=35), associated 
with care home (CH) residents, and FP patients (n=74), obtained between 2011-2017 
in England and Wales from Public Health England (PHE). Isolates were whole-
genome sequenced and in-depth bioinformatics analyses carried out to determine the 
epidemiology of these C. perfringens outbreak strains in tandem with full virulence 
profiling (toxin genes and AMR genes), virulence plasmids detection and comparison, 
and accessory virulence potentials on a strain-level (Figure 4.1). 
 
Figure 4.1: Schematic of dataset and phylogenomic analyses described in Chapter 4 
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4.2 Background 
C. perfringens is an important pathogen known to cause disease in humans and 
animals 84. This Gram-positive spore former has been associated with intestinal 
diseases in humans including foodborne and non-foodborne diarrhoea, and preterm 
NEC 8,24. Notably, the pathogenesis of C. perfringens-associated infections is largely 
attributed to the wide array of toxins this species can produce, with >20 toxins 
identified 10,17 . 
C. perfringens-associated FP, also termed acute watery diarrhoea, was first 
documented in the UK and USA in the 1940s 39. First present-day record of C. 
perfringens-type A FP outbreaks dated back to 1943 when children ate school meals 
severely contaminated with rod-shaped bacteria including C. perfingens 169. Typical 
symptoms appear within 8-14 hrs after food ingestion of live bacterial cells include 
intestinal cramp, watery diarrhoea without fever, and rare vomiting, which are 
normally resolved within 12-24 hrs 172. Suspected C. perfringens-outbreaks are 
defined in the UK as ‘two or more cases of illness with an aetiology suggestive of a 
toxin-mediated infection (point source distribution of cases with a predominance of 
diarrhoea and short duration of illness), and identification of a plausible source of C. 
perfringens exposure (based on analysis by Environmental or Health Protection 
teams), or culture of C. perfringens from one or more faecal specimens’ 316. 
Importantly, C. perfringens is the second most common foodborne pathogen in the 
UK after Campylobacter, however cases are under reported due to the mild and self-
limiting nature of the illness, and current estimate suggest ~ 80,000 cases/annum 
316,317.  
In the UK, AAD and non-foodborne outbreaks of C. perfringens diarrhoea were 
frequently reported in the 1980s amongst the elderly, particularly in hospital settings 
174. With this type of illness, symptoms are more severe than foodborne diarrhoea, and 
are longer lasting (3 days to several weeks), often chronic, and infections are more 
likely to be spread amongst cases 153. This type of C. perfringens infection has also 
been more commonly reported in elderly patients, especially those residing in CHs. In 
the North East of England between 2012-2014, these infections accounted for 83% of 
gastrointestinal CH outbreaks 316. Although fatality is uncommon and hospitalisation 
rate of these illnesses is currently low, C. perfringens gastrointestinal infections cause 
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an estimated 55 deaths/year in England and Wales according to the UK Food 
Standards Agency 318.  
The newly expanded and revised toxinotyping scheme classifies C. perfringens into 7 
toxinotypes (type A-G accordingly; formerly 5 types A-E) according to the 
combination of typing toxins produced 19. Human FP C. perfringens cases are 
primarily caused by type F strains, which produce CPE (encoded by cpe gene) 319. 
This potent pore-forming toxin is also reported to disrupt intestinal tight junction 
barriers, which is associated with intestinal disease symptoms 112. C. perfringens, and 
associated encoded toxins, have been extensively studied with respect to disease 
pathogenesis, with a strong focus on animal infections 87,135,138,230,320. Recent studies 
analysing a range of diverse C. perfringens strains (from both animal and human-
associated infections) has indicated a plastic and divergent pangenome, with a 
significant proportion of accessory genes predicted to be involved in virulence 
mechanisms, that may enhance host colonisation and disease initiation 17. However, 
to date there are limited studies describing human outbreak-associated C. perfringens 
infections, and no known studies have utilised WGS data to probe the genomic 
epidemiology of associated strains 17. 
To address this important knowledge gap, I applied in-depth genomics and 
phylogenetic analyses to whole genome sequences of 109 C. perfringens isolates 
associated with outbreaks or incidents of C. perfringens diarrhoea, either foodborne 
or non-foodborne-derived (mainly in CHs) collected between 2011-2017. 
Furthermore, I also identified the distribution of known virulence-related determinants 
including toxin and AMR genes, virulence-associated plasmid contents, within food 
as well as case isolates, and additionally probed putative functional capabilities of the 
accessory genomes. Importantly, I determined that isogenic strains were associated 
with 9 care-home (CH) outbreaks in North East England between 2013-2017, and 
additionally uncovered the significant involvement of virulence plasmid-carrying C. 
perfringens strains (prevalence of 82%) in these outbreaks. 
 
4.3 Hypothesis and aims 
Specific epidemic strains of C. perfringens are responsible for GI-associated 
outbreaks, specifically aiming to determine: 
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(1) Genomic epidemiology of FP and CH associated C. perfringens isolates. 
(2) Genomic virulence features of these outbreak-linked strains, including plasmids 
and accessory genomes. 
 
4.4 Study population 
Two distinct groups of C. perfringens isolates were obtained via a collaboration with 
Dr Corinne Amar at the Gastrointestinal Bacteria Reference Unit (GBRU) of PHE. A 
total of 35 novel isolates from CH non-foodborne diarrhoea outbreaks mainly in North 
East of England 321, and 74 isolates from different individuals from FP outbreaks 
between 2011-2017 in England and Wales were used in this study, with samples 
sequenced using Illumina platforms at WTSI (isolates PH001-PH090) and PHE 
(isolates PH091-PH156). I performed all the genomic and phylogenetic analyses 
described in this chapter, with computing assistance from Mr Shabhonam Caim for 
the PacBio long-read assembly of reference genome NCTC8239 (from NCTC3000 
project) used in this study. All the supporting materials are presented in Appendix 2. 
Clinical metadata and assembly statistics of isolates, and initial PCR identifications of 
cpe genes are detailed in Appendix 2 Table S4.1. 
 
4.5 Results 
4.5.1 Whole-genome based phylogenetic analysis reveals potential 
epidemiological clusters 
Initially, I analysed the population structure of all isolates sequenced associated with 
FP (n=74), and cases of diarrhoea from CHs (n=35) (Figure 4.2). The majority of CH 
isolates nested within cluster VIII, which implied a regional-specific (North East 
England) relationship among strains. Quality of the genomic assemblies of draft 
genomes was also determined (Figure 4.2C); >70% of isolates assemblies were <200 
contigs.  
Separate analysis of CH isolates indicated two distinct phylogenetic clades (Figure 
4.3A), with lineage I containing the reference genome NCTC8239 (from NCBI 
RefSeq database), a historical cpe-positive isolate (from salt beef) associated with an 
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outbreak of FP 39. The remaining isolates were within another clade, residing within 
lineages II, III and IV (clusters assigned via hierBAPS analysis) indicating these CH 
isolates may be genetically distinct from typical FP isolates as in Figure 4.2A.  
 
Figure 4.2: Population structure and sample distribution statistics for genome assemblies 
(A) Population structure of 109 C. perfringens isolates analysed in this study. Mid-point rooted maximum-
likelihood phylogeny inferred from 73,882 SNPs identified in 110 diarrhoea-associated C. perfringens 
isolates (including NCTC8239). The colour-coded rings indicated cohort-specific origins of isolates. 
Cluster VIII (green ring; clusters determined via hierBAPS clustering analysis) consists of primarily 
isolates obtained from multiple care home-associated outbreaks. Historical food poisoning isolate 
NCTC8239 was used as a public reference genome as indicated in the figure. Bootstrap values are 
represented in the tree. Branch lengths are indicative of the estimated nucleotide substitution per site 
(SNPs). (B) Temporal distribution of all 109 C. perfringens genomes included in this study. (C) Contig 
count distribution of C. perfringens genome assemblies in this study. More than 70% of the total 
assemblies are <200 contigs. 
 
Interestingly, 18 closely-related strains from North East England were observed to 
nest within lineage IVc (Figure 4.3B), which were obtained from 9 different CH 
outbreaks between 2013-2017. This suggests a close epidemiological and 
geographical link within this lineage, as confirmed by core-gene SNP investigation, 
indicating all these isolates lie within pair-wise genetic distances of <80 SNPs (29.9 ± 
16.6 SNPs; mean ± SD; Appendix 2 Table S4.2).  
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Figure 4.3: Phylogenomic analysis of care home-associated C. perfringens isolates 
(A) Mid-point rooted maximum-likelihood phylogeny inferred from 64,560 SNPs (in core gene alignment) 
identified in 35 care home-associated C. perfringens isolates. The colour strips indicate diarrhoea 
outbreaks, location of outbreaks and fAFLP types respectively corresponding to the isolates. Branch 
lengths are indicative of the estimated SNP distance. Lineages and sub-lineages were determined via 
hierBAPS (level 1 & 2) clustering analysis. NCTC8239, a food poisoning isolate, was used as a public 
reference genome in this tree. Bootstrapping values are represented on the tree. (B) Unrooted 
maximum-likelihood tree (inferred from 191 SNPs in 18 genomes) of a sub-lineage IVc showing SNP 
distances in between 18 North-East England-derived isolates of individual outbreaks (labeled in locations 
and years, and SNP range in outbreaks; branches are colour-coded corresponding to individual 
outbreaks). SNP distances between branches are indicated in red numbers. (C) Pairwise within-outbreak 
core-SNP distance between isolates. (D) Pairwise outside-sub-lineage (IVb vs IVc) SNP comparison 
between isolates. Data: Mann-Whitney test. **** P<0.0001. 
 
Notably, outbreak-associated CH isolates (within sub-lineage IVc) were all distinctly 
clustered within individual outbreaks, and pair-wise genetic distances were <20 SNPs 
(Figure 4.3C; 6.6 ± 6.6 SNPs; mean ± SD), compared to outside-sub-lineage (vs sub-
lineage IVb) pair-wise SNP count of 2460 ± 503 SNPs, suggesting potential 
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involvement of an isogenic strain (genetically highly similar) within individual 
outbreaks (Figure 4.3D).  
Importantly, the discriminatory power of WGS analysis was shown to be greater than 
the currently used fAFLP typing method, as fAFLP (type CLP 63, yellow-coded) 
failed to discriminate isolates from 6 different care-home outbreaks (CH outbreaks 2-
7; Figure 4.3A), while SNP analysis clearly distinguished these strains (Figure 4.3B) 
18. 
The FP phylogenetic tree also demonstrated a clear separation of major clades (Figure 
4.4A), where lineage I was a distinct clade from the remaining lineages II-VII. This 
may suggest two genetically distinct clusters of C. perfringens strains that are capable 
of causing diarrhoea in humans. Isolates from 3 foodborne-outbreaks in lineage VII 
appeared to be convergent in the phylogeny. Further analysis indicated that these 
isolates demonstrated geographical heterogeneity; isolates from 2 outbreaks in 
London (2013) were closely related, while isolates from North East (2015) were 
genetically more similar (Figure 4.4B). This may suggest geographical separation of 
a common ancestor at an earlier time point and may also indicate the potential 
widespread distribution of a closely related strain (Appendix 2 Table S4.3).  
Isolates from the same outbreaks appeared to be ‘clonal’ and isogenic, as pairwise 
genetic distances were between 0-21 SNPs (mean genetic distance: 2.6 ± 2.7 SNPs; 
Figure 4.4C), when compared to same-lineage-between-outbreaks SNP distances of 
>1200 SNPs (Figure 4.4D). Importantly, food source isolates were not distinguishable 
from human clinical isolates (genetically similar, 0-16 SNPs) in 7 individual FP 
outbreaks (Figure 4.4A). This is consistent with the hypothesis that contaminated food 
was the source of these C. perfringens FP outbreaks, which included all meat-based 
food stuffs i.e. goat curry, cooked sliced beef, lamb, chicken curry, three-bird roast, 
cooked turkey and cooked meat (Appendix 2 Table S4.1). Notably, isolates from 
different geographical locations converged within the same lineages, suggesting 
circulation and spread of genetically-similar strains between cities and towns, or 
potentially a larger reservoir of C. perfringens within food chains or humans, and 
therefore warrants further large-scale investigation 322. 
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Figure 4.4: Phylogenomic analysis of 75 foodborne-associated C. perfringens isolates 
(A) Mid-point rooted maximum-likelihood phylogeny of food-poisoning C. perfringens inferred from 
70,613 SNPs (in core gene alignment) identified in 75 individual isolates. NCTC8239, a food poisoning 
strain isolated in 1949, (encodes cpe gene) is a RefSeq public reference genome. Lineages were 
determined via hierBAPS clustering analysis. Bootstrap values are represented in the tree. (B) Unrooted 
maximum-likelihood tree inferred from 2,505 SNPs in lineage VII (31 isolates). Four distinct clusters are 
identified in different outbreaks comprising genetically-similar strains (labeled in locations and years, and 
SNP range in outbreaks; branches are colour-coded corresponding to outbreak labels). (C) Pairwise 
core-SNP distance comparison in between isolates within outbreaks. (D) Pairwise core-SNP 
comparisons of within-major-lineage isolates in between individual outbreaks. Lineage I: outbreaks 
1,4,13 and 14; Lineage IV: outbreaks 3 and 7; Lineage VII: outbreaks 2, 7 and 10. Data: Kruskal-Wallis 
test; **** P<0.0001.  
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4.5.2 Care home isolates possess higher virulence capacities 
Diarrhoea symptoms associated with C. perfringens infection are due to the pore-
forming toxin CPE, produced by C. perfringens type F strains 1,323. Additional 
virulence determinants implicated include sialidase (NanI), which has been linked to 
enhanced intestinal attachment and plays a potential accessory role in enhancing CPE 
cell-toxicity 118,182, and also pore-forming toxin perfringolysin (PFO), a toxin known 
to act synergistically with PLC (phospholipase produced by all C. perfringens strains) 
to inflict damage on intestinal cells 87. Moreover, drug-resistant C. perfringens were 
reported to be prevalent, particularly within poultry, thus AMR profiles of C. 
perfringens may be linked with  prolonged C. perfringens associated-infections, and 
may hamper downstream treatments strategies, particularly in vulnerable or immune-
compromised communities 131,183. To probe these important virulence-associated traits 
isolates were screened for toxin and AMR genes, based on both genome assemblies 
and raw sequence reads.  
Enterotoxin gene cpe was detected in all, but 4 isolates (PH017, PH029, PH045 and 
PH156 were cpe-negative), which was confirmed by PCR, with the exception of 
PH029, which was determined to be cpe-positive via PCR (96.4%; Appendix 2 Table 
S4.1). CH isolates (average 9.6 ± 1.0 toxin genes per isolate) encoded significantly 
more toxin genes (P<0.001; Mann-Whitney test) than FP (average 7.3 ± 1.9 toxin 
genes) isolates (Figure 4.5A). CH isolates in lineage II-IV generally possessed 
identical toxin profiles (Figure 4.6A), encoding significantly more toxin genes than 
FP isolates including colonisation-related sialidase-encoding genes nanI, nanJ and 
nagH, hemolysin PFO gene pfo, and cpb2 (Figure 4.5C-G) that transcribes a vital 
accessory toxin CPB2, which is also associated with CPE-mediated pathogenesis 89. 
CH isolates however, did not harbor many AMR genes; 6 isolates (out of 35; 17%) 
encoded tetracycline resistant genes tet(P), one isolate encoded aminoglycoside 
resistant gene APH(3'), and remaining isolates did not encode any acquired AMR 
genes, other than the intrinsic AMR gene mprF.  
In contrast, FP isolates had a more variable virulence gene profile (Figure 4.6B). 
Isolates in lineage I had identical toxin genes, including cpe, but these isolates did not 
encode toxins such as PFO, CPB2 and sialidase NanI, and only 3 isolates in this 
lineage carried tetracycline resistant genes (19%). Most isolates within lineages II-VII 
(92%; 53/58), which were genetically distinct from lineage I, encoded tetA(P). 
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Notably, tetA(P) was significantly enriched in all FP isolates (74.3%; 55/74; 
P<0.0001; Fisher’s exact test; Figure 4.5H) compared to CH isolates (17.1%; 6/35). 
Furthermore, most isolates in FP lineages II-VII also encoded toxin genes cpe, nanI 
and pfo, and 16 isolates (28%) possessed the accessory toxin gene cpb2, statistically 
these isolates (8.0 ± 1.5 toxin genes) encoded more toxin genes than those belonging 
to lineage I (4.9 ± 0.3 toxin genes; P<0.0001; Mann-Whitney test;  Figure 4.5I) 
suggesting isolates in lineages II-VII were more virulent than those in lineage I. 
Importantly, plasmid detection indicated that virulence plasmid pCPF5603 was 
associated with CH isolates (97% in CH plasmid-carrying isolates; 34/35), while 
plasmid pCPF4969 was linked to FP isolates (92% in FP plasmid-carry isolates; 4/49; 
P<0.0001; Figure 4.5J). 
 
Figure 4.5: Comparisons of toxin gene count, enrichments of toxin, AMR gene and plasmids 
(A) Toxin gene count comparison between CH and FP isolates. Data: mean ± SD. Mann-Whitney test. 
**** P<0.0001. Enrichments of variable toxin genes (B-G): (B) cpe (C) pfo (D) cpb2 (E) nanI (F) nanJ (G) 
nagH (H) Percentage of AMR gene tetA(P)-carrying isolates in CH and FP groups. (I) Toxin gene count 
comparison of isolates in FP lineage I and lineages II-VII. Data: mean ± SD. Mann-Whitney test. **** 
P<0.0001. (J) Main virulence plasmids found in CH and FP isolates. Data: percentage of isolates that 
carry either pCPF5603 or pCPF4969 plasmids (excluding isolates not detected to carry any plasmids). 
Data from (B)-(H) and (J): Fisher’s exact test (two-tailed). * P<0.05, ** P<0.01, **** P<0.0001, ns=non-
significant. 
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Figure 4.6: Full virulence profiles of C. perfringens isolates including virulence plasmids 
Binary heatmaps displaying presence and absence of toxin genes, AMR genes, plasmids, plasmid-
related sequences and tcp conjugative loci in corresponding isolates: (A) CH isolates (B) FP isolates. 
Outbreaks were colour-coded according to the colour system in previous figures in this chapter. Coloured 
cells represent presence of genes and white cells represent absence of genes. Heatmaps were 
generated in R.   
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4.5.3 Specific plasmid-associated lineages and potential CPE-plasmid 
transmission 
Most disease-associated toxins secreted by C. perfringens are plasmid-borne, 
including CPE, although notably chromosomally encoded cpe strains are primarily 
linked to food-poisoning 70,324. CPE has been associated not only with FP diarrhoea, 
but also a more severe and durable non-foodborne diarrhoea, which usually lasts >3 
days to several weeks 1,325. However, FP is thought to be caused by type F C. 
perfringens strains that chromosomally encode the cpe gene (e.g. NCTC8239), whilst 
non-foodborne diarrhoea is usually associated with plasmid-borne cpe strains (e.g. 
F5603) 173,322,325. Data in previous section (Figure 4.5C) demonstrated that CH isolates 
(non-foodborne) predominantly harboured pCPF5603 plasmids (33/35 isolates; 97%; 
this plasmid encodes cpb2 and cpe), whilst FP isolates carried primarily pCPF4969 
plasmids (45/75 isolates, 60%; 45/49 plasmid-carrying isolates, 92%; this plasmid 
encodes cpe but not cpb2). Both reference plasmids pCPF4969 and pCPF5603 were 
originally extracted from non-foodborne sporadic-diarrhoea-associated C. perfringens 
type F strains F4969 and F5603 45,326. Findings were confirmed by genome-wide 
plasmid-specific sequence search (pCPF5603:IS1151, pCPF4969:IS1470-like and 
conjugative system tcp genes which are present in both plasmids, Figure 4.6) 43,327.  
To further examine and confirm the predicted plasmids, plasmid contigs (complete 
single contig) were extracted from genome assemblies (3 isolates in both CH and FP 
groups), and compared with the reference plasmid sequence data (pCPF5603 and 
pCPF4969) from NCBI Nucleotide Database (Figure 4.7A-C). The extracted plasmid 
sequences from FP and CH isolates closely resembled the respective reference 
plasmids, with near-identical nucleotide identity (>99.0%), plasmid size and GC 
content (Table 4.1; Figure 4.7B-C), thus supporting the findings that these two near-
identical plasmids (pCPF4969 and pCPF5603) were present in these isolates. 
These data suggested potential circulation and transfer of plasmids in outbreak-
associated C. perfringens, given that pCPF4969 has previously been shown 
experimentally to transfer among C. perfringens strains via conjugation using the 
encoded tcp loci (cpe-positive to cpe-negative strains) 292. The data showed that 
plasmid-cpe C. perfringens strains (these strains did not encode another copy of cpe 
on the chromosome, confirmed by in-depth sequence search) were predominantly 
associated with FP (82.6%; 90/109), rather than previously reported chromosomal-cpe 
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strains (17.4%; 19/109 in this study). Importantly, plasmid transfer may have occurred 
in CH ‘outbreak 7’ isolates (n=4), as two isolates resided within lineage IV, whilst the 
remaining two isolates nested within the genetically distant CH lineage I (genetic 
distance >10,000 SNPs), however all 4 isolates harboured identical plasmid pCPF5603 
(Figure 4.6). This analysis also indicated that multiple distinct strains, but carrying the 






Genome features K-mer 
identity (%) 
(Read-based) 
Similarity by BLASTN 
(Assembly-based) 










pPH077 75,398 25.54 87 99.64% 99.98 100.00 
pPH032 75,402 25.53 87 99.58% 99.98 100.00 










pPH062 70,638 26.59 74 99.66% 99.98 100.00 
pPH041 70,811 26.57 75 99.53% 99.97 100.00 
pPH050 70,624 26.57 75 99.40% 99.98 100.00 
Table 4.1: Similarity comparisons of predicted plasmids with reference plasmids 
Predicted plasmids were compared with reference plasmids pCPF5603 and pCPF4969.K-mer identity 
(based on FASTQ) determined by PlasmidSeeker; BLASTN sequence similarity and coverage 
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Figure 4.7: Investigations on predicted plasmids carried by CH and FP isolates 
(A) Comparative genomic visualisation of reference plasmids pCPF4969 and pCPF5603 with annotated 
features. (B) Genomic comparison of pCPF5603 plasmid and pCPF5603-like plasmids computationally 
extracted from CH genomes. (C) Plasmid comparison in between pCPF4969 plasmid and FP-isolate 
predicted plasmids. (D) CPE-regions (Tn5565) extracted computationally from FP lineage I 
representative isolate assemblies (single contigs in the assemblies but without fIanking IS1470 
elements). (E) An extracted 11-kbp region of NCTC8239 that encodes cpe and flanking IS1470 elements 
compared to predicted plasmid pPH004. (F) Circular form Tn5565 from PH004, illustrated using 
DNAPlotter v17.0.1. Figures A-E were produced using Easyfig v2.2.2.  
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Interestingly, within the FP phylogeny there was a distinct lineage of isolates (lineage 
I) that may encode cpe chromosomally, as no known plasmids, nor plasmid-specific 
sequences were detected. These data support previous studies which indicated that C. 
perfringens with chromosomally-encoded cpe are genetically divergent from plasmid-
cpe carriers, and was further evidenced by historical chromosomal-cpe strain 
NCTC8239 (known to carry cpe on chromosomes) nesting within this lineage (FP 
lineage I; Figure 4.6) 322,326,328.  
To further investigate this hypothesis using genomic approaches, the cpe-encoding 
region (complete single contig from high-coverage assemblies) was extracted from 
representative isolates in lineage I (n=6), and comparative genomics was performed 
(Figure 4.7D). These consistently smaller (~4.0-4.3 kb) contigs were almost identical 
in nucleotide identity (>99.9%) when compared with the cpe-encoding region of 
chromosomal-cpe strain NCTC8239, confirming that these isolates possessed the 
same genomic architecture in the cpe encoding region as NCTC8239 (Figure 4.7E). 
Nevertheless, all these regions lacked the typical flanking elements IS1470 that is 
proposed to be present in chromosomal-cpe carriers (confirmed by genome-wide 
screening of IS1470, no single IS1470 element was detected in genomes of these 
isolates), and was confirmed as transposable element Tn5565 without flanking IS1470 
(Figure 4.7E-F) 173.  
Furthermore, PH029 was the only outbreak isolate not detected to encode cpe within 
the lineage I outbreak cluster, despite having a clonal relationship with PH028, PH104, 
PH105 and PH107 (Figure 4.6B), and indicated Tn5565 loss may have occurred due 
to extensive sub-culturing (this is supported by initial PCR results in the lab being cpe-
positive; see Appendix 2 Table S4.1). The data also indicates that cpe was closely 
associated with IS1469, independent of where it was encoded, as this IS was detected 
exclusively in all cpe-encoding genomes (100% sensitivity and specificity; Figure 
4.6A-B). 
 
4.5.4 Accessory genome virulence potentials 
The 109 C. perfringens isolates analysed in this study had a pangenome consisting of 
6,219 genes (Figure 4.8); 1,965 core genes (31.5%), and 4,254 accessory genes 
(68.5%). Based on these statistics, approximately 30-40% genes in any individual C. 
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perfringens strain are encoded within the accessory genome, potentially driving 
evolution and genome restructuring. Mobile genetic elements (MGEs) including 
plasmids, genomic islands and bacteriophages could potentially contribute to 
virulence, given the plasticity of the genome. To explore this in more detail, I further 
analysed the accessory genomes, comparing different sub-sets of C. perfringens 
isolates.  
 
Figure 4.8: Pangenome analysis of 110 C. perfringens isolates in Chapter 4 
(A) Linearised pangenome of 110 C. perfringens strains in this study including NCTC8239. Visualised 
by Phandango. Statistics showing addition of (B) conserved genes vs total genes and (C) New genes 
vs unique genes per genome during pangenome construction. (D) Proportion of core and accessory 
genes in the pangenome. 
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I first identified subset-specific genes using a bacterial pan-GWAS approach, with 
these genes further annotated based on NCBI RefSeq gene annotations and categorised 
under COG classes into 3 comparison groups: (1) CH vs FP; (2) FP outbreaks; (3) FP 
lineage I, FP lineage II-VII and CH-FP plasmid-CPE isolates (Figure 4.9A-D).  
 
Figure 4.9: Functional analysis of C. perfringens genomes 
(A) Subset-specific accessory genes comparison CH vs FP isolates. (B) Outbreak-specific isolate gene 
counts of COG-assigned food-poisoning accessory genomes. (C) Functional classification (COG) of 
representative outbreak- and group-specific accessory genes in FP isolates. (D) Whole-genome 
functional analysis of representative C. perfringens isolates including reference genome NCTC8239. 
Box (bottom): specific functional description of COG assignments used in this study. 
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Phosphotransferase system (PTS)-related genes (n=4) were encoded exclusively in 
CH isolates (Figure 4.9A and Appendix 2 Table S4.4). These genes might contribute 
to the isolates’ fitness to utilise complex carbohydrates (COG category G) in 
competitive niches, like the GI tract 329. PTS genes have also been related to virulence 
regulation in other pathogens including foodborne pathogen Listeria monocytogenes 
330. Heat-shock protein (Hsp70) DnaK co-chaperone was annotated in the FP-specific 
accessory genome, which may be involved in capsule formation 331. 
Accessory genes specific to each FP outbreak were variable (Figure 4.9B-C), but three 
annotated functional classes were conserved; L (replication, recombination & repair), 
M (cell wall/membrane/envelope biogenesis) and V (defense mechanisms). Prominent 
genes detected in all isolates included phage-related proteins (n=49) (L, M and S), 
glycosyltransferases (n=37) (M), restriction modification systems (n=16) (V), 
transposases (n=9) (L) and integrases (n=8) (L). It was evident that most genes were 
associated with phages, seemingly a major source of MGEs, potentially showing 
isolates’ adaptation to a particular niche. 
Isolates within the FP lineage I (n=17) generally had significantly smaller genomes 
(genome size 2.95 ± 0.03 Mb including NCTC8239; Table 4.2), compared to 
remaining isolates in this study (3.39 ± 0.08 Mb; n=93; P<0.0001), and were most 
similar to reference genome NCTC8239 (ANI≥99.40%), and appeared to lack 
plasmids (Figure 4.6). Correspondingly, less group-specific accessory genes were 
present compared with other isolates in lineages II-VII (Figure 4.9C). Notably, 
multidrug transporter ‘small multidrug resistance’ genes were exclusively detected in 
FP lineage I isolates, whereas ABC transporters were more commonly encoded in 
plasmid-carrying isolates (virulence plasmids pCPF5603 and pCPF4969 carry various 
ABC transporter genes). The Mate efflux family protein gene was detected solely in 
lineage II-VII isolates. 
 
4.6 Discussion 
Using WGS data and genomic analysis this work investigated a representative sub-set 
of 109 gastrointestinal outbreak-associated C. perfringens isolates obtained between 
2011-2017 in England and Wales in collaboration with PHE. Probing population 
variation, virulence-associated genes, plasmid contents and accessory genomes, this 
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study determined potential epidemic phylogenetic clusters and virulence determinants 
that were strongly associated with outbreak isolates. 
 
Table 4.2: Genome comparison of isolates within FP lineage I 
Genome sizes were based on genome assemblies of isolates. ANI (%) of each genome was compared 
with reference genome NCTC8239. 
 
Analysis of CH isolates (defined as non-foodborne outbreaks as no food samples were 
received by PHE that indicate foodborne illness) revealed a cluster of closely-related 
isogenic strains that carried plasmid pCPF5603, which encoded important toxin genes 
cpe and cpb2 (Figure 4.3A-B). Moreover, these isolates also displayed identical 
virulence gene profiles, including the potential to produce up to 10 toxins, which are 
linked to symptoms such as diarrhoea and cramping. These findings were important 
within the context of disease control and prediction/ epidemiology tracking of 
transmission modes, as most recent outbreaks in North East England have been 
reported to occur within CHs, 83% (out of 46 outbreaks) reported in 2012-2014 316. 
Indeed, this cluster of clonal strains was geographically linked to CHs in North East 
Isolate FP Lineage Genome Size (bp) GC (%) ANI (%) 
NCTC8239 I 3,008,497 28.19 100.00 
PH004 I 2,923,443 27.87 99.42 
PH005 I 2,934,006 27.93 99.43 
PH006 I 2,928,275 27.89 99.42 
PH007 I 2,946,980 27.89 99.42 
PH135 I 2,912,738 27.90 99.40 
 PH136 I 2,905,546 27.91 99.40 
PH115 I 2,977,232 27.87 99.51 
PH127 I 2,924,057 27.93 99.47 
PH080 I 2,983,246 27.90 99.47 
PH078 I 2,987,740 27.92 99.47 
PH081 I 2,984,289 27.89 99.47 
PH028 I 2,994,736 27.96 99.64 
PH029 I 2,954,967 27.92 99.65 
PH104 I 2,929,035 27.90 99.64 
PH107 I 2,914,363 27.91 99.66 
PH105 I 2,944,409 27.93 99.65 
Stats (mean ± SD) 2.95 ± 0.03 Mb 27.92 ± 0.07 99.51 ± 0.10 
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England, indicating a specific persistent clone was responsible for most 
gastrointestinal outbreaks in that region. 
A recent investigation into food-chain fresh meat products (>200 samples) indicated 
significant contamination of C. perfringens especially in beef (~30%), followed by 
poultry and pork (both ~26%). Importantly, 90% of C. perfringens strains isolated 
from those meat products were cpe-positive, indicating food chain or farmed animals 
as potential reservoirs of entero-toxigenic C. perfringens strains 322,332. Interestingly, 
18% prevalence of cpe-positive C. perfringens strains had previously been  reported 
in food handlers’ faeces (confirmed via PCR), indicating a potential role of the human 
reservoir in FP outbreaks 333. Moreover, presence of persistent identical C. perfringens 
genotypes within a CH setting was previously reported, which indicated that several 
individuals harboured identical strains (as determined via PFGE profiling) throughout 
a 9-month sampling period, which was linked to CH residence location, however none 
of these isolates were positive for the cpe gene 334. Determination of these potential 
reservoirs in the spread of cpe-positive C. perfringens will necessitate a One-Health-
approach, and large-scale WGS-based screening to ascertain the phylogenomics of 
strains isolated from diverse sources surrounding outbreak-linked vicinities, which is 
important in the context of public health, especially in immune-compromised 
populations including older adults residing within CHs. 
Through computational analysis this study determined that plasmid-cpe (specifically 
pCPF5603 or pCPF4969) carrying strains predominated within the outbreak-related 
C. perfringens isolates (~82%). These two virulence plasmids, pCPF5603 and 
pCPF4969, encoded several important virulence genes including cpe, cpb2 
(pCPF5603 only), ABC transporter and adhesin (also known as collagen adhesion 
gene cna), that could contribute to enhanced fitness and colonisation potential of C. 
perfringens within the GI tract (Figure 4.7A) 50. Interestingly, pCPF4969 also contains 
a putative bacteriocin gene that may allow C. perfringens to outcompete other bacteria 
in the wider gut microbiota, and thus overgrow, initiating disease symptoms 45. 
Typical C. perfringens-associated FP was previously thought to be primarily caused 
by chromosomal-cpe strains, which commonly assembled into  distinct clusters that 
lack the pfo gene, which was reflected in the FP lineage I data from this study 335-337. 
This is due to their phenotypic capacity to withstand high temperatures (via production 
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of a protective small acid soluble protein), and high salt concentrations during the 
cooking process, in addition to the shorter generation time, when compared to 
plasmid-cpe carrying strains 60,70. These chromosomal-cpe strains were also 
demonstrated in this study to possess a significantly smaller genome size compared to 
the rest of the isolates, and importantly they were not known to carry any plasmids. 
Nevertheless, plasmid-borne cpe-carrying strains (pCPF5603 or pCPF4969) have also 
been associated with previous FP outbreaks, albeit this was a relatively uncommon 
occurrence. Thus, it was surprising that these findings indicated nearly all CH outbreak 
isolated strains (97%; 34/35) carried a cpe-plasmid 323,324. Notably, pCPF5603-
carrying strains (encoding IS1151) have also been associated with FP in nursing 
homes in Japan (7 out of 9 isolates), and in this study, 34 out of 35 CH-associated 
isolates appeared to carry plasmid pCPF5603 327. The fact that plasmid-cpe strains 
could cause diverse symptoms including short-lived FP, and long-lasting non-
foodborne diarrhoea, indicates a potential role for the gut microbiome in modulating 
C. perfringens infection. Previous studies indicate that elderly people residing in CHs 
have a less diverse and less robust microbiota when compared to those residing in their 
own homes. This extends to individuals colonised with C. perfringens, which may link 
to the ability for food-poisoning associated C. perfringens strains to overcome gut 
microbiota-associated colonisation resistance mechanisms and ‘take-hold’ and thus 
initiate disease pathogenesis 183,334,338.  
Of note, ‘chromosomal-cpe’ was reported two decades ago to be encoded on a 
transposon-like element Tn5565 (6.3 kb, including flanking copies of IS1470), which 
could form an independent and stable circular-form in culture extracts (losing both 
copies of IS1470) 292,326. This transposition element TN5565 was thought to be 
integrated into the chromosome at a specific site as a unit, however, I observed that 
Tn5565 is potentially an ‘episome’ with both flanking IS1470 excised, instead of 
chromosome-encoded, in 6 of the foodborne isolates, as indicated by computational 
analysis (Figure 4.7D). The fact that computational analysis failed to detect any cpe, 
IS1469 (cpe-specific), and IS1470 (Tn5565-specific) in the high-sequencing-coverage 
PH029 genome (317X sequencing depth/coverage) indicated that Tn5565 can be lost 
or may be passed on to other C. perfringens cells. It should also be noted that flanking 
IS1470 of Tn5565 may not have been successfully assembled during the genome 
assembly process due to the repetitive nature of those sequences (short-read 
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sequencing). However, the loss of the whole element Tn5565 was also observed in 
public genome NCTC8239 (Accession: SAMN02436239; Tn5565 not detected in this 
55-contig short-read assembly but isolate sequenced by NCTC3000 project with 
Tn5565 detected in long-read PacBio assembly used in this study), supporting the 
hypothesis that this mobile genetic element with cpe can be potentially lost, possibly 
via sub-culturing as in the case of PH029. This strongly indicates the mobility of this 
transposable element, which might be critical for transmission and disease control. 
Hence, potential transfer of cpe on Tn5565 to cpe-negative strains may be possible 
(although the underlying plasmid transfer mechanisms will need to be determined), 
thus enhancing spread of food-poisoning C. perfringens isolates. Further 
epidemiology studies and laboratory experiments would be required to fully probe 
these questions.  
As WGS provides enhanced resolution to identify outbreak-specific clonal strains, this 
study highlighted the importance of implementing WGS for C. perfringens profiling 
in reference laboratories, in place of the conventional fAFLP 335,336,339. Routine C. 
perfringens surveillance of the CH environment and staff could prove critical for 
vulnerable populations, as outbreaks could rapidly spread, and this approach could 
potentially pinpoint the sources of contamination, and eventually eliminate persistent 
cpe-strains in the environment 334. In light of the potential rapid transmissibility of C. 
perfringens cpe-strains responsible for food-poisoning outbreaks, real-time portable 
sequencing approaches such as the MinION, could facilitate the rapid identification of 
outbreak strains, which had been recently been reported to identify outbreak 
Salmonella strains in <2h 314,340. 
These data highlighted the genotypic and epidemiological relatedness of a collection 
of C. perfringens strains isolated from disease-associated cases from across England 
and Wales, and indicates potential circulation of these strains, and the potential impact 
of plasmid-associated-cpe dissemination, linked to outbreak cases. This study 
highlights that further WGS phylogenetic and surveillance studies of diversely-
sourced C. perfringens isolates will be required to fully understand the potential 
reservoir of FP-associated strains, so that intervention or prevention measures can be 
devised to prevent the spread of epidemiologically important genotypes, particularly 
in vulnerable communities, including older adults residing in CHs. 
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4.7 Future research directions 
Long-read sequencing of representative samples on PacBio or Nanopore platforms 
especially chromosomal-cpe isolates will confirm whether Tn5565 that encodes cpe 
can be lost via extensive sub-culturing, as long-read techniques are more likely to 
capture the repetitive flanking regions of IS1470 which was not detected in short-read 
(albeit very high coverage) genome assemblies.  
Experimental confirmation of the presence of plasmids pCPF5603 and pCPF4969 can 
be determined in the laboratory via plasmid extraction and plasmid sequencing on a 
sub-set of CH and FP isolates. This will validate the findings using computational 
approaches in this study and potentially obtain novel plasmids not currently known in 
the databases. Additionally, transfer of these virulence plasmids can be tested using in 
vitro and in vivo models to understand the underlying mechanisms of FP and non-
foodborne diarrhoea caused by C. perfringens. 
There exists an opportunity to whole-genome sequence the complete collection of C. 
perfringens isolates at PHE to capture a better picture of the phylogeographical 
information of C. perfringens potential spillover and spread in the UK, which would 
significantly enhance the understanding of this prevalent gut pathogen in the context 
of public health. In addition, this approach will provide insights on the plasmid sub-
types of C. perfringens associated with either general FP outbreaks, sporadic 
outbreaks or those linked with CHs as an extension of this study. 
Care home outbreaks that involve mainly older adult communities has been an 
important issue over the years, with the rise of non-foodborne outbreaks detailed in 
this study, thus to monitor closely the spread of outbreak strains will require a closer 
collaboration with PHE, with additional samples obtained from various CHs 316. The 
main limitation, with respect to in-depth interpretation of these data, was the lack of 
completeness of the clinical metadata obtained from PHE. To pinpoint the key 
association of clinical isolates and strain virulence will necessitate an appropriate 
public health surveillance system to be in place. A potential discussion with PHE to 
improve C. perfringens surveillance and clinical data curation will form a key part of 
the future work plan. 
Importantly, a preliminary gastroenteritis model of C. perfringens has been set up 
during my PhD that is described in Chapter 8. Potentially, foodborne and non-
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foodborne associated C. perfringens can be used to establish novel food-poisoning or 
non-foodborne diarrhoea infection models. This would allow the determination of 
disease mechanisms, and development of translational research including preventative 
measures and therapies, particularly setting up a long-lasting diarrhoea model, which 
will be key to tackle this disease that affects primarily elderly communities. 
Currently there is an obvious lack of WGS information on outbreak-related C. 
perfringens strains. C. perfringens was ranked as one of the top foodborne pathogens 
in several countries including the UK, the USA and Canada (this could also include 
many developing countries were information is not available due to the short-duration 
and under-reporting of this illness) 170,317,341,342.  As C. perfringens foodborne illnesses 
is currently not linked to high mortality rates, this pathogen is understudied at the 
whole genome level, possibly due to limited research funding. However, foodborne 
illnesses is known to significantly contribute to morbidity in  populations, which 
directly impacts on the country’s economy, as reported previously that C. perfringens 
foodborne illnesses caused an estimated economic burden of USD382 million per 
annum in the USA 343,344. To tackle this issue globally, the first step would be to start 
with setting up collaborations with national surveillance units in a number of 
countries, and to whole-genome sequence the collected isolates, thus providing a 
better understanding of the global epidemiology. 
In conclusion, this is the first time C. perfringens-associated outbreaks have been 
investigated via WGS and bioinformatic techniques and demonstrated that isogenic 
strains caused multiple outbreaks particularly in CHs (non-foodborne outbreaks), 
possibly linked to geographical distribution. Moreover, these data indicated that 
plasmid pCPF5603 was associated with CH isolates, while plasmid pCPF4969 was 
exclusively linked to FP isolates. In addition, CH isolates encoded significantly more 
virulence genes (including colonisation-important sialidases, inferring a greater 
capacity in virulence) than FP isolates, which corresponded to the potentially longer 
duration of diarrhoea caused by these strains, compared to the more common short-
lived foodborne diarrhoea. Further works will be required to address research 
questions relevant to the actual spread and impact of C. perfringens foodborne and 
non-foodborne infections. 
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This chapter explores the microbial diversity in the caecal microbiome of healthy 
commercial boiler chickens, and those birds diagnosed with NE- or sub-clinical NE- 
(SNE). It also describes the phylogenetics and comparative genomics on C. 
perfringens isolates obtained from both case and control chickens (Figure 5.1). This 
study was conducted in collaboration with Dr Ron Dixon and Dr Joseph Brown at 
University of Lincoln in 2016. This study aims to understand if the caecal 
microbiomes of broiler chickens can be used to determine specific microbial markers 
associated with NE, and to identify NE-linked virulence genes in C. perfringens 
isolates using WGS and bioinformatics approaches. Field work and bacterial isolation 
were performed by Dr Joseph Brown. I performed all the bioinformatics analyses in 
this chapter unless otherwise indicated in the text or figure legends. 
 
 
Figure 5.1: Schematic of data source and bioinformatics analyses described in Chapter 5 
 
Chapter 5    Poultry NE: Caecal microbiome and C. perfringens    154 
 
5.2 Background 
Broiler chickens are solely bred for meat production, and represent a key global 
livestock member; estimated annual production of 50 billion birds worldwide 345. As 
broilers reach slaughter weight at a young age (4-7 weeks) they are susceptible to 
several welfare and infection issues. Importantly, poultry NE, an inflammatory gut 
infection in chickens, is responsible for a loss of US$6 billion per annum in the poultry 
industry, with C. perfringens reported to be the main causative agent 1,122,124,138.  
NE-associated pathologies are mainly characterised by gaseous lesions and mucosa 
necrosis in the gas-filled distended small intestine 145. Proposed key C. perfringens-
associated factors linked to NE include α-toxin, and more recently NetB and TpeL, 
(both pore-forming toxins) 146. Other aetiological factors that have been shown to 
increase risk of NE include high-protein diets and environmental stressors, which may 
alters gut microbiota/host immunity 148. In addition, SNE, which is a mild form of NE, 
is represented by poor growth and small intestinal ulcerative lesions and has also been 
associated with C. perfringens colonisation 146,346. 
NetB is considered to be an essential C. perfringens virulence factor in poultry NE as 
determined  in animal studies 122. Expression of this pore-forming toxin was reported 
previously to be higher (92%) in NE chickens as compared to healthy chickens (29%), 
thus supporting its vital role in disease progression 123. This toxin is known to be 
encoded exclusively on conjugative plasmids, indicating HGT may play a role in 
dissemination to NetB-negative strains 125. Collagen adhesin (encoded by gene cna) is 
another candidate disease determinant which has been associated with chicken NE 
isolates in a recent bacterial genomic study 230. 
The caecum represents the primary site for C. perfringens colonisation, which also 
contains the highest density of the chicken gut microbiota, therefore NE-induced 
alterations of this GI site are likely to reflect changes including  those microbiota 
members 347. Moreover, the chicken caecal microbiome is known to play a protective 
role in pathogen resistance to other enteric pathogens, including Campylobacter jejuni, 
and as such  intestinal microbiota disruption may impact development of C. 
perfringens-associated NE in broiler chickens, although direct biological impact is yet 
to be confirmed 348-350. 
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To date, it is unclear if and how the chicken caecal microbiome changes during NE 
and SNE, therefore a microbiota profiling study was carried out to understand if there 
are any diseased-specific disturbances induced after C. perfringens infection. 
Moreover, at present there are only two WGS-based studies on chicken-associated C. 
perfringens; one study examined 30 isolates (from both broilers and turkeys), while 
the other profiled 59 isolates (in which 22 were newly sequenced genomes). Thus, to 
further our understanding on C. perfringens virulence in the context of NE, I also 
performed comparative genomics on known isolates (60 chicken/NE- and SNE-
associated C. perfringens strains), alongside newly sequenced strains (22) specific to 
this project 230,290. 
 
5.3 Hypothesis and aims 
Broiler caecal contents exhibit microbiome signatures for poultry NE, and specific 
genotypes of chicken-associated C. perfringens are linked with poultry NE. To 
determine how the broiler gut microbiota changes during NE and SNE, and explore C. 
perfringens virulence potentials associated with disease via: 
(1) 16S rRNA metataxonomic analysis of broiler caecal contents from 11 caecal 
samples, including healthy chickens (n=3), NE chickens (n=3), and SNE chickens 
(n=5). 
(2) Perform comparative genomics on chicken-associated C. perfringens isolates using 
WGS technique from 60 bacterial genomes (22 newly sequenced and 38 public 
genomes). 
 
5.4 Study population 
5.4.1 Caecal microbiome analysis 
Individual caecal samples (n=11; Table 5.1) were obtained in 2016-2017, processed 
(genomic DNA extraction and 16S rRNA library preparation performed by Ms 
Charlotte Leclaire) and sequenced via 16S rRNA sequencing (targeting V1/V2) at 
WTSI. All samples were obtained from poultry farms in Lincolnshire, UK.  
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Sample ID Location Host status 
29 Lincolnshire, UK Healthy control 
2 Lincolnshire, UK Healthy control 
25 Lincolnshire, UK Healthy control 
14 Lincolnshire, UK NE 
33 Lincolnshire, UK NE 
36 Lincolnshire, UK NE 
21 Lincolnshire, UK SNE 
22 Lincolnshire, UK SNE 
26 Lincolnshire, UK SNE 
34 Lincolnshire, UK SNE 
38 Lincolnshire, UK SNE 
Table 5.1: Clinical data of broiler hosts 
Health conditions of chickens of which caecal microbiomes were sequenced and investigated. NE: 
Necrotic Enteritis; SNE: Sub-clinical Necrotic Enteritis. Data: n=11. 
 
5.4.2 Comparative genomics of C. perfringens isolates 
C. perfringens isolates (n=16) were obtained from broiler intestinal samples (Table 
5.2). Environmental strains (n=6) were isolated from chicken feed, surrounding straw 
and soil within the vicinities of poultry farms. 38 public genomes were retrieved from 
NCBI genome database (retrieved in July 2018) and subject to bioinformatics analysis, 
which made the total sample size 60 genomes. These isolates originated from countries 
including England, Belgium, Australia and USA and they can be further categorised 
into 4 groups based on the health conditions of the broiler hosts: healthy (n=14), NE 
(n=37), SNE (n=3) and environmental (n=6).  
 
5.5 Results 
5.5.1 NE and poultry caecal microbiome 
5.5.1.1 Microbiome diversity analysis 
Caecal contents of 11 individual chickens were sequenced on Illumina MiSeq platform 
to generate an average of 115,272 (range: 83,117-164,027) sequence reads per sample, 
with an average of 3,120 (range: 1,780-4,027) OTUs assigned (via QIIME) in each 
sample, clustering at 97% similarity (Appendix 3 Table S5.1). 
 
Chapter 5    Poultry NE: Caecal microbiome and C. perfringens    157 
 
Strain Source Origin Source Hosts 
FR002 In this study England Soil Environmental 
FR006 In this study England Straw Environmental 
FR011 In this study England Soil Environmental 
FR013 In this study England Faeces Environmental 
FR025 In this study England Soil Environmental 
FR063 In this study England Feed Environmental 
11 NCBI Belgium Birds Healthy 
An185 NCBI No information Birds Healthy 
An68 NCBI No information Birds Healthy 
C056 In this study England Birds Healthy 
CR034 In this study England Birds Healthy 
G050 In this study England Birds Healthy 
I056 In this study England Birds Healthy 
I060 In this study England Birds Healthy 
J060 In this study England Birds Healthy 
LLY_N11 NCBI No information Birds Healthy 
PBD1 NCBI Australia Birds Healthy 
PBS5 NCBI Australia Birds Healthy 
PC5 NCBI Australia Birds Healthy 
SAF-1 NCBI Australia Birds Healthy 
37 NCBI Belgium Birds NE 
48 NCBI Belgium Birds NE 
67 NCBI Belgium Birds NE 
96-7415 NCBI USA Birds NE 
98.78718-2 NCBI Denmark Birds NE 
BER-NE33 NCBI Australia Birds NE 
C033 In this study England Birds NE 
C036 In this study England Birds NE 
C55A In this study England Birds NE 
CP4 NCBI Canada Birds NE 
EHE-NE18 NCBI Australia Birds NE 
EHE-NE7 NCBI Australia Birds NE 
EUR-NE15 NCBI Australia Birds NE 
FC2 NCBI USA Birds NE 
GNP-1 NCBI USA Birds NE 
I055 In this study England Birds NE 
I058 In this study England Birds NE 
ITX1105-12MP NCBI USA Birds NE 
J36 In this study England Birds NE 
J55 In this study England Birds NE 
K473 NCBI Australia Birds NE 
NAG-NE1 NCBI Australia Birds NE 
NAG-NE31 NCBI Australia Birds NE 
NobL1 NCBI USA Birds NE 
Pennington NCBI USA Birds NE 
SOM-NE34 NCBI Australia Birds NE 
SOM-NE35 NCBI Australia Birds NE 
SYD-NE41 NCBI Australia Birds NE 
TAM-NE38 NCBI Australia Birds NE 
TAM-NE40 NCBI Australia Birds NE 
TAM-NE42 NCBI Australia Birds NE 
TAM-NE43 NCBI Australia Birds NE 
TAM-NE46 NCBI Australia Birds NE 
UDE95-1372 NCBI USA Birds NE 
W1319 NCBI Australia Birds NE 
Warren NCBI USA Birds NE 
WER-NE36 NCBI Australia Birds NE 
G035 In this study England Birds SNE 
G049 In this study England Birds SNE 
J46 In this study England Birds SNE 
Table 5.2: Information of 60 C. perfringens isolates analysed in this study  
 
Principal Component Analysis (PCA) indicated no distinct clustering of all 11 
samples, indicating NE and SNE may not manifest in distinctive microbiome 
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‘signatures’ (Figure 5.2A). However, disease-specific profiles may be masked by the 
fact that a probiotic mix was given to these broilers as a preventative measure against 
NE development. Indeed, probiotic-associated Bifidobacterium (mean relative 
abundance: 54.17 ± 30.12%; mean ± SD) and Lactobacillus (mean relative abundance: 
27.23 ± 19.27%) genera dominated the caecal microbiomes across all individual 
samples. Therefore, raw reads from these two genera were removed and a new PCA 
performed to understand the correlation of other secondary microbiota members 
(Figure 5.2B). This approach indicates a trend towards health-status clustering, 
however SNE microbiomes overlap with NE and control samples. Notably, healthy 
broiler caecal microbiomes seem to be positively associated with the genera Blautia 
and Ruminococcus, while an inverse relationship with Enterococcus is evident. NE-
associated profiles appear to be dominated by the genera Bacteroides, Clostridium, 
Faecalibacterium and Enterococcus.  
 
Figure 5.2: Clustering of caecal microbiomes via Principal Component Analysis 
PCA demonstrated microbial genera relations with caecal microbiomes obtained from healthy and 
diseased broiler chickens. (A) PCA on 11 microbiome samples. Factor loadings correlates the bacterial 
species with caecal microbiomes. (B) PCA on probiotic-removed microbiomes, revealing secondary 
genus correlations and displayed better clustering. Figures generated in R, using packages ggfortify and 
ggplot2, and functions autoplot and prcomp. 
 
Rarefaction analysis supports the availability of sufficient sequence reads to achieve 
asymptotic, i.e. optimal diversity of richness (at genus level; range: 15-25 genera) in 
each individual sample to represent each member of the microbiota (Figure 5.3). In 
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addition, Alpha-diversity analysis indicates there is no significant difference in genus 
diversity among 3 groups of samples including healthy, NE and SNE (mean range: 
1.83-1.96; Figure 5.3). 
 
 
Figure 5.3: Species richness and diversity analysis of caecal microbiome samples 
(A) Rarefaction curve (species richness) determined of each caecal sample. (B) Alpha-diversity of each 
group. Statistics generated by Mr Shabhonam Caim using R. Each curve is colour-labelled with sample 
ID. This rarefaction curve is generated based on the OTU (at genus level) assigned to the reads. Alpha-
diversity is determined by Fisher’s Alpha Index. Black bar represents mean of each group. Statistics test: 
Dunn’s multiple comparisons test (two-tailed). 
 
Relative bacterial genus abundance in each caecal sample was constructed to visualise 
microbiota profiles (Figure 5.4A). Thirty-eight genera were represented in the 
microbiome, with two genera most abundant, Bifidobacterium and Lactobacillus, 
which likely reflects the probiotic supplementation in the chicken feed.  A number of 
minor genera, which are usual intestinal microbiota members, were detected in these 
samples (relative abundance <10% in each sample) including Blautia, Coprococcus, 
Dorea and Oscillospira. The microbiota member Enterococcus, which is widely used 
as veterinary probiotic (especially Enterococcus faecium), was found at high levels in 
broilers 33 (52.1%; NE) and 38 (31.3%; SNE).  
Sequence reads of highly-dominant genera Bifidobacterium and Lactobacillus (Figure 
5.4B), also Enterococcus (potentially probiotics in origin; Figure 5.4C) were removed 
to visualise minor gut microbiota members of broilers in each group. It appeared that 
Clostridium genus was more prominent in NE group (broilers 14 and 36) than healthy 
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chickens. Notably, Blautia, Dorea, Oscillospira, Faecalibacterium and Ruminococcus 
were present in all broiler microbiotas, although in low abundance. 
 
Figure 5.4: Caecal microbiomes of healthy, NE and SNE chickens 
(A) Relative abundance of read counts on genus rank. (B) Major genera Bifidobacterium and 
Lactobacillus were removed (reads) in this figure. (C) Genus Enterococcus was further removed from 
(B) in this figure. Genera represented ≤0.10% of the total abundance reads are omitted in both figures. 
Broiler samples ID were indicated on the x-axes. Graphs were generated in R. 
 
Using an additional paired-end BLASTN approach in taxa assignment to 16S rRNA 
sequences, a number of important genera were mapped to reference sequences at 
species level (Appendix 3 Figure S5.1) 299. Lactobacillus genus were mainly 
composed of species Lactobacillus reuteri (common broiler gut member, also widely 
used as probiotic supplement), Lactobacillus salivarius (common swine gut 
microbiota member used as broiler probiotic that improves production and general 
health) and Lactobacillus vaginalis (frequently found in broiler gut and a persistent 
gut coloniser) 351-354. Enterococcus genus primarily consisted of species Enterococcus 
faecium, a widely-used probiotic reported to promote broiler growth and suppress C. 
jejuni and C. perfringens infections, while stimulating the growth of Lactobacillus and 
Bifidobacterium 355,356. Importantly, Clostridium genus was mainly assigned to C. 
perfringens sequences, denoting the potential NE-link of C. perfringens origins in NE-
broilers 14 and 36.  
5.5.1.2 Linear Discriminant Analysis (LDA) reveals NE-linked abundant taxa 
To identify taxa (or, OTUs) that varied in abundance consistently within particular 
groups, LDA (based on Kruskal-Wallis test; P<0.05 is considered as significant) was 
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performed with pooled data based on normalised sequence reads of assigned OTUs at 
genus level (Figure 5.5). Clostridium was shown to be significantly enriched within 
NE caecal microbiomes (mean relative abundance: 0.45% vs 0.02% in healthy 
individuals; LDA score: 3.3), confirming the frequent link of Clostridium, especially 
C. perfringens, to chicken NE. Butyrate-producing genus Roseburia increased 
significantly (mean relative abundance: 0.02% vs 0.00% in healthy individuals; LDA 
score:3.3) compared to control group. Interestingly, Staphylococcus genus was 
significantly under-abundant in NE samples. None of the OTUs in the SNE group was 
identified to be significantly varied in abundance. 
 
 
Figure 5.5: Differentially abundant OTUs identified via Linear Discriminant Analysis 
LDA shows three differentially abundant OTUs in categorical groups (healthy vs NE) determined at 
genus level. (A) LDA plot generated via LEfSe. Significant LDA cut-off as 2.5. P<0.05 (Kruskal-Wallis 
test). (B) Group comparison (healthy vs NE) of differentially abundant OTUs via Mann Whitney statistical 
test. *P<0.05. 
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5.5.2 Chicken-associated C. perfringens and virulence potentials 
5.5.2.1 Phylogenetic analysis reveals potential clonal expansion 
To further explore C. perfringens-associated NE and SNE (including 6 environmental 
isolates from broiler farms), a phylogenetic tree of 60 chicken-associated isolates was 
constructed based on 7,750 SNPs extracted from core gene alignment (Figure 5.6). 
Clustering was assigned via hierBAPS analysis and these 60 isolates clustered into 5 
major clades (hierBAPS level 1).  
 
Figure 5.6: Genetic relationship of chicken-associated isolates 
Mid-point rooted maximum-likelihood phylogeny constructed from 7,750 SNPs (in core gene alignment). 
Clusters assigned via hierBAPS analysis (level 1). ATCC13124 and NCTC8239 are reference genomes 
used in this tree. Bootstrap values are shown major nodes in the tree. Scale bar is indicative of nucleotide 
substitution per site. Newly sequenced genomes in this work are labelled in light blue. Green-labelled 
environmental isolates were obtained from chicken farms in Lincolnshire. 
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Two Australian isolates PBS5 and PC5 reside within a genetically distinct lineage I, 
suggesting a fundamental difference in genetic components of these isolates. 
Lincolnshire English isolates mainly reside within lineage V (12/16; 75%), and appear 
to converge within tight clusters, suggesting a close genetic relationship among these 
isolates. Toxinotype profiling indicated, out of 54 chicken isolates, 20 isolates were 
type G (37%; carry netB), 33 isolates type A (61%), and 1 isolate type C (carries cpb).  
Via SNP analysis, identical/highly-similar genetic clusters were determined. Isolates 
C56, I56 (both from the same bird) and J60 (another bird; lineage V) obtained from 
farms in Lincolnshire were determined as identical strains with no SNP difference (0 
SNPs). Another constricted cluster identified consisted of isolates G049, I058, I060 
and J36 (from 4 individual birds in Lincolnshire; lineage V) were determined as 
identical strains (0 SNPs). Isolates J055 and I055 (lineage V), both from the same 
individual bird isolated from different intestinal sites were confirmed as highly-similar 
strains (2 SNPs in pair-wise comparison). Nevertheless, no environmental isolates 
were found to be genetically similar to any NE or SNE strains at SNP level. 
Importantly, several publically available isolates also formed into highly-similar 
clusters. A sub-cluster in lineage IV, comprising 10 isolates obtained from three 
countries USA, Australia and Canada (Table 5.3) was determined to be an isogenic 
cluster (pair-wise SNP range: 1-86). Among these isolates, 4 strains (ITX1105-12MP, 
Warren, CP4 and Pennington) are near-identical (1-3 SNPs), suggesting a potential 
















































































CP4 0 34 3 85 2 36 36 37 35 1 
GNP-1 34 0 35 57 34 8 8 9 1 33 
ITX1105-12MP 3 35 0 86 3 37 37 38 36 2 
NAG-NE31 85 57 86 0 85 59 59 60 58 84 
Pennington 2 34 3 85 0 36 36 37 35 1 
TAM-NE38 36 8 37 59 36 0 0 5 9 35 
TAM-NE40 36 8 37 59 36 0 0 5 9 35 
TAM-NE46 37 9 38 60 37 5 5 0 10 36 
UDE95-1372 35 1 36 58 35 9 9 10 0 34 
Warren 1 33 2 84 1 35 35 36 34 0 
Table 5.3: Pairwise-SNP comparison between isolates in clonal sub-lineage within lineage V 
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5.5.2.2 Virulence association study suggests combinatory role of toxin and 
adhesin genes in NE 
Virulence profiles of these 60 chicken-associated isolates were also determined 
including toxins, AMR genes and collagen-binding protein/collagen adhesin (CBP; or, 
collagen adhesin), which was recently linked to C. perfringens NE-genotypes as 
represented in Figure 5.7 230. Using statistical test (Fisher’s exact test), NE-trait 
associations were determined based on 14 control isolates and 37 NE isolates (Figure 
5.8). 
 
Figure 5.7: Toxin, AMR and collagen-binding protein profiling of chicken-associated isolates 
Coloured cells indicate presence of genes, white cells represent absence of genes. CBP: Collagen-
binding proteins (collagen adhesin). Data: n=60. Heatmap was generated in R. 
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Figure 5.8: Enrichment of key virulence genes in control and NE case isolates 
(A) Comparison of total virulence gene counts between control (n=14) and NE (n=37) isolates. 
Comparisons of gene enrichments in between groups as follows: (B) netB (C) pfo (D) cpb2-var2 (E) cna 
(F) cnaA (G) cnaC (H) cnaD. Data: (A) Non-parametric Mann-Whitney test U test, two-tailed. () to (H) 
Fisher’s exact test, two-tailed. *P<0.05, **P<0.01, ***P<0.001. 
 
NE determinant NetB toxin gene netB was significantly enriched in NE isolates (51%; 
19/37; P<0.001), compared to control isolates (0%; 0/14) confirming previous findings 
on this NE-causing virulence gene (noting that environmental isolate FR063 also 
encoded netB) 122. Haemolytic toxin PFO was encoded in all but one NE isolates 
(97.2%), suggesting its important role, although most control isolates (11/14; 78.5%) 
also carried this toxin. Accessory toxin gene CPB2 (variant 2, which was known to be 
>10 times more necrotic that CPB2-variant 1 in human cells) was encoded more 
abundantly in NE isolates (P<0.05). Importantly, collagen adhesin variant genes cna 
(P<0.05), cnaA (P<0.005) and cnaC (P<0.05) were all determined to be significantly 
enriched in NE isolates, with cnaA entirely absent from control isolates (0/14; 0%), 
but present in 40% (15/37) of the NE isolates. A similar trend was observed for cna, 
only 1/14 (7%) control isolates, but 46% (17/37) of NE isolates carry this gene, 
confirming the strong association as observed in a previous study 230. 
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AMR genes emeA (encodes multidrug-efflux pump) and ermB (Macrolide-
Lincosamide-Streptogramin resistance; MLS) were each detected in one isolate (AMR 
genes frequently carried by E. faecalis) 229. Other AMR genes including tetA(P), 
tetB(P) and ermQ were frequently (31/51 isolates carried at least one of these genes) 
encoded in the examined isolates. Notably, 39.2% of the health and NE isolates (n=51) 
did not carry any acquired AMR genes. 
Additionally, these data suggest that numerous virulence potentials in NE-associated 
isolates may play a combinatory role in disease pathogenesis, as NE isolates carry 
significantly more virulence genes (n=8) than control isolates (n=4.5; P<0.005), 
implying the vital role of accessory virulence genes, rather than a particular major 
causative toxin gene in disease pathology. 
Potential combinatory effects of virulence genes were further investigated by Fisher’s 
exact test (Figure 5.9). Co-occurrence of 4 virulence determinants including toxin 
genes netB, pfo, cpb2 and CBP genes (≥1 cna variants) were significantly enriched in 
51.3% (19/37) of NE isolates, but not in control isolates (P<0.01; Figure 5.9A); 
combinations of three (pfo + cpb2 + CBP; Figure 5.9B) and two (CBP + either pfo or 
cpb2; Figure 5.9C-D) were also more abundantly detected in NE than control isolates 
(P<0.05). Hence, this data supports the crucial role of co-occurrent toxin and adhesin 
genes in C. perfringens-associated broiler NE. 
 
 
Figure 5.9: Comparison of key combinatory virulence genes in control and NE isolates 
Comparison of total combinatory virulence gene counts between control (n=14) and NE (n=37) isolates 
as follows: (A) netB + pfo + cpb2 + CBP (B) pfo + cpb2 + CBP (C) pfo + CBP (D) cpb2 + CBP. Data: 
Fisher’s exact test, two-tailed. *P<0.05, **P<0.01. CBP: collagen-binding protein (n≥1). CBP: Collagen-
binding proteins. 
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5.6 Discussion 
Although this was a small-scale study, healthy broiler caecal microbiomes were found 
to have enhanced abundance of the genera Blautia. Members of the Blautia genus are 
known to be butyrate producers, and reductions in this genus have previously been 
associated with a C. jejuni infection model 357. Moreover, Blautia obeum (later 
reclassified as Ruminococcus) has also been demonstrated to restrict the colonisation 
of gut pathogen Vibrio cholerae 358,359. As butyrate is an important energy source for 
intestinal cells, these Blautia spp. may act as key beneficial microbiota members, 
serving to enhance intestinal health of chickens by strengthening the epithelial barrier, 
thus preventing pathogenic microbes successfully colonising and initiating disease. 
Microbes associated with NE included Clostridium, Faecalibacterium and 
Enterococcus. Previous studies have indicated that Enterococcus (E. cecorum) is a 
poultry pathogen implicated in multiple disease representations such as sepsis and 
arthritis 360. In this study, species-level taxa assignment of the caecal samples indicated 
that E. faecium, which is also commonly used as a probiotic (no corresponding dietary 
information for broilers sampled in this study mean it is unclear if this was used as a 
probiotic), was likely the dominant species (although this approach is not ideal given 
the short length of the 16S rRNA V1+V2 sequences). This suggests that E. faecium 
(which is also associated with human intestinal disease) may be associated with NE as 
evidenced by the PCA analysis 356. Furthermore, Clostridium and Faecalibacterium 
were shown to increase in a C. jejuni chicken caecum infection model, implying their 
potential role in disease development 357. 
Clostridium genus, as identified in caecal microbiome data via LDA analysis, was 
significantly enriched, albeit at low levels, in NE individuals. Further species-level 
assignment indicated that sample 33 Clostridium OTUs mapped to C. perfringens 
(89.6% reads mapped to C. perfringens at species level; 629/702 sequence reads), 
indicating that even a small proportion (relative abundance: 0.45 ± 0.28%; mean ± 
SEM) of C. perfringens could be lethal to broiler hosts. Therefore, microbiota 
profiling of Clostridium may be useful as a potential biomarker for NE-onset, however 
larger studies would be required to verify these findings. 
Genus Roseburia, a normal intestinal microbiota member in both human and broilers, 
was frequently linked with healthy gut biomarkers as this genus of bacteria produces 
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the colonic fuel butyrate, which aids in epithelial barrier maintenance and helps restore 
beneficial gut microbiota 361,362. The significant enrichment of beneficial genus 
Roseburia, unlikely to be involved in NE pathology, was detected in NE samples 
(relative abundance: 0.02 ± 0.002%; mean ± SEM) could be a biased result due to 
complete genus absence (relative abundance: 0.00%) in all control isolates which is 
likely a consequence of limited number of samples (n=3). 
Probiotics, including Bifidobacterium and Lactobacillus, potentially also 
Enterococcus, have been frequently used in broiler farming primarily for the purpose 
of growth-promotion and prevention of bacterial infections 353,363,364. These taxa of 
beneficial bacteria have been reflected in caecal microbiome analysis, with 
predominant OTU proportions been assigned to Bifidobacterium and Lactobacillus 
across all samples. No significant changes in the OTU proportions of these two 
probiotics across three groups (P>0.20). Nevertheless, species-level analysis showed 
that predominant taxa L. reuteri and L. vaginalis are both frequently found in broilers’ 
gut and are persistent strains, therefore, I could not determine whether these strains 
were supplemented or inherent, due to the lack of reliable metadata 351,354. In addition, 
these data also could not definitively verify the colonisation of these probiotic-
associated genera in broilers’ intestines, or whether the high levels are more transient 
in nature, as it is common practice in poultry farms to administrate these strains in 
large amounts within the feed. Interestingly, supplementation of Lactobacillus was 
reported to increase the intestinal abundance of beneficial gut member Roseburia, 
which was not observed in this study (0.00% abudance in all control birds), further 
suggesting that the presence of Lactobacillus might be transient rather than persistent, 
although this effect can also be strain-specific 365. 
It has been consistently reported that Clostridium, particularly C. perfringens, is the 
primary infectious agent to cause chicken NE, further supported by the caecal 
microbiome profiles obtained in this study. As C. perfringens thrives at ambient bird 
body temperature (i.e. 40-42ºC), with a doubling time <8 mins in vitro (the shortest 
generation time known for a microorganism), this may link to its ability to rapidly 
overgrow and cause disease pathology 70. Moreover, as C. perfringens can secrete >20 
identified toxins, including NetB toxin which has been identified as an essential toxin 
in NE development, this also emphasises strong links between this pathogen and 
broiler-associated NE 121,125. I also determined most NE isolates encoded NetB and 
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that isolate FR063 (obtained from chicken feed) carries this toxin, which suggests NE-
associated strains may be sourced from the environment including feed and bedding, 
potentially acting as reservoirs, linked to NE outbreaks 366.  
Several studies indicate that collagen adhesin (encoded by cna) is also an important 
NE virulence factor 306,367,230,290. Collagen adhesin is known to facilitate bacterial 
colonisation within the gut, and in this study, this gene (including its variants cnaA 
and cnaC) was overabundant in NE-associated isolates (P<0.05), suggesting a strong 
association with NE outcome 367. Therefore, successful colonisation mediated by 
collagen adhesins could play an essential role in chicken NE development and NetB-
mediated pathology. 
PFO has been linked with bovine haemorrhagic enteritis 87, and a trend for presence 
of this toxin was also apparent in NE isolates. Furthermore, CPB2, or beta2-toxin, 
particularly variant 2 (known to be 10 times more toxic than variant 1 in human Caco2 
cells) was also found to be significantly enriched in NE isolates (P<0.005) 89, 
indicating that accessory toxins may also play an underrated role in chicken NE. 
In silico analysis indicates that the virulence capacity of C. perfringens linked to NE 
is mediated by a range of genes encompassing colonisation factors and toxins. Indeed, 
in contrast to previous studies, half of NE isolates did not encode NetB, suggesting 
this toxin alone may not be ‘essential’ for NE-associated pathology, and other 
accessory toxins such as CPB2 may also be involved. As these other factors appear to 
be important for NE, it could be proposed that e.g. cna variants should form part of 
the routine typing scheme to trace C. perfringens strains. These findings were 
supported by combinatory effects analysis, which demonstrated that co-occurrent 
virulence genes including netB, pfo, cpb2 and cna variant genes were associated with 
NE isolates (P<0.05) and may play an important role in NE disease progression 230.  
An important finding from this small-scale WGS-based analysis indicates cross-
continental clonal expansion in lineage (IV), as isogenic isolates were obtained from 
three different countries (USA, Australia and Canada). These data indicate global 
dissemination of NE-associated virulent genotypes, which is in agreement with a 
previous study that indicated clonal expansion of C. perfringens via multiple-locus 
variable-number tandem repeat analysis (n=328)368. To further determine the 
population structure of C. perfringens strains using WGS approaches, significantly 
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larger sample sizes will be required, which will allow a deeper understanding on the 
spread of C. perfringens in chicken farms worldwide, which is vital in the context of 
disease control. 
An obvious limitation of the microbiome study is the limited number of caecal samples 
available to determine the microbiome diversity of broiler chickens (n=11). In 
addition, the overabundance of genera Bifidobacterium and Lactobacillus could have 
masked the microbiome signals from other bacterial members, consequently, relative 
abundance alone could not be used to understand the associations of NE traits with 
caecal microbiomes, which necessitates other approaches including LDA as 
performed to determine differentially enriched OTUs 239,369. Importantly, poor 
metadata involving clinical statistics of the broiler hosts is also an apparent issue in 
further interpreting the isolate and caecal sequencing data presented in this chapter.   
 
5.7 Future research directions 
A more advanced, time-saving and in-depth shotgun metagenome technique can be 
applied to investigate disease-related caecal metagenome and related bacteria at 
species level. This will provide profound insights into the species- and strain-level 
information and functionalities of broiler caecal microbiome dynamics in diseased 
states. More importantly, with current single bacterial genome reconstruction in silico 
technique possible, de novo bacterial genomes can now confidently be extracted from 
shotgun metagenome data and subjected to further genomic analysis 313. 
The need of a larger sample size on caecal contents is apparent for future studies, 
including longitudinal caecal samples overtime would be required to understand the 
microbiota changes leading to disease progression.  
In conclusion, this small-scale caecal microbiome study identified Clostridium genus, 
particularly C. perfringens, as potential NE-associated caecal biomarker. Importantly, 
genomic analysis on 60 broiler-associated C. perfringens isolates indicates the 
potential farm-soil reservoir of NE-causing netB-positive strains, and the important 
role of co-occurrence of virulence genes (netB, pfo, cpb2 and cna variants) in NE 
disease progression. Furthermore, global clonal expansion of NE-associated C. 
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perfringens highlights the need for further investigation, which requires a large 
worldwide dataset on NE-related C. perfringens isolates.  
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Chapter 6 Population genomics of C. perfringens 
suggests potential zoonotic relevance, 




C. perfringens is a multi-host pathogen involved in numerous intestinal diseases in 
both humans and animals 1. Despite its medical importance, there is a significant lack 
of WGS-based studies probing the genomic relationships of this enteric pathogen.  My 
most recent published work using phylogenetic-based investigation analysed up to 56 
isolates (article reproduced in Appendix 7) identified a significant number of 
accessory genes (87.4%) within the pangenome. These data clearly highlighted that a 
much larger genomic study was required to fully explore C. perfringens genetic 
diversity. In this chapter, I have used WGS to examine an unprecedented 552 C. 
perfringens genomes obtained from a wide range of hosts (12 host species; from 
human adults to zoo animals) and multiple geographical regions (10 countries) 
spanning the past 90 years (1930s-2017), to explore the genomic population structure 
of this pathogen, determine diseased-linked phylogenetic clusters, and gain insights 
into its epidemiology and associated virulence features (Figure 6.1).  
This genomic-based work encompasses 552 genomes: 71 genome assemblies were 
retrieved from NCBI assembly databases; 22 genomes of NCTC isolates were re-
assembled for this analysis; 443 isolates were newly sequenced during my PhD 
including 101 (88 genomes +13 genomes analysed for within-host SNP variation) 
genomes described in Chapter 3, 109 genomes investigated in Chapter 4, 22 genomes 
examined in Chapter 5, and 249 are novel isolates analysed in this work, representing 
the largest phylogenetic and comparative genomics study on C. perfringens to date. 
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Figure 6.1: Schematic overview of data sources, analyses and inferences in Chapter 6 
 
6.2 Background 
C. perfringens-associated intestinal diseases have been described in humans and 
animals since 1890s when this pathogen was first isolated and named as C. welchii 370. 
C. perfringens is known to mainly affect early- and later-life individuals, including 
NEC in preterm infants, haemorrhagic enterocolitis in calves, enteritis in foals, 
enteritis in dogs, NE in chickens, and FP in humans, particularly older adults in CHs 
1,316. Descriptions of these diseases have been covered in Chapter 1. Conventionally, 
clinically-obtained C. perfringens strains are currently typed and classified into 7 
toxinotypes (A to G) according to the combination of typing toxins they encode 
(typing toxins are primarily carried on plasmids) to confirm disease symptoms and 
identify outbreak-associated strains 19,316. This typing system has contributed 
significantly to our understanding of C. perfringens epidemiology in the past century, 
particularly in animal agriculture 125. 
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While WGS is increasingly being applied to bacterial pathogens in recent years, 
providing greater insights into the epidemiology and pathogenesis, very few studies 
(n<5) have applied this comprehensive approach to C. perfringens 335,336,371. 
Moreover, WGS also offers better understanding of pathogens’ genomic contents, 
including capturing information on virulence and AMR genes, and genetic 
relationships to infer spread and transmission of microbes, which surpasses the 
resolutions that can be obtained using routine laboratory typing methods, including 
fAFLP and multilocus sequence typing (MLST), as demonstrated in Chapter 3 to 
Chapter 5 150,372,373. 
Previous WGS-based studies on C. perfringens have investigated host-specific isolates 
(chickens), and limited numbers of isolates (n=56), which have contributed to our 
phylogenetic understanding 17,230,290. In this work, I have applied WGS approaches to 
552 C. perfringens strain genomes, which encompass publicly available sequences 
from the NCBI genome database (comprising historical isolates dated from the 1940s 
and contemporary strains, n=112), and a newly sequenced collection generated during 
my PhD (from across the UK and Ireland [n=443] via collaborations with numerous 
research groups). This study reports the novel findings of these large-scale 
comparative genomics and phylogenetic investigations. 
 
6.3 Hypothesis and aims 
C. perfringens is a genetically diverse, zoonotic and widely-disseminated pathogen. 
This chapter aims to understand the genomic population structure and specific disease-
related traits of C. perfringens using a large international collection of isolates, 
specifically determining: 
(1) The pangenome of 552 C. perfringens isolates, both newly sequenced and publicly 
available genomes. 
(2) The population structure of C. perfringens isolates, targeted at identifying specific 
disease-related lineages. 
(3) Potential zoonotic relationships between human- and animal-derived isolates, 
aiming to identify disease-linked virulence genes. 
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(4) In-depth genetic relationship between strains of specific medically important 
lineages on SNP level, to identify potential disseminations of C. perfringens strains. 
 
6.4 Study population 
The dataset encompasses a wide range of isolates obtained from humans (n=417), 
including adults, older adults, children and infants (both healthy and diseased), 
animals (n=113) including chickens (NE and healthy), dogs, horses, cows, pigs, sheep 
(primarily diseased individuals) and healthy zoo animals, 6 environmental soil 
isolates, and 14 isolates from public databases with source undetermined (Figure 6.2; 
Appendix 4  Table S6.1). Geographically, isolates originated from England (highest 
proportion of 68%; 380/552), Scotland (5), Wales (4), Ireland (17), Belgium (4), 
Denmark (1), Switzerland (2), Canada (12), USA (27) and Australia (21; Figure 6.4). 
Isolates were obtained from as early as 1930s (historical strains from NCTC 
collection) to contemporary isolates collected in 2017, and notably for this study 
include a comparable proportion of healthy and disease-isolated strains (healthy vs 
diseased: 43.6% vs 55.2%). These data provide the largest and most diverse genomic 
picture of C. perfringens to date, enabling construction of phylogenetic relationships 
between historical and present-day isolates from different geographical locations, and 
healthy versus disease-associated strains, thus allowing determination of certain 
disease-related phylogenetic clusters, which is vital for understanding C. perfringens 
dissemination and evolution.  
All genome assemblies were determined (pair-wise alignment via mummer) to have a 
genome-wide ANI >95%, which confirms the C. perfringens species delineation 
(Appendix 4  Table S6.1) 217. The majority of genome assemblies are of high quality 
within 1-100 contigs (89.3%; 493/552), with 75.7% (418/552) classified as very high-
quality assemblies at 1-50 contigs (high integrity).  
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Figure 6.2: Statistics of C. perfringens genomes described in Chapter 6 
(A) Number of contigs in the assemblies. (B) Isolate categories according to isolation region. (C) Isolate 
categories according to human/animal/environmental sources. (D) Isolate categories according to hosts. 
(E) Isolate categories according to health conditions. 
 
6.5 Results 
6.5.1 Construction of pangenome and phylogeny 
6.5.1.1 Pangenome construction reveals genome plasticity 
A total of 552 genomes were used to construct a pangenome of 1,251 core genes and 
15,500 accessory genes (Figure 6.3). A phylogenetic tree was constructed based on 
SNPs in the core gene alignment (Figure 6.5). Both bootstrap values (well-supported 
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in all major nodes, values range: 93-100), and hierBAPS analysis confirmed accurate 
phylogenetic clustering of isolates. 
Previously I reported a snapshot of C. perfringens pangenome plasticity (core genome: 
12.6% in the pangenome) based upon 56 C. perfringens isolates 17. Notably, the 
pangenome of 552 C. perfringens described in this section demonstrated a 
significantly higher diversity; 7.4% core genome (pangenome-wide), equivalent to 
~40% core genes (1,251/3,000 genes) in a single C. perfringens genome 
(approximately 3,000 genes per genome).  
6.5.1.2 Phylogeography demonstrate distinct sub-clusters 
Using hierBAPS, all isolates (n=552) clustered into 11 major distinct clades (Figure 
6.4A; I-XI). The data did not demonstrate strong phylogeographical clustering which 
was indicative of frequent transmission between regions. Clonal sub-clades appear to 
exist in several clusters including lineages II, III, X and XI. The complete phylogenetic 
tree with annotations is available on iTOL13. 
6.5.1.3 Distinct lineages implicate potential subspecies delineation 
ANI was also examined for 552 C. perfringens genomes (pair-wise comparison). In 
relation to type strain ATCC13124 genome, ANI analysis indicated that all genomes 
belong to C. perfringens at species level of >95% (range: 95.95-99.20%; mean ± SD: 
98.22 ± 0.69%). The majority of genomes (445, 80.6%) shared ANI > 98.24% with 
type strain ATCC13124, while the remaining 107 genomes (19.4%) had 95.95% ≤ 
ANI ≤ 97.89% (Figure 6.4B). This may indicate potential subspecies delineation of 
isolates within genetically distinct lineages I and II (ANI: 95-96%) and lineages III 
and V (ANI: 97%), while the difference of 0.35% ANI between the highest ANI in 
lineage V (isolate NCTC8449) and the rest of the lineages (isolate Q100.CN12; 
excluding lineages I, II and III), further supports the substantial genetic difference, 
which is also exemplified by the deep branching phylogeny. 
                                                 
13 https://itol.embl.de/tree/149155215181110611541772786 
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Figure 6.3: Pangenome constructed from 552 isolates of C. perfringens 
(A) Linearised pangenome visualised by Phandango aligned with mid-point rooted core-genome 
phylogeny with host labels. (B) New genes vs unique gene statistics, with pangenome statistics. (C) 
Core genes (conserved genes) vs total genes statistics. Statistical plots generated via R. 
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Figure 6.4: Phylogeography of 552 C. perfringens strains 
(A) Mid-point rooted maximum-likelihood phylogeny inferred from 11,349 SNPs (from alignment of 1,251 
core genes) identified in 552 C. perfringens genomes. The ring indicates the regions of isolation. Branch 
lengths are indicative of nucleotide substitution per site. Phylogenetic clustering identified via hierBAPS 
analysis. Some commonly known isolates are labelled in the tree including ATCC13124, str 13, F4969, 
FORC025, NCTC8081, NCTC8239 and SM101. (B) ANI (%) comparison of 552 isolates in this study in 
relation to reference genome ATCC13124. Isolates of specific distinct and deep-branching lineages (I, 
II, III and V) indicate potential subspecies delineation according to ANI. 
 
6.5.2 Potential inference of zoonotic dissemination 
C. perfringens has consistently been implicated in both human and animal diseases 1. 
Nevertheless, no study to date has ever investigated the potential zoonotic transfer of 
this pathogen, inferred via WGS techniques, due to scarcity of genomic sequence data 
(only 58 C. perfringens genomes available prior to June 2018, which has recently risen 
to 112 in November 2018) 374. To understand potential zoonotic reservoirs, an in-depth 
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pangenome and robust phylogenetic analysis is required and will be addressed in this 
chapter. 
6.5.2.1 Phylogenetic analysis 
The genetic diversity of C. perfringens was assessed via phylogenetic analysis. One 
striking initial observation was co-clustering and extensive mixing of animal and 
human isolates (Table 6.1; Figure 6.5), indicating potential zoonotic spread between 
humans and animals, especially within lineages IV and VI (Figure 6.5A). Strains in 
lineage VII-XI were mainly associated with humans (95.6%; 297/311), while lineage 
III was dominated by animal isolates (76.2%). Human isolates were also predominant 
in lineages I (83.3%), II (81.0%) and V (94.8%).  
 
Lineage Human isolates (%) Animal isolates (%) P-value  
I 83.3 (5/6) 16.7 (1/6) >0.99 
II 81.0 (17/21) 19.0 (4/21) >0.99 
III 23.8 (10/42) 76.2 (32/42) <0.01** 
IV 40.0 (6/15) 60.0 (9/15) <0.01** 
VI 54.7 (58/106) 45.3 (48/106) <0.01** 
VII-XI 95.4 (297/311) 4.6 (14/311) <0.01** 
Table 6.1: Proportion comparison of human and animal isolates within various lineages 
Lineage V was omitted from statistics as sources of 44.7% (17/38) was unable to be determined. 5 
isolates from lineage VI, 2 from lineage IV and 1 from lineage XI were omitted due to undetermined 
sources. Data: Fisher’s exact test, two-tailed; comparison with isolate proportion of assumed equal 
distribution in the major lineages. 
 
The phylogenetic association of human and animal isolates was supported via a 
focused analysis on two highly similar sub-clusters in lineages VI and VII, comprising 
both human and animal isolates (ANI>99.0%; Table 6.2). Notably, the mixing of 
isolates from USA (FC2) and Denmark (98.78718-2) in lineage VI indicated the 
spread of C. perfringens was not confined to regional populations. The absence of 
accessory genes unique to either group (human and animal) determined via pan-
GWAS analysis, indicates that C. perfringens may have a stable host-independent 
accessory genome, or may indicate the potential spread of this pathogen between 
different host populations. 
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Figure 6.5: Isolate host distribution and proportion in the phylogenetic tree 
Mid-point rooted maximum-likelihood phylogeny inferred from 11,349 SNPs (alignment of 1,251 core 
genes) identified in 552 C. perfringens genomes. (A) Colour ring indicates hosts of isolates. Coloured 
branches represent either human or animals’ isolates. Pie charts represent the proportion of human- and 
animal-derived origins (B) Green branches and nodes represent bootstrap replicate values > 70 (well-
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Lineage Strain Country Host ANI (%) 
VI Q137.2.2C UK Human 100.00 
 FC2 USA Animal 99.06 
 98.78718-2 Denmark Animal 99.15 
 Q049.2.3C UK Human 99.48 
 Q106.10C UK Human 99.29 
 I055 UK Animal 99.39 
 J55 UK Animal 99.39 
 C036 UK Animal 99.34 
 Q164.1C UK Human 99.15 
VII M092.1C UK Human 100.00 
 M128.2.3C UK Human 99.07 
 Q106.8C UK Human 99.04 
 Q107.4C UK Human 99.03 
 LHZ155 UK Animal 99.14 
 LHZ158 UK Animal 99.12 
 C033 UK Animal 99.72 
 G050 UK Animal 99.89 
 M092.2C UK Human 99.99 
Table 6.2: Isolates in lineages VI and VII sub-clusters identified as highly similar 
 
6.5.2.2 Virulence analysis 
Given the high number of virulence elements, the distribution of toxin and AMR genes 
in the pangenome of human and animal isolates was investigated (Figure 6.6).  
Toxin genes including plc (encodes PLC), ccp (encodes clostripain) and colA (encodes 
collagenase) were present in all isolates. Importantly, several toxin genes were 
statistically enriched in each group of isolates (Fisher’s exact test; as P<0.05 unless 
otherwise stated). Sialidase encoding genes nanI (76.3%), nagH (76.6%) and nanJ 
(70.4%) were enriched in animal isolates (n=113), with the important pore-forming 
toxin gene pfoA also enriched in animal isolates compared to human-derived strains 
(92.3% vs 62.6%; P<0.0001). Accessory toxin gene cpb2 was statistically enriched, 
with variant 1 associated with humans (P<0.05), while variant 2 was linked with 
animals (P<0.0001). Further analysis into CPB2 variants, via comparing human and 
animal origins, indicated only 8.5% (6/71) of CPB2-positive animal-derived isolates 
harbour CPB2 variant 1, while 91.55% (65/71) of these carry CPB2 variant 2, 
demonstrating a strong veterinary association of CPB2 variant 2 (P=0.0001). In 
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addition, there was a comparable proportion of human-derived CPB2 variant 1 
(31.75%; 60/189) and variant 2 (68.25%; 129/189) among CPB2-positive isolates. 
 
Figure 6.6: Predicted key virulence genes in human and animal C. perfringens isolates  
(A) Predicted toxin genes. (B) Comparison of significantly-enriched toxin genes in both animal and 
human groups (C) Predicted AMR genes. * P<0.05, ** P<0.01, **** P<0.0001; Fisher’s exact test (two-
tailed). 
 
Other statistically enriched toxin genes in animals included etx, lam, cpb, netB, netF 
and tpeL (P<0.05), corresponding with clinical findings that these toxin genes are 
primarily associated with animals, and rarely reported in human isolates 1,125,375. 
Overall, toxin genes were more significantly enriched (P<0.001; Fisher’s exact test) 
within animal isolates (42.8%; 9/21 genes), when compared to human isolates (4.7%; 
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1/21 genes), suggesting host-specificity and evolutionary host-adaptations of 
virulence toxin genes, which correlates with the fact that most of these enriched genes 
are plasmid-borne (Figure 6.6). 
A total of 9 acquired AMR genes were identified in all genomes (n=530). The most 
common AMR gene was tetA(P) [70.1%; 387/552], a well-known tetracycline efflux 
pump in C. perfringens 376. Other relatively common AMR genes include tetracycline-
resistant tetB(P) [39.7%; 139/552] and erythromycin-resistant ermQ [3.9%; 22/552]. 
Importantly, only one AMR gene mefA (encodes macrolide efflux pump) was 
statistically increased in animal isolates (Fisher’s exact test, P=0.045). These results 
support the possible common spread of C. perfringens between human and animal 
populations. 
 
6.5.3 Prevalence and disease associations of virulence potentials  
One prominent observation during analysis was that distribution of virulence genes in 
distinct lineages seemed to differ. This section will focus on discussing the overall 
distribution of virulence potentials across distinct phylogenetic lineages including 
toxinotypes, accessory toxins, AMR potentials and virulence plasmids, and 
associations with disease-phenotypes (Figure 6.7). 
6.5.3.1 Toxinotypes 
Toxinotype A was the most common type in this pangenome (Figure 6.7), encoding 
only one typing toxin plc (65.5%; 362/552), followed by type F (carries cpe; 28.8%; 
159/552), type G (carries netB; 3.6%; 20/552), type C (0.9%; 5/552), type D (0.54%; 
3/552), type E (0.36%; 2/552), and type B (0.18%; 1/552). This pangenome included 
all 7 toxinotypes, with 6 toxinotypes out of 7 (except type E) detected in lineage VI, 
suggesting substantial genomic diversity in this lineage. Lineage V consisted of 
primarily type F isolates (84.2%; 32/38; encode cpe). The presence of type F isolates 
in 8/11 (72.7%) major lineages, indicates the extensive mobility of the cpe gene, 
usually carried on virulence plasmids. 
6.5.3.2 Accessory toxins 
PFO, a haemolytic toxin, was also encoded in all but one isolate in lineage VI (99.13%; 
115/116), while it was entirely absent from lineage V, a cluster linked to FP (0%; 
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0/38), and partially present in lineage VII and VIII (24%; 35/146), a lineage 
comprising mainly neonatal isolates (82.8%; 121/146). This important toxin was 
statistically enriched in diseased isolates (77.7%; 237/305) when compared to isolates 
obtained from healthy hosts (58.85%; 137/241; P<0.0001, Fisher’s exact test), 
suggesting its role in disease pathogenesis. 
 
Figure 6.7: Distribution of key accessory virulence genes 
Mid-point rooted maximum-likelihood phylogeny aligned with predicted key accessory virulence genes. 
 
Another observation was the low prevalence of collagen binding protein encoding 
genes cna and cnaC in lineages I (0%), II (0%) and VII+VIII (23.9%; 35/146). There 
was a reduced proportion of cna in healthy-host-derived isolates (38.1%; 92/241), 
while cna was increased in disease-linked isolates (46.8%; 143/305; P=0.06). 
Importantly, cnaC was statistically enriched (P<0.001) in disease-associated isolates 
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(59.3%; 181/305) compared to healthy-host isolates (29.9%; 72/241), again implying 
the important role of cnaC in C. perfringens virulence. 
Sialidase nanI was exclusively absent from lineage V (0%; 0/38), with low prevalence 
of sialidases nagH and nanJ (both 10.5%; 4/38), representing a distinctive feature of 
lineage V. This sialidase is known to contribute to human colonic cell adherence, and 
was not detected in any of the isolates in this FP-associated clade, which may link to 
the often short-duration of FP symptoms 182. 
It was evident that only one variant of CPB2 could be encoded in each CPB2-positive 
genome (98.2%; 226/271), with the exception of 5 isolates (within lineage II and IV) 
that carry both variants. CPB2 variant 1 in lineage VI (33.6%; 39/116) was comparable 
to CPB2 variant 2 (40.5%; 47/116), a lineage known to comprise an extensive mixture 
of animal and human isolates, denoting the potential veterinary origin of CPB2 variant 
1 (shown in previous section) 151. Disease-association wise, CPB2 variant 2 was 
enriched (P=0.004) in diseased-host isolates (42.6%; 130/305) compared with healthy-
host-derived isolates (29.8%; 72/241), suggesting a role of CPB2 variant 2 in disease 
development 377. 
6.5.3.3 AMR potentials 
The prevalence of most commonly acquired AMR genes, namely tetA(P), tetB(P) and 
ermQ, was examined in this 552 strain pangenome, with the aim to link specific 
clusters to AMR potentials (Figure 6.8).  
It was determined that 71.1% (393/552) of the isolates in the pangenome encode 
tetA(P), 25.7% encoded tetB(P)(142/552), and 3.9% of the isolates encoded ermQ 
(22/552). 
Of note, isolates in lineage I, V and X encoded statistically less AMR genes (P=0.02; 
Mann-Whitney test) compared to other lineages. In lineage V, there was only 10.5% 
(4/38) isolates that carried 1 AMR gene tetA(P), this could be due to the reason that 
17 (out of 38) isolates in this lineage were obtained from NCTC collection of pre-
antibiotic era (before 1950), and all these NCTC isolates (100%; 17/17) did not carry 
any identified acquired AMR genes. Similarly, most isolates in lineage X (78.9%; 
30/38), mainly contemporary FP-linked CH isolates, were found not to carry any 
Chapter 6    Population genomics of C. perfringens    187 
 
acquired AMR genes either. Lineage I also displayed low prevalence of AMR carriage 
(16.6%; 1/6).  
By contrast, the majority of isolates in remaining lineages encoded more acquired 
AMR genes (P=0.02) than lineages I, V and X, most commonly tetA(P) as represented 
in lineage II (71.4%; 15/21), III (88.1%; 37/42), IV (70.6%; 12/17), VI (50.0%; 
58/116), VII + VIII (99.3%; 145/146), IX (55.9%; 29/34) and XI (81.4%; 48/59).  
 
Figure 6.8: Distribution of key AMR genes in the phylogeny 
Mid-point rooted maximum-likelihood phylogeny aligned with predicted key AMR genes and AMR gene 
count statistics. 
 
Importantly, lineage VII and VIII, a lineage comprised primarily of neonatal isolates 
(82.8%; 121/146), displayed the highest prevalence of tetracycline efflux pump 
tetA(P) at 99.3%, suggesting a selective pressure on the acquisition of AMR genes 
within the hospital environment, especially NICU 378.  
Multiple AMR genes (n=3), namely tetA(P), tetB(P) and ermQ (a macrolide-
lincosamide-streptogramin B resistance gene) were detected in several isolates in 
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lineage VI (n=4; neonatal), lineage VIII (n=4; chicken), and lineage IX (n=12; 
neonatal). Acquisition of erythromycin-resistant determinant ermQ may be linked to 
the common prescription of this antibiotic during pregnancy to prevent Streptococcus 
infections, similarly, erythromycin is also known to be frequently administered in the 
broiler chicken industry 379-381. 
6.5.3.4 Prevalence of virulence plasmids 
Virulence plasmids are an important aspect in the spread of disease-relevant virulence 
factors in C. perfringens including important toxins CPE (FP-linked) and NetB (NE-
linked), and AMR genes 51,130,292. Most virulence plasmids of C. perfringens are 
conjugative, carrying conjugative systems consisting of conjugative loci (tcp genes) 
41,291. To examine the prevalence of conjugative virulence plasmids in C. perfringens, 
conjugative-plasmid-specific Tcp systems (a total of 10 known Tcp loci, different 
plasmids carry different numbers of Tcp loci) were screened as these genes would 
indicate the presence of conjugative plasmids (Figure 6.9). 
Around half (46.5%) of the strains analysed encoded conjugative plasmids, with low 
prevalence  (P=0.017; Mann-Whitney test) detected in lineages II (28.5%; 6/21), V 
(10.5%;4/38) and VI + VII (15.0%; 22/146), when comparing with other lineages, e.g. 
lineages I (83.3%; 5/6), III (71.4%; 30/42), IV (64.7%; 11/17), VI (57.7%; 67/116), 
IX (94.1%; 32/34), X (86.8%; 33/38) and XI (83.1%;49/59). 
Importantly, it was also observed that cpe was encoded on plasmids (100% cpe-Tcp 
pairing) in all lineages (III, IV, VI, VII, VIII, IX, X and XI) with the exception of 
lineage V (Figure 6.9). Lineage V contained 89.4% cpe-carrying isolates (34/38), 
however, only 8.8% (3/34) of these isolates appeared to co-encode conjugative 
plasmids, suggesting these cpe toxin genes may be encoded within the chromosome, 
supported by the presence of historical FP isolates SM101 and NCTC8239 in this 
cluster 382. The presence of Tcp in all lineages (100%) implicated the widespread 
nature of C. perfringens conjugative plasmids. 
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Figure 6.9: Distribution of predicted Tcp loci in the phylogeny 
Mid-point rooted maximum-likelihood phylogeny aligned with predicted Tcp loci (conjugative loci: 
conjugative plasmid-related). 
 
6.5.4 A persistent circulating genotype in the UK that causes both non-
foodborne diarrhoea and FP 
Sporadic diarrhoea isolate F4969, isolated in 1990s in Europe (exact location could 
not be determined), has long been used to investigate diarrhoea-associated virulence 
features in C. perfringens 116. This strain carries a well-known plasmid pCPF4969 that 
encodes cpe, an enterotoxin linked to both foodborne and non-foodborne diarrhoea as 
described in Chapter 4 22. Notably, this isolate apparently clustered within lineage XIb 
(using hierBAPS), which consisted primarily of isolates from FP patients (81.5%; 
31/38) in North East England (Figure 6.10).  
Data further suggested a close genetic relationship between this sporadic diarrhoea 
strain F4969 and FP strains isolated between 2011-2017, as SNP analysis revealed 
genetic distance between isolates within lineage XIb to be 64.4 ± 22.0 SNPs (mean ± 
SD; range of 34-83 SNPs; pair-wise comparison) versus isolates outside of lineage 
XIb (XIa, closest sub-lineage) at 377.8 ± 55.9 SNPs (Figure 6.10C). Genome ANI 
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analysis supported the findings, all pair-wise ANI values were >99.77%, indicating 
highly-similar core-genome nucleotide identity (Table 6.3). 
 
Figure 6.10: Genetic relationship of isolates nested within lineage XI 
Figure above reveals potential regional circulating CPE-strains in North East England and Scotland. (A) 
Position of lineage XI in the pangenome tree. (B) zoomed-in mid-point rooted maximum-likelihood 
phylogeny constructed from 2,809 core-gene SNPs. Lineages assigned via hierBAPS analysis (level 2). 
Scale bar is indicative of nucleotide substitution per site. Bootstrap values are shown on the tree. (C) 
The pair-wise SNP comparison of lineage XIb and lineage Xa with respect to isolate F4969. **** 
P<0.0001 (Mann-Whitney test). (D) The depiction of potential spread of closely-related strains (lineage 
XIb) across UK between 2013-2015. Map generated via R using package rworldmap. 
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Importantly, 5 isolates (CLP isolates) obtained from Scotland (healthy individuals) 
nested within this North-East England clade, indicating this strain was regional-
specific, potentially a diarrhoea-causing strain with CPE-encoding virulence plasmid. 
Nevertheless, as source information of strain F4969 was only available as ‘Europe’, it 
suggests this cluster may represent a persistent C. perfringens genotype, potentially 
widespread in Europe and possibly linked to North East England and Scotland regions 
(Figure 6.10D). 
 
Strain Year Case Region ANI (%) IS1470-like SNP 
CPE_F4969 1990s Sporadic diarrhoea Europe 100 Detected 0 
PH014 2013 Food poisoning  England 99.84 Detected 43 
PH091 2013 Food poisoning  England 99.83 Detected 43 
PH092 2013 Food poisoning  England 99.83 Detected 42 
PH095 2013 Food poisoning  England 99.82 Detected 42 
M125.2.4C 2015 Healthy child England 99.80 Not detected 54 
CLP2R01 2014 Healthy adult Scotland 99.80 Detected 34 
CLP2R02 2014 Healthy adult Scotland 99.80 Detected 34 
CLP2R03 2014 Healthy adult Scotland 99.80 Detected 34 
CLP3R02 2014 Healthy adult Scotland 99.80 Detected 34 
CLP3R03 2014 Healthy adult Scotland 99.80 Detected 34 
PH044 2015 Food poisoning  England 99.78 Detected 83 
PH155 2015 Food poisoning  England 99.77 Detected 83 
PH046 2015 Food poisoning  England 99.77 Detected 83 
PH042 2015 Food poisoning  England 99.77 Detected 83 
PH035 2015 Food poisoning  England 99.78 Detected 82 
PH036 2015 Food poisoning  England 99.78 Detected 82 
PH037 2015 Food poisoning  England 99.77 Detected 82 
PH039 2015 Food poisoning  England 99.78 Detected 82 
PH040 2015 Food poisoning  England 99.78 Detected 82 
PH041 2015 Food poisoning  England 99.78 Detected 82 
PH043 2015 Food poisoning  England 99.78 Detected 82 
PH047 2015 Food poisoning  England 99.78 Detected 82 
PH048 2015 Food poisoning England 99.78 Detected 82 
PH154 2015 Food poisoning  England 99.77 Detected 82 
Table 6.3: Comparative analysis of isogenic strains within F4969-related lineage XIb 
SNP distance and ANI were performed with respect to strain F4969. IS1470-like is a specific insertion 
sequence for plasmid pCPF4969 that was first identified in strain F4969. 
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Of note, an English isolate M125.2.4C obtained from a child in London was only 54 
SNPs different from the F4969 type strain, and 12 SNPs different from FP strains 
PH092 and PH095, indicating a wider and longer-term reservoir of this disease-
causing C. perfringens genotype. However, this isolate does not carry the CPE plasmid 
that is considered as the causative agent of C. perfringens-associated diarrhoea (Figure 
6.10D; refer to discussion in Chapter 4 for potential plasmid dissemination on FP-
related isolates). 
 
6.5.5 Lineage IX and X: revealing potential intercontinental transfer and 
care-home-derived persistent genotypes  
C. perfringens can be associated with persistent diarrhoea and ‘less healthy conditions’ 
(i.e. long-term hospitalisation) in vulnerable communities, including older adults 
289,334. As FP in CHs were reported frequently in North East England between 2011-
2014 (described in Chapter 4), it is therefore important to understand the spread of C. 
perfringens strains among this group of individuals, which is critical to limiting any 
associated public health impact 316.  
Isolates (n=8; total n=17 sequenced) sourced from the Irish ELDERMET study 
(elderly microbiome), were detected to lie within lineages IX and X (Figure 6.11A; 
Table 6.6) 289. Isolates shared a close genetic relationship within sub-lineages Xc and 
Xd (76.7 ± 37.1 SNPs; mean ± SD; range of 10-98 SNPs) versus isolates outside these 
lineages (lineages Xa and Xb) at 372.8 ± 128.5 SNPs (with respect to isolate 
FORC025; P<0.0001; Mann-Whitney test), as confirmed by pair-wise comparison of 
ANI of >99.78% (Table 6.4).  
Notably, isolate FORC025, a FP isolate obtained in South Korea in 2015 (NCBI source 
data), demonstrated a strong genetic similarity to Irish ELDERMET isolate EM297-
T0 (SNP difference: 13 SNPs; lineage Xc), and other English FP isolates (n=28; FP 
isolates obtained from CHs in North East England) in lineage Xc and Xd. However, 
these isolates (FORC025 and EM297-T0) did not carry cpe (causative toxin for FP 
encoded in virulence plasmids) in their genomes. This could indicate the potential loss 
of the CPE plasmid (predicted to be plasmid pCPF5603, confirmed absence of the 
plasmid by plasmid-specific IS search of IS1151, a unique sequence encoded in 
pCPF5603) in both FORC025 and EM297-T0, as implicated by the remaining 28 
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isolates (93%; 28/30) carrying CPE virulence plasmids, and the fact that FORC025 
was an FP isolate can be attributed to its CPE toxin production.  
 
Figure 6.11: Potential intercontinental transfer and care-home-derived persistent genotypes  
(A) Genetic relationship of isolates nested within lineages IX and X and associated virulence profiles 
and metadata. (B) Care home-related clade and potential interregional spread as far as far-east between 
2011-2017. FORC025 is an FP isolate from South Korea (SAMN04209542). Clustering determined using 
hierBAPS (level 1& 2). Bootstrap values are represented in the tree. Map generated in R using package 
rworldmap. 
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Importantly, these findings imply the potential link between CH isolates in Ireland and 
North East England, as demonstrated by this close genetic relationship (Figure 6.11B). 
Furthermore, as FORC025 is a Korean FP isolate, this would suggest intercontinental 
transfer of a persistent genotype of FP-causing C. perfringens strain(s), sharing 
surprisingly high genomic similarity with those in Europe (10-191 SNPs; 74.2 ± 38.9 
SNPs) in the same clade (Figure 6.11B). 
ID Year Case Region ANI (%) IS1151 Lineage SNP 
FORC025 2015 FP Korea 100.00 Not detected Xc 0 
EM297-T0 2011 CH Ireland 99.95 Not detected Xc 13 
PH123 2015 FP England 99.91 Detected Xc 10 
PH124 2015 FP England 99.91 Detected Xc 10 
PH072 2016 CH-FP England 99.78 Detected Xc 84 
PH054 2015 FP England 99.91 Detected Xc 10 
PH055 2015 FP England 99.92 Detected Xc 10 
PH100 2014 CH-FP England 99.92 Detected Xc 55 
PH016 2014 CH-FP England 99.79 Detected Xd 85 
PH018 2014 CH-FP England 99.79 Detected Xd 85 
PH019 2014 CH-FP England 99.79 Detected Xd 85 
PH030 2014 CH-FP England 99.81 Detected Xd 85 
PH031 2014 CH-FP England 99.80 Detected Xd 85 
PH052 2015 CH-FP England 99.78 Detected Xd 87 
PH053 2015 CH-FP England 99.78 Detected Xd 87 
PH073 2016 CH-FP England 99.78 Detected Xd 86 
PH074 2016 CH-FP England 99.78 Detected Xd 85 
PH075 2016 CH-FP England 99.78 Detected Xd 86 
PH076 2016 CH-FP England 99.79 Detected Xd 85 
PH077 2016 CH-FP England 99.79 Detected Xd 86 
PH079 2017 CH-FP England 99.79 Detected Xd 89 
PH096 2013 CH-FP England 99.78 Detected Xd 87 
PH097 2014 CH-FP England 99.79 Detected Xd 87 
PH098 2014 CH-FP England 99.79 Detected Xd 86 
PH101 2014 CH-FP England 99.79 Detected Xd 87 
PH102 2014 CH-FP England 99.66 Detected Xd 191 
PH103 2014 CH-FP England 99.78 Detected Xd 88 
PH138 2016 CH-FP Wales 99.83 Detected Xd 98 
PH139 2016 CH-FP Wales 99.82 Detected Xd 97 
PH140 2016 CH-FP Wales 99.82 Detected Xd 97 
Table 6.4: Comparative analysis of highly-similar strains within lineages Xc and Xd 
 
Interestingly, three isolates in lineage IXb (EM165-T0-4, EM169-T0-2 and EM313-
T6) and two isolates in IXc (EM124-T3-6 and EM186-T0-5) were highly similar at 
the SNP level (all isolates obtained from long-stay CH residents in the ELDERMET 
study; Table 6.5). In lineage IXb, pair-wise SNPs were shown to be 3.6 ± 3.5 SNPs 
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(mean ± SD; range of 0-7 SNPs; ANI>99.99%), while IXc two isolates differed by 
only 1 SNP, confirming highly-similar persistent strains (<7 SNPs; ANI>99.99%) 
circulating in long-stay Irish CHs and their potential relationship with English isolates 
(Figure 6.11). Notably, with respect to their virulence capacity, these elderly isolates 
were all type A according to current toxinotyping scheme, 53% (9/17), and did not 
harbour any other major typing/ accessory toxins, with an exception of EM200-T6 that 
carried CPB2-variant2 (Table 6.6).  
EM165-T0 and EM169-T0 were previously demonstrated to be identical via PFGE 
technique 334. In this current work, WGS provided a higher resolution showing 4 SNPs 
difference between these two CH isolates (Table 6.5), highlighting the robustness of 
WGS when applied in routine CH surveillance of C. perfringens strains. 
 
Lineage Strain Host ANI (%) SNP 
IXb EM165-T0-4 Long-stay OA 100.00 0 
 EM169-T0-2       Long-stay OA 99.99 4 
 EM313-T6         Long-stay OA 99.99 7 
IXc EM124-T3-6 Long-stay OA 100.00 0 
 EM186-T0-5 Long-stay OA 99.99 1 
Table 6.5: Strain similarity comparison of Irish ELDERMET C. perfringens strains 
 
Strain cpb cpe etx iap ibp netB pfo plc Toxinotype 
EM082-T6-5 - - - - - - + + A 
EM095-T0-2 - - - - - - - + A 
EM124-T3-6 - - - - - - - + A 
EM151-T0-4 - - - - - - + + A 
EM159-T0-8 - - - - - - + + A 
EM159-T6-2 - - - - - - - + A 
EM165-T0-4 - - - - - - - + A 
EM169-T0-2 - - - - - - - + A 
EM177-T0-6 - - - - - - + + A 
EM186-T0-5 - - - - - - - + A 
EM200-T6 - - - - - - + + A 
EM297-T0 - - - - - - + + A 
EM313-T6 - - - - - - - + A 
EM322-T0 - - - - - - + + A 
EM325-T0 - - - - - - - + A 
EM331-T0 - - - - - - + + A 
EM342-T0 - - - - - - + + A 
Table 6.6: In silico toxinotyping of ELDERMET C. perfringens isolates 
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6.5.6 Genome features and potential intra-regional spread of food-
poisoning-derived isolates within distinctive lineage V 
Human FP can be caused by three sub-types of type-F C. perfringens strains as 
identified by cpe gene encoded exclusively on: (1) chromosome (or, more accurately 
carried on transposable element Tn5565, frequently found to be integrated into 
chromosome); (2) plasmid pCPF5603; or (3) plasmid pCPF4969, as described in 
Chapter 4 60,322. Historically, type-F FP isolates were mainly described as 
chromosomal-cpe strains that were determined to be genetically distinct from plasmid-
carrying strains, characterised by the lack of pfo gene in these strains including strains 
NCTC8239 and SM101 322,382. This section describes the unique genome features and 
potential intra-regional spread of chromosomal-cpe strains using primarily isolates 
from NCTC collection that were not discussed in Chapter 4. 
Historical isolates from NCTC collection (n=15) clustered in lineages Vc and Vd 
(n=33) as a genetically distinct lineage (lineage V, exemplified by the long branching), 
supported by bootstrap values of 100% on major divergent nodes (Figure 6.12A). All 
the isolates in FP-associated lineage Vc and Vd shared a close genetic relationship 
(pair-wise ANI>99.3%; within-lineage pair-wise SNP: 314.1 ± 110.1 SNPs, Table 6.7; 
Figure 6.12B), agreeing with previous observations 60,322. These isolates did not 
encode accessory toxin PFO (0%; 0/37) and sialidase NanI (0%; 0/37). Data showed 
that 92% (34/37) of these isolates carried CPE as FP-causative toxin, with the 
exception of NCTC8678 (FP human isolate in 1951), Q146.2.5C (child isolate 
obtained in 2014) and PH029 (English FP isolate), possibly due to the loss of Tn5565-
cpe, potentially during the sub-culturing processes as discussed previously in Chapter 
4.  
Notably, lineage Vb was genetically distinct (compared with lineage Vc and Vd, pair-
wise SNP: 824.4 ± 169.4 SNPs; Figure 6.12B) from lineages Vc and Vd  (within-
lineage Vc and Vd pair-wise SNP: 314.1 ± 110.1 SNPs), and these three FP isolates 
in lineages Vb (PH015, PH032 and PH033) were obtained from English CHs, the other 
was a chicken isolate NCTC10240. These strains carried sialidase NanJ (100%;4/4) 
and CPB2 (75%;3/4), while isolates in lineages Vc and Vd did not (100%; 33/33). 
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Figure 6.12: Genetic relationship of isolates within lineage V 
(A) Genetic relationship of isolates nested within lineage V consists of mainly food-poisoning associated 
isolates. (B) Pair-wise SNP distances between isolates within and across sub-clades of lineage V shown 
in Tukey box plots. Origins of NCTC isolates are not determined in the labels as majority of the metadata 
are incomplete. Sub-lineages are assigned via hierBAPS analysis (level 2). Stats: Mann-Whitney test, 
two-tailed; **** P<0.0001. 
 
With regard to AMR, only recent isolates PH135, PH136, Q146.2.5C and PH127 
(n=4) were computationally predicted to encode acquired AMR gene tetA(P), an efflux 
pump effective against tetracycline, while the rest of the isolates did not carry any 
acquired AMR gene (89%; 33/37).  
The genomes of these isolates in lineage V had a smaller genome size (range 3.0-3.2 
Mb vs average genome size of 3.6 Mb; except Darmbrand isolate NCTC8081 3.6 Mb), 
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implicating the lack of plasmid acquisition in these isolates or a distinct genome 
arrangement 17,383. 
Human Darmbrand (also known as enteritis necroticans) isolate NCTC8081 is a heat-
resistant type C isolate that carries conjugative-plasmid-derived CPB (or, beta-toxin; 
conjugative system detected; Table 6.7) responsible for malnutrition-associated 
necrotizing gut infections primarily in children post-war 158. The inclusion of this 
isolate in lineage V might indicate the genetic relatedness to the rest of the FP-derived 
isolates, which agrees with previous findings 383. NCTC8081 bore the general 
characteristic of lineage V isolates: lacking PFO, CPB2, NanI, NanJ and acquired 
AMR genes (it is a pre-antibiotic-era isolate). It had, however, a relatively larger 
genome of 3.6 Mb (vs 3.0 Mb), denoting a high acquisition of mobile genetic elements, 
potentially virulence plasmids that transformed this isolate from type F to type C 
which carried CPB 383. Interestingly, NCTC8081 was the only conjugative-plasmid-
carrying isolate in lineage Vc and Vd.  
 
6.5.7 Two-year NEOM isolates: long-term persistence and detection of 
deadly toxin genes 
The two-year NEOM project is a continuation of NEOM study (preterm infant study 
described in Chapter 3), which includes additional two year post NICU discharge 
samples from former NEOM participants that were screened for C. perfringens in 
faecal samples, aiming to determine potential persistence 12. A total of 25 isolates were 
obtained from 23 of the original NEOM NICU preterm infants. 
The two-year NEOM isolate Q135.2.1C shared ANI of 99.95% with preterm isolates 
from NEOM preterm infants Q124 (n=4) and Q125 (n=4), with only 44 SNPs 
difference, denoting potential within-ward transfer of C. perfringens (Figure 6.13). 
This finding gives a snapshot that certain hospital-acquired strains may persist long-
term (i.e. two years post discharge from NICU) in the infant gut.  
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Strain Case pfo cpe Tcp loci ANI (%) 
NCTC8239 FP Not detected Detected Not detected 100.00 
NCTC10239 Undetermined Not detected Detected Not detected 99.50 
NCTC10612 FP Not detected Detected Not detected 99.82 
NCTC10613 FP Not detected Detected Not detected 99.48 
NCTC10614 FP Not detected Detected Not detected 99.84 
NCTC8081 Darmbrand Not detected Detected Detected 99.20 
NCTC8238 Undetermined Not detected Detected Not detected 99.88 
NCTC8247 Undetermined Not detected Detected Not detected 99.57 
NCTC8359 FP (food) Not detected Detected Not detected 99.66 
NCTC8678 FP Not detected Not detected Not detected 99.49 
NCTC8679 FP Not detected Detected Not detected 99.50 
NCTC8797 Undetermined Not detected Detected Not detected 99.50 
NCTC8798 FP (food) Not detected Detected Not detected 99.86 
NCTC8799 FP Not detected Detected Not detected 99.66 
NCTC9851 FP (food) Not detected Detected Not detected 99.84 
PH004 FP Not detected Detected Not detected 99.43 
PH005 FP Not detected Detected Not detected 99.42 
PH006 FP Not detected Detected Not detected 99.42 
PH007 FP Not detected Detected Not detected 99.42 
PH028 FP Not detected Detected Not detected 99.64 
PH029 FP Not detected Not detected Not detected 99.65 
PH078 FP Not detected Detected Not detected 99.47 
PH080 FP Not detected Detected Not detected 99.47 
PH081 FP Not detected Detected Not detected 99.47 
PH104 FP Not detected Detected Not detected 99.64 
PH105 FP Not detected Detected Not detected 99.65 
PH107 FP Not detected Detected Not detected 99.66 
PH115 FP Not detected Detected Not detected 99.51 
PH127 FP Not detected Detected Not detected 99.47 
PH135 FP Not detected Detected Not detected 99.40 
PH136 FP Not detected Detected Not detected 99.40 
Q146.2.5C Healthy child Not detected Not detected Not detected 99.39 
SM101 FP Not detected Detected Not detected 99.85 
Table 6.7: Highly similar strains (ANI >99.3%) identified in lineage V 
 
Another isolate Q154.2.6C (two-year NEOM study) shared ANI of >99.91% with 
NEOM isolate M087.1C (only 16 SNPs between these two isolates; Figure 6.13; Table 
6.8). This genomic similarity indicates a larger or shared C. perfringens reservoir 
between two hospitals QCCH and SMH, as infant Q154 (isolate Q154.2.6C) was 
resident in QCCH during NEOM, with infant M087 a patient in SMH; yet notably 
they both harboured a genetically-similar C. perfringens isolate M087.1C, with infant 
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Q154 colonised with this strain (Q154.2.6C) two years after the NEOM study. 
However, as QCCH and SMH had frequent patient transfer, it is not surprising that 
certain strains of bacteria including C. perfringens may be circulating in the hospital 
settings or among healthcare staff.  
 
Figure 6.13: Phylogenetic positions of hospital-associated C. perfringens strains 
Blue-labelled strains indicate isolates from infants 2 years after previous hospital admission (SMH and 
QCCH; 2-year NEOM) that are genetically closely related. 
 
Importantly, isolate Q041.2.4C (type D) carried the highly virulent pore-forming toxin 
coding gene etx, while Q061.2.1C (type E) encoded ITX gene (Figure 6.8). As 76% 
(32/42) of isolates in lineage III consisted of animal isolates, this suggests these 
potentially lethal strains may be animal-derived. This was supported by previous 
findings which showed that toxinotypes D and E were associated with enterotoxaemia 
in animals including lambs (type D), calves and rabbits (type E), nevertheless these 
toxinotypes have never been linked with human diseases 109. Furthermore, there has 
never been any report on healthy children carrying type D and E isolates, indicating a 
potential zoonotic/environmental transfer of veterinary-origin C. perfringens strains 
that necessitates a better understanding. WGS-based studies of C. perfringens genetic 
Chapter 6    Population genomics of C. perfringens    201 
 
diversity have been very limited to date, a larger study will be required to probe the 
origins of these potentially dangerous strains.  
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M009.2.1C + - - + - - - - + A 
M040.2.1C + - - + - - - - - A 
M125.2.4C + + - + - - - - + A 
M128.2.3C + - - + - - - - + A 
M135.2.3C + + - + - - - - + A 
M137.2.1C + + - + - - - - - A 
Q012.2.1C + + - + - - - - - A 
Q034.2.1C + + - + - - - - + A 
Q036.2.1C - - - + - - - - + A 
Q041.2.4C - - - + + - - - + D 
Q048.2.1C + - - + - - - - - A 
Q049.2.3C + + - + - - - - + A 
Q061.2.1C + - - + - + + + + E 
Q063.2.1C + + - + - - - - + A 
Q135.2.1C + - - + - - - - + A 
Q137.2.2C + + - + - - - - + A 
Q137.2.3C + + - + - - - - + A 
Q138.2.5C + - - + - - - - - A 
Q138.2.7C + - - + - - - - - A 
Q146.2.5C + - - + - - - - - A 
Q154.2.6C + - - + - - - - - A 
Q161.2.3C + + - + - - - - + A 
Q182.2.2C - - - + - - - - + A 
Q210.2.1C + + + + - - - - - A 
Q213.2.1C + - - + - - - - + A 
Table 6.8: AMR and toxinotyping profiles of 25 two-year NeoM isolates with PFO screening 
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6.5.8 Zoo-associated C. perfringens strains: an exploratory study 
As C. perfringens has been linked with several veterinary intestinal infections in 
animals including NE in avian species, the presence of virulent C. perfringens strains 
in animals’ gut could pose a potential health risk 384. Knowledge on C. perfringens 
diversity and their infectious role in wild animals is still poorly understood although 
significant progress has been made in recent years 385. C. perfringens in zoo animals 
is still not well understood although a pathogenic role has been reported, including a 
typical C. perfringens-associated gastroenteritis, represented by intestinal necrosis and 
abdominal distention, was reported in young black-footed ferrets back in 1990 386. A 
total of 17 isolates were obtained from zoo animals to initially explore the genomics 
of these strains (Table 6.9). This section describes the virulence profiles of 17 isolates 
obtained from zoo animals kept in Africa Alive, Banham Zoo in Suffolk (UK) and 
Welsh Mountain Zoo in Conwy County (Wales, UK).  
All 17 isolates were type A, and mostly encoded accessory toxin PFO (82%; 14/17). 
Importantly, 76% of the isolates (13/17) encoded AMR efflux pump tetA(P), 
indicating the potential wide-spread tetracycline resistance in zoo animals. 
Importantly, a lion isolate LHZCP161 carried 4 acquired AMR genes, including 
gentamicin-resistant ANT(6)-Ib, tetracycline resistant tet44 and tetA(P), and 
macrolide-lincosamide-streptogramin resistant gene ermQ, revealing a snapshot of 
potential multidrug-resistance-gene reservoirs in animals. 
Notably, multiple strains (n=2) of C. perfringens were detected in 6/10 (60%) 
individuals, namely seriema, aardvark, European brown bear 1, Europe brown bear 2, 
lion and snow leopard, as determined by phylogenetic lineages. As only a maximum 
of 2 isolates were taken from these 7 samples, this indicates a larger diversity of strains 
could potentially be present within an individual animal. 
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Strain Host 















































LHZ459 Seriema - - - - + + + A II 
LHZ460 Seriema - - - - - + + A VI 
LHZ472 Aardvark - - + + - + - A VI 
LHZ474 Aardvark - - + - - + + A III 
LHZ476 Yellow mongoose - - + + - + + A VI 
LHZ513 Goose - - + + - + + A VI 
LHZ574 Colobus monkey - - - - - + + A I 
LHZCP154 European brown bear - - + - - + + A IV 
LHZCP155 European brown bear - - + - - + + A VII 
LHZCP157 European brown bear - - + - - + + A III 
LHZCP158 European brown bear - - + - - + - A VII 
LHZCP161 Lion + + + - + + - A VI 
LHZCP162 Lion - - - - - + + A VI 
LHZCP163 Snow leopard - - + - - + + A VI 
LHZCP164 Snow leopard - - + - - + + A II 
LHZCP170 Colobus monkey - - + + - + + A VI 
LHZCP171 Colobus monkey - - + + - + + A VI 
Table 6.9: AMR and toxin screening of zoo-associated C. perfringens strains 
 
6.6 Discussion 
Significant pangenome diversity was detected within 552 C. perfringens, representing 
the lowest bacterial core genome reported to date at 7.4%. This extreme trait is an 
uncommon observation in other bacteria, with previous studies demonstrating larger 
core genomes  including C. difficile (30.3%; 40 genomes), S. enterica (16%; 206 
genomes) and E. coli (13%; 307 genomes) 29,387,388. In agreement with my previous 
smaller scale study, these data indicate that C. perfringens has a highly variable 
pangenome at 92.6% accessory genome17, with an average of 3.6 new genes expected 
to be added to this open pangenome of 552 genomes for each new C. perfringens 
genome included. More isolates from different geographical regions around the globe 
should be included, which will further enhance our understanding of this potentially 
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unprecedented variability of the C. perfringens pangenome. This observation also 
implicates the potential adaptability of C. perfringens in difference ecological niches, 
i.e. acquiring new genes, which warrants further in-depth investigation. 
Given the high variability of C. perfringens pangenome, there is a potential to assign 
certain lineages, especially I, II, III and V, into C. perfringens subspecies, based on 
both genomic clustering and ANI comparison. JFP isolates were obtained from foals 
and dogs, known to carry NetF toxin, linking to specific foal enteritis pathology, and 
were demonstrated to be phylogenetically distinct from common C. perfringens 
isolates using MLST, and confirmed by this WGS study 40. Notably, food-poisoning 
related historical isolates in lineage V were evidently a deep-branching cluster, 
phenotypically they are known as ultra-heat-resistant types compared to common C. 
perfringens strains, possibly due to small acid proteins 60. Potentially, these lineages 
of isolates might differ in pathogenicity, as seen in both JFP and food-poisoning 
isolates, with experimental validation required for the remaining isolates. 
Phylogenomically, this substantial distinction of these lineages is demonstrated for the 
first time in this study. 
This large-scale, genomic-based study outlines some vital observations in the 
phylogenetical distributions of C. perfringens in a global and one health context. 
Strains of C. perfringens have long been considered as a zoonotic enteric pathogen, 
affecting primarily neonates of humans and animals, resulting in potentially fatal 
enterocolitis including, NE in chickens, haemorrhagic enterocolitis in calves and NEC 
in human preterm infants 1,389. Specific toxinotype F strains, a main causative 
pathotype (encoding CPE) for self-limiting human FP diarrhoea, have also been 
implicated in diarrhoeal disease in dogs and neonatal pigs, presented with resembling 
symptoms of enteric mucosal necrosis to profuse diarrhoea 156,390,391. Type F C. 
perfringens was suggested to be prevalent within the food chain, as CPE was detected 
in 1.4% of 887 retailed foods in America 392.  
In this study, the substantial mixing and co-clustering of human and animal isolates 
(Figure 6.5) in several major lineages supports the potential zoonotic origin and spread 
of C. perfringens strains, confirmed by highly similar ANI values (>99.0%) in several 
sub-lineages, indicating the high similarities between animal- and human-derived 
strains. However, some clusters were dominated by either human (lineages VII-XI) or 
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animal-predominant (lineages I-II) strains, suggesting a fundamental difference in 
genomic components that allow colonisation of these strains in different host species, 
which may require further experimental analysis 382. This also points to the potential 
niche or host adaption, impacting genome evolution and host range. This adaption may 
be due to various mechanisms including acquisition and loss of genes, genome 
rearrangement and inactivation of genes, and HGT (plasmids and phages), which has 
been observed in Salmonella, resulting in narrow-host-range serovars, i.e. certain 
serovars can only colonise limited range of hosts 393. This genetic aspect of C. 
perfringens is currently not well understood and will require in-depth genomic 
analysis in the future, nevertheless, these current data demonstrated that isolates in 
lineage V have significant genome reduction compared to the remaining isolates, 
suggesting potential genetic and evolutionary adaptation. In brief, this robust 
phylogenetic analysis indicated no definite distinction between animal- and human-
derived C. perfringens strains as has been observed in other bacterial species including 
C. difficile. This is further supported by the absence of overlapping accessory genes 
between these two sub-sets of isolates although potential niche adaptation appears to 
be occurring in limited lineages 394. 
Data analysis indicates that more toxin genes were encoded by animal-associated 
isolates, with these toxin genes plasmid-borne rather than encoded chromosomally 
including etx, lam, cpb, netB and netF. As these toxins are mainly associated with 
clinical diseases in animals, e.g. ETX in sheep and goat enterotoxaemia (affects brain 
primarily), this suggests these plasmid carrying strains may be readily picked up by 
grazing animals from environmental sources i.e. soils 80,157. However, these data are 
somewhat biased, as animal isolates in the public domain were mainly obtained from 
diseased individuals rather than healthy, although as reported in this study, a healthy 
child’s isolate (toxinotype D) also encoded for the deadly toxin gene etx. To determine 
whether these plasmid-borne toxin genes are human, environment or animal-
associated will require a large-scale genomic study. 
Surprisingly, a limited number of AMR genes (maximum 4 acquired AMR genes in a 
single genome) were observed consistently, with the majority of isolates only 
encoding tetracycline resistance genes. Compared to C. difficile, a current serious issue 
in healthcare-associated diarrhoea, this species encodes significantly more AMR 
genes (up to 11 AMR genes in a single genome) including tetracycline, clindamycin 
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and aminoglycosides-resistant genes 29. C. perfringens has also been implicated in 
AAD of hospitalised patients, which can potentially be attributed to its endospore 
forming nature that may circumvent the effect of antibiotics, however, no such isolates 
been sequenced to date 24,325. This also indicates current antibiotics used in clinical 
settings are still effective against C. perfringens infections excluding tetracycline.  
In the analysis, CPB2-var1 was associated with humans, while CPB2-var2 was linked 
to animal isolates. Although these two variants of toxin CPB2 (likely to be carried on 
plasmids) have similar (74%) nucleotide identity, their correlation with pathogenicity 
remains unclear 395. In fact, the host-specific association of this toxin gene might not 
be as clear-cut as initially thought. CPB2-var1 (or, consensus CPB2), was first 
identified in C. perfringens str13 (human gas gangrene strain) 37; this toxin variant can 
also be detected in both porcine (as high as 93%) and equine-related strains including 
D21/98 (accession: AJ537530) 395. CPB2-var2 (or, atypical CPB2) was detected in 
both environmental strain FORC003 (source: aquarium water; accession: 
CP009558.1) and human FP isolate F5603 (accession: AB236337.1) 377. However, 
this variant was also detected in chicken isolates EHE-NE18 (accession: CP025503.1), 
LLY_N11 (accession: CP023413.1) and Del1 (accession: CP019578.1). Using this 
(limited) available data, it appears that the host-specific association is not definitive, 
as both variants were detected in both human and animal hosts. Hence, the presence 
of the toxin variants should rely upon the spread of its encoding plasmids 41,125. 
Moreover, there is more work to be done to understand the pathogenicity of this toxin 
in relation to disease development, even though current thinking in the field suggests 
this toxin may not be clinically important 151. 
The widespread nature of C. perfringens conjugative plasmids was observed; with 
plasmids present in all genetic clusters, and in both human and animal isolates. C. 
perfringens toxin genes are known to be primarily plasmid-encoded, including the six 
major typing toxins (further in-depth details as described in Chapter 1) 41,42. 
Particularly, the food-poisoning-related toxin CPE is plasmid-encoded, with in vitro 
transfer between C. perfringens strains, converting type A strain to type F strain via 
the CPE-encoding conjugative plasmid being previously demonstrated 51,292. 
Importantly, it is postulated that conjugative transfer of plasmids is also likely to occur 
in vivo and the actual dissemination of conjugative plasmids might have been wider 
than previously thought 43,292. This phenomenon may explain the high level of genetic 
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diversity observed in the pangenome analysis, and could play a crucial role in host 
adaptation, as these plasmids commonly encode colonisation-important collagen 
binding protein or related sialidase as discussed in Chapter 3 and Chapter 4 115,305,396. 
Notably, previously considered accessory (non-essential) toxins including PFO, 
collagen adhesins (cna and cnaC) and CPB2-var2 were all statistically enriched 
(P<0.05) in diseased-associated isolates, confirming the important roles these toxins 
may play as virulence determinants. CPB2-var2, also known as CPB2h1, was 
demonstrated experimentally to be >10 times more potent than CPB2-var1 (CPB2h2) 
in Caco-2 cells, supporting its statistical association with enteric diseases 89. 
Colonisation factors including collagen adhesin genes cna and cnaC have previously 
been implicated in chicken and turkey NE, however their widespread presence in 
numerous C. perfringens isolates as determined in this study highlights the need for 
future in-depth experimental research 230. 
Importantly, the ‘type’ human sporadic diarrhoeal isolate F4969 (encodes CPE; 
isolated in 1990s), isolated from a patient residing in Europe (specific region 
unknown), was shown to be genetically closely related (mean pair-wise SNP 
comparison: 64.4 ± 22.0 SNPs) to Scottish and London isolates (mainly FP isolates, 
18/24; isolated between 2011-2017). These data indicate a significant public health 
concern, as F4969-like strains appear to be persistent FP-related C. perfringens strains, 
that have been in circulation for ~ 20 years, which is likely disseminated across North 
East England, or could be a regional persistent genotype (Europe) attributed to 
regional clonal expansion 337. These data also demonstrated the wider reservoir, 
including colonisation within healthy individuals. 
This analysis also indicated a more global spread of FP strains, as a South Korean 
isolate FORC025 (accession: SAMN04209542), isolated from a FP patient in 2015 
(stool sample), was demonstrated to be genetically closely related (pair-wise SNP: 
74.2 ± 38.98 SNPs; range: 10-191) to English and Welsh isolates (n=29; lineages Xc 
and Xd). This South Korean FP isolate, was highly similar to 4 English FP isolates at 
10 SNPs difference, and one Irish CH isolate (EM297-T0; 13 SNPs) in the same sub-
lineage Xd, indicating intercontinental transfer, the first time this has been implicated. 
Nevertheless, as sequencing data of C. perfringens is currently limited on the Asian 
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continent, it would be interesting to obtain further isolates and data to compare with 
European-derived FP isolates, to determine the extent of this dissemination.  
Following these strain dynamics is particularly important in more vulnerable or 
disease-prone communities, such as elderly people residing in CHs, where FP-related 
genotypes of C. perfringens appear to be prevalent 334. As C. perfringens is a serious 
issue in this setting, further precautions should be taken including handling the 
catering in these premises 316. Furthermore, routine surveillance on human- and 
environment-derived C. perfringens could be implemented as part of the disease-
control policy to reduce the incidence of CH-related FP cases. 
Importantly, the robustness of SNP analysis in epidemiology was demonstrated 
throughout this study, including the capacity to link healthy-individual isolates with 
disease-associated isolates in specific regions. Currently WGS is not employed in C. 
perfringens surveillance on a national level (including UK and Canada), therefore the 
bigger picture of C. perfringens extra-regional/global circulation is unknown 
presently. Hence, it is proposed that public health agencies could implement WGS on 
outbreak-associated C. perfringens isolates to further understand this pathogen, which 
may contribute to the disease monitoring and control (a more thorough discussion in 
Chapter 4 on FP case isolates and WGS). 
For many years, traditional typing methods including MLST have been used to define 
‘chromosomal-CPE’, which indicated that these C. perfringens strains were 
genetically distinct from strains of other sources, including plasmid-CPE strains 382. 
These strains did not carry PFO and were highly heat-resistant, which was attributed 
to presence of small acid proteins 60. This WGS analysis confirmed these previous 
findings as chromosomal-CPE strains formed an exclusively distinct cluster, lineage 
Vc, comprising historical FP isolates and contemporary FP isolates from PHE. These 
isolates did not encode PFO, sialidases NanI, NanJ and NagH. Interestingly, these 
strains do not appear to carry any conjugative plasmids (except Darmbrand isolate 
NCTC8081) and had a smaller genome (approximately 3.0 Mb, compared to 3.2-3.8 
Mb), indicating less evolutionary adaption via MGEs. Furthermore, lack of  NanI in 
these strains may correlate with the characteristic self-limiting symptoms of FP 
diarrhoea, implying rapid pathogen clearance due to absence of key colonisation 
factors 116.  
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The long-term persistence and inter-hospital spread of C. perfringens demonstrated in 
two-year NEOM isolates raises significant concerns for at-risk preterm infants 
residing in healthcare units. As C. perfringens is strongly associated as a causative 
agent of preterm NEC, extra strategies should be implemented to eradicate this 
pathogen from neonatal wards 8. Another healthcare-associated pathogen C. difficile, 
also a proficient spore former, causes AAD and in some patients pseudomembranous 
colitis, which has risen dramatically over the last decade, mainly due to the spread and 
persistence of hyper-virulent strains 30,397.  
The detection of deadly toxin producers in a healthy child suggests the important role 
of host defence and gut microbiota in colonisation resistance 398,399. This indicates that 
whether C. perfringens is pathogenic or a mere commensal in the gut hinges on the 
impact of the host immune system, and the role of other microbiota members as 
discussed in Chapter 3, including the findings that supplementation of certain 
probiotics significantly reduces incidence of preterm NEC. This reflects the disease 
susceptibilities in particular groups including early-life and later-life individuals. 
Furthermore, this may suggest the future infection research on C. perfringens-
associated gut diseases should be directed towards understanding the impact of gut 
microbiota members on C. perfringens rather than merely the disease-causing toxins. 
Due to the large numbers of preterm hospital-acquired preterm-associated isolates 
(33.5%; n=185) and FP-related isolates (19.7%; n=109), relative to other diseases, 
host, and geographical location of strains, this may have influenced interpretation of 
the global C. perfringens phylogeny. Thus, for an even further in-depth study of C. 
perfringens genomic structure and relationships, community-acquired human and 
animal isolates from a broad regional spread, would be required. 
 
6.7 Future research directions 
This study analysed an unprecedented WGS dataset of C. perfringens isolates (n=552), 
obtained from a wide range of hosts from a number of geographical regions. 
Nevertheless, to obtain an even wider picture of C. perfringens population structure 
will requires the inclusion of strains from under represented diseased populations 
including nonfood-borne diarrhoea, enterocolitis-associated isolates from various 
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animal populations, and isolates of different toxinotypes, to better understand the 
evolutionary relationships and circulation of virulence plasmids.  
As C. perfringens-associated FP is a worldwide issue, the addition of FP-associated 
strains from other continents including Asia and Africa, especially equatorial 
countries, where temperatures may favour spread and growth of C. perfringens, would 
be interesting to include. Analysis of these strains would advance the understanding 
of the strains causing FP and help develop/design effective preventative measure for 
these issues 327,400,401. 
This analysis has revealed our apparent lack of understanding with respect to animal-
associated C. perfringens genotypes, although previous studies have frequently 
toxinotyped these strains. To better understand the potential zoonotic transfer of C. 
perfringens will require routine surveillance of animal-associated C. perfringens 
strains from farms and zoos, including pets, particularly from households with infected 
humans. This is critical as previous studies have indicated that for other pathogens, 
e.g. C. difficile, animals can potentially serve as reservoirs and carriers of hyper-
virulent genotypes, which is important in the One Health context 394,402. Of note, only 
a handful of sequences available to date are of animal-associated strains, albeit chicken 
isolates are well represented. 
Although toxinotyping is used to rapidly identify toxinotypes, which do in some cases 
link well with disease representations (particularly veterinary field) 1,20; WGS 
approaches in this study have proved a far more discriminatory method to 
comprehensively understand clinical strains including toxin carriage, specific 
virulence genes including AMR, assignment of sub-types via phylogenetic analysis, 
and tracking potential global/regional disseminations at SNP level. With the 
technological advancements of real-time WGS, it is possible to whole-genome 
sequence an isolate in under 2 h and obtain relevant information 314. Hence, it is 
proposed that WGS should progressively replace the conventional labour-intensive 
and time-consuming PCR approach (toxinotyping only) and be routinely implemented 
for national surveillance of C. perfringens outbreaks to monitor these isolates at the 
strain level. This important advancement will unveil more detailed clinically relevant 
information including virulence plasmids, accessory toxin genes and AMR, all of 
which are deemed critical to clinicians and veterinary medicine. 
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In conclusion, this work has analysed a total of 552 genomes (443 newly sequenced) 
of C. perfringens, representing the largest population genomic study of C. perfringens 
to date. Pertinent findings include, significant pangenomic variations (7.4% core 
genome in the pangenome), zoonotic potentials, virulence determinants associated 
with sub-clusters of isolates, substantial conjugative plasmid distributions, intra-
regional disseminations and long-term persistence, which have provided novel 
genomic and biological insights into the largest collection of C. perfringens genomes. 
Hypotheses generated from this analysis will allow in-depth genomic and 
experimental analyses to be carried out, thus advancing the understanding of this 
important enteric pathogen. 
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Chapter 7 Phenotypic characterisation of preterm-





The key aims of the study presented in this chapter were to characterise the virulence 
traits of clinically important C. perfringens strains including gas production, hydrogen 
sulphide generation, cell toxicity and antibiotic resistance, to identify strain-specific 
virulence traits/genotypes associated with preterm-NEC. An additional aim was to 
identify hyper-virulent strains of C. perfringens to take forward for the development 
of a C. perfringens infection model detailed in Chapter 8 (Figure 7.1). 
 
Figure 7.1: Schematic of examined isolates, experimental analysis and aims of Chapter 7 
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7.2 Background 
C. perfringens has been linked with numerous intestinal diseases in both humans and 
animals, including as an emerging candidate linked to preterm-NEC 1,8,9. This enteric 
pathogen is known for its resilience to stressful environmental conditions, and prolific 
production of an arsenal of >20 toxins 403. 
Although C. perfringens is classified as an anaerobe, this pathogen possesses a 
complex system to handle oxidative stress including genes that encode superoxide 
dismutase and superoxide reductase, however the underlying mechanisms are still not 
well understood 404. These aerotolerant properties, and the ability to form endospores 
links to C. perfringens ability to survive in aerobic environments for considerable 
periods of time, which is vital for survival and transmission, particularly in hospital 
environments 15,405,406. 
C. perfringens is also capable of reducing sulphite to generate gas such as hydrogen 
sulphide, which is often used to confirm presence of C. perfringens using TSC 
differential agar, on which C. perfringens forms pitch black colonies <20 h incubation 
due to precipitations of ferrous sulphide in this agar 11,71. Importantly, excessive 
hydrogen sulphide is proposed as a potential mediator of intestinal inflammation and 
is associated with the inflammatory bowel disease Ulcerative Colitis 72,407. 
Importantly,  excessive gas production by C. perfringens may be linked to specific 
enteric disease symptoms, and in the case of NEC may be associated with the extensive 
intestinal inflammation and formation of gas cysts that are characteristic of this disease 
12,73. 
C. perfringens has the potential to secrete a combination of >20 toxins, although no 
single strain is currently known to produce all toxins, and this potent virulence feature 
has long been considered as the primary pathogenesis trait of this bacterium 1,121. 
Several studies have examined molecular toxicity of C. perfringens secreted 
molecules against epithelial cells including bovine epithelial cells and human cell line 
Caco-2, with these studies indicating that CPE can directly damage these cell types 
85,114. However, to date there are no studies specifically probing how different 
clinically relevant strains interact with gut epithelial cells, including preterm-NEC-
associated isolates, thus our current understanding on this important C. perfringens 
pathogenesis trait is currently limited. 
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Comparative genomics in Chapter 3 indicates that NEC-associated isolates may be 
defined as ‘hypervirulent’ strains, as they encode significantly more toxin genes 
(particularly PFO encoding gene pfo), when compared with control isolates 
(potentially commensal C. perfringens). Nevertheless, specific phenotypes of strain-
specific characteristics associated with NEC-linked isolates has yet to be determined. 
This chapter will explore specific phenotypic virulence traits associated with NEC-
linked isolates including; oxygen sensitivity, gas generation, hydrogen sulphide 
production, molecular toxicity against mammalian intestinal cell lines, antibiotic 
resistance, growth kinetics and sporulation-related features, with the aim of linking 
genotype to virulence phenotype and additionally allowing for selection of ‘hyper-
virulent’ strains for use in a mouse infection model (Chapter 8). 
 
7.3 Hypothesis and aims 
It is hypothesised that disease-associated C. perfringens isolates exhibit strain-specific 
virulence properties, and that certain strains are more virulent than other non-
pathogenic strains. The aims of this chapter are: 
(1) To characterise various C. perfringens-associated virulence factors in selected 
NEC or non-NEC C. perfringens isolates via multiple in vitro approaches and identify 
key phenotypic traits; 
(2) To identify suitable hyper-virulent strains for use in a pre-clinical model that is 
described in Chapter 8. 
 
7.4 Isolate selection and information 
A total of 10 C. perfringens isolates were selected for their associations with preterm 
NEC: from patients in Bell Staging I (BELL 1), II and III (BELL 2/3), and from control 
samples (non-NEC). Isolates LH019, LH115 and LH043 were isolated from BAMBI 
samples and were newly sequenced. The relevant information of the isolates is detailed 
in Table 7.1. 
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Table 7.1: Selected C. perfringens isolates with clinical metadata 
* These isolates were characterised as C. perfringens-associated-NEC, hyper-virulent strains as defined 
in Chapter 3. RH: Rosie Hospital (Cambridge, UK); SMH: St Mary’s Hospital (London, UK); QCCH: 




7.5.1 Growth kinetics assay 
C. perfringens is reported to double in 12-17 mins at 37°C (log phase), and 8-12 mins 
at 43°C in optimal medium, making this pathogen the fastest-growing microorganism 
ever known 70. Here the growth kinetics of these 10 isolates were investigated using 
rich media BHI at 37°C in anaerobic conditions, which is the normal mammalian body 
temperature, to compare growth dynamics and generation times. 
Doubling time of all tested isolates ranged between 12-19 mins at 37°C, which is in 
agreement with previous studies analysing cpe-carrying strains 70. Moreover, between 
NEC and non-NEC strains there was no statistical variations in mean generation time 
(P>0.05; Table 7.2). Notably, isolate LH115 (Bell 1) had the fastest generation time 
at 12.47 mins during log phase, while M009 (non-NEC) was the slowest at 19.09 mins 
(Figure 7.2). All isolates grew to confluency (~109 CFU/ml) from approximately 103 
CFU/ml within 5-7 hours.  
 
 





1 Q215* QCCH BELL 2/3 28+1 40 days 40 
2 Q088* QCCH BELL 2/3 27+1 24 days 24 
3 Q143* QCCH BELL 2/3 31+1 19 days 19 
4 Q020* QCCH BELL 2/3 27+1 19 days 19 
5 LH019 RH BELL 1 24+5 56 days 32 
6 M010 SMH BELL 1 27+4 16 days 16 
7 LH115 NNUH BELL 1 24+3 49 days 28 
8 LH043 RH Non-NEC 25+5 42 days / 
9 M009 SMH Non-NEC 28+1 15 days / 
10 Q167 QCCH Non-NEC 26+0 13 days / 
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Table 7.2: Statistics of C. perfringens generation time based on Bell staging groups 
 
 
Figure 7.2: Growth kinetics of C. perfringens isolates and generation time comparison 
(A) Growth kinetics of C. perfringens isolates in CFU and optical density over 24h. (B) Generation time 
comparisons between isolates in various groups. Mean generation time is calculated during the log 
growth phase. Data represent 3 biologically-independent cultures (n=3), one-way ANOVA, Dunn’s 
multiple comparison test. OD: Optical Density. 
 
 Bell 2/3 Bell 1 Non-NEC 
Minimum 14.05 12.47 13.43 
Median 15.79 13.45 17.21 
Maximum 16.68 18.84 19.09 
Mean ± SD 15.58 ± 1.27 14.92 ± 3.43 16.58 ± 2.88 
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7.5.2 Gas production 
C. perfringens was first associated with human disease during World War I, gas 
gangrene, which was so-called due to the characteristic gas production and associated 
pathology  408,409. Importantly, preterm-NEC has also been described as ‘intestinal gas 
gangrene’, reflecting the fulminant formation of gas cysts in the intestine, coupled 
with tissue necrosis, hallmark NEC representations 190. Thus, it is hypothesised that 
certain extra-virulent strains may generate more gases than others, which may be 
associated with mechanical injuries within the intestinal lamina propria. 
Gas production of all 10 selected strains was measured in the first 10 hours, as 
described in the method section. Strain-specific variations were observed: NEC-
associated strains generated a larger gas volume than the non-NEC strains at seeding 
concentrations of 103 CFU/ml (Figure 7.3). Statistically, Bell 2/3 isolates generated 
significantly more gases than Bell 1 (mean: 22.2 ml vs 16.4 ml; P<0.01) and non-NEC 
isolates (mean: 22.2 ml vs 18.9 ml; P<0.01; Figure 7.3B). Positive control E. coli was 
observed to produce gas in anaerobic conditions at high CFU/ml (starting CFU at 106 
CFU/ml). By contrast, B. bifidum was not observed to generate gas, even at high CFU 
seeding concentration (103-fold > C. perfringens strains at 106 CFU/ml).  
 
Figure 7.3: Gas production assay on selected C. perfringens isolates  
(A) Accumulated gas production of C. perfringens. Confluent cultures were inoculated at 103 CFU/ml 
(exception: B. bifidum and E. coli at 106 CFU/ml) and sealed in 30ml-sterile air-tight gas vials (50ml) in 
anaerobic chamber prior to experiment. All cultures and equipment were pre-reduced overnight before 
experiment. Measurements were taken every hour and the experiments stopped at 10h. ND: Not 
Detectable. Data: means ± SEM (n=3). (B) Comparisons of isolates’ gas production in groups. Each dot 
represents one technical replicate. Data: means ± SEM, one-way ANOVA (Kruskal-Wallis test, α=0.05; 
Dunn’s multiple comparison test). ** P<0.01.  
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7.5.3 Hydrogen sulphide assay 
Microorganisms are capable of producing hydrogen sulphide via utilisation of 
compounds containing organic sulphur, e.g. thiosulphate, sulphite and sulphate 410. C. 
perfringens, is known to produce sulphite in TSC media to form pitch-black colonies, 
resulting from the precipitation of ferrous sulphide71. Importantly, hydrogen sulphide 
is also known to be cytotoxic to mammalian cells 411. Here, I hypothesised that C. 
perfringens may initiate pathogenesis via production of hydrogen sulphide, which 
correlates with epithelial cell cytotoxicity (Figure 7.4) 72,407.  
 
Figure 7.4: Hydrogen sulphide assay on selected C. perfringens isolates  
(A) Blackening scoring system for H2S detection. Data representation: mean ± SEM (n=3). B. longum 
was cultured for a continuous 20h (2x), no sign of black stain observed. ND: Not Detectable. This 
experiment was performed in 3 independent cultures for each isolate. (B) H2S visual measurement test. 
Blackening scoring - 1: slight black stain on the strip; 5: 50%black strip; 10:100% black strip. The degree 
of blackening was used as a H2S concentration/production gauge. (C) Comparison for blackening scores 
on H2S production. Data representation: means ± SEM. One-way ANOVA Dunn’s multiple comparisons 
test, n=3. ** P<0.01, *** P<0.001, ns: non-significant. (D) Necrotic effect of NaHS (H2S donor) on IEC-6 
monolayer system at 2h-incubation. Data: each bar represents necrosis percentage of tissues with 
percentages indicated on top of each bar. Physiological concentration of hydrogen sulphide in 
mammalian gut ranges from 1-1000ppm. * P<0.05, ** P<0.01 (two-tailed t-test, unpaired Welch’s 
correction, n=3). 
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In this assay, visual-quantification was employed to determine relative concentration 
of hydrogen sulphide production (H2S strips), and NaHS, a known hydrogen sulphide 
donor, was incubated with IEC-6 monolayers, a rat small intestine cell line 412. 
Significant variation was observed over the 10 selected strains (Figure 7.4). Using a 
visual scoring method (Figure 7.4A) strains LH019 and M009 did not produce H2S in 
the first 8 h, and B. longum (non-sulphite reducer) was not observed to generate H2S 
as expected (Figure 7.4B). Group comparison on blackening scoring showed that Bell 
2/3 isolates produced significantly higher concentration (8.0 ± 0.6; mean ± SD) of H2S 
than Bell 1 (4.3 ± 3.3; P<0.01) and non-NEC isolates (3.6 ± 3.0; P<0.001; Figure 7.4C). 
Toxicity of H2S was tested in IEC-6 monolayers (Figure 7.4D), with H2S 
concentration at 103 ppm causing slight necrosis (6.3% vs mean baseline 4.9%; 
P<0.05). At 104 ppm significant necrosis was observed (19.8%, P<0.01), which 
experimentally indicated that H2S is directly cytotoxic to mammalian epithelial layers 
at high concentration. 
 
7.5.4 Oxygen tolerance assay 
Oxygen-sensitivity was tested over a period of 14 days of ambient-air exposure. This 
oxygen tolerance trait may be expected to facilitate host-to-host and/or nosocomial 
transmissions of particularly virulent strains 15. Results indicated that Q143 (Bell 2/3) 
had >104-fold more viability, than the least aerotolerant strain Q167 (non-NEC) 
(Figure 7.5A), which had no detectable re-growth at day 14. Bell-staging group 
comparison indicated that isolates associated with Bell 2/3 were significantly more 
aerotolerant (P<0.0001), than non-NEC isolates at day 14 (Figure 7.5B). Strains with 
only a 100-fold CFU reduction (at 106 CFU/ml) after two weeks were Bell 2/3 isolates 
Q143, Q020, Q215, Q088 (100%) and Bell 1 isolate M010, and were thus identified 
as oxygen-resilient isolates. 
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Figure 7.5: Oxygen tolerance assay on selected C. perfringens isolates  
(A) Viability of C. perfringens strains exposed to ambient air over 14 days. Anaerobic NEC-associated 
C. perfringens isolates from various Bell stages and non-NEC individuals are shown in the brackets 
(n=3). The experiment stopped at 336h (14 days). Data: mean; n=3 (independent cultures). (B) 
Comparisons of C. perfringens viability (%) after exposure to ambient air at 4 time-points across 
experimental period according to clinical groups. Each dot represents SEM and mean percentage of 
viable cells compared to Day 0 control within each Bell staging group. For all time-points, no statistically 
significant differences were found in between diseased/non-diseased groups except time-point 336 h. 
Data: mean (n=3). Central bars represent group mean. One-way ANOVA Dunn’s multiple comparisons 
test. **** P<0.0001. 
 
7.5.5 Sporulation capacity 
Sporulation capacity was determined as trait may directly link to C. perfringens 
transmission capacity and ability to survive through harsh environments and passed 
on to the next host 15. C. perfringens is known to be a spore-forming species, however 
it has been reported to be relatively difficult to sporulate in vitro, unless cultured in 
Duncan-Strong (DS) medium (developed in the late 1960s) 61.  
Initially to determine if C. perfringens strains could be sporulated in rich BHI media, 
two strains were randomly selected: Q215 and LH115. These two strains were 
incubated anaerobically for 6 days, then treated with 70% ethanol for 4h and plated 
out on BHI agar (Figure 7.6A). Results show that neither strain sporulated, which is 
in agreement with previous literature 61.  
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Figure 7.6: Sporulation assay on selected C. perfringens isolates 
(A) Sporulation capacities of over-culturing of two strains in BHI media for 6 days. Two strains were 
incubated in rich media BHI for a consecutive 6 days, cultures were immersed in 70% ethanol for 4 h 
and plated on BHI agar. No sporulated colonies observed. (B) Sporulation capacity of C. perfringens 
strains. Pure bacterial cultures (24h Duncan-Strong medium culturing) were immersed in 70% ethanol 
for 4h to eliminate vegetative cells before being washed with PBS and spotted onto BHI growth medium 
supplemented with 0.1% sodium taurocholate as a germinant. Strains M009 and Q167 were below LOD 
(50 CFU/ml) as no single colony was detected (ND: non-detected) on BHI plates even after 48h DS 
medium culturing. Varied sporulation capacity of each strain was displayed in this assay. Data: mean ± 
SEM (n=3). Dotted line represents LOD.  
 
DS modified medium was then employed to examine sporulation capacity of 10 
selected strains (Figure 7.6B). After 24h-incubation, and 4h-70% ethanol treatment to 
eliminate vegetative cells, most strains displayed sporulation on 0.1% taurocholate 
supplemented BHI agar, with the exception of strains M009 and Q167 (both non-NEC) 
that did not sporulate, even after prolonged 48h-incubation in DS modified medium. 
These results demonstrated variation in sporulation capacities between strains as 
colonies >105 CFU/ml (or, spores/ml) were recovered in strains Q143, Q020 and 
LH115 (strains Q215 and LH115 did not sporulate in BHI for 6 days), while <104 
CFU/ml, were recovered from the remaining strains, and both M009 and Q167 did not 
sporulate after 48h. 
 
7.5.6 Bile salt assays 
Primary bile salts including taurocholate are known to induce spore germination, 
which has previously been linked to enhanced pathogenicity in C. difficile 68,413. 
Conversely, secondary bile salts (e.g. deoxycholate and chenodeoxycholate), 
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produced after de-conjugation of primary bile salts by certain gut microbiota members, 
have been reported to inhibit either the germination/growth of C. perfringens 413. Thus, 
this assay was designed to understand the variation of C. perfringens spores’ responses 
to bile salts, including primary bile salts taurocholate and cholate, and secondary 
inhibitory bile salts deoxycholate and chenodeoxycholate. 
Most strains (7/8) exhibited higher mean germination potency (>1.0 fold) on 
taurocholate-supplemented BHI, when compared to control (BHI not supplemented 
with taurocholate; Figure 7.7A). Notably, spores of three strains (Q215, Q020 and 
LH019) had significantly enhanced germination on taurocholate when compared to 
cholate (P<0.05). Overall, taurocholate (1.2 ± 0.4-fold change) significantly improved 
germination in comparison to germination in the presence of cholate (0.8 ± 0.2-fold 
change; P=0.017; Figure 7.7B). Importantly, secondary bile salts including 
chenodeoxycholate and deoxycholate inhibited germination (or, growth) of all strains 
(8/8). A mixed-bile assay was carried out to determine whether more physiological-
like conditions and concentrations of bile salts impacted C. perfringens spore 
germination. Strains Q215 and Q088 cultured overnight in BHI before being plated on 
BHI agar supplemented with 0.1% taurocholate, 0.1% cholate and 0.1% deoxycholate 
(secondary bile salt) had no growth after 20h incubation. Furthermore, different 
concentrations of deoxycholate were used to determine MIC, and this assay showed 
that 0.05% had limited inhibition activity on strain Q215 at 72h, indicating 0.1% is the 
MIC for C. perfringens inhibition (>7 days), which is a physiological concentration 
414. 
Finally, primary bile salts taurocholate and cholate were investigated for their ability 
to impact vegetative cell growth of strains Q215 and Q088, however no statistical 
difference was observed (P=0.500; Figure 7.7C). 
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Figure 7.7: Bile salt assays on selected C. perfringens isolates 
(A) Responses of C. perfringens spores to bile-salt germinants supplemented at 0.1%. The number of 
colony-forming units (CFU; representing germinated spores) present on plates in the presence of a 
germinant is expressed as a fold-change with respect to the number of CFU recovered on plates in the 
absence of a germinant. Tested strains were subjected to ethanol treatment (70% ethanol, 4h 
immersion) prior to being plated (n=3 biological replicates for each strain). A fold-change of one 
(represented by dotted black line) indicates that a germinant had no effect on the CFU recovered. Data: 
mean and range, Welch's unpaired non-parametric t-test (* P < 0.05, ** P<0.01). (B) Comparison of the 
effect of different bile salt supplementations on germination potency. Data: Mean ± SD, Welch's two-
tailed unpaired t- test, * P<0.05. (C) Bile salt responses of vegetative cells. Data: Mean with range, no 
statistical difference observed. 
 
 
7.5.7 Minimum inhibitory concentration assay 
C. perfringens has a range of AMR profiles, with tetracycline resistance particularly 
widespread 126,415. Thus, a MIC assay was performed to determine the resistance 
profiles of C. perfringens strains to tetracycline, gentamicin and penicillin, as these 
are commonly prescribed in neonatal clinical settings (i.e. NICU) 416. 
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Four NEC-associated strains (out of 7) were demonstrated to display tetracycline MIC 
≥ 4μg/ml, while 3 out 7 strains had MIC ≤ 0.125 μg/ml (LOD; no growth was observed; 
Figure 7.8A). Non-NEC strain LH043 displayed the highest MIC (32 μg/ml). 
Resistance towards gentamicin was high (MIC ≥ 64μg/ml) in all C. perfringens strains 
with the exception of strain Q088 (MIC ≥ 32μg/ml; Figure 7.8B). Seven out of 8 
strains had MIC ≥ 128μg/ml towards gentamicin, which indicates that this antibiotic 
is generally ineffective towards inhibiting C. perfringens. 
Importantly, all tested strains showed no resistance towards penicillin (MIC ≤ 0.125 
μg/ml; Figure 7.8C). The lowest observed MIC was in strain LH019 (no detectable 
growth at LOD 0.015μg/ml). 
 
Figure 7.8: Minimum Inhibitory Concentrations of specific antibiotics against C. perfringens  
(A) Tetracycline; (B) Penicillin; and (C) Gentamicin. ATCC13124 was used as a control strain. Data: 
Mean ± SEM (2 separate experiments). LOD: Limit of detection. 
 
7.5.8 Toxicity against mammalian intestinal epithelial cells 
7.5.8.1 Necrosis assay 
C. perfringens strains are known to secret pore-forming toxins that could necrotise gut 
epithelial tissues 1,403. Strain variation in pore-forming capacities has previously been 
hypothesised, as C. perfringens can be pathogenic or a commensal member of the gut 
microbiota 417. A necrosis assay was therefore performed using intestinal epithelial 
monolayers (IEC-6 and Caco-2 cell lines), with co-incubation of sterile-filtered 
soluble media (10h-incubation with 1% starting inoculum across all 10 strains) to 
compare and determine cell toxicities. 
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Figure 7.9: Necrosis assay performed on Caco-2 monolayer 
(A) Necrosis percentage of Caco-2 monolayer co-cultured with C. perfringens sterile-filtered 
supernatants after 2h. (B) Statistics compare each group. Caco-2 P31 was used in this assay. 
Supernatants of C. perfringens (10 h-incubation with 1% starting inoculum) were sterile-filtered before 
used. Each well was co-incubated with 15% supernatants of either 1:2 or 1:4 dilution in the working 
media.  Promega membrane integrity kit was employed to examine the necrosis percentage. (Data: 
mean ± SEM; n=3; **** P<0.0001, *** P<0.001, ** P<0.01, * P<0.05. One-way ANOVA with Bonferroni 
multiple comparison test). Normal cell death percentage is indicated by black dashed line (control). 
 
In the Caco-2 model, a human colonic cell line, 7 strains including all Bell 2/3 isolates 
(Q215, Q088, Q143 and Q020) and all Bell 1 isolates (LH115, M010s and LH019), 
were shown to induce significant necrosis (Bell 2/3: 20.59 ± 5.40%; Bell 1: 13.68 ± 
3.88%; negative control: 2.00 ± 2.32%; mean ± SD), compared to control at 1:2 
dilution (P<0.0001; Figure 7.9A-B). Notably, Q215 (Bell 2/3 NEC case isolate) 
induced 28.93 ± 0.42% necrosis (mean ± SD, n=3 technical replicates) in under 2 h, 
which was the most potent necrotising isolate. By contrast, none of the non-NEC 
strains (LH043, M009 and Q167) induced significant necrosis on Caco-2 monolayers 
(3.72 ± 1.87% in 1:2 dilution; P>0.05). 
In IEC-6 (rat small intestinal cell line) monolayers, comparable results were observed 
(1:4 dilution). Bell 2/3 isolates Q215, Q088, Q143 and Q020 (group mean ± SD: 39.71 
± 20.9%), Bell 1 group strains M010 and LH115 (64.81 ± 25.75%; except LH019) 
demonstrated significantly higher necrosis (P<0.01; control necrosis %: 2.18 ± 1.03%) 
(Figure 7.10A-B). Again, none of the non-NEC strains (mean necrosis ± SD: 13.61 ± 
11.73%) induced significant necrosis (P>0.05). Overall, significantly higher necrosis 
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was observed in Bell 2/3 (P<0.01) and Bell 1 isolates (P<0.001), when compared to 
non-NEC isolates (Figure 7.10B). 
 
 
Figure 7.10: Necrosis assay performed on IEC-6 monolayer 
(A) Necrosis percentage of IEC-6 monolayer co-cultured with C. perfringens sterile-filtered supernatants 
(2h incubation). (B) Statistics compare each group. Each well was co-incubated with either 1:4 or 1:8 
dilution in the working media.  Promega membrane integrity kit was employed to examine the necrosis 
percentage. (Data: mean ± SEM; n=6; **** P<0.0001, *** P<0.001, ** P<0.01. One-way ANOVA with 
Bonferroni multiple comparison test). Normal cell death percentage is indicated by black dashed line 
(control). Data were based on two independent experiments. 
 
7.5.8.2 Apoptosis assay 
A further cell death assay was performed to understand C. perfringens capacity to 
induce programmed necrosis i.e. apoptosis. Similar to what was described in the 
necrosis assay, supernatants of Bell 2/3 strains Q215, Q088, Q143 and Q020 induced 
significant levels of apoptosis-associated caspase enzymes (caspases 3 and 7) after 3h 
co-incubation with Caco-2 cells (P<0.01; 24376 ± 8661 RLU vs control background: 
5230 ± 128 RLU) (Figure 7.11A). Bell 1 isolates M010 and LH115 (not LH019) also 
induced significant apoptosis in this model (P<0.0001; mean RLU: 31327 ± 8562 
RLU). Overall, supernatants from NEC-associated isolates inducex significantly 
greater caspase activities (P<0.01) in Caco-2 monolayers as compared to non-NEC 
isolates (5593 ± 661 RLU), where no significant levels of apoptosis were detected 
(P>0.05; Figure 7.11B). 
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Figure 7.11: Apoptosis assay performed on Caco-2 monolayer 
(A) Caspase activity measured via RLU (marker of apoptosis) of Caco-2 monolayer co-cultured with C. 
perfringens sterile-filtered supernatants (3h incubation). (B) Statistics compare each group. Bacterial 
supernatants diluted in BHI have negligible luminescence background. All data represent 3 biological 
triplicates (n=3) in a single experiment (data are shown as mean ± SEM). Staurosporine was used as 
the agent for positive control. Data: One-way ANOVA test was performed with Bonferroni’s multiple 
comparison test to compare each group with control group. Significance: * P<0.05, ** P<0.01, *** 
P<0.001, **** P<0.0001. 
 
Supernatants of C. perfringens strains showed similar patterns in caspase activity in 
IEC-6 monolayers, with all Bell 2/3 isolates (13900 ± 3582 RLU) and two Bell 1 
isolates (M010 and LH115; 13951 ± 4411 RLU) inducing significant levels of 
apoptosis (P<0.0001; Figure 7.12). Again, spent media of all three non-NEC isolates 
did not induce any apoptotic capacity in this rat cell line model (P>0.05; 4736 ± 529 
RLU). 
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Figure 7.12: Apoptosis assay performed on IEC-6 monolayer 
(A) Caspase activity measured via RLU (marker of apoptosis) of IEC-6 monolayer co-cultured with C. 
perfringens sterile-filtered supernatants (3h incubation). (B) Statistics compare each group. Bacterial 
supernatants diluted in BHI have negligible luminescence background. All data represent 6 biological 
triplicates (n=6) in two independent experiments (data are shown as mean ± SEM). Caspase-Glo 3/7 
Assay (Promega) was used for measurement of caspase activity of the cells and performed according 
to the manufacturers' instructions.  Staurosporine was used as the agent for positive control. Data: One-
way ANOVA test was performed with Bonferroni’s multiple comparison test to compare each group with 
control group. * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001. 
 
7.5.9 PFO expression assay 
As PFO appears to be a NEC-associated toxin (Chapter 3), which may correlate with 
the enhanced cell death observed in the cell line studies described above, presence of 
PFO was phenotypically confirmed to link to genotyped pfo-carrying strains. In brief, 
5% sheep-blood-BHI-agar was used to demonstrate PFO production, as PFO is known 
to be haemolytic, and displays beta-haemolysis (complete haemolysis) on blood agar 
87.  
All pfo-carrying strains (8/8) exhibited beta-haemolysis on blood agar plates, 
confirming expression of pfo (Figure 7.13). In contrast, all non-NEC strains, not pfo-
encoding, did not exhibit haemolytic effects (3/3; 100%). 
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Figure 7.13: PFO expression assay on selected C. perfringens isolates 
Expression of PFO secretion exhibiting beta-haemolysis (complete haemolysis) on sheep blood agar by 
(A) strains harbour PFO gene, and (B) strains do not harbour PFO gene. Strains were streaked on BHI-
based sheep blood agar (5%) and incubated anaerobically for 20 h before visual examinations. Lysis of 
red blood cells can be observed in all (100%) PFO-carrying strains. 
 
7.5.10 Virulence and AMR correlations: genotype vs phenotype 
Necrotic tissue is the hallmark symptom of C. perfringens infections, including 
poultry NE and NEC, which is linked to secreted toxins 73. Notably, necrotising 
capacities of these 10 strains in Caco-2 monolayers (Figure 7.14A), correlated with 
presence or absence of pfo. This data indicates that PFO may be the main necrosis-
inducer, linking to cytotoxicity ability in both Caco-2 and IEC-6 models, and 
confirmed by secretion of PFO on blood agar (Figure 7.13).  
Interestingly, pfo-negative, Beta-2-toxin-carrying strains M009 and LH43 did not 
show potent necrotic capacity. Notably, although LH043 possesses 8 toxin genes 
(excluding pfo), this strain showed the least cytotoxicity, highlighting that PFO is a 
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potent cytotoxin to colonic cells, which may link to NEC phenotypes (as described in 
Chapter 3).  
 
Figure 7.14: Phenotypes and genotypes virulence comparison 
(A) Necrotising phenotypes expressed in Caco-2 cells, and (B) AMR phenotypes on tetracyclines, vs 
genotyping profiles of examined strains. Heatmaps were generated using R. AMR profiles were based 
on CARD database. 
 
To associate exotoxin genes with necrosis traits, Fisher’s exact test was performed to 
correlate enrichment of genes between significant-necrosis group (Q215, Q088, Q143, 
Q020, M010, LH115) and non-significant-necrosis group (LH019 considered as non-
significant taking IEC-6 model into account, LH043, M009, Q167). PFO was shown 
to be enriched in significant-necrosis group (P=0.033; two-tailed, OR: 30), while other 
toxin genes (cpb2, nanJ, nanI and nagH) were not significantly associated with either 
group (P>0.05; 0.05<OR<14). 
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Importantly, tetracycline resistance was directly correlated with presence of acquired 
AMR genes tetA(P) and tetB(P) as isolates (Q020, LH019 and M010), that do not 
encode these two genes were highly susceptible to this antibiotic (MIC < 0.125 μg/ml; 
Figure 7.14). Multidrug-resistant clinical strain LH043 (also encoded erythromycin-
resistant gene ermQ) displayed the highest resistance against tetracycline at MIC 32 
μg/ml. Importantly, tetracycline ribosomal-protection gene tetB(P) seemingly could 
enhance isolates resistance against tetracycline, as all 4 isolates that harboured this 
gene had MIC ≥ 8 μg/ml (range 8-32 μg/ml), while three isolates that only encoded 
tetA(P) demonstrated a relatively lower MIC ≤ 4 μg/ml (range: 1-4 μg/ml). 
 
7.5.11 Selection of strains for pre-clinical models 
This section describes the selection of suitable hyper-virulent strains for use in 
establishing a pre-clinical model that is described in Chapter 8. 
PCA analysis, based on phenotypic traits as demonstrated in this chapter, (n=10) 
revealed that non-NEC strains exhibited a distinctly less virulent phenotypic profile, 
when compared to NEC-associated strains (Figure 7.15A). Bell 2/3 isolates Q215, 
Q088, Q143 and Q020 formed a cluster, (Figure 7.15A) with LH019 clustering more 
closely with non-NEC strains. 
A virulence scoring system was used to gauge the virulence of these strains based on 
subjective ranking of pathogenicity based on the data from the comparative analyses 
(primarily 0-4 system, 4 showed strongest characteristic; otherwise 0-1 in binary 
characteristic; Figure 7.15B). Strains Q215 and Q143 (both from Bell 2/3) were ranked 
as the top-two strains, specifically strain Q215 displayed the strongest necrotising 
capacity (4/4). Hence, these two strains (Q215 and Q143) were selected as the hyper-
virulent strains to be used in pre-clinical models. In addition, Bell 2/3 isolates 
exhibited higher virulence scoring (P<0.05) compared to non-NEC isolates (Figure 
7.15C-D). This suggested Bell 2/3 isolates as hyper-virulent strains in contrast to non-
NEC strains, supported by hyper-virulent genotypes as described in Chapter 3. 
 
Chapter 7    Phenotypic characterisation of C. perfringens    232 
 
 
Figure 7.15: Overall phenotypic virulence traits of all selected C. perfringens isolates  
(A) PCA based on phenotypic traits. Embedded figure showing clustering of isolates (top right corner of 
the figure). (B) Virulence scoring of each strain. Data: total virulence scoring (0-34). (C) Comparisons of 
groups. Data: mean ± SEM. One-way ANOVA, Bonferroni’s multiple comparisons test. * P<0.05, ns: 
non-significant. (D) Individual virulence scoring breakdowns. Overall virulence traits (n=10) examined 
using scoring system 0-4/0-1; where 0 is least and 4 (or, 1) shows strongest, or binary characteristics. 
Heatmap generated in R. 
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7.6 Discussion 
Most C. perfringens-related studies have concentrated on characterising the vast array 
of toxins this pathogen can secrete 21,121,418,419. However, in the wider context of 
pathogenesis, C. perfringens is expected to encode and display a range of features that 
may enhance its virulence capabilities, particularly within hospital settings. Thus, in 
this chapter I sought to perform in-depth phenotyping on 10 selected C. perfringens 
strains based on 10 key virulence traits (classified by cell toxicity, survival and 
colonisation), with data indicating significant virulence variations between strains, 
including presence of non-pathogenic strains and hypervirulent strains that may link 
to clinical symptoms 420. 
C. perfringens is the fastest growing microbes characterised to date 70, with growth 
kinetic studies indicating that the strains profiled in this study had an average 15.68 ± 
2.33 mins generation time. Although individual isolate differed in doubling rates, there 
were no statistical differences between NEC vs non-NEC strains. However, this rapid-
growing trait could potentially contribute to its pathogenic role in clinical contexts, 
and correlates with the rapid symptom initiation observed in NEC (often <8h) and 
food-poisoning diarrhoea (within 8-12 h) allowing C. perfringens to proliferate and 
release toxic factors 73,319,323,421.  
The gas-producing capacity of C. perfringens (using batch fermentation) has not been 
reported in the literature to date. Notably, overall NEC strains had enhanced gas 
production relative to non-NEC strains which may correlate with distinctive NEC 
symptoms, namely abdominal distension and pneumatosis intestinalis- the formation 
of gas cysts on the gut wall, both of which have been associated with C. perfringens 
overgrowth. This mechanical damage, brought about by gas build-up, may directly 
damage the intestinal barrier, leading to tissue necrosis and the severe pathology 
observed in preterm infants diagnosed with Bell 2/3 NEC.   
The type of gas produced by C. perfringens will also have a direct impact on tissue 
necrosis, via direct cytotoxicity to epithelial cell lining the GI tract. These studies 
indicated that NEC-associated strains produced more hydrogen sulphide than non-
NEC isolates, which is clinically important as previous studies have linked H2S with 
Ulcerative Colitis, and direct necrosis of the gut epithelium, and also enhancement of 
the detrimental inflammatory processes observed in these patients 72,422-424. These 
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pathogenesis factors are also characteristic of preterm-NEC, highlighting that 
hydrogen sulphide production by C. perfringens may be linked to key NEC pathology, 
which is the first time this has been reported. 
As an anaerobe, C. perfringens does not grow in aerobic conditions; however, 
previous studies and analysis of NEC and non-NEC strains as described in this chapter 
indicates this pathogen can survive in aerobic environments >2 weeks, suggesting a 
strong detox-catalyst system, which appears to be strain-specific 56. Importantly, this 
oxygen insensitivity trait poses a significant threat in clinical contexts and links 
directly to bacterial transmission. As C. perfringens can survive on ambient surfaces, 
spread of this pathogen could potentially be in the form of vegetative cells, thus 
increasing infection risk in vulnerable patients i.e. preterm infants and elderly patients 
8,334. More classically appreciated is C. perfringens transmission being linked to its 
ability to form environmentally resistant spores, and interestingly NEC-associated 
Bell 2/3 strains appeared to more readily sporulate, when compared to non-NEC 
strains highlighting another effective transmission mechanism for potentially more 
virulent strains and initiation of disease once resident in the gut.  
From an intervention perspective, this would indicate that specific hygiene practices 
are required to prevent ready transmission of C. perfringens between wards and 
patients, as in the case of C. difficile endospores that can be detected on inanimate 
surface, washed bedsheets and even room air in the hospital wards 425-428. Moreover, 
as C. perfringens spores survived extended time-periods in 70% ethanol, which is 
currently extensively used as disinfectant, other measures e.g. hydrogen peroxide 
decontamination on ward surfaces, or a more advanced disinfection technology cold-
air plasma sterilisation (also, nonthermal plasma) should be implemented to introduce 
more effective decontamination approach in order to prevent dissemination of this 
pathogen in healthcare settings 425,426,429,430.  
Bile salts have been extensively studied in relation to C. difficile infection, 
nevertheless relatively fewer studies have addressed the impact of bile salts in C. 
perfringens germination 68,431. Primary bile salt taurocholate is a known germinant in 
spore formers including C. difficile, and this work revealed that C. perfringens can 
germinate in the presence of this bile acid. Importantly, accumulation of bile salts 
(including taurocholate) in preterm-infant intestines (primarily ileum, the common site 
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of NEC), possibly due to limited enterohepatic circulation capacity, has been 
implicated in the development of NEC, as well as in a rodent model 432-434. This 
hypothesis was further supported by a recent study showing that bile salt 
concentrations (i.e. taurocholate, detected as early as the first three days) are higher in 
preterm infants who later developed NEC 435,436. This could further explain why 
preterm infants are susceptible to C. perfringens-associated NEC, as C. perfringens 
spores can be potentially inoculated from the environment, germinate in the presence 
of high concentration of bile salt taurocholate and thrive in the gut. To probe this 
aspect further will require a mechanistic study in C. perfringens mouse model and bile 
salt administration. 
Importantly, secondary bile salts (deoxycholate and chenodeoxycholate) have been 
linked to the inhibition of C. difficile, and C. perfringens in this study 431,437. Secondary 
bile salts are produced by certain gut microbiota members through metabolism of 
primary bile salts (taurocholate), which is linked to a key colonisation resistance 
mechanism of the gut microbiota 438,439. Importantly, deoxycholate was shown to exert 
inhibitory effects on C. perfringens at physiological concentrations i.e. 0.1% (>7 days), 
and at 0.05% for up to 72h in vitro, even in mixed bile conditions, i.e. taurocholate 
and deoxycholate, the growth of C. perfringens was inhibited due to the bacteriostatic 
effect of deoxycholate. Interestingly, these data may link to the effectiveness of current 
probiotic strategies in NICUs, where preterm infants are given probiotic bacteria 
including Bifidobacterium, a bacterial species know to produce secondary bile salt via 
bile salt hydrolase. Crucially, administration of B. bifidium has been shown to 
significantly reduce NEC incidence (ongoing Hall lab BAMBI study), which is 
potentially associated with the inhibitory effect of secondary bile salts against C. 
perfringens and other pathogens 301,439,440.  
A global emergency is the rise of AMR and emergence of ‘super bugs’ that are 
refractory to currently available antibiotics. C. perfringens strains are widely reported 
to possess tetracycline resistance elements tetA(P) and tetB(P), and analysis of the 
isolates tested in this chapter indicated widespread tetracycline-resistance, which 
correlated with presence of one or two tet elements 17,126,415,441; while susceptible 
strains (M010, LH019, Q020) did not encode any tet genes. Clinical isolate LH043 
had the highest tetracycline MIC at 32g/ml; with the lowest MIC of tet-carrying 
strains at 2 g/ml (Q167), further highlighting tetracycline should not be used to treat 
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C. perfringens infection 17. Moreover, C. perfringens strains appear intrinsically 
resistant to the broad-spectrum antibiotic gentamicin, which is still widely used in 
NICUs as a prophylactic antibiotic. Conversely, penicillin appears to be an effective 
option to treat C. perfringens infection 442, with no beta-lactamase genes encoded in 
any of the C. perfringens genomes in this study, which may explain the effectiveness 
of penicillin observed. 
Toxicity of C. perfringens sterile-filtered secretory supernatants were tested against 
both rodent small intestinal (IEC-6) and human colonic models (Caco-2) and 
demonstrated similar trends: Bell 2/3 isolates (n=4) were significantly more 
necrotising than Bell 1 (P<0.01) and non-NEC isolates (P<0.001). This virulence trait 
is expected to link directly to C. perfringens association with NE and NEC, both 
diseases characterised by necrosis of tissues 1. Importantly, PLC (a cell membrane 
damaging enzyme), known to be secreted by all C. perfringens strains 76, does not link 
to necrotising capacity, as non-NEC strain supernatants do not induce epithelial cell 
death. This suggested necrosis of cells is related to certain toxins, and previous genome 
analysis (Chapter 3) indicated that most non-NEC strains do not encode any pfo genes 
(gene enriched in NEC-associated isolates) that transcribes pore-forming haemolytic 
toxin PFO. This toxin could be critical to disease initiation of both NEC and NE, as 
previous studies have indicated that PFO may act synergistically with PLC to damage 
(bovine) epithelial cells, and therefore presence of this gene may distinguish between 
pathogenic and commensal C. perfringens 25,87. In this study, only the pfo gene was 
significantly enriched (P<0.05) in those isolates that could damage intestinal epithelial 
monolayers, further highlighting a PFO cytotoxicity link. However, to definitively 
prove this virulence gene, molecular Koch’s postulates would have to be fulfilled by 
carrying out detailed in vivo and mutant experiments. CPB2 has previously been 
associated with NEC, however, non-NEC strains M009 and LH043 that encoded 
CPB2 toxin gene did not significantly induce necrosis in epithelial monolayers, and 
were not associated with necrosis-phenotypes (P>0.05) 8. 
Overall, these data support the hypothesis that NEC-associated strains display a hyper-
virulent phenotype, which correlates with the intestinal pathology characteristic of 
preterm-NEC patients, further supporting the data presented in Chapter 3. 
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7.7 Future research directions 
Full profiling of the toxins secreted by C. perfringens strains could be conducted via 
a large-scale protein profiling study of case and control isolates in the preterm cohort. 
Initial work had been carried out, seeking to identify the full profile of secreted toxins 
in spent media using mass spectrometry approaches, however, data resolution was 
quite low as too many proteins were detected, making some toxins undetectable due 
to noise. Toxin probes might need to be developed to be able to quantify toxin levels 
and correlate back to genomic sequence data to gain in-depth understanding of strain-
specific toxin secreting capacity. 
To better mimic the biological context of C. perfringens infection, in vitro models 
could be optimised, e.g. using micro-aerobic in vitro human intestinal infection models 
(such as IVOCs), to enable C. perfringens to grow in anaerobic or microaerophilic 
conditions, while most intestinal cell lines cannot be cultured anaerobically. In this 
way, investigation of colonisation and infection could be observed, and a larger-scale 
phenotypic study could be conducted involving multiple C. perfringens strains, even 
looking into the infection mechanisms.  
Furthermore, to further develop preventative measure against C. perfringens infection, 
in vitro continuous culture human colonic models could be utilised to understand the 
real impact of the wider microbiota on C. perfringens overgrowth, and test bile 
salt/probiotic therapies based on the secondary bile salt inhibition hypothesis.  
In addition, it will be important to understand the oxygen systems in C. perfringens 
where NGS approaches can be applied i.e. RNAseq. As C. perfringens strains are 
cultured in aerobic condition, RNA can be extracted at different time points to 
investigate the expressed genes under aerobic conditions in order to pinpoint the genes 
involved in detoxifying oxygen. 
Crucially, to fully explore pathogenesis of C. perfringens, animal models (such as a 
mouse model) are required to more closely replicate complex host responses. 
Development of a novel pre-clinical model for C. perfringens infection will be 
described in the following chapter.  
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Chapter 8 A novel oral-challenge mouse model of 
C. perfringens infection unveils 




The primary aim of the study presented in this chapter was to establish a C. perfringens 
oral-challenge infection model to probe C. perfringens pathogenesis using 
fluorescently-tagged hyper-virulent NEC-linked strains identified in Chapter 7 (Figure 
8.1).  
 
Figure 8.1: Schematic of study aims, experiments and analyses presented in Chapter 8 
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8.2 Background 
C. perfringens has been recognised as the causative agent for numerous intestinal 
diseases in humans including preterm NEC and FP (gastroenteritis), as discussed in 
Chapter 3 and Chapter 4 respectively 1. Furthermore, this notorious food-borne 
pathogen is also linked with AAD, which is a prolonged gastroenteritis (commonly >3 
days, up to 60-70 days) frequently diagnosed in antibiotic-treated elderly patients 
residing within hospital wards, with symptoms attributed to the CPE toxin 24,325,443. 
Primary clinical symptoms in C. perfringens-FP patients include rapid appearance (8-
14h) of watery diarrhoea (usually self-limiting, low hospitalisation rate), intestinal 
cramp without fever or vomiting, which symptoms are distinguishable from other food 
pathogens such as Salmonella 1. While in C. perfringens-NEC patients, abdominal 
distention (frequently <24h) and tissue necrosis in the intestine is commonly observed, 
which leads to high mortality rates (~40%) 73. 
Though various animals, including rabbits (mainly intestinal loop model), rats and 
chickens have been studied as models for C. perfringens intestinal infections 
122,347,444,445; small animals (i.e. mice), which represent a more economical and 
tractable model system, have never been shown to be intestinally-infected by C. 
perfringens. Previous studies have used mice for different C. perfringens diseases, 
with a focus on toxins, namely CPE (intestinal loop model) 446 and CPB (IV injection 
model) 447. However, to date no mouse model has been established using oral 
challenge, the natural mode of transmission in humans, which may be due to 
difficulties of C. perfringens colonisation in the murine gut, although a recent 
American study showed that up to 12% (48/416)  of house mice (Mus musculus; non-
laboratory) carried C. perfringens as commensals (a PCR-based study) 448-450. 
The closest oral-challenge C. perfringens mouse model, to mimic human infection, is 
the type C-enterotoxaemia infection model, where BALB/c mice are intra-gastrically 
infected with C. perfringens type C strains. This model successfully induces disease 
<48h, however this study did not determine the long-term colonisation of C. 
perfringens, and was not optimised as a model to study intestinal infection, rather the 
focus was on systemic infection enterotoxaemia associated with CPB production from 
C. perfringens type C strains80. 
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Another enterotoxaemia oral-route infection model, using BALB/c mice, was 
developed to determine rapid (<8 h) systematic disease symptoms after challenge with 
ETX-producing C. perfringens type D strains 451. Notably, this study involved sealing 
the anus of infected mice indicating a failure to establish a reproducible disease model 
using ‘normal’ unsealed mice (which did not display symptoms), despite pre-treating 
with 1-7 days of broad-spectrum antibiotics, fasting and diet changes. Furthermore, 
this study did not explore murine gut colonisation of C. perfringens strains, 
highlighting the need for another model that more closely mimics clinically-relevant 
intestinal disease symptoms.  
Development of a new in vivo mouse model could utilise the most common inbred 
mouse line, C57BL/6 mice (never reported before), which leverages a multitude of 
reagents and KO models, which could be used to understand colonisation and 
pathology of C. perfringens after natural oral infection. Establishment of such a 
clinically relevant model would allow a platform for e.g. vaccine development, testing 
of novel anti-infection treatments, and probing disease pathogenesis and mechanisms 
of protective immunity, that have relevance for serious intestinal C. perfringens 
infections such as gastroenteritis (in older adult communities) and NEC (in premature 
infants).  
It is apparent that there is currently a lack of an appropriate mouse intestinal C. 
perfringens infection model, which is limiting the research community’s ability to   
further understand underlying disease mechanisms. In this current chapter, a 
preliminary yet reproducible mouse model (using C57BL/6 mice) of C. perfringens-
associated gastroenteritis was demonstrated with significant weight loss and marked 
signs of colitis determined by histology. Moreover, successful and persistent intestinal 
colonisation of C. perfringens was assessed and confirmed for the first time. 
 
8.3 Hypothesis and aims 
It is hypothesised that hyper-virulent C. perfringens strains could induce NEC-like or 
gastroenteritis disease symptoms in mice. The aims of this study are: 
(1) Construct antibiotic-resistant and fluorescence-tagged C. perfringens strains for 
real-time colonisation tracking using in vivo imaging. 
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(2) Set up preliminary C. perfringens infection mouse model using hyper-virulent 
NEC-associated C. perfringens strains identified in Chapter 7. 
 
8.4 Results 
8.4.1 Construction of fluorescence tagged C. perfringens  
This work aimed to generate GFP-tagged C. perfringens strains for use in real-time 
tracking and imaging in vivo. The GFP plasmid (5,008 bp-GFP-tagged plasmid; Figure 
8.2A) was a gift from Dr Duncan Gaskin, and based on a reconstructed Clostridium 
sporogenes plasmid (original plasmid backbone pMTL8315 obtained from ClosTron), 
which was successfully introduced into C. perfringens strains Q215 and M010 by 
electroporation as described in the method section 248. 
E. coli GFP-tagged stocks were confirmed to fluoresce brightly, and C. perfringens 
ATCC13124 reference strain was confirmed not to fluoresce under epifluorescence 
microscopy using GFP-filter (Figure 8.2B). Transformed strains Q215-GFP and 
M010-GFP were also confirmed to fluoresce brightly under epifluorescence 
microscopy (comparable to positive control), validated by the positive antibiotic 
selection (thiamphenicol resistance in anaerobic conditions; Figure 8.2C). In addition, 
both transformants were examined for plasmid stabilities by sub-culturing over 60 
generations over 4 consecutive days, with >90% plasmid retention (n=3; Figure 8.2D). 
Strain Q215-GFP was then employed in infection model 2 (described later in this 
chapter). 
8.4.2 Establishing a C. perfringens oral-challenge infection model 
8.4.2.1 Isolate selection 
Isolates Q215, Q143 (both hyper-virulent NEC strains) and Q088 (another NEC-
associated strain; used in the preliminary study only) were selected based upon the 
phenotypic virulence scoring scheme as described in Chapter 7 and were used to 
establish an infection model in 3-5 weeks old C57BL/6 mice. 
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Figure 8.2: Construction of GFP-C. perfringens transformants Q215-GFP and M010-GFP 
(A) Plasmid map for pMTL8315fdx-gfp+. (B) Fluorescence image of stock GFP-E. coli and reference 
strain C. perfringens ATCC13124. (C) Comparing images wild-type and GFP-C. perfringens. (D) Plasmid 
retention tests in transformants. Plasmids remained stable (>90%) in both transformants over 60 
generations of in vitro sub-culturing. Experiment stopped at 60 generations. White bars represent 20μm. 
Data: Mean ± SEM (n=3). 
 
8.4.2.2 Antibiotic pre-treatment is required for C. perfringens colonisation in 
mice 
An initial study, used non-antibiotic treated C57BL/6 mice (aged 7-9 weeks), however 
these mice did not show substantial colonisation of C. perfringens strain Q215 (day 1 
around 103 CFU/g; n=3) as CFUs were undetectable after day 1 (Figure 8.3A). Based 
on these data, a pretreatment with a combination of antibiotics routinely used in 
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preterm infants i.e. gentamicin and benzylpenicillin was administered to mice prior to 
C. perfringens oral gavage, however strain Q215 was again undetectable after day 1 
(Figure 8.3B). These data indicate that human-associated C. perfringens do not 
efficiently colonise the intestine of adult C57BL/6 mice and indicated a stronger 
antibiotic scheme may be required to allow C. perfringens strain Q215 murine gut 
colonisation and subsequent infection/pathology. 
 
Figure 8.3: Intestinal colonisation of C. perfringens isolate Q215 in mice post oral challenge 
(A) Mice without antibiotic pre-treatment. (B) Mice treated with gentamycin 5mg/kg (0.1mg per mouse), 
benzylpenicillin 25mg/kg (1mg per mouse) for 4 days, followed by 2 days sterile water, and then oral 
challenge with C. perfringens. ND: Not Detectable. Dotted lines indicate limit of CFU detection (50 
CFU/g). 7- to 9-week-old C57BL/6 mice were used in this experiment. Black bars indicate means (n=3).  
 
A murine model for the related pathogen C. difficile has been developed that uses a 
cocktail of antibiotics (kanamycin, gentamicin, colistin, metronidazole and 
vancomycin followed by single oral dose of clindamycin after two-day cessation of 
antibiotic cocktail) to establish and maintain colonisation 448,452. Juvenile mice (3-4 
weeks old) were used in place of adult mice (7-9 weeks old) in the following studies, 
aiming to mimic preterm intestinal infection in humans as these younger mice would 
have a relatively immature intestinal microbiota and immune system that should 
facilitate pathogenic infection. An initial study was carried out using this established 
antibiotic scheme for C. difficile infection 448 (Figure 8.4A), using C. perfringens 
strains Q215, Q143 and Q088. All challenged mice did not show significant 
differences in weight gain nor CFU from faecal pellets for the first three days post 
challenge (P>0.05; Figure 8.4B-D). Notably, high CFUs were recovered from all three 
groups (n=3 in each group; >106 CFU/g) indicating stable colonisation of C 
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perfringens after antibiotic administration, highlighting the feasibility of this antibiotic 
scheme for subsequent mouse work.  
 
Figure 8.4: Preliminary colonisation study on C. perfringens in juvenile mice 
(A) Scheme of experimental design. Three NEC-associated hypervirulent strains Q215, Q088 and Q143 
were tested in mice, divided into 4 groups including control group (n=3 in each group). (B) Daily weight 
changes of mice over experimental period (pre- and post-challenge). (C) Relative weight change over 
time did not show significant changes. Weight change is based on weight on day 0. (D) Intestinal 
colonisation (CFU/g) of C. perfringens in 3- to 4-week mice over 3 days post challenge. NEC-associated 
isolate Q215(red) shows highest colonisation among all. Dotted line indicates LOD (50 CFU/g).  
Data: (B) and (C) mean ± SEM (n=3). (D) Each dot represents mean (of 3 technical replicates) of each 
mouse. One-way ANOVA, Dunn’s multiple comparison test. Abx: Antibiotic. Antibiotics used in pre-
treatment: kanamycin (0.40 mg/ml), gentamicin (0.035 mg/ml), colistin (850U/ml), metronidazole (0.215 
mg/ml), and vancomycin (0.045 mg/ml), followed by clindamycin (30 mg/kg). 
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8.4.2.3 Infection model (1) 
C. perfringens strain Q215 was selected for this infection study due to the slightly 
higher CFUs obtained, when compared to the other strains after preliminary testing 
(as above). The experimental scheme of this study is illustrated in Figure 8.5A. Eight 
mice were challenged with 109 CFU of C. perfringens strain Q215 vegetative cells 
after antibiotic treatment, with the  control group (n=6) also treated with the antibiotic 
cocktail for 4 days, followed by PBS gavage. Another untreated (i.e. no antibiotics) 
control group (n=5) was also used for comparison. Animals were monitored daily for 
C. perfringens colonisation (Figure 8.5B-C), weight changes (Figure 8.5E-F) and 
potential symptoms of disease. In the C. perfringens infection group, C. perfringens 
was cleared completely in all mice after 5 days post challenge (as determined by CFU 
counts), with most mice cleared of C. perfringens after day 4 (6/8 mice; Figure 8.5B-
C). Significant weight loss (P<0.05; Figure 8.5E-F) was observed on day 2 in C. 
perfringens infected mice, when compared to mice in the antibiotic-only group and 
untreated group. All mice (n=8) in the C. perfringens infection group recovered from 
the initial weight loss (comparable to untreated group) and did not display an overt 
sign of disease throughout the experimental period.  
To determine if loss of C. perfringens at later time-points was due to microbiota re-
colonisation after antibiotic administration, overall microbiota load (as determined by 
16S rRNA qPCR) was monitored. Notably there was no significant change in the C. 
perfringens-infection group from day 1 to 8 post challenge (P>0.05), indicating gut 
clearance of C. perfringens may be due to intrinsic resistance from other intestinal 
microbiota members (Figure 8.5D). There was a significant increase in 16S rRNA 
copies from day 7 prior to oral infection (P<0.001), suggesting a less diverse 
microbiota in young mice at 3 weeks old, which developed overtime to a more 
complex adult-like gut microbiome. 
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Figure 8.5: Induction of C. perfringens-associated infection in juvenile mice 
(A) Scheme of experimental design. Strain Q215 was tested in mice (n=8; 3-4 weeks old), divided into 
3 groups including control group (n=5) and Abx-only group (n=6). Abx-only and Abx+ C. perfringens 
groups were performed in two separate experiments. (B) and (C) Intestinal colonisation (CFU/g) of C. 
perfringens in 3 to 4-week adult mice (infection group, n=8) over 7 days post challenge. Dotted line 
indicates LOD (50 CFU/g). CFU could not be detected after 5 days post challenge. (D) Relative 
comparison of overall microbiota load between 3 mice post challenge using 16S rRNA qPCR (via 16S 
rRNA universal primers). Lower CT values indicate higher PCR-targeted products, i.e. microbial species. 
(E) Relative weight post challenge in all mice. Relative weight is based on the weight on day 0.  (F) Daily 
weight changes of mice (%) over experimental period (post-challenge), based on weight on the previous 
day. 
Data: (B) mean ± SEM (n=8). (C) Each bar represents mean, and each dot represents one individual 
mouse (mean of three technical replicates). Paired t test, two-tailed. * P<0.05, ** P<0.01, ns=non-
significant. (D) Each dot represents one technical replicate of one individual mouse. One-way ANOVA, 
Dunn’s multiple comparison test. *** P<0.001, ns=non-significant. (E) and (F) Data shown are means ± 
SEM. Abx: Antibiotic. Antibiotics used in pre-treatment: kanamycin (0.40 mg/ml), gentamicin (0.035 
mg/ml), colistin (850U/ml), metronidazole (0.215 mg/ml), and vancomycin (0.045 mg/ml), followed by 
clindamycin (150 mg/kg). 
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Next, I sought to explore whether there were any changes in intestinal histopathology 
of mice challenged with C. perfringens, which may correspond to the evident initial 
weight loss. Histology (Figure 8.6A-C; raw data shown in Appendix 5 Table S8.1) 
staining indicated that colonic sections from mice infected with C. perfringens strain 
Q215 exhibited mild to moderate colitis (pathological score range: 7.0-11.0/14.0; 
mean ± SD: 9.3 ± 1.6; P<0.001) compared to untreated (score range: 0.5-4.0; mean ± 
SD: 1.7 ± 1.3) and antibiotic-only treated mice (score range: 1.5-4.5; mean ± SD: 3.2 
± 1.5; Figure 8.6D-E).  
Colonic tissues from mice treated with antibiotic cocktail alone and untreated mice 
appeared normal, although some sections displayed minimal to mild pathological 
changes including epithelial hyperplasia in antibiotic-treated mice (Figure 8.6A-B); 
while tissue sections from mice challenged with C. perfringens showed moderate 
immune cell infiltrations (mean ± SD: 2.5 ± 0.5/4.0), substantial epithelial hyperplasia 
and marked goblet cell loss (mean ± SD: 3.2 ± 0.9/5.0), and mucosal ulcerations (mean 
±  SD: 3.5 ± 0.4/5.0; Figure 8.6C), indicating C. perfringens-associated pathogenesis 
in these mice. 
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Figure 8.6: Histology on colon sections and pathological scoring. 
Representative H&E-stained mice colon sections of (A) untreated group (B) Abx-only group, and (C) 
infection group (treated with C. perfringens strain Q215), showing epithelial changes (hyperplasia and 
goblet cell loss), intestinal inflammation (immune cell infiltration) and altered mucosal architecture 
(ulceration). Grey arrowhead- normal colonic goblet cells in untreated mice; yellow bracket- the length 
of normal colonic crypts as in (A); yellow arrowhead- erosion; black arrowhead- loss of goblet cells; red 
arrowhead- immune cell infiltration. Magnification: x40, scale bar 50 μm. (D) Pathological score of colons 
from mice of each group (control, Abx and infection groups). Each dot represents one mouse (bar: 
mean). One-way ANOVA, Dunn’s multiple comparison test. *** P<0.001, **** P<0.0001. (E) Pathological 
score of colons from mice of each group, graded according to three general features (total 0-14): 
inflammatory infiltration (0-4), epithelial hyperplasia and goblet cell loss (0-5), and mucosal architecture 
(0-5). Mean score of each group is represented in the bars. 
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8.4.2.4 Infection model (2): tetracycline model 
As C. perfringens strain Q215 was observed to be cleared from the mouse intestines 
after day 4 or day 5, I next sought to prolong the colonisation period, as it is 
hypothesised that overgrowth of C. perfringens in the gut initiates pathogenesis with 
associated disease symptoms. To provide this extended infection in the presence of a 
depleted gut microbiota, tetracycline was administered to mice in drinking water post 
C. perfringens gavage.  
The experimental scheme is illustrated in Figure 8.7A, with three strains employed in 
this study including Q215, Q215-GFP (derived from Q215, described in section 8.4), 
and Q143, which all carry tetracycline resistance genes i.e. tet resistance determinants 
as described in Chapter 3, confirmed by phenotypic approaches (Chapter 7).  
Similar to the previous study, mice infected with Q215 showed significant weight loss 
(P<0.05) on day 2, 6 (mean daily weight loss: 2.4%) and 7, and slower overall weight 
gain as compared to the group treated with antibiotic alone (Figure 8.7B-C). Infection 
with the recombinant strain Q215-GFP, also induced significant (P<0.01) weight loss 
on day 8, confirming the strain colonisation-effect (Figure 8.7B-C). The additional 
administration of tetracycline changed the weight dynamics, suggesting the potential 
role of other microbiota members in contributing to pathological changes. 
Notably, mice challenged with Q143 consistently gained weight throughout the study 
period after oral infection, although apparently there had a slower growth rate from 
day 3 to day 5 post challenge. 
Both Q215 and Q215-GFP groups appeared to be cleared of C. perfringens on day 5, 
which is in agreement with previous data, suggesting that tetracycline supplementation 
did not help prolong the colonisation of strain Q215 (Figure 8.7D). Surprisingly, 
although there was no weight loss or overt symptoms in mice infected with Q143, 
CFUs for strain Q143 remained significantly higher in mice (>106 CFU/g; P<0.001) 
throughout the post-challenge period (7 days). 
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Figure 8.7: Induction of C. perfringens infection with tetracycline supplementation 
(A) Scheme of experimental design (n=5 in each group). This study was performed in one single 
experiment. (B) Relative weight post challenge in all mice. Relative weight is based on the weight on 
day 0. (C) Daily weight changes of mice (%) over experimental period (pre- and post-challenge), based 
on weight on the previous day. (D) Intestinal colonisation (CFU/g) of C. perfringens in each group (n=5 
in each group; 3-4 weeks old mice) over 7 days post challenge. Dotted line indicates LOD (50 CFU/g).  
Data: (B) mean ± SEM (n=5 in each group). One-way ANOVA, Dunn’s multiple comparison test 
(compared with Abx group as control). * P<0.05. (C) mean ± SEM (n=5 in each group). Dunn’s multiple 
comparison test. * P<0.05, *** P<0.001. (D) Each dot represents CFU/g of each individual mouse from 
each experimental group (colour-coded). Dunn’s multiple comparison test. *** P<0.001, **** P<0.0001, 
ns=non-significant. CFU/g recovered from Q143 group was significantly higher than the other two 
infection groups (Q215 and Q215-GFP) throughout the whole post-challenge period. Pre-antibiotic 
treatment: kanamycin (0.40 mg/ml), gentamicin (0.035 mg/ml), colistin (850U/ml), metronidazole (0.215 
mg/ml), and vancomycin (0.045 mg/ml), followed by clindamycin (150 mg/kg). Tetracycline 
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Colonic histology indicated that all mice infected with the three strains C. perfringens 
exhibited mild to moderate colitis (Figure 8.8A-D; raw data shown in Appendix 5 
Table S8.2), having significantly higher pathological scores (pathological score range: 
5.5-11.0/14.0; mean ± SD: 7.9 ± 1.9; P<0.0001) when compared to mice treated with 
antibiotics alone (score range: 1.0-4.0; mean ± SD: 2.4 ± 1.2; Figure 8.8E-F). 
Importantly, colonic tissues from group Q143 displayed moderate immune cell 
infiltration (mean score: 2.7/4.0), epithelial hyperplasia and goblet cell loss (3.4/5.0) 
and mucosal ulcerations (3.3/5.0), having the highest pathological mean score (9.4 ± 











(Figure printed on next page) 
Figure 8.8: Comparison of histology on colon sections and pathological scoring  
Representative H&E-stained mice colon sections of (A) Abx-only group (B) Q215 group (C) Q215-GFP 
group, and (D) Q143 group (all treated with Abx cocktail prior to oral challenge and supplemented with 
tetracycline post challenge), showing epithelial changes (hyperplasia and goblet cell loss), intestinal 
inflammation and altered mucosal architecture (ulceration). Grey arrowhead- normal colonic goblet cells 
in untreated mice; yellow bracket- the length of ‘normal’ (uninfected) colonic crypts; yellow arrowhead- 
erosion; black arrowhead- loss of goblet cells; red arrowhead- immune cell infiltration. Magnification: 
x40, scale bar 50 μm. (E) Pathological score of colons from mice of each group (including data of 
untreated group from previous experiment for comparison). Each dot represents one mouse (bar: mean). 
One-way ANOVA, Dunn’s multiple comparison test. ** P<0.01, **** P<0.0001, ns=non-significant. (F) 
Pathological score of colons from mice of each group, graded according to three general pathological 
features (total 0-14): inflammatory infiltration (0-4), epithelial hyperplasia and goblet cell loss (0-5), and 
mucosal architecture (0-5). Mean score of each group is represented in the bars. 
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8.5 Discussion 
Oral infection of 3-week old C57BL/6 mice with NEC-associated type-A C. 
perfringens strains induced colitis-like histological changes in colonic sections, in 
tandem with significant weight loss on days 2 and 6. This is the first time C. 
perfringens has been shown to naturally infect and colonise C57BL/6 mice (via oral 
route) with associated intestinal pathology. 
To date, no clinically-relevant small animal infection models have been developed for 
C. perfringens-associated enterocolitis. Initial studies highlighted a robust microbiota 
was present in mice housed within the UEA DMU, as indicated by efficient 
colonisation resistance against C. perfringens infection. Thus, an antibiotic pre-
treatment (5-antibiotic cocktail + clindamycin) regimen was used to deplete the 
resident microbiota, as has previously been used for C. difficile-infection in C57BL/6 
mice 453. Faecal CFU data demonstrated that C. perfringens strain Q215 successfully 
colonised for 4-5 days in mice with an antibiotic-disturbed gut microbiota, which 
correlated with significant colonic histopathological changes. Importantly, a similar 
antibiotic regimen was also used in a highly-reproducible C. jejuni mouse infection 
model that mimics several human infection symptoms and several immunological 
aspects after high C. jejuni CFU colonisation 449. The importance of antibiotic-induced 
microbiota disturbances was further highlighted in infection model 2, with the addition 
of tetracycline. Notably, weight loss was more pronounced in this model suggesting 
prolonged administration of tetracycline directly impacts disease severity, which 
correlated with enhanced histopathology, likely linked to depleted colonisation 
resistance abilities of the resident gut microbiota. Associated systemic biomarkers 
should be examined to determine the systemic impact of this pathogen, and how this 
links to poor growth. Importantly, this model (model 2) was only performed in a single 
experiment, thus further work is required to investigate the impact of different 
antibiotic regimens on the mouse microbiome, which will help with development of a 
robust and clinically relevant C. perfringens infection model. 
Notably, serious C. perfringens infection is often associated with vulnerable 
individuals, that are expected to have a disturbed microbiota as a result of prolonged 
antibiotic usage, including preterm infants and elderly CH residents 289,334. From these 
data it also appears that C. perfringens required a disturbed (murine) gut microbiota 
to initiate successful colonisation after the natural route of oral infection 8,289. 
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Significant weight loss (P<0.05; 6.6% daily weight loss) was observed on day 2, which 
is similar to findings previously described for the C. difficile relapse mouse model 452. 
Nevertheless, all infected mice regained body weight from day 3 onwards, which may 
be correlated with the gut clearance of C. perfringens from day 3. The significant 
pathological changes observed in colonic sections was somewhat unexpected, as mice 
did not display any overt distress symptoms throughout study period. However 
frequent diarrhoea was observed, which does suggest intestinal changes and is similar 
to what is observed for the mouse pathogen Citrobacter rodentium, which is used as 
a model for human enteropathogenic E. coli 454-458. 
General histopathological changes were observed in C. perfringens-challenged mice, 
including extensive goblet cell loss, hyperplasia in the crypts, immune cell infiltration, 
mucosal erosion and a certain degree of oedema. These observations are similar to 
those observed in the C. rodentium infection model 454. In fact, pathological changes 
seen during C. rodentium infection are driven by the host immune system rather than 
direct damage. Goblet cell reduction, and associated mucus depletion is a pathogen-
mediated immune subversion that facilitates enhanced colonisation of C. rodentium 
and is similar to what was observed in this C. perfringens model 459. These 
pathological signs may primarily be the result of ‘indirect immune damage’ rather than 
‘direct damage’ during C. perfringens infection, as only limited mucosal erosions 
(caused by pore-forming toxins) were observed 451,455. Furthermore, significant 
immune cell infiltration observed exclusively in C. perfringens-challenged mice (8 
days post-challenge) also supports the idea of immune-mediated pathology. This 
implicates the importance of the under-studied immune-driven aspect of C. 
perfringens intestinal infections, in contrast to the conventional thought of C. 
perfringens pathology as the sole result of toxin-driven direct damage 82,460. 
However, although NEC strains were used in these studies, these symptoms do not 
clinically replicate the very serious intestinal pathology associated with preterm-NEC 
infection e.g. complete intestinal necrosis and abdominal distention 73. There are 
several possible factors that could explain lack of NEC disease symptoms such as diet 
and age. As C. perfringens is known to require a high-protein diet to thrive in the gut, 
the normal mouse chow diet may not favour this pathogen, thus impacting overall 
growth and expression of certain virulence factors e.g. toxins. In addition, although 
young mice were used (3- to 4-week-old) these mice are already weaned and therefore 
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considered as ‘adult’ mice with an adult-like gut microbiota and host immune system, 
that would be expected to impact on optimal C. perfringens colonisation and disease 
pathogenesis. Correspondingly, serious C. perfringens intestinal infection is rarely 
seen in healthy human adults, with the exception of FP (large oral consumption) and 
AAD (weaker host immunity) cases 1,322. Therefore, it will be necessary to further 
optimise this experimental protocol for a NEC-specific model.  
Based on disease activities and pathologies it appears this infection regimen is more 
similar to gastroenteritis-associated C. perfringens infection, and therefore may 
represent an appropriate model for testing associated pathogenesis. The rapid 
intestinal clearance (4-5 days) of C. perfringens strain Q215, and recovery of weight 
gain (day 3) in infection model 1 closely resembles the self-limiting symptoms of 
human FP (24-48h) and may link to the spontaneous clearance observed in these 
patients, however to note strain Q215 is not a FP-related type F strain as it does not 
encode CPE. The intrinsic clearance of pathogen C. perfringens within the murine gut, 
which is likely host immune-mediated, warrants further investigation, also linking to 
potential bacterial colonisation factors, which are expected to vary from strain to strain 
116,182,454. Indeed, strain-level colonisation variations was demonstrated in the 
tetracycline model, as strain Q143 was maintained at high CFU throughout the study 
period. Notably, strain Q143 was shown to be highly-sporulant, exhibiting >104 log 
compared to Q215 (Chapter 7). Consequently, sporulation capacity could be an 
important factor for C. perfringens colonisation in mice. Importantly, C. difficile is 
known to form spores more readily than C. perfringens, which is directly linked to its 
ability to persist in both the human and murine gut, as shown in clinical and mouse 
studies 448,452.  
 
8.6 Future research directions 
To further optimise this infection model, it is necessary to modify the oral challenge 
protocol to include administration of C. perfringens spores instead of vegetative cells 
to potentially optimise the colonisation of strain Q215. Furthermore, more C. 
perfringens strains could be tested to understand whether commensal C. perfringens 
(not disease-associated) can also induce disease symptoms in antibiotic-treated mice. 
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The data obtained could be correlated with the genotyping data and link genotype to 
phenotypes, thus answering several questions postulated in Chapter 3 and Chapter 7. 
Potentially, a different antibiotic scheme could also be applied. There are currently 
several antibiotic pre-treatment regimens employed in C. difficile studies, including 
the cefoperazone model which have successfully established infection models 461.  
Following the successful colonisation of C. perfringens in mice, and associated enteric 
infection pathology, there is a possibility to develop a rigorous oral-challenge 
gastroenteritis model of FP or long-term AAD using FP-related type F strains 
(obtained from PHE). This model would allow development of preventative measures 
and testing of treatments such a probiotic supplementation or vaccines which could be 
clinically vital to older adult communities 289. This potential FP or AAD infection 
model would represent the first of its kind in the field of C. perfringens research. 
In addition, an optimised model could be used to probe specific pathogenesis traits of 
C. perfringens including exploring the role of  toxin gene pfo, associated with clinical 
NEC representations, as presented in Chapter 3, via construction of pfo-knockout and 
pfo-complementing mutant strains (using technique e.g. CRISPR-Cas9 system as 
demonstrated in C. difficile) to confirm the essentiality of this virulence gene linking 
to diseases under Koch’s molecular postulate 462. This established model will be 
valuable in probing other accessory virulence genes including those related to host 
colonisation.  
Faecal content DNA of infection model 1 has been sent for 16S rRNA sequencing, 
with the aim to identify taxa related to clearance of C. perfringens, and also explore 
the overall impact of the antibiotic cocktail on the murine gut microbiome, including 
recovery following antibiotic pre-treatment. These data will allow a greater 
understanding of the changes in bacterial taxa and may facilitate further optimisation 
of this infection protocol. 
In conclusion, this is the first time that C. perfringens strains have been shown to 
naturally infect C57BL/6 mice and induced mild-to-moderate intestinal colitis. Further 
work is required to characterise the host immune-driven biomarkers of this infection 
model to probe pathological mechanisms, and to optimise this disease model to more 
closely mimic human infections including preterm-NEC, human FP (gastroenteritis) 
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and AAD, which is essential for downstream C. perfringens mechanistic studies and 
therapy development.  
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9.1 Background 
Since the discovery of C. perfringens (previously named as C. welchii) >120 years 
ago, this pathogen has been associated with numerous histotoxic diseases, including 
the notorious gas gangrene 408,463. Due to its importance in military research (as gas 
gangrene was one of the most common medical issues in traumatic soldiers during 
World War I and II), scientists focused on understanding the disease progressions of 
C. perfringens-mediated gas gangrene, resulting in development of a gas gangrene 
mouse model in early 1990s and sequencing of C. perfringens strain 13 (gas gangrene 
strain), which was the first anaerobic Gram-positive pathogen to be whole-genome 
sequenced back in 2002 37,77,84. 
Apart from gas gangrene, C. perfringens has been frequently linked with numerous 
intestinal diseases in both humans and animals including preterm-NEC, which has 
been termed as ‘gas gangrene of the bowels’ 74. As such, C. perfringens-related typing 
toxins have been extensively studied in the past few decades, and successfully linked 
with human and veterinary disease representations. Nevertheless, in this genomic era 
only a small number of C. perfringens strains (n<120) have been whole-genome 
sequenced, perhaps the most genomically understudied enteric pathogen, highlighting 
the lack of understanding of C. perfringens genomes compared to other important 
pathogens including C. difficile and Salmonella, both of which have been extensively 
sequenced leading to subsequent development of disease models and therapeutics 1. 
Importantly, no appropriate C. perfringens-associated small animal infection models 
have ever been described, thus hindering our understanding of natural C. perfringens 
intestinal infection mechanisms in mammals. Studies have implicated that C. 
perfringens-associated diseases are not purely caused by key typing toxins alone, there 
exists potentially a combination of several virulence elements including colonisation 
factors encoded in certain C. perfringens strains, or perhaps, some unidentified novel 
virulence genes that might be involved in disease progressions 116,118,230,290. 
This underlying background drove the initial foundation of this PhD project, with the 
provision of C. perfringens isolates from key collaborators Prof J S Kroll (preterm 
cohort; n=189), Dr C Amar (FP and CH cohorts; n=109), and Dr R Dixon (poultry NE 
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cohort; n=22), this project developed to investigate and explore extensively the 
virulence-associated determinants and epidemiology of C. perfringens from various 
aforementioned cohorts, to probe global spread and cluster-specific genome features 
of C. perfringens, additionally phenotypic pathogenicity of selected strains was 
determined and more importantly, a novel mouse infection model was established, 
contributing to the new knowledge of C. perfringens in both human and veterinary 
medicine via multiple in silico, in vitro and in vivo approaches. 
 
9.2 Impacts and future perspectives of key findings 
WGS-based phylogenetic clustering of a huge collection (n=552) of C. perfringens 
isolates was visualised for the very first time in Chapter 6, suggesting the potential re-
assignment of sub-species due to the unprecedented core-genome genetic variability 
observed. Indeed, this genetic variation was expected as a number of previously 
published studies indicated significant polymorphisms observed in C. perfringens 
housekeeping genes via various PCR-based typing studies including fAFLP and PFGE 
27,150,325,382,464. In agreement with previous studies, chromosomal-cpe C. perfringens 
strains are identified as a highly distinct cluster (96%<ANI<97%; lineage V) in the 
phylogeny, also reported to possess distinguished phenotypic expression including 
high heat-resistance, suggesting the potential sub-species assignment to this cluster of 
C. perfringens as they displayed similar-range of genome nucleotide identity 382.  
Moreover, C. perfringens has been described frequently as a gut ‘commensal’ as this 
bacterial species is often isolated from healthy individuals, however, no specific 
investigations have been undertaken to understand what defines a commensal C. 
perfringens. Importantly, I have shown that several phylogenetic clusters can be 
considered ‘commensal’ C. perfringens, encoding significantly less virulence genes, 
and colonisation factors, with all isolates originating from ‘healthy’ individuals. For 
the first time, this WGS data has highlighted that specific clusters of strains could 
potentially be avirulent C. perfringens, and therefore a normal member of the gut 
microbiota 241. Nevertheless, carriage rates of commensal C. perfringens in normal 
healthy populations is currently unknown, and this warrants further genomic 
investigations via a large-scale study.  
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With regard to the current toxinotyping scheme, updated recently to 7 toxinotypes (C. 
perfringens is the only known pathogen to be commonly typed according to the 
combination of key toxins), the various studies presented in this thesis strongly 
indicate that this method should not be solely relied on for determining disease 
associations, especially in human-related intestinal diseases, due to the low-resolution 
of  information garnered about a particular isolate. A full genomic profile is thus 
preferred to comprehensively define virulence capacity and disease links. This is 
evidenced by the fact that type A isolates (only encode typing toxin PLC) were 
commonly diagnosed and associated with diseases (preterm NEC, chicken NE, human 
FP etc), highlighting  the important role ‘secondary’ virulence factors may play, as 
discussed throughout e.g. PFO, CPB2, colonisation elements collagen adhesins and 
NanI 115,182,395,465, with these important virulence genes largely ignored in current 
typing schemes. WGS techniques should gradually replace all marker-gene-based 
typing methods especially in surveillance laboratories, to facilitate epidemiological 
investigation, as demonstrated in Chapter 3 and Chapter 4 of this thesis. This is 
particularly important in the context of public health surveillance and disease control 
on a national level. 
Clonal expansion of certain disease-related C. perfringens case isolates has been 
reported for the first time in this thesis. This expansion may link to optimal fitness of 
the clonal strains, or attributed to the source of contaminations, as in the cases of food-
poisoning, CH-associated diarrhoea and NICU wards. Further molecular work will be 
necessary to shed light on the underlying virulence arsenal of hypervirulent disease-
causing C. perfringens strains. 
In addition, the widespread nature and reservoirs of C. perfringens plasmids is yet to 
be determined. This area of research is of greater interest to C. perfringens researchers, 
as shown in Chapter 4, as plasmids are directly linked to specific disease cohorts. 
Importantly, C. perfringens virulence plasmids are critical for the transfer of important 
virulence genes among C. perfringens strains including colonisation factors, toxins 
and AMR genes 41,291. Large-scale plasmid investigations should be obtained from a 
wider population of C. perfringens isolates, and WGS applied to understand the 
distribution of virulence plasmids, as currently only 48 sequenced plasmids are on the 
NCBI genome database (November 2018).  
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The identification of hypervirulent strains associated with preterm-NEC, from a 
multicentre study, has shed new light on how C. perfringens genotypes may be linked 
to NEC disease progression. Since the 1970s this pathogen has been considered as one 
of the major culprits behind this fatal infection, which has been further confirmed by 
recent sequencing-based large-scale studies 8,9. NEC disease initiation is suggested to 
be multifactorial, including an immature gut microbiota and immune system, in 
tandem with more virulent C. perfringens, which is similar to other neonatal animal 
cases that share similar disease representations 73,199,466. Hence, C. perfringens routine 
surveillance is necessary, especially in NICUs, given that this pathogen is crucial to 
the development of NEC – the deadliest mortality cause in premature neonates. This 
suggestion is supported by the fact that hypervirulent genotypes appear to be 
circulating in NICU wards (as demonstrated in Chapter 3), which necessitates future 
in-depth sample collections to confirm this finding. 
Notably, I demonstrated that toxinotype D and E strains were detected in two healthy 
children, indicating reservoirs of certain animal-associated plasmids (especially 
plasmids that carry ETX, ITX and CPB) may be more widely disseminated than 
previously thought. Interestingly, toxinotypes D and E strains (carrying plasmids 
encoding ETX and ITX) mainly infect cattle and sheep, which typically having a 
higher body temperature (39.0-40.0ºC) than humans (36.5-37.5ºC), indicating that 
temperature might play an important role in C. perfringens ‘overgrowing’, and 
dictating whether a virulent strain can proliferate and cause disease. Body temperature 
may also explain the fact that C. perfringens predominately affects animals, rather 
than humans, and typically chickens (body temperature 41.0-45.0ºC), cows (38.3-
40.0ºC), foals (37.7-38.8ºC), piglets (38.0-40.0ºC) 70. 
This factor may also clarify the difficulties encountered establishing a mouse infection 
model of C. perfringens. As mice has a similar body temperature to human (36.5-
37.5ºC), this model is more closely expected to mimic C. perfringens-associated 
human infections. In this body of work, I demonstrated a novel oral-challenged C. 
perfringens mouse model that exhibited significant colitis induced by C. perfringens 
NEC strains, albeit the expected NEC-like lesions were not observed. This may also 
suggest that strains without CPE could potentially induce gastroenteritis in humans, 
which is supported by the finding in Chapter 4 that certain FP case isolates did not 
encode CPE. This novel study will be improved once the microbiome is considered 
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(samples undergoing sequencing), thus allowing future development of preventative 
measures against gastroenteritis, such as probiotic supplementation. This new disease 
model offers the opportunity to study disease mechanisms of C. perfringens after 
optimisation. 
The food chain as a reservoir of C. perfringens is an intriguing aspect of research, as 
previously highly toxigenic strains (encoding cpe, cpb2 and netB) have been isolated 
from raw meats (detected up to 12.9% of the 232 samples) 467,468. This can potentially 
be attributed to accidental contamination from human handling, however, this 
reservoir and route of spread of C. perfringens remains to be deciphered 333. Notably, 
the dissemination of this pathogen may be universal, as indicated by the zoonotic 
findings, therefore I postulated that C. perfringens is a zoonotic agent that has no host 
boundaries, that can thrive in a wide host range. 
Overall, my PhD work has significantly enhanced our understanding of multi-host 
pathogen C. perfringens. Using computational methods, I delved into the genomic 
contents and SNP-based epidemiological tracking, and also determined the phenotypic 
strain-specific virulence via in vitro approaches and finally, developed a novel in vivo 
model, which may allow more translational aspects of C. perfringens-related intestinal 
diseases to be addressed. These findings lay the groundwork for further investigations 
on C. perfringens as a medically important pathogen, particularly the important 
contribution of WGS data on C. perfringens isolates to the wider research community. 
 
9.3 Translational aspects of research 
Pathogen genomes convey important genetic information on their potential phenotypic 
virulence, which is crucial in medical microbiology. Currently >20 toxin genes have 
been identified and characterised in C. perfringens, and with these additional WGS 
information other novel toxin genes or factors may be discovered, as represented by 
the recently characterised foal-NE-associated NetF toxin 102.  
Phage therapy represents a promising strategy to treat infections, while minimising the 
occurrence of multi-drug resistance in the microbiome, that may lead to secondary 
complications 469,470. Probing bacteriophage contents in C. perfringens genomes could 
lead to further understanding of the role they play in virulence, as well as the 
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identification of temperate/lytic phages within bacterial genomes 293,295,471. Potentially, 
novel C. perfringens-specific phages could be screened, isolated and characterised for 
therapeutic applications, owing to the huge culture collections of C. perfringens strains 
currently in place and its associated genomic information to replicate the successful 
trials in a recent poultry study 472. 
From a diagnostic perspective, it is vital to rapidly detect C. perfringens with full 
virulence profiles at early stages, including rapid onset NEC. With the current 
technology of real-time Nanopore sequencing, samples can be metagenome-
sequenced within <7h from sample reception, identification of bacterial population at 
species/strain level, and full virulence profiles including AMR potentials 315. This 
promising pipeline could be used for C. perfringens rapid diagnosis in clinical settings, 
thus allowing quick clinical decisions with respect to treatment strategies. Furthermore, 
with the current binning-based genome-reconstruction techniques, single genomes of 
C. perfringens can be confidently extracted from shotgun metagenome data to infer 
full pathogenicity profiles in under 1-2 h 313. 
Lastly, the novel in vivo model described in this thesis is an important step forward in 
C. perfringens pre-clinical research, particularly for future mechanistic understanding 
of disease development. Confirmation of disease-essential virulence elements 
including the hypothesised PFO will require the fulfilment of Koch’s molecular 
postulates via testing of pfo knock-out and complemented strains in this disease model. 
Further therapeutic approaches including phage therapy can potentially be explored 
using the optimised models, which is crucial in pre-clinical trials. 
Overall, this PhD research has contributed significantly to the genomic, phenotypic, 
pre-clinical and clinical knowledge of C. perfringens. These data should pave the way 
for future in-depth research to combat this notorious yet understudied pathogen, 
particularly in vulnerable communities including neonates and the elderly, via modern 
therapies or preventative measures. 
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Appendix 1  Supplementary data for Chapter 3 
This appendix contains all the supplementary materials for Chapter 3. 
 
Table S3.1: Clinical data from preterm neonates of 88 C. perfringens isolates in this 
study. 
Table S3.2: Assembly statistics of isolates (n=90) in this study including reference 
genomes ATCC13124 and NCTC8239. 
Table S3.3: Genes specific to NEC-associated isolates (Scoary simplified outputs). 
Table S3.4: Genes specific to lineage II and III isolates (Scoary simplified outputs). 
Table S3.5: Pair-wise SNP distances and ANI value (%) of lineage IIIc isolates.  
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Table S3.1: Clinical data from preterm neonates of 88 C. perfringens isolates in this study. DOL: 
days of life. 
 Infant ID Isolate ID DOL NEC/ Control 
Admission 
Hospital 
1 M009 M009.1C 15 Control SMH 
2 M010 M010.1C 16 NEC (Bell I) SMH 
3  M010.CN1 15 NEC (Bell I) SMH 
4 M011 M011.1C 16 NEC (Bell I) SMH 
5 M030 M030.1C 82 NEC (Bell I) SMH 
6  M030.N1C 71 NEC (Bell I) SMH 
7 M087 M087.10C 62 Control SMH 
8  M087.13C 73 Control SMH 
9  M087.1C 31 Control SMH 
10  M087.4C 44 Control SMH 
11  M087.7C 52 Control SMH 
12 M088 M088.10C 45 Control SMH 
13  M088.1C 17 Control SMH 
14  M088.24C 79 Control SMH 
15  M088.4C 31 Control SMH 
16 M089 M089.1C 22 Control SMH 
17  M089.3C 30 Control SMH 
18 M090 M090.1C 15 Control SMH 
19  M090.3C 24 Control SMH 
20 M091 M091.1C 39 Control SMH 
21 M092 M092.1C 35 Control SMH 
22 M094 M094.1C 33 Control SMH 
23 M096 M096.1C 18 Control SMH 
24  M096.3C 29 Control SMH 
25 M111 M111.1C 23 Control SMH 
26 M112 M112.1C 16 Control SMH 
27  M112.4C 23 Control SMH 
28 M124 M124.1C 30 Control SMH 
29 M125 M125.1C 23 Control SMH 
30  M125.4C 29 Control SMH 
31 Q020 Q020.CN1 19.5 NEC (Bell II/III) QCCH 
32  Q020.CN4 19 NEC (Bell II/III) QCCH 
33 Q087 Q087.1C 37 Control QCCH 
34 Q088 Q088.CN1 13 NEC (Bell II/III) QCCH 
35  Q088.CN12 24 NEC (Bell II/III) QCCH 
36  Q088.CN3 16 NEC (Bell II/III) QCCH 
37  Q088.CN6 17 NEC (Bell II/III) QCCH 
38  Q088.CN9 22 NEC (Bell II/III) QCCH 
39 Q090 Q090.5C 25 Control QCCH 
40  Q090.8C 32 Control QCCH 
41 Q096 Q096.10C 51 Control QCCH 
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 Infant ID Isolate ID DOL NEC/ Control 
Admission 
Hospital 
42  Q096.13C 59 Control QCCH 
43  Q096.16C 67 Control QCCH 
44  Q096.1C 15 Control QCCH 
45  Q096.4C 36 Control QCCH 
46 Q097 Q097.1C 25 Control QCCH 
47  Q097.4C 32 Control QCCH 
48  Q097.7C 38 Control QCCH 
49 Q100 Q100.CN1 29 NEC (Bell II/III) QCCH 
50  Q100.CN10 38 NEC (Bell II/III) QCCH 
51  Q100.CN12 39 NEC (Bell II/III) QCCH 
52  Q100.CN4 32 NEC (Bell II/III) QCCH 
53  Q100.CN7 35 NEC (Bell II/III) QCCH 
54 Q101 Q101.1C 47 Control QCCH 
55 Q105 Q105.1C 41 Control QCCH 
56  Q105.4C 49 Control QCCH 
57 Q106 Q106.10C 46 Control QCCH 
58  Q106.1C 12 Control QCCH 
59  Q106.4C 33 Control QCCH 
60  Q106.7C 39 Control QCCH 
61 Q107 Q107.12C 67 Control QCCH 
62  Q107.1C 22 Control QCCH 
63  Q107.4C 37 Control QCCH 
64  Q107.7C 45 Control QCCH 
65  Q107.9C 59 Control QCCH 
66 Q118 Q118.1C 54 Control QCCH 
67  Q118.4C 60 Control QCCH 
68 Q126 Q126.1C 42 Control QCCH 
69 Q135 Q135.CN1 29 NEC (Bell II/III) QCCH 
70  Q135.CN4 34 NEC (Bell II/III) QCCH 
71 Q137 Q137.1C 19 Control QCCH 
72  Q137.4C 25 Control QCCH 
73 Q138 Q138.1C 12 Control QCCH 
74  Q138.4C 21 Control QCCH 
75 Q142 Q142.1C 53 Control QCCH 
76 Q143 Q143.1C 16 NEC (Bell II/III) QCCH 
77  Q143.CN1 13 NEC (Bell II/III) QCCH 
78  Q143.CN4 17 NEC (Bell II/III) QCCH 
79  Q143.CN8 19 NEC (Bell II/III) QCCH 
80 Q164 Q164.1C 67 Control QCCH 
81 Q167 Q167.10C 43 Control QCCH 
82  Q167.1C 13 Control QCCH 
83  Q167.4C 27 Control QCCH 
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 Infant ID Isolate ID DOL NEC/ Control 
Admission 
Hospital 
84  Q167.7C 34 Control QCCH 
85 Q168 Q168.1C 30 Control QCCH 
86  Q168.4C 41 Control QCCH 
87  Q168.7C 50 Control QCCH 
88 Q215 Q215.CN1 40 NEC (Bell II/III) QCCH 
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Table S3.2: Assembly statistics of isolates (n=90) in this study including reference genomes 
ATCC13124 and NCTC8239 
Average Nucleotide Identities (ANI) generated by mapping with reference genome ATCC13124. 
ANI≥95% computationally confirms species designation 217. Statistics were based on genome annotation 
by Prokka v1.13 218. Reference genomes are shaded in grey. 
 
 Isolate Genome 
(bp) 




1 ATCC13124 3,256,683 n/a n/a 1 3,256,683 28.38 2,879 100.00 
2 NCTC8239 3,008,497 n/a n/a 2 2,940,812 28.19 2,803 97.18 
3 M009.1C 3,228,292 1,329,895 102 22 351,119 28.05 2,971 98.3 
4 M010.CN1 3,344,094 1,714,993 128 17 2,122,759 28.08 3,060 98.65 
5 M010.1C 3,344,966 2,293,122 171 18 2,122,622 28.08 3,060 98.65 
6 M011.1C 3,345,019 2,617,284 195 15 1,000,076 28.08 3,062 98.66 
7 M030.1C 3,205,090 1,991,040 155 19 2,037,290 28.23 2,938 98.6 
8 M030.N1C 3,207,141 1,894,558 147 16 2,036,992 28.22 2,946 98.61 
9 M087.10C 3,462,641 2,325,014 167 27 323,469 28.05 3,231 98.53 
10 M087.13C 3,455,084 1,967,057 142 23 405,742 28.02 3,222 98.54 
11 M087.1C 3,284,487 1,889,985 143 35 205,249 28.11 3,057 98.34 
12 M087.4C 3,460,509 2,131,041 153 28 405,776 28.04 3,234 98.54 
13 M087.7C 3,456,430 2,159,055 156 27 405,758 28.04 3,219 98.53 
14 M088.10C 3,144,583 2,377,740 189 45 159,921 28.10 2,885 98.34 
15 M088.1C 3,162,957 1,990,062 157 38 148,763 28.09 2,900 98.33 
16 M088.24C 3,147,539 2,126,494 168 39 159,840 28.10 2,887 98.34 
17 M088.4C 3,177,376 2,439,554 191 35 243,556 28.14 2,924 98.34 
18 M089.1C 3,462,801 2,122,381 153 27 405,750 28.05 3,228 98.54 
19 M089.3C 3,458,059 2,189,234 158 30 405,751 28.03 3,224 98.54 
20 M090.1C 3,453,643 2,391,039 173 27 405,601 28.01 3,221 98.54 
21 M090.3C 3,418,228 2,106,126 154 26 405,787 28.01 3,172 98.54 
22 M091.1C 3,107,914 2,024,086 162 26 256,827 28.09 2,827 98.35 
23 M092.1C 3,184,687 2,471,758 194 37 225,186 28.22 2,900 98.41 
24 M094.1C 3,123,459 2,482,864 198 34 173,532 28.08 2,840 98.31 
25 M096.1C 3,402,370 2,118,403 155 20 981,998 28.11 3,165 99.02 
26 M096.3C 3,403,754 2,134,587 156 26 381,709 28.11 3,164 99.01 
27 M111.1C 3,170,976 2,081,022 164 46 185,786 28.13 2,901 98.38 
28 M112.1C 3,171,762 2,227,274 175 37 177,430 28.14 2,901 98.37 
29 M112.4C 3,171,262 2,168,563 170 40 196,214 28.13 2,901 98.37 
30 M124.1C 3,166,878 1,727,552 136 31 187,477 28.12 2,914 98.33 
31 M125.1C 3,167,259 2,151,147 169 32 266,888 28.13 2,913 98.32 
32 M125.4C 3,165,453 2,400,356 189 31 268,068 28.12 2,911 98.32 
33 Q020.CN4 3,240,291 2,419,945 186 19 2,028,783 28.11 2,956 98.57 
34 Q020.CN1 3,242,179 2,528,412 194 16 2,027,560 28.12 2,963 98.57 
35 Q087.1C 3,280,619 2,014,395 153 25 370,656 28.10 2,972 98.38 
36 Q088.CN1 3,062,159 1,403,417 114 11 1,934,220 28.22 2,876 96.15 
37 Q088.CN3 3,065,157 1,327,748 108 18 1,747,693 28.23 2,882 96.14 
38 Q088.CN6 3,066,288 1,679,544 136 17 1,934,223 28.24 2,878 96.15 
39 Q088.CN9 3,287,606 1,300,904 98 21 371,237 28.13 2,976 98.38 
40 Q088.CN12 3,286,041 2,711,369 206 21 370,678 28.12 2,975 98.38 
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 Isolate Genome 
(bp) 




41 Q090.5C 3,194,717 1,387,128 108 14 700,330 28.14 2,900 98.6 
42 Q090.8C 3,202,127 1,584,605 123 16 700,360 28.19 2,906 98.61 
43 Q096.10C 3,194,624 2,480,928 194 29 247,015 28.18 2,918 98.34 
44 Q096.13C 3,244,272 1,873,957 144 28 182,180 28.14 2,977 98.33 
45 Q096.16C 3,190,020 1,912,783 149 27 1,650,471 28.17 2,954 96.14 
46 Q096.1C 4,147,421 1,605,746 96 46 220,673 28.10 3,998 98.31 
47 Q096.4C 3,309,035 2,186,855 165 21 2,087,340 28.17 3,055 98.59 
48 Q097.1C 3,160,474 1,813,042 143 25 440,486 28.13 2,913 98.28 
49 Q097.4C 3,154,351 2,460,896 195 21 275,007 28.12 2,914 98.27 
50 Q097.7C 3,196,530 2,063,679 161 27 385,797 28.10 2,965 98.27 
51 Q100.CN10 3,177,242 1,577,556 124 21 355,350 28.11 2,911 98.29 
52 Q100.CN1 3,209,378 2,178,043 169 26 239,497 28.11 2,963 98.25 
53 Q100.CN4 3,211,356 1,994,849 155 23 239,759 28.12 2,966 98.26 
54 Q100.CN7 3,212,734 2,016,704 156 22 195,946 28.11 2,968 98.25 
55 Q100.CN12 3,212,162 1,652,692 128 21 282,818 28.11 2,964 98.24 
56 Q101.1C 3,231,229 1,427,677 110 22 231,485 28.17 2,981 98.4 
57 Q105.1C 3,138,208 1,136,678 90 28 241,908 28.17 2,880 98.33 
58 Q105.4C 3,136,273 1,385,214 110 33 231,285 28.09 2,879 98.33 
59 Q106.10C 3,494,367 1,618,543 115 24 782,807 28.07 3,251 99.12 
60 Q106.1C 3,125,382 1,387,392 110 39 188,844 28.12 2,838 98.33 
61 Q106.4C 3,100,264 1,439,868 116 20 1,962,756 28.28 2,934 96.15 
62 Q106.7C 3,092,582 1,314,111 106 15 1,966,081 28.27 2,925 96.14 
63 Q107.12C 3,295,802 1,243,651 94 16 2,107,591 28.11 2,996 98.62 
64 Q107.1C 3,143,128 1,281,583 101 27 243,728 28.14 2,878 98.3 
65 Q107.4C 3,270,656 1,445,861 110 29 321,580 28.13 2,990 98.4 
66 Q107.7C 3,133,904 1,426,136 113 21 352,768 28.16 2,869 98.35 
67 Q107.9C 3,299,946 1,771,584 134 15 2,108,040 28.12 2,999 98.61 
68 Q118.1C 3,333,932 1,483,468 111 24 378,475 28.04 3,056 98.41 
69 Q118.4C 3,374,700 1,403,074 103 30 378,470 28.03 3,094 98.41 
70 Q126.1C 3,203,802 1,827,538 142 14 1,945,226 28.09 3,029 96.09 
71 Q135.CN1 3,156,272 1,509,457 119 32 188,322 28.13 2,900 98.3 
72 Q135.CN4 3,154,909 1,035,124 82 38 188,305 28.13 2,901 98.29 
73 Q137.1C 3,459,480 1,613,628 116 26 406,919 28.03 3,223 98.54 
74 Q137.4C 3,456,126 1,603,842 116 24 405,596 28.03 3,226 98.54 
75 Q138.1C 3,460,229 1,687,249 121 23 405,744 28.04 3,233 98.53 
76 Q138.4C 3,459,336 1,555,756 112 21 405,744 28.03 3,225 98.54 
77 Q142.1C 3,146,959 1,528,544 121 36 215,934 28.16 2,862 98.3 
78 Q143.1C 3,459,999 1,804,361 130 21 405,770 28.04 3,227 98.53 
79 Q143.CN1 3,460,998 1,725,528 124 25 405,749 28.04 3,230 98.54 
80 Q143.CN4 3,458,736 1,618,971 117 28 405,767 28.03 3,224 98.53 
81 Q143.CN8 3,460,283 1,607,717 116 24 405,740 28.04 3,228 98.53 
82 Q164.1C 3,360,445 1,713,473 127 19 2,084,408 28.11 3,114 98.94 
83 Q167.10C 3,193,775 1,778,950 139 21 582,989 28.14 2,934 98.29 
84 Q167.1C 3,191,399 1,952,892 152 17 582,691 28.15 2,930 98.31 
85 Q167.4C 3,192,114 1,912,392 149 18 582,697 28.15 2,932 98.3 
86 Q167.7C 3,187,987 1,770,156 138 18 2,030,903 28.14 2,927 98.3 
87 Q168.1C 3,172,313 1,763,212 138 59 115,338 28.09 2,856 98.3 
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88 Q168.4C 3,183,576 1,933,586 151 16 769,066 28.13 2,921 98.3 
89 Q168.7C 3,195,069 1,772,728 138 13 871,716 28.16 2,939 98.3 





Mean 3,263,705 1,858,221 142 25 752,353 28.12 3,009 98.27 
Max 4,147,421 2,711,369 206 59 3,256,683 28.38 3,998 100.00 
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Table S3.3: Genes specific to NEC-associated isolates (Scoary simplified outputs) 
Gene Annotation Sensitivity Specificity Odds ratio 
group_3210 hypothetical protein 75.00 80.77 12.60 
group_434 membrane protein 91.67 73.08 29.86 
group_578 hypothetical protein 91.67 73.08 29.86 
group_1083 N-acetyltransferase 83.33 71.79 12.73 
group_2242 hypothetical protein 91.67 67.95 23.32 
group_583 glycosyl hydrolase family 25 75.00 67.95 6.36 
group_1523 hypothetical protein 75.00 66.67 6.00 
group_2185 hypothetical protein 75.00 66.67 6.00 
group_412 hypothetical protein 75.00 66.67 6.00 
group_1493 hypothetical protein 75.00 65.38 5.67 
group_1495 hypothetical protein 75.00 64.10 5.36 
group_2947 hypothetical protein 75.00 64.10 5.36 
group_2186 hypothetical protein 75.00 64.10 5.36 
group_1050 helix-turn-helix domain-containing 
protein 75.00 64.10 5.36 
group_1053 membrane protein 75.00 64.10 5.36 
group_2943 ParA family protein 75.00 64.10 5.36 
group_1522 hypothetical protein 75.00 64.10 5.36 
group_1052 CAP domain-containing protein 75.00 64.10 5.36 
group_1499 hypothetical protein 75.00 64.10 5.36 
group_2946 hypothetical protein 75.00 64.10 5.36 
group_428 hypothetical protein 75.00 64.10 5.36 
group_1049 chromosome partitioning protein ParB 75.00 64.10 5.36 
group_338 thioester-forming surface-anchored 
protein 75.00 64.10 5.36 
group_2926 pilus biosynthesis protein HicB 75.00 64.10 5.36 
group_163 recombinase 75.00 64.10 5.36 
group_264 ImmA/IrrE family metallo-
endopeptidase 75.00 64.10 5.36 
group_1498 class D sortase 75.00 64.10 5.36 
group_1497 type II toxin-antitoxin system 
PemK/MazF family toxin 75.00 64.10 5.36 
group_2179 hypothetical protein 75.00 64.10 5.36 
group_431 hypothetical protein 75.00 64.10 5.36 
group_2178 hypothetical protein 75.00 64.10 5.36 
group_2949 hypothetical protein 75.00 64.10 5.36 
group_1501 type VI secretion protein 75.00 64.10 5.36 
group_2184 DNA-binding response regulator 75.00 64.10 5.36 
group_2927 addiction module toxin, HicA family 75.00 64.10 5.36 
group_2920 cell wall-binding protein 75.00 64.10 5.36 
group_2948 DNA topoisomerase III 75.00 64.10 5.36 
spo0A sporulation transcription factor Spo0A 75.00 64.10 5.36 
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Gene Annotation Sensitivity Specificity Odds ratio 
group_1494 hypothetical protein 75.00 64.10 5.36 
group_1048 hypothetical protein 75.00 64.10 5.36 
group_2714 sugar ABC transporter substrate-
binding protein 75.00 62.82 5.07 
group_3131 HAMP domain-containing protein 75.00 62.82 5.07 
group_219 hypothetical protein 75.00 62.82 5.07 
group_1830 DNA-binding response regulator 75.00 62.82 5.07 
group_2715 sugar ABC transporter permease 75.00 62.82 5.07 
group_1831 hypothetical protein 75.00 62.82 5.07 
group_576 hypothetical protein 75.00 62.82 5.07 
group_1262 PIG-L family deacetylase 75.00 62.82 5.07 
group_1059 glycoside hydrolase family 65 protein 75.00 62.82 5.07 
group_2717 endo-beta-galactosidase 75.00 62.82 5.07 
group_2716 carbohydrate ABC transporter 
permease 75.00 62.82 5.07 
group_2773 NusG domain II-containing protein 100.00 61.54 inf 
group_2772 heptaprenyl diphosphate synthase 100.00 61.54 inf 
group_552 S-layer homology domain-containing 
protein 100.00 61.54 inf 
group_2054 FAD:protein FMN transferase 100.00 61.54 inf 
group_1703 M protein trans-acting positive 
regulator (MGA) 100.00 60.26 inf 
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Table S3.4: Genes specific to lineage II and III isolates (Scoary simplified outputs) 
Gene Annotation Sensitivity Specificity Odds ratio 
group_412 hypothetical protein 92.11 100.00 inf 
group_1174 hypothetical protein 94.74 98.08 918.00 
group_2717 endo-beta-galactosidase 92.11 94.23 190.56 
group_1830 DNA-binding response regulator 92.11 94.23 190.56 
group_3131 HAMP domain-containing protein 92.11 94.23 190.56 
group_2715 sugar ABC transporter permease 92.11 94.23 190.56 
group_1059 glycoside hydrolase family 65 protein 92.11 94.23 190.56 
group_1262 PIG-L family deacetylase 92.11 94.23 190.56 
group_2714 sugar ABC transporter substrate-
binding protein 
92.11 94.23 190.56 
group_1831 hypothetical protein 92.11 94.23 190.56 
group_2716 carbohydrate ABC transporter 
permease 
92.11 94.23 190.56 
group_431 hypothetical protein 89.47 94.23 138.83 
group_1523 hypothetical protein 84.21 94.23 87.11 
group_2584 phosphoserine phosphatase 97.37 92.31 444.00 
group_2596 Crp/Fnr family transcriptional 
regulator 
97.37 92.31 444.00 
group_2594 purine-nucleoside phosphorylase 97.37 92.31 444.00 
group_2595 nicotinamide riboside transporter 
PnuC 
97.37 92.31 444.00 
group_145 hypothetical protein 97.37 90.38 347.80 
group_2947 hypothetical protein 84.21 90.38 50.13 
group_1499 hypothetical protein 84.21 90.38 50.13 
group_2920 cell wall-binding protein 84.21 90.38 50.13 
group_338 thioester-forming surface-anchored 
protein 
84.21 90.38 50.13 
group_1495 hypothetical protein 84.21 90.38 50.13 
group_2179 hypothetical protein 84.21 90.38 50.13 
group_2178 hypothetical protein 84.21 90.38 50.13 
group_1049 chromosome partitioning protein ParB 84.21 90.38 50.13 
group_2184 DNA-binding response regulator 84.21 90.38 50.13 
group_2946 hypothetical protein 84.21 90.38 50.13 
group_1494 hypothetical protein 84.21 90.38 50.13 
group_163 recombinase 84.21 90.38 50.13 
group_2949 hypothetical protein 84.21 90.38 50.13 
group_1501 type VI secretion protein 84.21 90.38 50.13 
group_2948 DNA topoisomerase III 84.21 90.38 50.13 
group_1048 hypothetical protein 84.21 90.38 50.13 
group_1497 type II toxin-antitoxin system 
PemK/MazF family toxin 
84.21 90.38 50.13 
group_428 hypothetical protein 84.21 90.38 50.13 
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group_1050 helix-turn-helix domain-containing 
protein 
84.21 90.38 50.13 
group_264 ImmA/IrrE family metallo-
endopeptidase 
84.21 90.38 50.13 
group_2186 hypothetical protein 84.21 90.38 50.13 
spo0A sporulation transcription factor Spo0A 84.21 90.38 50.13 
group_2943 ParA family protein 84.21 90.38 50.13 
group_1522 hypothetical protein 84.21 90.38 50.13 
group_1052 CAP domain-containing protein 84.21 90.38 50.13 
group_2926 pilus biosynthesis protein HicB 84.21 90.38 50.13 
group_1498 class D sortase 84.21 90.38 50.13 
group_1053 membrane protein 84.21 90.38 50.13 
group_2927 addiction module toxin, HicA family 84.21 90.38 50.13 
group_1493 hypothetical protein 81.58 90.38 41.63 
group_2765 ABC transporter ATP-binding protein 97.37 86.54 237.86 
group_2764 ABC transporter ATP-binding protein 97.37 86.54 237.86 
group_840 hypothetical protein 94.74 86.54 115.71 
group_2637 RNA polymerase subunit sigma-24 94.74 86.54 115.71 
group_552 S-layer homology domain-containing 
protein 
92.11 86.54 75.00 
group_2773 NusG domain II-containing protein 92.11 86.54 75.00 
group_2772 heptaprenyl diphosphate synthase 92.11 86.54 75.00 
group_2054 FAD:protein FMN transferase 92.11 86.54 75.00 
group_841 zinc transporter ZupT 97.37 84.62 203.50 
group_1703 M protein trans-acting positive 
regulator (MGA) 
92.11 84.62 64.17 
group_654 CotH protein 97.37 80.77 155.40 
group_1845 response regulator 97.37 80.77 155.40 
group_1844 potassium-transporting ATPase A 
chain 
97.37 80.77 155.40 
group_2726 DNA-binding response regulator 97.37 80.77 155.40 
group_2718 VTC domain-containing protein 97.37 80.77 155.40 
group_2725 potassium-transporting ATPase 
subunit B 
97.37 80.77 155.40 
group_877 sensor histidine kinase 97.37 80.77 155.40 
group_2719 hypothetical protein 97.37 80.77 155.40 
group_662 potassium-transporting ATPase 
subunit KdpC 
97.37 80.77 155.40 
group_881 sensor histidine kinase KdpD 97.37 80.77 155.40 
group_1835 DNA-binding response regulator 97.37 80.77 155.40 
group_1836 hypothetical protein 94.74 80.77 75.60 
group_575 hypothetical protein 86.84 80.77 27.72 
group_2575 thiol-activated toxin perfringolysin O 92.11 78.85 43.48 
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group_1228 DNA-binding response regulator 100.00 76.92 inf 
group_506 diacylglyceryl transferase 97.37 76.92 123.33 
group_882 FUSC family protein 97.37 76.92 123.33 
group_836 hypothetical protein 94.74 76.92 60.00 
group_347 3-phosphoglycerate dehydrogenase 100.00 75.00 inf 
group_165 hypothetical protein 100.00 75.00 inf 
group_2557 alanine--glyoxylate aminotransferase 
family protein 
100.00 75.00 inf 
group_729 hypothetical protein 97.37 75.00 111.00 
group_370 FAD-dependent oxidoreductase 81.58 75.00 13.29 
group_236 hypothetical protein 84.21 73.08 14.48 
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Table S3.5: Pair-wise SNP distances and ANI value (%) of lineage IIIc isolates 
























































































































M087.10C 0 2 0 1 0 0 2 0 0 0 0 1 2 0 0 1 99.99 
M087.13C 2 0 2 3 2 2 4 2 2 2 2 3 4 2 2 3 99.99 
M087.4C 0 2 0 1 0 0 2 0 0 0 0 1 2 0 0 1 99.99 
M087.7C 1 3 1 0 1 1 3 1 1 1 1 2 3 1 1 2 99.99 
M089.1C 0 2 0 1 0 0 2 0 0 0 0 1 2 0 0 1 99.99 
M089.3C 0 2 0 1 0 0 2 0 0 0 0 1 2 0 0 1 99.99 
M090.1C 2 4 2 3 2 2 0 2 2 2 2 3 4 2 2 3 99.99 
M090.3C 0 2 0 1 0 0 2 0 0 0 0 1 2 0 0 1 99.99 
Q137.1C 0 2 0 1 0 0 2 0 0 0 0 1 2 0 0 1 99.99 
Q137.4C 0 2 0 1 0 0 2 0 0 0 0 1 2 0 0 1 99.99 
Q138.1C 0 2 0 1 0 0 2 0 0 0 0 1 2 0 0 1 99.99 
Q138.4C 1 3 1 2 1 1 3 1 1 1 1 0 3 1 1 2 99.99 
Q143.1C 2 4 2 3 2 2 4 2 2 2 2 3 0 2 2 3 99.99 
Q143.CN1 0 2 0 1 0 0 2 0 0 0 0 1 2 0 0 1 99.99 
Q143.CN4 0 2 0 1 0 0 2 0 0 0 0 1 2 0 0 1 99.99 
Q143.CN8 1 3 1 2 1 1 3 1 1 1 1 2 3 1 1 0 100.00 
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Appendix 2  Supplementary data for Chapter 4 
This appendix contains all the supplementary materials for Chapter 4. 
 
Table S4.1: Clinical and genomic (assembly and annotation) data of 109 outbreak-
associated C. perfringens newly-sequenced isolates in this study. 
Table S4.2: Pair-wise SNP distance (from core-gene alignment) among 18 CH 
isolates in lineage IVc recovered from 9 outbreaks between 2013-2017. 
Table S4.3: Pair-wise SNP distance among clonal FP isolates within lineage VII.  






Appendix 2    299 
 
Table S4.1: Clinical and genomic (assembly and annotation) data of 109 outbreak-associated C. 
perfringens newly-sequenced isolates in this study 
ANI (Average Nucleotide Identity) was compared with reference genome (RefSeq) C. perfringens 
NCTC8239. Cohort: CH represents care home-associated; FP denotes food poisoning isolates. 
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Table S4.2: Pair-wise SNP distance (from core-gene alignment) among 18 CH isolates in lineage 















































































































PH016 0 9 6 19 17 21 17 29 23 25 23 25 61 39 54 22 25 52 
PH018 9 0 7 20 18 22 18 30 24 26 24 26 62 40 55 23 26 53 
PH019 6 7 0 17 15 19 15 27 21 23 21 23 59 37 52 20 23 50 
PH030 19 20 17 0 2 20 16 16 10 12 10 12 50 28 43 11 14 41 
PH031 17 18 15 2 0 18 14 14 8 10 8 10 48 26 41 9 12 39 
PH052 21 22 19 20 18 0 6 30 24 26 24 26 62 40 55 23 26 53 
PH053 17 18 15 16 14 6 0 26 20 22 20 22 58 36 51 19 22 49 
PH073 29 30 27 16 14 30 26 0 20 4 20 6 56 38 53 21 24 51 
PH074 23 24 21 10 8 24 20 20 0 16 6 16 54 32 47 15 18 45 
PH075 25 26 23 12 10 26 22 4 16 0 16 2 52 34 49 17 20 47 
PH076 23 24 21 10 8 24 20 20 6 16 0 16 54 32 47 15 18 45 
PH077 25 26 23 12 10 26 22 6 16 2 16 0 52 34 49 17 20 47 
PH079 61 62 59 50 48 62 58 56 54 52 54 52 0 54 77 53 54 45 
PH096 39 40 37 28 26 40 36 38 32 34 32 34 54 0 55 31 32 45 
PH097 54 55 52 43 41 55 51 53 47 49 47 49 77 55 0 46 47 68 
PH098 22 23 20 11 9 23 19 21 15 17 15 17 53 31 46 0 17 44 
PH101 25 26 23 14 12 26 22 24 18 20 18 20 54 32 47 17 0 45 
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Table S4.3: Pair-wise SNP distance among clonal FP isolates within lineage VII 








































































































































































































































                            
PH035     0 1 1 3 2 1 4 3 4 2 1 0 1 4              
PH036     1 0 0 2 1 2 3 2 3 3 2 1 0 3              
PH037     1 0 0 2 1 2 3 2 3 3 2 1 0 3              
PH039     3 2 2 0 3 4 5 4 5 5 4 3 2 5              
PH040     2 1 1 3 0 3 4 3 4 4 3 2 1 4              
PH041     1 2 2 4 3 0 5 4 5 3 2 1 2 5              
PH042     4 3 3 5 4 5 0 5 6 6 5 4 3 6              
PH043     3 2 2 4 3 4 5 0 5 5 4 3 2 5              
PH044     4 3 3 5 4 5 6 5 0 6 5 4 3 2              
PH046     2 3 3 5 4 3 6 5 6 0 3 2 3 6              
PH047     1 2 2 4 3 2 5 4 5 3 0 1 2 5              
PH048     0 1 1 3 2 1 4 3 4 2 1 0 1 4              
PH154     1 0 0 2 1 2 3 2 3 3 2 1 0 3              
PH155     4 3 3 5 4 5 6 5 2 6 5 4 3 0              
PH056                   0 2 3 3 3 1 1 1 1 2 1 2  
PH057                   2 0 3 3 3 1 1 1 1 2 1 2  
PH058                   3 3 0 4 4 2 2 2 2 3 2 3  
PH059                   3 3 4 0 4 2 2 2 2 3 2 3  
PH060                   3 3 4 4 0 2 2 2 2 3 2 3  
PH061                   1 1 2 2 2 0 0 0 0 1 0 1  
PH062                   1 1 2 2 2 0 0 0 0 1 0 1  
PH063                   1 1 2 2 2 0 0 0 0 1 0 1  
PH065                   1 1 2 2 2 0 0 0 0 1 0 1  
PH066                   2 2 3 3 3 1 1 1 1 0 1 2  
PH067                   1 1 2 2 2 0 0 0 0 1 0 1  
PH068                   2 2 3 3 3 1 1 1 1 2 1 0  
PH143                               0 
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Regulatory DnaK co-chaperone. 
Direct interaction between DnaK 
and DjlA is needed for the 
induction of the wcaABCDE 
operon, involved in the synthesis 
of a colanic acid polysaccharide 
capsule, possibly through 
activation of the RcsB RcsC 
phosphotransfer signaling 
pathway. The colanic acid 
capsule may help the bacterium 
survive conditions outside the 
host (By similarity) 
O restriction modification 
system DNA specificity 
V 
hydrolase, family 25 M NA S 
toxin secretion phage lysis holin S Inherit from COG: peptidase' M 
HNH endonuclease V NA S 
Cell wall anchor domain protein M NA S 
serine threonine protein kinase T TRANSCRIPTIONal K 
Plays a major role in protein 
secretion by helping the post-
translocational extracellular 
folding of several secreted 
proteins (By similarity) 
O PTS System G 
EA59 protein S PTS System G 
NA S PTS system, galactitol-
specific IIc component 
G 
NA S PTS system, galactitol-
specific IIc component 
G 
response regulator T NA S 
Histidine kinase T NA S 
NA S ribonuclease S 
Histidine kinase T Toxic component of a toxin-
antitoxin (TA) module. A 
stable (half-life 27.6 
minutes) endoribonuclease 
that in the absence of 
cognate antitoxin RnlB 
causes generalized RNA 
degradation. Degrades late 
enterobacteria phage T4 
mRNAs, protecting the host 
against T4 reproduction. 
Activity is inhibited by 
cognate antitoxin RnlB and 
by enterobacteria phage T4 
protein Dmd. Targets cyaA 
mRNA 
A 
cell division protein FtsK D NA S 
transposase L phage protein S 
Mor transcription activator family S 
  




Appendix 3  Supplementary data for Chapter 5 
This appendix comprises all supplementary materials for Chapter 5. 
 
Table S5.1: Summary statistics of 16S rRNA sequences analysed including OTU 
numbers detected. 
Figure S5.1: Reads assigned to 16S rRNA sequences including species level using 
paired-end BLASTN approach.  




Table S5.1: Summary statistics of 16S rRNA sequences analysed including OTU numbers 
detected 
Sample Host condition 
Sequencing 
platform 
No. of OTUs Raw reads 
29 Healthy control Illumina MiSeq 2,749 83,117 
2 Healthy control Illumina MiSeq 2,772 89,344 
25 Healthy control Illumina MiSeq 4,027 143,001 
14 NE Illumina MiSeq 3,050 126,582 
33 NE Illumina MiSeq 3,857 164,027 
36 NE Illumina MiSeq 3,236 135,808 
21 SNE Illumina MiSeq 3,440 150,198 
22 SNE Illumina MiSeq 1,780 60,036 
26 SNE Illumina MiSeq 4,972 112,820 
34 SNE Illumina MiSeq 1,792 79,227 
38 SNE Illumina MiSeq 2,641 123,828 
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Appendix 4  Supplementary data for Chapter 6 
This appendix comprises all supplementary materials for Chapter 6. 
 
Table S6.1: Details of all C. perfingens isolates (n=552) included in this thesis with 
basic assembly statistics, origin data and public database accessions (NCBI/ENA). 
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Table S6.1: Details of all C. perfingens isolates (n=552) included in this thesis with basic 
assembly statistics, origin data and public database accessions (NCBI/ENA)  
A total of 90 genome assemblies were downloaded from NCBI assembly databases whereas 22 
genomes of NCTC isolates were re-assembled in this study from raw-read sequencing data. The 
remaining isolates are newly sequenced in my PhD work. The data are arranged in the alphabetical 
order of isolate strain names. ANI (%) were compared with type strain ATCC13124. 
 
Strain 





Contigs Source Region/Country Study/Site ANI 
11 3197244 35 Birds Belgium Public database 98.62 PRJNA422745 
13 3085740 2 Undetermined 
Undetermined: 
from NCBI 
Public database 98.50 PRJNA79 
37 3481068 74 Birds Belgium Public database 98.60 PRJNA422745 
48 3250386 33 Birds Belgium Public database 98.60 PRJNA422745 
67 3448290 48 Birds Belgium Public database 98.64 PRJNA422745 
1207 3207161 95 Undetermined 
Undetermined: 
from NCBI 
Public database 98.56 PRJNA267549 
2789STDY5
608889 
3321076 48 Adults 
Undetermined: 
from NCBI 
Public database 98.78 PRJEB10915 
96-7415 3383570 48 Birds USA Public database 98.94 PRJNA422745 
98.78718-2 3608029 55 Birds Denmark Public database 98.97 PRJNA422745 
An185 3254381 71 Birds 
Undetermined: 
from NCBI 
Public database 98.54 PRJNA377666 
An68 3263985 47 Birds 
Undetermined: 
from NCBI 
Public database 98.53 PRJNA377666 
ATCC13124 3256683 1 Undetermined 
Undetermined: 
from NCBI 
Public database 100.00 PRJNA304 
B_ATCC362
6 
3896305 98 Sheep 
Undetermined: 
from NCBI 
Public database 98.96 PRJNA20027 
BER-NE33 3428087 14 Birds Australia Public database 98.68 PRJNA422745 
BzA 3282838 64 Undetermined 
Undetermined: 
from NCBI 
Public database 98.59 PRJNA451295 
C_JGS1495 3661329 84 Pigs 
Undetermined: 
from NCBI 
Public database 98.30 PRJNA20025 
C033 3198143 41 Birds 
Midlands, 
England 
Lincolnshire 98.41 PRJEB25766 
C036 3213346 14 Birds 
Midlands, 
England 
Lincolnshire 99.05 PRJEB25766 
C056 3125087 35 Birds 
Midlands, 
England 
Lincolnshire 98.32 PRJEB25766 
C55A 3375555 20 Birds 
Midlands, 
England 
Lincolnshire 97.15 PRJEB25766 
CLP2R01 3470089 42 Adults Scotland Scotland 98.55 PRJEB25766 
CLP2R02 3472015 47 Adults Scotland Scotland 98.54 PRJEB25766 
CLP2R03 3468756 43 Adults Scotland Scotland 98.54 PRJEB25766 
CLP3R02 3471259 40 Adults Scotland Scotland 98.54 PRJEB25766 
CLP3R03 3471795 51 Adults Scotland Scotland 98.54 PRJEB25766 
CP4 3642209 98 Birds Canada Public database 98.99 PRJNA294154 
CPE_F4969 3510272 74 Adults 
Undetermined: 
from NCBI 
Public database 98.61 PRJNA20031 
CR034 3257012 14 Birds 
Midlands, 
England 
Lincolnshire 97.11 PRJEB25766 
D_JGS1721 4045016 221 Sheep 
Undetermined: 
from NCBI 
Public database 98.62 PRJNA28587 
E_JGS1987 4127102 101 Cows 
Undetermined: 
from NCBI 
Public database 98.41 PRJNA20029 
EHE-NE18 3663932 4 Birds Australia Public database 98.75 PRJNA341531 
EHE-NE7 3430497 88 Birds Australia Public database 98.46 PRJNA422745 
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Contigs Source Region/Country Study/Site ANI 
EM082-T6-5 3294625 20 Older adults Ireland ELDERMET 98.66 PRJEB28308 
EM095-T0-2 3167702 35 Older adults Ireland ELDERMET 98.30 PRJEB28308 
EM124-T3-6 3195277 30 Older adults Ireland ELDERMET 98.60 PRJEB28308 
EM151-T0-4 3219100 24 Older adults Ireland ELDERMET 98.56 PRJEB28308 
EM159-T0-8 3394504 49 Older adults Ireland ELDERMET 98.43 PRJEB28308 
EM159-T6-2 3273806 41 Older adults Ireland ELDERMET 98.33 PRJEB28308 
EM165-T0-4 3249888 24 Older adults Ireland ELDERMET 98.56 PRJEB28308 
EM169-T0-2 3268354 24 Older adults Ireland ELDERMET 98.56 PRJEB28308 
EM177-T0-6 3297346 20 Older adults Ireland ELDERMET 98.63 PRJEB28308 
EM186-T0-5 3203537 24 Older adults Ireland ELDERMET 98.61 PRJEB28308 
EM200-T6 3489434 45 Older adults Ireland ELDERMET 98.61 PRJEB28308 
EM297-T0 3312580 18 Older adults Ireland ELDERMET 98.52 PRJEB28308 
EM313-T6 3260252 19 Older adults Ireland ELDERMET 98.55 PRJEB28308 
EM322-T0 3298048 20 Older adults Ireland ELDERMET 98.65 PRJEB28308 
EM325-T0 3310070 30 Older adults Ireland ELDERMET 98.60 PRJEB28308 
EM331-T0 3313180 37 Older adults Ireland ELDERMET 98.43 PRJEB28308 
EM342-T0 3420719 31 Older adults Ireland ELDERMET 98.60 PRJEB28308 
EUR-NE15 3588449 62 Birds Australia Public database 98.76 PRJNA422745 
F262 3464306 53 Cows 
Undetermined: 
from NCBI 
Public database 98.59 PRJNA51969 
FC2 3486930 81 Birds USA Public database 98.95 PRJNA422745 
FORC003 3395109 2 Undetermined 
Undetermined: 
from NCBI 
Public database 98.46 PRJNA259939 
FORC025 3343822 1 Undetermined 
Undetermined: 
from NCBI 
Public database 98.53 PRJNA299533 
FR002 3325832 13 Soil 
Midlands, 
England 
Lincolnshire 99.09 PRJEB25766 
FR006 3259735 15 Soil 
Midlands, 
England 
Lincolnshire 98.57 PRJEB25766 
FR011 3388890 23 Soil 
Midlands, 
England 
Lincolnshire 98.65 PRJEB25766 
FR013 3432631 26 Soil 
Midlands, 
England 
Lincolnshire 98.54 PRJEB25766 
FR025 3253037 12 Soil 
Midlands, 
England 
Lincolnshire 98.59 PRJEB25766 
FR063 3480913 47 Soil 
Midlands, 
England 
Lincolnshire 98.58 PRJEB25766 
G035 3429313 22 Birds 
Midlands, 
England 
Lincolnshire 97.19 PRJEB25766 
G049 3698052 46 Birds 
Midlands, 
England 
Lincolnshire 98.62 PRJEB25766 
G050 3228163 26 Birds 
Midlands, 
England 
Lincolnshire 98.39 PRJEB25766 
GNP-1 3725979 128 Birds USA Public database 99.00 PRJNA422745 
I055 3385548 19 Birds 
Midlands, 
England 
Lincolnshire 99.11 PRJEB25766 
I056 3136168 47 Birds 
Midlands, 
England 
Lincolnshire 98.32 PRJEB25766 
I058 3648990 90 Birds 
Midlands, 
England 
Lincolnshire 98.62 PRJEB25766 
I060 3688521 57 Birds 
Midlands, 
England 
Lincolnshire 98.61 PRJEB25766 
ITX1105-
12MP 
3651954 252 Birds USA Public database 99.04 PRJNA422745 
J060 3134537 57 Birds 
Midlands, 
England 
Lincolnshire 98.33 PRJEB25766 
J36 3694265 46 Birds 
Midlands, 
England 
Lincolnshire 98.62 PRJEB25766 
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Contigs Source Region/Country Study/Site ANI 
J46 3322108 14 Birds 
Midlands, 
England 
Lincolnshire 97.15 PRJEB25766 
J55 3385936 22 Birds 
Midlands, 
England 
Lincolnshire 99.11 PRJEB25766 
JFP718 3652220 56 Dogs Canada Public database 97.11 PRJNA327316 
JFP727 3624033 47 Horses Canada Public database 97.11 PRJNA327317 
JFP728 3579626 85 Horses Canada Public database 97.11 PRJNA327319 
JFP771 3495308 81 Dogs Canada Public database 98.96 PRJNA327398 
JFP774 3548595 56 Dogs Canada Public database 97.12 PRJNA327402 
JFP795 3578912 67 Dogs Canada Public database 97.12 PRJNA327404 
JFP796 3601148 114 Dogs Canada Public database 97.11 PRJNA327405 
JFP801 3580610 59 Horses USA Public database 97.11 PRJNA327406 
JFP804 3625968 117 Horses USA Public database 97.11 PRJNA327409 
JFP810 3830406 95 Dogs Canada Public database 97.11 PRJNA327410 
JFP826 3660408 70 Dogs USA Public database 97.11 PRJNA327411 
JFP828 3564370 54 Horses USA Public database 97.12 PRJNA327440 
JFP829 3639686 108 Horses USA Public database 97.11 PRJNA327441 
JFP833 3521770 96 Horses USA Public database 98.97 PRJNA327442 
JFP834 3549140 121 Horses USA Public database 98.96 PRJNA327443 
JFP836 3599532 51 Dogs USA Public database 97.11 PRJNA327444 
JFP914 3819232 79 Dogs Switzerland Public database 97.12 PRJNA327445 
JFP916 3660641 67 Dogs Switzerland Public database 97.12 PRJNA327446 
JFP921 3601767 78 Dogs USA Public database 97.12 PRJNA327447 
JFP922 3612099 76 Dogs USA Public database 97.12 PRJNA327448 
JFP923 3589715 48 Dogs USA Public database 97.13 PRJNA327449 
JFP941 3594640 64 Dogs Canada Public database 97.11 PRJNA327450 
JFP961 3617219 66 Dogs Canada Public database 97.12 PRJNA327451 
JFP978 3585277 68 Horses USA Public database 98.96 PRJNA327452 
JFP980 3654588 67 Horses USA Public database 97.11 PRJNA327453 
JFP981 3580367 68 Horses USA Public database 98.96 PRJNA327455 
JFP982 3670557 62 Horses USA Public database 97.12 PRJNA327456 
JFP983 3657522 46 Horses USA Public database 97.11 PRJNA327457 
JFP986 3669049 58 Horses USA Public database 97.10 PRJNA327458 
JFP992 3657868 70 Horses USA Public database 97.11 PRJNA327459 
JJC 3259329 69 Undetermined 
Undetermined: 
from NCBI 
Public database 98.63 PRJNA215269 
JP55 3347300 1 Horses Canada Public database 98.98 PRJNA276414 
JP838 3530414 1 Dogs USA Public database 97.15 PRJNA276513 
K473 3411764 55 Birds Australia Public database 98.55 PRJNA422745 
LH019 3605600 28 Infants East of England BAMBI 96.54 PRJEB25762 
LH020 3572073 22 Infants East of England BAMBI 96.57 PRJEB25762 
LH023 3607194 26 Infants East of England BAMBI 96.54 PRJEB25762 
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Contigs Source Region/Country Study/Site ANI 
LH024 3605555 29 Infants East of England BAMBI 96.55 PRJEB25762 
LH031 3293275 16 Infants East of England BAMBI 98.57 PRJEB25762 
LH032 3289023 15 Infants East of England BAMBI 98.58 PRJEB25762 
LH033 3294377 13 Infants East of England BAMBI 98.58 PRJEB25762 
LH035 3290682 15 Infants East of England BAMBI 98.57 PRJEB25762 
LH043 3294719 18 Infants East of England BAMBI 98.57 PRJEB25762 
LH044 3292797 18 Infants East of England BAMBI 98.57 PRJEB25762 
LH045 3287528 15 Infants East of England BAMBI 98.57 PRJEB25762 
LH046 3231068 24 Infants East of England BAMBI 98.36 PRJEB25762 
LH047 3229224 25 Infants East of England BAMBI 98.36 PRJEB25762 
LH048 3236291 25 Infants East of England BAMBI 98.36 PRJEB25762 
LH051 3350033 16 Infants East of England BAMBI 98.62 PRJEB25762 
LH055 3253813 14 Infants East of England BAMBI 98.56 PRJEB25762 
LH056 3349772 18 Infants East of England BAMBI 98.61 PRJEB25762 
LH057 3349425 16 Infants East of England BAMBI 98.61 PRJEB25762 
LH059 3347675 15 Infants East of England BAMBI 98.61 PRJEB25762 
LH060 3176811 27 Infants East of England BAMBI 98.31 PRJEB25762 
LH062 3313187 53 Infants East of England BAMBI 98.32 PRJEB25762 
LH063 3311517 52 Infants East of England BAMBI 98.32 PRJEB25762 
LH064 3313206 47 Infants East of England BAMBI 98.32 PRJEB25762 
LH065 3255191 15 Infants East of England BAMBI 98.57 PRJEB25762 
LH066 3358561 34 Infants East of England BAMBI 98.42 PRJEB25762 
LH067 3363409 36 Infants East of England BAMBI 98.43 PRJEB25762 
LH070 3364587 40 Infants East of England BAMBI 98.42 PRJEB25762 
LH071 3362921 38 Infants East of England BAMBI 98.43 PRJEB25762 
LH080 3173380 30 Infants East of England BAMBI 98.27 PRJEB25762 
LH083 3718165 58 Infants East of England BAMBI 98.96 PRJEB25762 
LH084 3758696 53 Infants East of England BAMBI 98.96 PRJEB25762 
LH086 3721164 66 Infants East of England BAMBI 98.96 PRJEB25762 
LH101 3273117 17 Infants East of England BAMBI 98.61 PRJEB25762 
LH102 3270536 15 Infants East of England BAMBI 98.61 PRJEB25762 
LH103 3274777 21 Infants East of England BAMBI 98.61 PRJEB25762 
LH105 3273978 20 Infants East of England BAMBI 98.61 PRJEB25762 
LH107 3303134 31 Infants East of England BAMBI 98.41 PRJEB25762 
LH108 3303663 30 Infants East of England BAMBI 98.41 PRJEB25762 
LH109 3306644 27 Infants East of England BAMBI 98.41 PRJEB25762 
LH111 3303073 30 Infants East of England BAMBI 98.41 PRJEB25762 
LH112 3364130 32 Infants East of England BAMBI 98.42 PRJEB25762 
LH113 3365350 42 Infants East of England BAMBI 98.43 PRJEB25762 
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Contigs Source Region/Country Study/Site ANI 
LH114 3364314 38 Infants East of England BAMBI 98.42 PRJEB25762 
LH115 3364031 39 Infants East of England BAMBI 98.42 PRJEB25762 
LH116 3365880 37 Infants East of England BAMBI 98.42 PRJEB25762 
LH120 3272004 15 Infants East of England BAMBI 98.61 PRJEB25762 
LH121 3275022 20 Infants East of England BAMBI 98.61 PRJEB25762 
LH122 3272157 14 Infants East of England BAMBI 98.60 PRJEB25762 
LH135 3292320 18 Infants East of England BAMBI 98.57 PRJEB25762 
LH136 3292069 19 Infants East of England BAMBI 98.57 PRJEB25762 
LH137 3287845 14 Infants East of England BAMBI 98.57 PRJEB25762 
LH139 3291122 16 Infants East of England BAMBI 98.57 PRJEB25762 
LHC1 3313944 54 Infants East of England BAMBI 98.32 PRJEB25762 
LHC13 3252214 16 Infants East of England BAMBI 98.57 PRJEB25762 
LHC14 3350685 17 Infants East of England BAMBI 98.61 PRJEB25762 
LHC5 3231824 26 Infants East of England BAMBI 98.36 PRJEB25762 
LHZ154 3225350 26 
Zoo animals: 
bear 
Wales Zoo Microbiome 98.40 PRJEB28309 
LHZ155 3195467 21 
Zoo animals: 
bear 
Wales Zoo Microbiome 98.41 PRJEB28309 
LHZ157 3336624 18 
Zoo animals: 
bear 
Wales Zoo Microbiome 97.35 PRJEB28309 
LHZ158 3208816 18 
Zoo animals: 
bear 
Wales Zoo Microbiome 98.42 PRJEB28309 
LHZ161 3310316 59 
Zoo animals: 
lion 
East of England Zoo Microbiome 98.47 PRJEB28309 
LHZ162 3326006 19 
Zoo animals: 
lion 
East of England Zoo Microbiome 99.05 PRJEB28309 
LHZ163 3281094 13 
Zoo animals: 
leopard 
East of England Zoo Microbiome 98.59 PRJEB28309 
LHZ164 3101486 17 
Zoo animals: 
leopard 
East of England Zoo Microbiome 96.17 PRJEB28309 
LHZ170 3306129 22 
Zoo animals: 
monkey 
East of England Zoo Microbiome 98.66 PRJEB28309 
LHZ171 3303919 19 
Zoo animals: 
monkey 
East of England Zoo Microbiome 98.66 PRJEB28309 
LHZ459 3169911 21 
Zoo animals: 
seriema 
East of England Zoo Microbiome 96.13 PRJEB28309 
LHZ460 3448674 11 
Zoo animals: 
seriema 
East of England Zoo Microbiome 98.61 PRJEB28309 
LHZ472 3352988 20 
Zoo animals: 
aardvark 
East of England Zoo Microbiome 99.02 PRJEB28309 
LHZ474 3335111 22 
Zoo animals: 
aardvark 
East of England Zoo Microbiome 97.23 PRJEB28309 
LHZ476 3363510 13 
Zoo animals: 
mongoose 
East of England Zoo Microbiome 98.71 PRJEB28309 
LHZ513 3366540 13 
Zoo animals: 
goose 
East of England Zoo Microbiome 98.71 PRJEB28309 
LHZ574 3469057 18 
Zoo animals: 
monkey 
East of England Zoo Microbiome 96.71 PRJEB28309 
LLY_N11 3446916 4 Birds 
Undetermined: 
from NCBI 
Public database 98.91 PRJNA403823 
M009.1C 3228292 22 Infants London, England NEOM 98.30 PRJEB25762 
M009.2.1C 3261764 26 Children London, England NEOM 98.58 PRJEB28307 
M009.2C 3227979 24 Infants London, England NEOM 98.30 PRJEB25762 
M010.1C 3344966 18 Infants London, England NEOM 98.65 PRJEB25762 
M010.2C 3347565 18 Infants London, England NEOM 98.66 PRJEB25762 
M010.CN1 3344094 17 Infants London, England NEOM 98.65 PRJEB25762 
M010.CN2 3346940 17 Infants London, England NEOM 98.65 PRJEB25762 
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Contigs Source Region/Country Study/Site ANI 
M010f.1C 3345584 18 Infants London, England NEOM 98.65 PRJEB25762 
M011.1C 3345019 15 Infants London, England NEOM 98.66 PRJEB25762 
M011f.1C 3347080 21 Infants London, England NEOM 98.66 PRJEB25762 
M030.1C 3205090 19 Infants London, England NEOM 98.60 PRJEB25762 
M030.2C 3206308 16 Infants London, England NEOM 98.61 PRJEB25762 
M030.N1C 3207141 16 Infants London, England NEOM 98.61 PRJEB25762 
M030.N2C 3209453 16 Infants London, England NEOM 98.60 PRJEB25762 
M030.N3C 3205909 14 Infants London, England NEOM 98.60 PRJEB25762 
M030.N4C 3202137 13 Infants London, England NEOM 98.60 PRJEB25762 
M040.2.1C 3143104 35 Children London, England NEOM 98.30 PRJEB28307 
M087.10C 3462641 27 Infants London, England NEOM 98.53 PRJEB25762 
M087.11C 3456083 28 Infants London, England NEOM 98.53 PRJEB25762 
M087.13C 3455084 23 Infants London, England NEOM 98.54 PRJEB25762 
M087.1C 3284487 35 Infants London, England NEOM 98.34 PRJEB25762 
M087.2C 3283083 33 Infants London, England NEOM 98.34 PRJEB25762 
M087.4C 3460509 28 Infants London, England NEOM 98.54 PRJEB25762 
M087.5C 3462398 29 Infants London, England NEOM 98.53 PRJEB25762 
M087.7C 3456430 27 Infants London, England NEOM 98.53 PRJEB25762 
M087.8C 3456813 24 Infants London, England NEOM 98.54 PRJEB25762 
M088.10C 3144583 45 Infants London, England NEOM 98.34 PRJEB25762 
M088.11C 3146349 44 Infants London, England NEOM 98.34 PRJEB25762 
M088.1C 3162957 38 Infants London, England NEOM 98.33 PRJEB25762 
M088.24C 3147539 39 Infants London, England NEOM 98.34 PRJEB25762 
M088.2C 3173224 37 Infants London, England NEOM 98.33 PRJEB25762 
M088.4C 3177376 35 Infants London, England NEOM 98.34 PRJEB25762 
M088.5C 3179386 37 Infants London, England NEOM 98.34 PRJEB25762 
M089.1C 3462801 27 Infants London, England NEOM 98.54 PRJEB25762 
M089.2C 3452649 28 Infants London, England NEOM 98.54 PRJEB25762 
M089.3C 3458059 30 Infants London, England NEOM 98.54 PRJEB25762 
M089.4C 3454935 31 Infants London, England NEOM 98.54 PRJEB25762 
M090.1C 3453643 27 Infants London, England NEOM 98.54 PRJEB25762 
M090.2C 3456978 28 Infants London, England NEOM 98.54 PRJEB25762 
M090.3C 3418228 26 Infants London, England NEOM 98.54 PRJEB25762 
M090.4C 3453548 28 Infants London, England NEOM 98.54 PRJEB25762 
M091.1C 3107914 26 Infants London, England NEOM 98.35 PRJEB25762 
M091.2C 3108502 27 Infants London, England NEOM 98.35 PRJEB25762 
M092.1C 3184687 37 Infants London, England NEOM 98.41 PRJEB25762 
M092.2C 3180571 34 Infants London, England NEOM 98.41 PRJEB25762 
M094.1C 3123459 34 Infants London, England NEOM 98.31 PRJEB25762 
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Contigs Source Region/Country Study/Site ANI 
M094.2C 3134877 36 Infants London, England NEOM 98.32 PRJEB25762 
M096.1C 3402370 20 Infants London, England NEOM 99.02 PRJEB25762 
M096.2C 3402836 23 Infants London, England NEOM 99.02 PRJEB25762 
M096.3C 3403754 26 Infants London, England NEOM 99.01 PRJEB25762 
M096.4C 3345030 20 Infants London, England NEOM 99.02 PRJEB25762 
M111.1C 3170976 46 Infants London, England NEOM 98.38 PRJEB25762 
M111.2C 3167862 46 Infants London, England NEOM 98.38 PRJEB25762 
M112.1C 3171762 37 Infants London, England NEOM 98.37 PRJEB25762 
M112.2C 3172334 45 Infants London, England NEOM 98.37 PRJEB25762 
M112.4C 3171262 40 Infants London, England NEOM 98.37 PRJEB25762 
M112.5C 3166211 44 Infants London, England NEOM 98.38 PRJEB25762 
M124.1C 3166878 31 Infants London, England NEOM 98.33 PRJEB25762 
M124.2C 3161455 33 Infants London, England NEOM 98.33 PRJEB25762 
M125.1C 3167259 32 Infants London, England NEOM 98.32 PRJEB25762 
M125.2.4C 3496522 30 Children London, England NEOM 98.53 PRJEB28307 
M125.2C 3168973 32 Infants London, England NEOM 98.32 PRJEB25762 
M125.4C 3165453 31 Infants London, England NEOM 98.32 PRJEB25762 
M125.5C 3164915 32 Infants London, England NEOM 98.31 PRJEB25762 
M128.2.3C 3425328 48 Children London, England NEOM 98.40 PRJEB28307 
M135.2.3C 3327279 31 Children London, England NEOM 98.72 PRJEB28307 
M137.2.1C 3142190 46 Children London, England NEOM 98.31 PRJEB28307 
MJR7757A 3585666 274 Undetermined 
Undetermined: 
from NCBI 
Public database 96.62 PRJNA272114 
NAG-NE1 3334514 128 Birds Australia Public database 98.71 PRJNA422745 
NAG-NE31 3469324 116 Birds Australia Public database 99.01 PRJNA422745 
NCTC10239 3081789 7 Undetermined 
Undetermined: 
from NCTC 
Public database 97.16 PRJEB28310 
NCTC10240 3035468 4 Birds 
Undetermined: 
from NCTC 
Public database 97.19 PRJEB28310 
NCTC10578 3353304 8 Undetermined 
Undetermined: 
from NCTC 
Public database 98.57 PRJEB28310 
NCTC10612 3065426 5 Undetermined 
Undetermined: 
from NCTC 
Public database 97.14 PRJEB28310 
NCTC10613 3215051 35 Undetermined 
Undetermined: 
from NCTC 
Public database 97.20 PRJEB28310 
NCTC10614 3106776 17 Undetermined 
Undetermined: 
from NCTC 
Public database 97.19 PRJEB28310 
NCTC10719 3657605 25 Pigs 
Undetermined: 
from NCTC 
Public database 98.31 PRJEB6403 
NCTC13170 3310238 1 Undetermined 
Undetermined: 
from NCTC 
Public database 99.03 PRJEB28310 
NCTC2544 3195093 1 Undetermined 
Undetermined: 
from NCTC 
Public database 98.60 PRJEB28310 
NCTC2837 3306216 3 Undetermined 
Undetermined: 
from NCTC 
Public database 98.61 PRJEB28310 
NCTC3182 3877250 34 Sheep 
Undetermined: 
from NCTC 
Public database 98.60 PRJEB28310 
NCTC8081 3665176 21 Undetermined 
Undetermined: 
from NCTC 
Public database 97.18 PRJEB28310 
NCTC8238 3051538 2 Undetermined 
Undetermined: 
from NCTC 
Public database 97.16 PRJEB28310 
NCTC8239 3008497 2 Undetermined 
Undetermined: 
from NCTC 
Public database 97.18 PRJEB28310 
NCTC8246 3391864 3 Undetermined 
Undetermined: 
from NCTC 
Public database 99.07 PRJEB28310 
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NCTC8247 3011897 2 Undetermined 
Undetermined: 
from NCTC 
Public database 97.15 PRJEB28310 
NCTC8359 3202545 21 Undetermined 
Undetermined: 
from NCTC 
Public database 97.21 PRJEB28310 
NCTC8449 3096490 29 Undetermined 
Undetermined: 
from NCTC 
Public database 97.89 PRJEB6403 
NCTC8503 3577234 9 Sheep 
Undetermined: 
from NCTC 
Public database 98.61 PRJEB28310 
NCTC8678 3005443 6 Undetermined 
Undetermined: 
from NCTC 
Public database 97.17 PRJEB28310 
NCTC8679 3151371 11 Undetermined 
Undetermined: 
from NCTC 
Public database 97.20 PRJEB28310 
NCTC8797 3021559 5 Undetermined 
Undetermined: 
from NCTC 
Public database 97.16 PRJEB28310 
NCTC8798 3084171 14 Undetermined 
Undetermined: 
from NCTC 
Public database 97.18 PRJEB6403 
NCTC8799 3108291 7 Undetermined 
Undetermined: 
from NCTC 
Public database 97.17 PRJEB28310 
NCTC9851 3035210 6 Undetermined 
Undetermined: 
from NCTC 
Public database 97.20 PRJEB28310 
NobL1 3508314 241 Birds USA Public database 98.29 PRJNA422745 
PBD1 3428087 14 Birds Australia Public database 98.68 PRJNA422745 
PBS5 3110163 10 Birds Australia Public database 95.95 PRJNA422745 
PC5 3099804 11 Birds Australia Public database 95.95 PRJNA422745 
Pennington 3749339 148 Birds USA Public database 99.02 PRJNA422745 
PH004 2923443 95 Adults 
South East 
England 
PHE 97.13 PRJEB25764 
PH005 2934006 96 Adults 
South East 
England 
PHE 97.13 PRJEB25764 
PH006 2928275 95 Adults 
South East 
England 
PHE 97.13 PRJEB25764 
PH007 2946980 81 Adults 
South East 
England 
PHE 97.12 PRJEB25764 
PH014 3423911 42 Adults London, England PHE 98.55 PRJEB25764 
PH015 3081476 100 Older adults 
North East 
England 
PHE 97.21 PRJEB25764 
PH016 3518998 66 Older adults 
North East 
England 
PHE 98.47 PRJEB25764 
PH017 3291535 23 Older adults 
North East 
England 
PHE 98.61 PRJEB25764 
PH018 3475247 26 Older adults 
North East 
England 
PHE 98.47 PRJEB25764 
PH019 3487876 25 Older adults 
North East 
England 
PHE 98.47 PRJEB25764 
PH020 3397222 33 Older adults 
North East 
England 
PHE 98.51 PRJEB25764 
PH021 3445998 31 Older adults 
North East 
England 
PHE 98.50 PRJEB25764 
PH022 3401212 36 Adults 
North East 
England 
PHE 98.33 PRJEB25764 
PH023 3325484 35 Adults 
North East 
England 
PHE 98.32 PRJEB25764 
PH024 3331444 28 Adults 
North East 
England 
PHE 98.33 PRJEB25764 
PH025 3320821 34 Adults 
North East 
England 
PHE 98.32 PRJEB25764 
PH026 3335204 37 Adults 
North East 
England 
PHE 98.33 PRJEB25764 
PH028 2994736 82 Adults London, England PHE 97.12 PRJEB25764 
PH029 2954967 97 Adults London, England PHE 97.12 PRJEB25764 
PH030 3427777 27 Older adults 
North East 
England 
PHE 98.47 PRJEB25764 
PH031 3430445 21 Older adults 
North East 
England 
PHE 98.47 PRJEB25764 
PH032 3139693 109 Older adults 
North East 
England 
PHE 97.16 PRJEB25764 
PH033 3163229 105 Older adults 
North East 
England 
PHE 97.17 PRJEB25764 
PH035 3422738 32 Adults 
North East 
England 
PHE 98.54 PRJEB25764 
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PH036 3430269 30 Adults 
North East 
England 
PHE 98.54 PRJEB25764 
PH037 3426315 26 Adults 
North East 
England 
PHE 98.54 PRJEB25764 
PH039 3432249 23 Adults 
North East 
England 
PHE 98.54 PRJEB25764 
PH040 3426487 25 Adults 
North East 
England 
PHE 98.54 PRJEB25764 
PH041 3433511 31 Adults 
North East 
England 
PHE 98.54 PRJEB25764 
PH042 3427997 34 Adults 
North East 
England 
PHE 98.54 PRJEB25764 
PH043 3421670 43 Adults 
North East 
England 
PHE 98.54 PRJEB25764 
PH044 3426828 29 Adults 
North East 
England 
PHE 98.54 PRJEB25764 
PH045 3191860 32 Adults 
North East 
England 
PHE 98.30 PRJEB25764 
PH046 3425020 35 Adults 
North East 
England 
PHE 98.54 PRJEB25764 
PH047 3422937 43 Adults 
North East 
England 
PHE 98.54 PRJEB25764 
PH048 3428504 34 Adults 
North East 
England 
PHE 98.54 PRJEB25764 
PH050 3315627 59 Adults 
South West 
England 
PHE 98.30 PRJEB25764 
PH051 3480399 27 Older adults 
North East 
England 
PHE 98.57 PRJEB25764 
PH052 3481680 34 Older adults 
North East 
England 
PHE 98.47 PRJEB25764 
PH053 3484752 25 Older adults 
North East 
England 
PHE 98.47 PRJEB25764 
PH054 3476853 57 Adults 
North East 
England 
PHE 98.52 PRJEB25764 
PH055 3441127 27 Adults 
North East 
England 
PHE 98.52 PRJEB25764 
PH056 3395441 23 Adults 
North East 
England 
PHE 98.56 PRJEB25764 
PH057 3398027 18 Adults 
North East 
England 
PHE 98.56 PRJEB25764 
PH058 3396864 22 Adults 
North East 
England 
PHE 98.56 PRJEB25764 
PH059 3395953 24 Adults 
North East 
England 
PHE 98.56 PRJEB25764 
PH060 3399028 20 Adults 
North East 
England 
PHE 98.56 PRJEB25764 
PH061 3396723 20 Adults 
North East 
England 
PHE 98.55 PRJEB25764 
PH062 3397544 21 Adults 
North East 
England 
PHE 98.56 PRJEB25764 
PH063 3395429 19 Adults 
North East 
England 
PHE 98.56 PRJEB25764 
PH065 3392964 20 Adults 
North East 
England 
PHE 98.56 PRJEB25764 
PH066 3398355 18 Adults 
North East 
England 
PHE 98.56 PRJEB25764 
PH067 3392663 21 Adults 
North East 
England 
PHE 98.55 PRJEB25764 
PH068 3399957 23 Adults 
North East 
England 
PHE 98.56 PRJEB25764 
PH072 3492601 59 Older adults 
North East 
England 
PHE 98.56 PRJEB25764 
PH073 3537414 35 Older adults 
North East 
England 
PHE 98.46 PRJEB25764 
PH074 3522802 26 Older adults 
North East 
England 
PHE 98.46 PRJEB25764 
PH075 3538037 29 Older adults 
North East 
England 
PHE 98.46 PRJEB25764 
PH076 3450640 23 Older adults 
North East 
England 
PHE 98.46 PRJEB25764 
PH077 3491708 23 Older adults 
North East 
England 
PHE 98.47 PRJEB25764 
PH078 2987740 70 Older adults 
North East 
England 
PHE 97.12 PRJEB25764 
PH079 3496302 26 Older adults 
North East 
England 
PHE 98.46 PRJEB25764 
PH080 2983246 73 Adults 
North West 
England 
PHE 97.13 PRJEB25764 
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PH081 2984289 67 Adults 
North West 
England 
PHE 97.12 PRJEB25764 
PH082 3394345 30 Older adults 
North East 
England 
PHE 98.65 PRJEB25764 
PH083 3410579 21 Older adults 
North East 
England 
PHE 98.64 PRJEB25764 
PH084 3392793 22 Older adults 
North East 
England 
PHE 98.65 PRJEB25764 
PH085 3394191 23 Older adults 
North East 
England 
PHE 98.64 PRJEB25764 
PH091 3337668 491 Adults London, England PHE 98.58 PRJEB25764 
PH092 3378829 378 Adults London, England PHE 98.56 PRJEB25764 
PH095 3348605 446 Adults London, England PHE 98.58 PRJEB25764 
PH096 3422714 239 Older adults 
North East 
England 
PHE 98.48 PRJEB25764 
PH097 3371290 398 Older adults 
North East 
England 
PHE 98.50 PRJEB25764 
PH098 3454553 245 Older adults 
North East 
England 
PHE 98.48 PRJEB25764 
PH100 3354426 184 Older adults 
North East 
England 
PHE 98.52 PRJEB25764 
PH101 3481641 87 Older adults 
North East 
England 
PHE 98.47 PRJEB25764 
PH102 3420587 311 Older adults 
North East 
England 
PHE 98.49 PRJEB25764 
PH103 3448541 274 Older adults 
North East 
England 
PHE 98.49 PRJEB25764 
PH104 2929035 214 Adults London, England PHE 97.14 PRJEB25764 
PH105 2944409 379 Adults 
North East 
England 
PHE 97.16 PRJEB25764 
PH107 2914363 246 Adults London, England PHE 97.15 PRJEB25764 
PH115 2977232 317 Adults 
North East 
England 
PHE 97.17 PRJEB25764 
PH117 3285816 246 Adults 
North East 
England 
PHE 98.35 PRJEB25764 
PH118 3282569 214 Adults 
North East 
England 
PHE 98.35 PRJEB25764 
PH119 3289115 215 Adults 
North East 
England 
PHE 98.35 PRJEB25764 
PH120 3274008 185 Adults 
South West 
England 
PHE 98.31 PRJEB25764 
PH121 3233465 289 Adults 
South West 
England 
PHE 98.32 PRJEB25764 
PH122 3282469 371 Adults 
South West 
England 
PHE 98.32 PRJEB25764 
PH123 3429751 156 Adults 
North East 
England 
PHE 98.52 PRJEB25764 
PH124 3431905 132 Adults 
North East 
England 
PHE 98.52 PRJEB25764 
PH125 3406444 363 Adults 
North East 
England 
PHE 98.63 PRJEB25764 
PH126 3408431 418 Adults 
North East 
England 
PHE 98.62 PRJEB25764 
PH127 2924057 262 Adults 
North East 
England 
PHE 97.13 PRJEB25764 
PH128 3436609 352 Adults 
Midlands, 
England 
PHE 98.97 PRJEB25764 
PH129 3441457 266 Adults 
Midlands, 
England 
PHE 98.97 PRJEB25764 
PH130 3446961 250 Adults 
Midlands, 
England 
PHE 98.96 PRJEB25764 
PH132 3418685 466 Adults 
Midlands, 
England 
PHE 98.98 PRJEB25764 
PH133 3432746 347 Adults 
Midlands, 
England 
PHE 98.98 PRJEB25764 
PH134 3446865 192 Adults 
Midlands, 
England 
PHE 98.96 PRJEB25764 
PH135 2912738 356 Adults London, England PHE 97.15 PRJEB25764 
PH136 2905546 312 Adults London, England PHE 97.16 PRJEB25764 
PH138 3401096 222 Older adults 
North East 
England 
PHE 98.52 PRJEB25764 
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PH139 3402225 97 Older adults 
North East 
England 
PHE 98.52 PRJEB25764 
PH140 3386184 257 Older adults 
North East 
England 
PHE 98.53 PRJEB25764 
PH143 3528864 256 Adults 
South West 
England 
PHE 98.54 PRJEB25764 
PH147 3267085 351 Adults 
North East 
England 
PHE 98.35 PRJEB25764 
PH154 3413080 177 Adults 
North East 
England 
PHE 98.55 PRJEB25764 
PH155 3411087 209 Adults 
North East 
England 
PHE 98.55 PRJEB25764 
PH156 3172681 239 Adults 
North East 
England 
PHE 98.31 PRJEB25764 
Q012.2.1C 3135616 46 Children London, England NEOM 98.32 PRJEB28307 
Q020.CN1 3242179 16 Infants London, England NEOM 98.57 PRJEB25762 
Q020.CN2 3243904 21 Infants London, England NEOM 98.57 PRJEB25762 
Q020.CN4 3240291 19 Infants London, England NEOM 98.57 PRJEB25762 
Q020.CN5 3241785 21 Infants London, England NEOM 98.58 PRJEB25762 
Q020f.CN1 3244276 22 Infants London, England NEOM 98.57 PRJEB25762 
Q034.2.1C 3186736 28 Children London, England NEOM 96.16 PRJEB28307 
Q036.2.1C 3427754 28 Children London, England NEOM 98.61 PRJEB28307 
Q041.2.4C 3573312 61 Children London, England NEOM 98.59 PRJEB28307 
Q048.2.1C 3232498 44 Children London, England NEOM 98.31 PRJEB28307 
Q049.2.3C 3347476 40 Children London, England NEOM 99.20 PRJEB28307 
Q061.2.1C 3442469 40 Children London, England NEOM 97.15 PRJEB28307 
Q063.2.1C 3317138 30 Children London, England NEOM 98.62 PRJEB28307 
Q087.1C 3280619 25 Infants London, England NEOM 98.38 PRJEB25762 
Q087.2C 3283123 29 Infants London, England NEOM 98.38 PRJEB25762 
Q088.CN1 3062159 11 Infants London, England NEOM 96.15 PRJEB25762 
Q088.CN10 3403885 27 Infants London, England NEOM 98.30 PRJEB25762 
Q088.CN12 3286041 21 Infants London, England NEOM 98.38 PRJEB25762 
Q088.CN13 3065620 16 Infants London, England NEOM 96.15 PRJEB25762 
Q088.CN2 3069367 19 Infants London, England NEOM 96.15 PRJEB25762 
Q088.CN3 3065157 18 Infants London, England NEOM 96.14 PRJEB25762 
Q088.CN4 3068997 16 Infants London, England NEOM 96.15 PRJEB25762 
Q088.CN6 3066288 17 Infants London, England NEOM 96.15 PRJEB25762 
Q088.CN7 3063712 13 Infants London, England NEOM 96.16 PRJEB25762 
Q088.CN9 3287606 21 Infants London, England NEOM 98.38 PRJEB25762 
Q090.5C 3194717 14 Infants London, England NEOM 98.60 PRJEB25762 
Q090.6C 3200511 24 Infants London, England NEOM 98.61 PRJEB25762 
Q090.8C 3202127 16 Infants London, England NEOM 98.61 PRJEB25762 
Q090.9C 3201249 23 Infants London, England NEOM 98.61 PRJEB25762 
Q096.10C 3194624 29 Infants London, England NEOM 98.34 PRJEB25762 
Q096.11C 3187873 30 Infants London, England NEOM 98.32 PRJEB25762 
Q096.13C 3244272 28 Infants London, England NEOM 98.33 PRJEB25762 
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Q096.14C 3239882 33 Infants London, England NEOM 98.33 PRJEB25762 
Q096.16C 3190020 27 Infants London, England NEOM 96.14 PRJEB25762 
Q096.17C 3184400 32 Infants London, England NEOM 98.33 PRJEB25762 
Q096.1C 4147421 46 Infants London, England NEOM 98.31 PRJEB25762 
Q096.2C 4086994 39 Infants London, England NEOM 98.32 PRJEB25762 
Q096.4C 3309035 21 Infants London, England NEOM 98.59 PRJEB25762 
Q096.5C 3305014 17 Infants London, England NEOM 98.58 PRJEB25762 
Q097.1C 3160474 25 Infants London, England NEOM 98.28 PRJEB25762 
Q097.2C 3152325 26 Infants London, England NEOM 98.27 PRJEB25762 
Q097.4C 3154351 21 Infants London, England NEOM 98.27 PRJEB25762 
Q097.5C 3151690 25 Infants London, England NEOM 98.28 PRJEB25762 
Q097.7C 3196530 27 Infants London, England NEOM 98.27 PRJEB25762 
Q097.8C 3152354 26 Infants London, England NEOM 98.27 PRJEB25762 
Q100.CN1 3209378 26 Infants London, England NEOM 98.25 PRJEB25762 
Q100.CN10 3177242 21 Infants London, England NEOM 98.29 PRJEB25762 
Q100.CN11 3177983 21 Infants London, England NEOM 98.29 PRJEB25762 
Q100.CN12 3212162 21 Infants London, England NEOM 98.24 PRJEB25762 
Q100.CN13 3210861 19 Infants London, England NEOM 98.25 PRJEB25762 
Q100.CN2 3214133 27 Infants London, England NEOM 98.26 PRJEB25762 
Q100.CN4 3211356 23 Infants London, England NEOM 98.26 PRJEB25762 
Q100.CN5 3212371 20 Infants London, England NEOM 98.26 PRJEB25762 
Q100.CN7 3212734 22 Infants London, England NEOM 98.25 PRJEB25762 
Q100.CN8 3213979 18 Infants London, England NEOM 98.25 PRJEB25762 
Q101.1C 3231229 22 Infants London, England NEOM 98.40 PRJEB25762 
Q101.2C 3238879 21 Infants London, England NEOM 98.40 PRJEB25762 
Q105.1C 3138208 28 Infants London, England NEOM 98.33 PRJEB25762 
Q105.2C 3137322 27 Infants London, England NEOM 98.33 PRJEB25762 
Q105.4C 3136273 33 Infants London, England NEOM 98.33 PRJEB25762 
Q105.5C 3134159 35 Infants London, England NEOM 98.33 PRJEB25762 
Q106.10C 3494367 24 Infants London, England NEOM 99.12 PRJEB25762 
Q106.11C 3475235 26 Infants London, England NEOM 99.12 PRJEB25762 
Q106.1C 3125382 39 Infants London, England NEOM 98.33 PRJEB25762 
Q106.2C 3137937 28 Infants London, England NEOM 98.32 PRJEB25762 
Q106.4C 3100264 20 Infants London, England NEOM 96.15 PRJEB25762 
Q106.5C 3091941 14 Infants London, England NEOM 96.14 PRJEB25762 
Q106.7C 3092582 15 Infants London, England NEOM 96.14 PRJEB25762 
Q106.8C 3267326 31 Infants London, England NEOM 98.39 PRJEB25762 
Q107.10C 3297761 20 Infants London, England NEOM 98.61 PRJEB25762 
Q107.12C 3295802 16 Infants London, England NEOM 98.62 PRJEB25762 
Appendix 4    322 
 









Contigs Source Region/Country Study/Site ANI 
Q107.13C 3296932 15 Infants London, England NEOM 98.61 PRJEB25762 
Q107.1C 3143128 27 Infants London, England NEOM 98.30 PRJEB25762 
Q107.2C 3143673 26 Infants London, England NEOM 98.30 PRJEB25762 
Q107.4C 3270656 29 Infants London, England NEOM 98.40 PRJEB25762 
Q107.5C 3268477 27 Infants London, England NEOM 98.39 PRJEB25762 
Q107.7C 3133904 21 Infants London, England NEOM 98.35 PRJEB25762 
Q107.8C 3134078 23 Infants London, England NEOM 98.36 PRJEB25762 
Q107.9C 3299946 15 Infants London, England NEOM 98.61 PRJEB25762 
Q118.1C 3333932 24 Infants London, England NEOM 98.41 PRJEB25762 
Q118.2C 3376789 26 Infants London, England NEOM 98.41 PRJEB25762 
Q118.4C 3374700 30 Infants London, England NEOM 98.41 PRJEB25762 
Q118.5C 3375850 22 Infants London, England NEOM 98.41 PRJEB25762 
Q124.1C 3591545 17 Infants London, England NEOM 97.20 PRJEB25762 
Q124.2C 3592345 19 Infants London, England NEOM 97.20 PRJEB25762 
Q124.4C 3591925 17 Infants London, England NEOM 97.20 PRJEB25762 
Q124.5C 3591587 18 Infants London, England NEOM 97.21 PRJEB25762 
Q125.1C 3592250 16 Infants London, England NEOM 97.21 PRJEB25762 
Q125.2C 3592243 17 Infants London, England NEOM 97.20 PRJEB25762 
Q125.4C 3592144 17 Infants London, England NEOM 97.21 PRJEB25762 
Q125.5C 3591863 17 Infants London, England NEOM 97.20 PRJEB25762 
Q126.1C 3203802 14 Infants London, England NEOM 96.09 PRJEB25762 
Q126.2C 3202647 15 Infants London, England NEOM 96.09 PRJEB25762 
Q126.3C 3204069 16 Infants London, England NEOM 96.09 PRJEB25762 
Q126.4C 3203065 14 Infants London, England NEOM 96.09 PRJEB25762 
Q135.2.1C 3527791 31 Children London, England NEOM 97.24 PRJEB28307 
Q135.CN1 3156272 32 Infants London, England NEOM 98.30 PRJEB25762 
Q135.CN2 3158560 29 Infants London, England NEOM 98.30 PRJEB25762 
Q135.CN4 3154909 38 Infants London, England NEOM 98.29 PRJEB25762 
Q135.CN5 3157891 34 Infants London, England NEOM 98.31 PRJEB25762 
Q137.1C 3459480 26 Infants London, England NEOM 98.54 PRJEB25762 
Q137.2.2C 3333854 21 Children London, England NEOM 99.11 PRJEB28307 
Q137.2.3C 3372422 90 Children London, England NEOM 98.90 PRJEB28307 
Q137.2C 3460184 26 Infants London, England NEOM 98.53 PRJEB25762 
Q137.4C 3456126 24 Infants London, England NEOM 98.54 PRJEB25762 
Q137.5C 3460469 25 Infants London, England NEOM 98.54 PRJEB25762 
Q138.1C 3460229 23 Infants London, England NEOM 98.53 PRJEB25762 
Q138.2.5C 3283796 25 Children London, England NEOM 98.62 PRJEB28307 
Q138.2.7C 3282195 28 Children London, England NEOM 98.61 PRJEB28307 
Q138.2C 3458864 24 Infants London, England NEOM 98.53 PRJEB25762 
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Q138.4C 3459336 21 Infants London, England NEOM 98.54 PRJEB25762 
Q138.5C 3459391 23 Infants London, England NEOM 98.54 PRJEB25762 
Q142.1C 3146959 36 Infants London, England NEOM 98.30 PRJEB25762 
Q142.2C 3142942 36 Infants London, England NEOM 98.31 PRJEB25762 
Q143.1C 3459999 21 Infants London, England NEOM 98.53 PRJEB25762 
Q143.2C 3458899 23 Infants London, England NEOM 98.53 PRJEB25762 
Q143.CN1 3460998 25 Infants London, England NEOM 98.54 PRJEB25762 
Q143.CN2 3459787 24 Infants London, England NEOM 98.53 PRJEB25762 
Q143.CN4 3458736 28 Infants London, England NEOM 98.53 PRJEB25762 
Q143.CN5 3459306 24 Infants London, England NEOM 98.53 PRJEB25762 
Q143.CN7 3460400 24 Infants London, England NEOM 98.53 PRJEB25762 
Q143.CN8 3460283 24 Infants London, England NEOM 98.53 PRJEB25762 
Q143f.CN7 3454358 26 Infants London, England NEOM 98.54 PRJEB25762 
Q146.2.5C 3026392 97 Children London, England NEOM 97.11 PRJEB28307 
Q154.2.6C 3320860 63 Children London, England NEOM 98.32 PRJEB28307 
Q161.2.3C 3312339 21 Children London, England NEOM 98.52 PRJEB28307 
Q164.1C 3360445 19 Infants London, England NEOM 98.94 PRJEB25762 
Q164.2C 3361328 21 Infants London, England NEOM 98.94 PRJEB25762 
Q167.11C 3191571 17 Infants London, England NEOM 98.31 PRJEB25762 
Q167.1C 3191399 17 Infants London, England NEOM 98.31 PRJEB25762 
Q167.20C 3193775 21 Infants London, England NEOM 98.29 PRJEB25762 
Q167.2C 3191805 20 Infants London, England NEOM 98.30 PRJEB25762 
Q167.4C 3192114 18 Infants London, England NEOM 98.30 PRJEB25762 
Q167.5C 3191783 20 Infants London, England NEOM 98.31 PRJEB25762 
Q167.7C 3187987 18 Infants London, England NEOM 98.30 PRJEB25762 
Q167.8C 3192625 16 Infants London, England NEOM 98.29 PRJEB25762 
Q168.1C 3172313 59 Infants London, England NEOM 98.30 PRJEB25762 
Q168.2C 3172634 64 Infants London, England NEOM 98.30 PRJEB25762 
Q168.4C 3183576 16 Infants London, England NEOM 98.30 PRJEB25762 
Q168.5C 3193363 16 Infants London, England NEOM 98.30 PRJEB25762 
Q168.7C 3195069 13 Infants London, England NEOM 98.30 PRJEB25762 
Q168.8C 3184875 17 Infants London, England NEOM 98.30 PRJEB25762 
Q182.2.2C 3346383 39 Children London, England NEOM 98.56 PRJEB28307 
Q210.2.1C 3283184 24 Children London, England NEOM 98.61 PRJEB28307 
Q213.2.1C 3109696 15 Children London, England NEOM 96.15 PRJEB28307 
Q215.CN1 3282615 24 Infants London, England NEOM 98.69 PRJEB25762 
Q215.CN2 3281952 17 Infants London, England NEOM 98.69 PRJEB25762 
SAF-1 3300478 93 Birds Australia Public database 98.61 PRJNA422745 
SM101 2921996 3 Undetermined 
Undetermined: 
from NCBI 
Public database 97.17 PRJNA12521 
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Contigs Source Region/Country Study/Site ANI 
SOM-NE34 3418437 2 Birds Australia Public database 98.45 PRJNA422745 
SOM-NE35 3567592 59 Birds Australia Public database 98.46 PRJNA422745 
SYD-NE41 3738529 31 Birds Australia Public database 98.64 PRJNA422745 
TAM-NE38 3646969 78 Birds Australia Public database 99.00 PRJNA422745 
TAM-NE40 3645901 78 Birds Australia Public database 99.00 PRJNA422745 
TAM-NE42 3363281 109 Birds Australia Public database 98.91 PRJNA422745 
TAM-NE43 3275545 28 Birds Australia Public database 98.64 PRJNA422745 
TAM-NE46 3677993 216 Birds Australia Public database 99.00 PRJNA422745 
UDE95-1372 3644497 124 Birds USA Public database 99.00 PRJNA422745 
W1319 3308237 12 Birds Australia Public database 98.75 PRJNA422745 
WAL_14572 3462156 35 Undetermined 
Undetermined: 
from NCBI 
Public database 98.57 PRJNA46397 
Warren 3776328 184 Birds USA Public database 99.03 PRJNA422745 














Appendix 5  Supplementary data for Chapter 8 
This appendix contains all supplementary materials for Chapter 8. 
 
Table S8.1: Raw pathological scoring of colonic sections for each mouse in infection 
model (1). 
Table S8.2: Raw pathological scoring of colonic sections for each mouse in each 




Colonic sections were scored single-blinded by Dr Lindsay J Hall. Values given for 
single criteria are not additive but represent the final score value that include all 
relevant criteria (as below): 
1. Inflammatory infiltration (0-4) 
2. Epithelial hyperplasia and goblet cell loss (0-5) 
3. Mucosal architecture (0-5) 
  




Table S8.1: Raw pathological scoring of colonic sections for each mouse in each individual 
group for infection model 1. 





























Mouse 1 0.5 0.5 0.5 1.5 
Mouse 2 1 0 0.5 1.5 
Mouse 3 0.5 0 0.5 1 
Mouse 4 1 1 2 4 





Mouse 1 1.5 0.5 1.5 3.5 
Mouse 2 0.5 0.5 0.5 1.5 










Mouse 1 2 1.5 3.5 7 
Mouse 2 2 3 3 8 
Mouse 3 2.5 3 3.5 9 
Mouse 4 2.5 4 4 10.5 
Mouse 5 3.5 4 3.5 11 








Table S8.2: Raw pathological scoring of colonic sections for each mouse in each individual 
group for infection model 2 (tetracycline model). 






















Mouse 1 1 0.5 1.5 3 
Mouse 2 0.5 0.5 0.5 1.5 
Mouse 3 1 0.5 1 2.5 
Mouse 4 0.5 0 0.5 1 














Mouse 1 1.5 2 3 6.5 
Mouse 2 2 1.5 2 5.5 
Mouse 3 2 1.5 2.5 6 
Mouse 4 3 1.5 2 6.5 
















 Mouse 1 3 3 4 10 
Mouse 2 2 2 3 7 
Mouse 3 2 3.5 3 8.5 
Mouse 4 2 2.5 2.5 7 














Mouse 1 2 2.5 2.5 7 
Mouse 2 2.5 2.5 2 7 
Mouse 3 3 4 4 11 
Mouse 4 3 4 4 11 








Appendix 6  Presentations and awards 
Seminars/ oral presentations 
1. Kiu R., Caim S., Amar C., Hall L. (2018) Phylogenomic analysis of food-
poisoning associated Clostridium perfringens identifies isogenic strains in 
multiple outbreaks, and novel virulence-related features. Quadram Institute 
Bioscience (QIB). Hall laboratory seminar. 4 September 2018.  
2. Kiu R., Hall L. (2018) Understanding the role of Clostridium perfringens in 
intestinal diseases. Quadram Institute Bioscience (QIB). Hall laboratory 
seminar. 23 May 2018.  
3. Kiu R., Caim S., Hall L. (2018) Probing genomic aspects of the multi-host 
pathogen Clostridium perfringens. The Institute for Microbiology and 
Infection (IMI) at the University of Birmingham. 2018 Junior Awards for 
Microbiology (J.A.M.) March Seminar. 9 March 2018.  
4. Kiu R. (2018) The role of Clostridium perfringens in intestinal diseases. 
Quadram Institute Bioscience (QIB). Director’s luncheon. 15 February 2018.  
5. Kiu R., Hall L. (2018) The role of Clostridium perfringens in intestinal 
diseases. Quadram Institute Bioscience (QIB). Hall laboratory seminar. 25 
November 2017.  
6. Kiu R., Caim S., Hall L. (2017) Probing genomic evolutionary & virulence 
traits in the multi-host pathogen Clostridium perfringens. Quadram Institute 
Bioscience (QIB). Gut Health & Food Safety ISP Research-In-Progress 
Seminar. 4 September 2017.  
7. Kiu R., Hall L. (2018) The role of Clostridium perfringens in intestinal 
diseases. Public Health England, Colindale. Collaboration and knowledge 
exchange meeting. 24 July 2017.  
8. Kiu R. (2017) The role of Clostridium perfringens in intestinal diseases. 
Quadram Institute Bioscience (QIB). Hall laboratory seminar. 9 May 2017.  
9. Kiu R. (2016) The role of Clostridium perfringens in early life intestinal 
diseases. Institute of Food Research (IFR). Hall laboratory seminar. 19 
October 2016.  




10. Kiu R., Hall L. (2016) The role of Clostridium perfringens in early life 
intestinal diseases. Institute of Food Research (IFR). IFR Student Seminar. 6 
October 2016.  
11. Kiu R., Hall L. (2016) The role of Clostridium perfringens in early life 
intestinal diseases. Trinity College Dublin, The University of Dublin, Ireland. 
Dublin Knowledge Exchange Programme oral presentation. 26 September 
2016.  
12. Kiu R., Hall L. (2016) Impact of early life gut microbiota on infection risk and 
resistance. Institute of Food Research (IFR). Annual Progress Meeting. 12 
August 2016.  
13. Kiu R., Hall L. (2016) Impact of early life gut microbiota on infection risk and 
resistance. Institute of Food Research (IFR). Hall laboratory seminar. 1 June 
2016.  
14. Kiu R. (2016) Impact of early life gut microbiota on infection risk and 
resistance. Institute of Food Research (IFR). Collaboration and knowledge 
exchange meeting. 18 May 2016.  
15. Kiu R., Hall L. (2016) Impact of early life gut microbiota on infection risk and 
resistance. Institute of Food Research (IFR). PhD Transfer Panel Meeting. 14 
March 2016.  
16. Kiu R., Hall L. (2016) Pre-term gut wars: Villain vs Hero. Institute of Food 
Research (IFR). IFR Coffee Break Science. 11 March 2016. 
17. Kiu R., Hall L. (2016) How early life microbiota impacts on gut infection 
resistance. Institute of Food Research (IFR). Hall laboratory seminar. 19 
February 2016. 
18. Kiu R., Hall L. (2015) How early life microbiota impacts on infection 









 Poster presentations 
1. Kiu R., Caim S., Alexander S., Pachori P., Hall L. (2018) Probing Genomic 
Aspects of the Multi-Host Pathogen Clostridium perfringens. Reveals 
Significant Pangenome Diversity, and a Diverse Array of Virulence Factors 
Microbiology Society Annual Conference 2018.  
2. Kiu R., Caim S., Pickard D., Bedwell H., Alcon C., Ketskemety J., Shaw A., 
Sim K., Brown J., Belteki G., Clarke P., Dixon R., Dougan G., Kroll S., Hall 
L. J. (2017) Probing evolutionary relationship and virulence traits of 
Clostridium perfringens. Microbiology Society Annual Conference 2017.  
3. Kiu R., Caim S., Pickard D., Bedwell H., Alcon C., Ketskemety J., Shaw A., 
Sim K., Brown J., Belteki G., Clarke P., Dixon R., Gordon G., Kroll J. S., Hall 
L. J. (2017) Probing evolutionary relationship and virulence traits of 
Clostridium perfringens. Microbes in Norwich 2017.  
4. Leclaire C., Kiu R., Caim S., Flegg Z., O'Neill I., Hall L. J. (2017) Bile salt 
hydrolase activity in Bifidobacteria, a probiotic trait? Microbes in Norwich  
5. Kiu R., Caim S., Pickard D., Bedwell H., Alcon C., Ketskemety J., Shaw A., 
Sim K., Brown J., Belteki G., Clarke P., Dixon R., Dougan G., Kroll S., Hall 
L. (2017) Probing evolutionary relationship and virulence traits of Clostridium 
perfringens UEA FMH Postgraduate Research Conference.  
6. Kiu R., Caim S., Pickard D., Bedwell H., Alcon C., Ketskemety J., Shaw A., 
Sim K., Brown J., Belteki G., Clarke P., Dixon R., Dougan G., Kroll S., Hall 
L. (2017) Probing evolutionary relationship and virulence traits of Clostridium 
perfringens. IFR Student Science Showcase.  
7. Kiu R., Lawson M. L., Hall L. H. (2015) How early life microbiota impacts 
immune function and infection resistance. IFR Science Symposium. 
8. Kiu R., Lawson M., Alcon C., Walker A., Carding S., Hall L. (2015) How 
early life microbiota impacts infection resistance Wageningen, the Netherlands. 
IFR-Wageningen University Student Symposium.  
 
 




Awards and scholarships 
1. Kiu R. (2018) J.A.M. Talks Invited Speaker Travel Grant by Microbiology 
Society. March 2018. 
2. Kiu R. (2018) Microbiology Society Annual Conference (Birmingham, UK) 
Travel Award. April 2018. 
3. Kiu R. (2017) Conference on the Molecular Biology and Pathogenesis of the 
Clostridia (CLOSTPATH) Travel Award. July 2017. 
4. Kiu R. (2017) Microbiology Society Annual Conference (Edinburgh, UK) 
Travel Award. April 2017. 
5. Kiu R. (2015) UEA Faculty of Medical and Health Sciences Postgraduate 
Research International Bursary (2015-2017). January 2015. 
  




Appendix 7  Peer-reviewed publications 
All published peer-reviewed journal articles (including a genome report, a major 
research article, a Review article and a rebuttal article) during my PhD (2015-2018) 
were reproduced in this section (in chronological order): 
1. Kiu, R., Caim, S., Alcon-Giner, C., Belteki, G., Clarke, P., Pickard, D., Dougan, 
G., Hall, L J. Preterm infant-associated Clostridium tertium, Clostridium cadaveris, 
and Clostridium paraputrificum strains: genomic and evolutionary insights. 
Genome Biol Evol 9, 2707-2714, doi:10.1093/gbe/evx210 (2017). 
• My contribution in this work as first author: 
▪ Isolation of bacterial strains and DNA extraction. 
▪ Performed bioinformatics analysis and graphing. 
▪ Wrote up the entire article. 
 
2. Kiu, R., Caim, S., Alexander, S., Pachori, P. & Hall, L. J. Probing genomic aspects 
of the multi-host pathogen Clostridium perfringens reveals significant pangenome 
diversity, and a diverse array of virulence factors. Front Microbiol 8, 2485, 
doi:10.3389/fmicb.2017.02485 (2017). 
• My contribution in this work as joint-first author: 
▪ Performed bioinformatics analysis independently/with major 
support from Mr Shabhonam Caim (also joint-first author). 
▪ Graphed figures and wrote up the entire article (including results 
and discussion). 
 
3. Kiu, R. & Hall, L. J. An update on the human and animal enteric pathogen 
Clostridium perfringens. Emerging Microbes & Infections 7, 141, 
doi:10.1038/s41426-018-0144-8 (2018). 
• My contribution in this work as first author: 
▪ Researched existing literature and wrote up the Review article. 
▪ Researched and graphed new figures. 
 
4. Kiu, R. & Hall, L. J. Response: Commentary: Probing genomic aspects of the 
multi-host pathogen Clostridium perfringens reveals significant pangenome 
diversity, and a diverse array of virulence factors. Frontiers in Microbiology 9, 
doi:10.3389/fmicb.2018.01857 (2018). 
• My contribution in this work as first author: 
▪ Wrote up the rebuttal article. 
▪ Performed bioinformatics analysis.  
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